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The thyroid gland is the target of the commonest forms of autoimmune disease. 
Development of goitre, with an increase in the number of thyrocytes and other cells in 
the thyroid, is one of m anifestation of thyroid autoim m unity in some cases. The 
enlargement of the gland is not simply the effect of stimulation of the thyrocytes with 
TSH (Hashimoto’s disease), or with thyroid stimulating antibodies (Graves’ disease), but 
involves many other factors, including cell to cell signalling among the various 
populations of cells in the gland by cytokines or other mediators.
Another consequence of disease is the generation of new blood vessels and 
infiltration of a variety of mononuclear ceils which form aggregates or are diffusely 
distributed between and w ithin the thyroid follicles. It seems likely that the 
mononuclear cells migrate from peripheral blood into thyroid tissue where they are 
retained by interaction with other cells including thyroid epithelial cells by means of 
cytokines released locally. The interaction of cytokines and growth factors w ith 
thyrocytes could also influence their functional pattern.
Finally, the thyroid gland is richly innervated by nerves of different types 
(adrenergic, cholinergic, and peptidergic) which terminate close to blood vessels and 
follicular cells. It is likely, therefore, that neurotransmitters released locally may 
directly influence the activity of the follicular cells.
Previous studies showed that a soluble form of the interleukin-2 receptor (sIL- 
2R) is present in increased quantities in serum of patients with Graves' disease. Less 
information is available for the cytokines production among these patients, and the 
role of neuropeptides in the gland is not clear. The aim of this study was to determine 
the role of some of these bioactive peptides in Graves' disease.
The concentration of soluble IL-2 receptor was increased in serum of the 
patients with Graves' disease (7.5 fold compared to healthy controls). Experiments 
on stimulation of blood cells in vitro showed that part of the increase in production of 
SÏL-2R is due to the elevation of thyroid hormones, w hile reduction of IL-2 
production may be a second factor. In addition, the concentration of sIL-2R depends 
on other, unknown factors in the plasma, because dilution of whole blood with 
medium caused an increase in sIL-2R production.
Stimulation of diluted (1:11 diluted with medium) whole blood of patients 
with untreated Graves' disease with a mixture of LPS/PHA caused a release of IL-2 
and IL-4 that was significantly higher than from the reference group, after 72 h. The 
production of IL - 6  was also higher than from the reference group, after 4  h. The 
production of INF-y depended on the stim ulator applied, but incubation of
I
unstimulated whole blood of the patients released less INF-y than control. Finally, 
TN F-a production of whole blood of the patients was higher than the reference group 
after 4 h, and was lower than the reference group after 72 h. These results m ay 
indicate that cytokine production by immune cells has a different pattern compared
with healthy controls.
The effects of m ethim azole, thyroid hormones, and TSH  on cytokines
production were also investigated. These compounds did not affect the production of 
IL-2 and IL-4, while they decreased the production of IL-6 , INF-y, and T N F-a. This 
shows that high concentrations of TSH (in H ashim oto’s disease), and thyroid 
hormones (in Graves' disease) could influence the production of IL-6 , INF-y, and 
TN F-a. Furtherm ore, it also shows that methim azole directly influences the 
production of these cytokines.
The effects of various growth factors, cytokines, and neuropeptides on iodine 
uptake and growth of rat FRTL-5 thyroid epithelial cells were investigated.
In the absence of TSH, the iodine uptake of thyrocytes was increased by ÏGF- 
1 (in the presence of insulin), TGF, IL-6 , INF-y, neuropeptide Y, low doses of VIP 
and tachykinins, high doses of iodine, and thyroid hormones. On the other hand, 
iodine uptake was decreased by FGF, high doses of LPS, VIP, and tachykinins, and 
SNAP. The growth of cells was increased by insulin, IGF, FGF, low doses of VIP, 
high doses of thyroid hormones, inorganic iodine, and SNAP. The growth of cells 
was decreased by high doses of VIP.
In the presence of TSH, the iodine uptake of thyrocytes was increased by 
insulin, IGF, TGF, endothelin-1, low doses of IL -I and LPS, IL-6 , INF-y, PACAP, 
low doses of VIP and tachykinins, high doses of SNAP, and noradrenaline. On the 
other hand, iodine uptake was decreased by inorganic iodine, thyroid hormones, 
FGF, high dose of IL-1, LPS, and tachykinins, and low doses of SNAP. The growth 
of cells was increased by high doses of thyroid hormones, insulin, IGF, FGF, 
endothelin-1, low doses o f LPS, IL-6 , and low doses of VIP. The grow th of 
thyrocytes was decreased by IL-4, INF-y, high doses of VIP, and PACAP.
The pattern of iodine uptake and growth of cells changed when the cells were 
treated with high concentrations of thyroid hormones and TSH, before and during 
stimulation with the growth factor, cytokine, or neuropeptide. In m ost cases the 
hormones antagonised the action of the peptides. The stimulatory effects of IG F-1, 
TGF-p, endothelin-1, interferon-y, PACAP and VIP on iodine uptake were all 
reduced. In addition, thyroid hormones prevented the inhibitory effects of IL-1 and 
LPS. However, there was a large potentiation of the increase in iodine uptake caused 
by noradrenaline.
The actions on growth rate were sim ilar. The stim ulatory effects of 
endothelin-1 and LPS were reduced, as were the inhibitory effects of TGF-(5, IL-4
I
and interferon-y. The only exceptions were slight growth stimulatory effects in the
presence of VIP and neuromedin-U.
C om bination of IL-1 w ith some of the growth factors, cytokines, and
neuropeptides revealed that the effects of IL-1 were inhibitory. This may have
implications for the situation in autoimmune disease or inflammation, where there is
evidence for the presence of IL-1 within the gland. The effects were greater in the
presence of TSH, so IL-1 may act to lim it the growth and activity of the thyroid in
both Hashimoto's and Graves’ diseases.
Combination of some of the stimulators with noradrenaline also revealed that
noradrenaline is directly involved in the pathogenic mechanisms of hyperthyroidism,
and not just in eliciting the symptoms. il
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General Introduction
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SECTION ONE 
THYROID GLAND
1.1.1 Structure
The thyroid is the largest endocrine gland in the human body. In adults, its 
weight is approximately 20 g (Marshall 1992). The gland synthesises and secretes 
three hormones: the thyroid hormones thyroxine (T4 ) and triiodothyronine (T3 ), 
both of which are iodinated derivatives of tyrosine, and calcitonin, a polypeptide 
hormone that is functionally unrelated to other thyroid hormones, and is involved in 
calcium homeostasis.
The thyroid gland is situated in the anterior part of the neck. It consists of 
two somewhat pear-shaped lobes that lie to the sides of the trachea, and a smaller 
isthmus joining the medial aspects of the lobes. The lobes are about 5 cm long, 3 cm 
across at the wddest part, and 2 cm thick at the lower pole (McDougall, 1992).
The gland is highly vascular. A euthyroid gland has a blood flow rate of 
about 100 ml/min. In Graves’ hyperthyroidism this can increase to one litre/min and 
this is clinically apparent by a palpable thrill and a bruit (Halmi, 1986). There are 
four main arteries supplying blood to the thyroid. The superior thyroid arteries arise 
as the first branch of the external carotid artery and the inferior arteries arise from a 
branch of the first part of the subclavian artery. There is a rich anastomosis between 
superior and inferior vessels as well as between the lobes. The arteries divide into 
lobar and then lobular branches supplying a lobule consisting of some 20-50 
follicles. A plexus of veins on the surface of the thyroid drains into the superior and 
middle thyroid veins, which in turn drain into internal jugular veins. There is a rich 
lymphatic supply that follows the veins.
The thyroid encloses a num ber of nerve fibres, m ost of which are 
sympathetic (Halmi, 1986; Ahrén, 1991), The nerves supplying the thyroid itself 
mostly arise from the middle cervical ganglion and travel with the inferior thyroid 
artery. Some sympathetic fibres from the superior cervical ganglion also reach the 
thyroid along with the superior thyroid artery. These nerves are vasoconstrictors. 
Some contain neuropeptides (Ahrén, 1986 a; and 1991), though few effects on the 
thyroid have been demonstrated.
The epithelial cells of the thyroid that produce and secrete thyroid hormones 
are arranged in spherical structures called follicles. The follicular cells are cuboidal 
with a length of about 10 ^m . Under stimulation, they become progressively more
1
columnar and can be as tall as 20 pm . This appearance is characteristic of Graves’ 
hyperthyroidism that has not been treated; however, a similar appearance is found if 
the thyroid is lacking iodine and the gland is stimulated to make maximal quantities 
of hormone by pituitary thyroid stimulating hormone (TSH). A single layer of 
fo llicu lar cells surrounds colloidal m aterial containing stores of horm ones 
incorporated into a protein called thyroglobulin. The dimensions of the follicle, the 
fo llicular cells and colloid m aterial vary from  1 0 0  to 1 0 0 0  pm  in diam eter 
depending on the availability of iodine, the effect of physiological and pathological 
stimulators, and the presence of goitrogens. Smaller follicles appear to be more 
active. When there is excessive prolonged stimulation, the quantity of colloid 
m aterial decreases reflecting release of stored hormone from thyroglobulin 
(McDougall, 1992).
Groups of 20-50 follicles form  lobules, which have a fine covering of 
connective tissue that is continuous with the capsule of the gland. Each follicle is 
surrounded by delicate capillaries, but with standard staining techniques these are 
not well demonstrated because they collapse. The rich lymphatic system is also 
difficult to demonstrate in specimens from normal glands, but lymphatics are well 
seen when carcinoma invades them (McDougall, 1992).
The internal structure of the follicular cells reflects their active involvement 
in protein formation and secretion. The cytoplasm is rich in mitochondria, rough 
endoplasmic reticulum, Golgi apparatus and secretory droplets. The nucleus is 
round or oval and is central in cuboidal cells, but more basal in columnar ones. 
Numerous microvilli project from the apical end of the cells into the colloid (Halmi, 
1986).
Parafollicular cells (C cells) which produce and secrete calcitonin lie 
betw een follicles. They are d ifficult to see in sections of normal thyroid 
(McDougall, 1992).
1.1.2 Function
There are two physiologically important thyroid hormones: L-thyroxine, 
which is more abundant in the circulation and L-triiodothyronine, which is the more 
im portant horm one at the cellular level. Thyroxine and triiodothyronine are 
designated as T4  and T3  because they contain 4 and 3 iodine atoms per molecule 
respectively (figure 1 . 1 ).
The form ation and secretion of T 3  and T 4  are largely controlled by 
thyrotrophin (TSH). TSH is synthesised in, and secreted from, special cells in the 
anterior pituitary. Thyrotrophin releasing hormone (TRH) from the hypothalamus 
stimulates TSH release, and increased concentrations of T 3  or T 4  in the circulation
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Figure 1.1: S tructure o f m onoiodotyrosine (M IT), d iiodotyrosine (D IT), 
triiodothyronine (T3 ), thyroxine (T4 ), and reverse triiodothyronine (rTs).
suppress it (Marshall, 1992; Vassart and Dumont, 1992). Several other hormones, 
neurotransm itters, drugs and clinical conditions modulate this control system 
(McDougall, 1992), which is summarised in figure 1.2. The hypothalamus is under 
less well defined control from higher centres. Finally, the thyroid is able to ‘auto 
regulate’ all steps of synthesis and release of hormones, although this is much less 
important than the TSH control mechanism (McDougall, 1992).
1.1.2.1 Thyrotrophin Releasing Hormone
TRH is a tripeptide, L-(pyro)Glu~L-His-L-Prolinamide, with a relative 
molecular mass of 362 (Guillemin, 1978). TRH is formed in hypothalamic cells as a 
precursor consisting of five copies of the active molecule; the tripeptide is formed 
post translationally (Lechan et al, 1986). In addition, TRH is produced in many 
other sites in the brain, spinal cord, retina, gastrointestinal tract, pancreas and 
prostate (Griffiths, 1987; Gkonos et al, 1994).
TRH, formed in neurone bodies of hypothalamic neurones, travels in the 
axons to the primary vascular plexus o f the portal system where it gains access to 
the blood and is transported to the anterior pituitary. There it interacts with high 
affinity receptors on specific cells, thyrotrophs, which produce TSH. TRH causes a 
rapid release and a slower formation of TSH from these cells. TRH or TRH-like 
peptides are believed also to stim ulate anterior pituitary cell p roliferation 
(Pawlikowski and Slowinska-KIencka, 1994).
In normal people, injection of TRH causes a brisk rise in serum TSH from 
its normal basal range of approximately 0.4-5.0 mU/1 which reaches a peak at 20-30 
min and falls towards normal by 60-90 min. One to 4  h after injection of TRH, there 
is a rise in serum Tg of up to 70%, and a 15-20% rise in T 4  (Marshall 1992). This 
demonstrates the sequence: hypothalamus - pituitary - thyroid.
In patients who are hyperthyroid, irrespective of the cause, injection of TRH 
fails to produce a surge in serum TSH. Therefore, high levels of T 4  or T 3 , or both, 
inhibit the effect of TRH on the pituitary. In contrast, in primary hypothyroidism 
where the thyroid is failing and the levels of T 4  and T 3  are low, TSH is high and 
TRH causes a dramatic increase in serum TSH which falls to the baseline slowly 
(Kolesnick and Gershengorn, 1985; McDougall, 1992).
TRH has a half-life of about 5 min in blood. It is degraded by peptidases 
though some is excreted intact in the urine. When injected intravenously, only about 
1-2% crosses the blood-brain barrier (Marshall, 1992).
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Figure L 2 : Simplified diagram of the control of thyroid function, and additional 
factors modulating the action of TRH on TSH secretion by the thyrotroph. Positive 
effects are indicated by solid line, while broken lines indicate negative effects.
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1.1.2.2 Thyrotrophin
About 5% of anterior pituitary cells secrete TSH. These thyrotrophs are 
predom inantly located in the anterom edial aspect of the gland. TSH  is a 
glycoprotein of relative molecular mass 29000 which comprises two non-covalently 
bound polypeptide chains designated alpha and beta. The alpha subunit, o f relative 
molecular mass 14000, is identical to those of luteotrophin (LH), follitrophin (FSH) 
and chorionic gonadotrophin (HCG) (Pierce and Parsons, 1981). The beta subunit 
has a relative molecular mass of 15000 with a protein core of 113 am ino acids 
which confers unique biological and immunological properties on each hormone. 
The gene which encodes the beta subunit is on a different chromosome from that for 
the alpha chain (Chin et al, 1985). The thyrotroph produces an excess of alpha units 
and therefore the production of the beta subunit is the rate lim iting step. 
Carbohydrate moieties are added at a post translational step (McDougall, 1992).
The main negative feedback control for production and secretion of TSH is 
the level of free thyroid hormones in the blood. The thyrotroph is rich in enzymes 
which deiodinate T4  to T3  (5 ’ deiodinase, type II), and about 50% of the T 3  in the 
thyrotroph is formed in the cell by this mechanism. Therefore, intrathyrotroph T 3  is 
a more important regulator of TSH synthesis than serum T 3  (De Vito, 1989).
Chin and co-workers (1985) have shown in a mouse model that T3  in supra- 
physiological amounts lowers the level of mRNAs which control formation of the 
TSH subunits, particularly the beta subunit. It appears that T 3  has a direct action at 
the chromosomal level. High levels of thyroid hormones also reduce the number of 
TRH receptors on the thyrotroph and T 3  may have a minor inhibitory role on the 
hypothalamus (De Vito, 1989).
TSH concentrations show diurnal variation, peak levels being from  about 12 
midnight to 3 or 4  A.M. and the nadir occurring from about 1 1  A.M . till noon 
(Adriaanse et al, 1992). The diurnal range is about 1 mU/1. The secretion is pulastile 
with peaks every 10 minute which are on average 50% greater than the basal values 
(Greenspan et al, 1986).
TSH combines with a specific transmembrane receptor in the follicular cells. 
The receptor has an extracellular region containing 398 amino acids, seven 
transmembrane segments and an intracellular tail (Vassart et al, 1992). The beta 
subunit of TSH interacts with the extracellular region of the receptor, while the 
alpha subunit interacts with the cell membrane through the carboxyl end of the 
alpha subunit or a sugar residue attached to it.
This interaction produces several important intracellular signals (Takazawa 
et al, 1995; Corvilain et al, 1994). There is an increase in cAMP, which probably 
controls iodine uptake into the follicular cell (Chan et al, 1987). There is also an
■ ■> •'
increase in phosphatidyl inositol degradation and changes in microtubules which 
result in increased iodide transport into the follicular lumen and increased iodine 
organification (Corvilain et al, 1994) and iodination of thyroglobulin (Kondo et ai,
1989).
1.1.2.3 Formation Of Thyroid Hormones
The functional unit of the thyroid is the follicle. Follicles consist of an outer 
layer of epithelial cells surrounding the central mass of colloid. The follicular cells 
are critical for the production and secretion of thyroid hormones, although some of 
the synthetic steps occur at the interface of the apex of the cell and the colloid. 
Iodide is transported into the cell and combines with tyrosine to form iodotyrosines. 
These are coupled to form  thyroxine and triiodothyronine hormones which are 
stored in the colloid, on molecules of thyroglobulin from which they are released as 
required (Weiss et al, 1984 a; and 1984 b). The synthesis of thyroid hormones takes 
place in 4 steps.
Iodine in the serum is actively transported into the follicular cell by a 
mechanism situated at the base of the cell. This is the first and main rate-limiting 
step in biosynthesis of the thyroid hormones. There is a Na+/I" symporter, and 
probably an 1 “ channel which concentrates iodine against a chemical and electrical 
gradient (Carrasco, 1993). The concentration of iodine inside the cell is 20-40 times 
that in the extracellular fluid, and the ratio can be increased when the thyroid is 
under TSH stimulation (Marcocci, 1989). Thyroid cells must be intact to trap iodine 
and the mechanism can be saturated by excess iodine (M any et al, 1992), or 
inhibited by other anions such as thiocyanate and perchlorate. The transport requires 
oxidative metabolism and phosphorylation and is increased by high levels of TSH 
(Carrasco, 1993).
All subsequent steps in form ation and storage of thyroid hormones take 
place at the colloid interface (De Vijlder et al, 1989). Iodine which has been trapped 
is rapidly transferred to the lumen of the follicle where it combines with tyrosine in 
thyroglobulin molecules. Iodide must be oxidised to T  for this to occur. This is 
achieved by an enzyme, thyroid peroxidase, in the presence of hydrogen peroxide 
(H 2 O 2 ) (Carrasco, 1993). This peroxidase is found in microsomes and is the 
antigen against which antimicrosomal antibodies are directed (McDougall, 1992).
The H 2 O 2  necessary for this process is generated via NADH-cytochrome b5 
reductase or NADPH-cytochrome C reductase (Hall 1989). The generation of H 2 O 2  
is contro lled  through the C a^^/phospholipase-C  pathway, w hich releases 
diacylglycerol and inositol 1,4,5-trisphosphate (IP 3 ) from phosphatidylinositol 4,5- 
bisphosphate (Takazawa et al, 1995); diacylglycerol activates protein kinase-C,
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while IP3  activates Ca2+ release from the endoplasmic reticulum (Bjorkman and 
Ekholm, 1992).
The com bination  o f one iod ine atom  w ith  ty ro sin e  p roduces 
monoiodotyrosine (MIT), while binding of two produces diiodotyrosine (DIT), The 
m ost im portant action of anti-thyroid drugs such as propylth iouracil and 
methimazole are to interfere with this synthetic step, preventing the organification 
of iodine (Carrasco, 1993).
Two iodotyrosines then combine to form iodothyronine: two DIT molecules 
produce T 4  and one MIT plus one DIT produces T 3  (figure 1.1). The tertiary 
structure of thyroglobulin brings the precursor DIT molecules into apposition. 
Coupling is thought to involve formation of a diphenylether ring, and is catalysed 
by the same peroxidase enzyme which is involved in oxidation and organification of 
iodine (Marshall, 1992).
T hyroglobulin  makes up the m ajority of the colloid. It is a large 
glycoprotein of relative m olecular mass 660000, consisting of two dim ers of 
330000 (M althiéry and Lissitzky, 1987). It contains approximately 5170 amino 
acids, of which 120-130 are tyrosine, and about 10% of the total w eight are 
carbohydrate, Iodination is a post translational step which takes place at the 
interface of the cell and colloid (Chambard et ai, 1987). In the normal euthyroid 
person, when there is adequate iodine in the diet, it has been determined that each 
thyroglobulin m olecule has approxim ately 7-10 M IT, 5-10 DIT, and 2 T 4  
molecules, and there is one T3  for every 2 or 3 thyroglobulin molecules (Chambard 
et al, 1987).
Before thyroid hormones are secreted, thyroglobulin has to be taken into the 
follicular cell and hydrolysed to release the active horm ones. D roplets of 
thyroglobulin are engulfed by pseudopods from the apex of the cell. Colloid 
droplets enclosed in apical membranes are taken into the cytoplasm of the follicular 
cell, and lysosomes containing proteolytic enzymes migrate towards them and fuse 
with them producing phagolysosomes. Migration of these organelles is regulated by 
in tracellu lar m icrotubules and m icrofilam ents. Enzym atic degradation  o f 
thyroglobulin produces T 4 , T 3 , MIT, DIT and amino acids. The first two are 
secreted into the circulation, while the iodotyrosines are deiodinated by intracellular 
deiodinases and the iodine used again for iodination of new thyroglobulin  
(Marshall, 1992).
1.1.2.4 Transport O f Hormones In Serum
Almost all thyroid hormone in the circulation is reversibly bound to carrier 
proteins. The small proportion of unbound, or free hormone is metabolically active.
In serum only 0.03 % of T 4  and 0.3 % of T 3  are free, so thyroid hormones are not 
lost in the urine unless there is severe proteinuria (Marshall, 1992), The protein- 
bound hormone acts as a buffer, so that sudden changes in levels of hormones in the 
blood do not cause sudden alterations in thyroid function.
Three plasma proteins are important in transport: thyroid binding globulin 
(TBG), thyroid binding pre albumin (TBPA), and albumin.
TBG is a single chain glycoprotein produced by the liver. It has a relative 
molecular mass of 54000 and is present in the lowest concentration of the three, 
approximately 10-20 mg/1 (Tani et al, 1994). The affinity of TBG for T4  and T3  is 
the highest of the transport proteins and although present in the low est 
concentration, it carries approximately two-thirds of both hormones. There is one 
binding site for T3  and T 4  on each molecule. When TBG is fully saturated, it can 
carry 150-360 nmoles of T 4  per litre. Since the reference range for T4 is 56-150 
nmol/1, TBG is about one-third saturated. TBG has a half-life of about 5-6 days, and 
its major site of metabolism is the liver (Robbins and Edelhoch, 1986).
T hyroxine binding  pre album in is present at a concen tration  o f 
approximately 250 mg/1 and has the capacity to bind 300 pig T 4 . However, it has a 
lower affinity than TBG for T 4  and normally carries about 10-20% of the circulating 
hormone. It consists of four identical polypeptide chains which are arranged so 
there is a central channel containing two T4  binding sites. Usually only the first site 
is occupied and only one out of 300 TBPA molecules carries T4 . TBPA transports 
very little T3 . TBPA is produced in the liver, has a half-life of about 1-2 days and it 
is very sensitive to illness and malnutrition, which cause the level to fall as a direct 
result of lowered synthesis. It contains no carbohydrate (Robbins and Edelhoch, 
1986).
Albumin has the largest capacity for binding thyroid hormones. However, 
because it has the lowest affinity, it carries only 5-15% of T 4  and about 30-50% of 
T3  (Robbins and Edelhoch, 1986).
1.1.2.5 Actions Of Thyroid Hormones
Thyroid hormones in excess or deficiency have dramatic effects on whole 
animals and on organ systems. In humans, foetal brain and skeletal development are 
greatly impaired by lack o f thyroid hormones. The oxygen consumption of almost 
all tissues increases with increasing levels of thyroid hormones, the exceptions 
being the spleen, testis and adult brain (McDougall, 1992).
The actions of thyroid hormones occur mainly in the nucleus and to a lesser 
extent at the cell membrane and mitochondria. Thyroid hormones enter the cell by 
diffusion or by binding to a surface receptor and then bind to a nuclear receptor.
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The receptor has highest affinity for triac (deaminated T3 ), then T3 , T4  and reverse 
T3 , and this is consistent with the relative metabolic effects of these hormones 
(Bracco et al, 1993).
There are two genes encoding thyroid receptor proteins, one on chromosome 
3, the other on chromosome 17. There are designated c-erb-A beta and c-erb-A 
alpha respectively (Brent, 1994). Although the two receptors are slightly different 
structurally, they have the same affinities for thyroid hormones. The receptor has 
been found in all thyroid hormone responsive cells, and there is good correlation 
between the amount of receptor in a tissue and the effect of thyroid hormones on 
that tissue (Brent, 1994). Under normal conditions about 50% of the receptor sites 
are occupied by thyroid hormones; therefore, the receptor capacity is low. There is 
also good correlation between the number of receptor sites occupied by T 3  and the 
thyromimetic effects. Among the sites occupied, about 80% contain T 3  and 10-15% 
contain T 4  (McDougall, 1992).
T3  modulates gene expression, usually positively. After addition of T 3 , to 
responsive cells in vitro, it is possible to dem onstrate an increase in RNA 
polymerase 1, ribosomal RNA, RNA polymerase II and messenger RNA. This is 
followed by synthesis of new protein (Brent, 1994).
Many proteins are known to be produced in increased amounts following 
increases in thyroid hormone receptor occupancy. These include growth hormone, 
malic enzyme, acetylcoenzyme A carboxylase, fatty acid synthetase, and glucose-6 - 
phosphate dehydrogenase (Brent, 1994; W einberger et al, 1986). Som ew hat 
paradoxically, thyroid hormone decreases formation of TSH and prolactin in 
pituitary cells (Davis et al, 1986).
Thyroid hormone causes an increase in transport of glucose into cells within 
minutes. The time course is not consistent with a nuclear effect causing translation 
or transcription of proteins which would facilitate this and provides evidence for 
effects not involving the classic receptor pathway. In contrast, a similar increase in 
transport of amino acids is delayed for many hours and probably is due to a nuclear 
action of T 3 , rather than an action on plasma membranes (McDougall, 1992).
1.1.2.6 Metabolism Of Thyroid Hormones
T4  is the most abundant thyroid hormone. It is converted to the more active 
form, T 3  ^ by removal of an outer ring iodine by the enzyme 5 ’ deiodinase. There are 
two forms of this enzyme: one, type I, is found in liver, kidney and muscle cells; the 
other forms, type II, is in pituitary and brown fat cells (Brent, 1994). An alternative 
breakdown pathway is through formation of reverse T3  (rTs) by enzymatic removal 
of an inner ring iodine (Brent, 1994). This enzyme is a 5 deiodinase (figure 1.3).
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The deiodination of T 4  forms about 50% T 3  and 50% rTg. The extent of outer ring 
deiodination is reduced in severe illness, starvation, and by medications such as 
propylthiouracil, steroids, and propranolol (Beech et al, 1993). These factors inhibit 
the 5 ’ deiodinase enzyme, type I, which is also involved in deiodination of rTs; 
therefore, the concentration of T 3  is lower and that of rT 3  is higher under these 
circumstances. Normally about 80% of T4  is broken down by deiodination, and the 
rem ainder by being conjugated with glucuronide or sulphate in the liver, 
deam inated, decarboxylated, or subjected to ether cleavage. The net result is 
formation of metabolically inert compounds, although deaminated T4  (tetrac) and 
T3  (triac) do retain activity. These compounds are also subject to deiodination which 
removes all activity (McDougall, 1992).
1 .1 .2.7 Auto-Regulation Of Thyroid Function
The control mechanisms described for the synthesis of thyroid hormones, 
although exquisitely sensitive to alterations of free thyroid hormone level in blood, 
do not work instantaneously. In addition, they fail to account for potential changes 
in thyroid hormone levels brought about by rapid changes in plasma inorganic 
iodine. The amount of iodine in the diet varies considerably; and there are also 
sources of iodine such as medications and antiseptics which suddenly provide many 
orders of magnitude of iodine more than is required for normal function. The 
thyroid has several well-recognised mechanisms independent of the hypothalamic- 
pituitary axis which help preserve normality. This was termed auto regulation by 
Ingbar in 1972 (Nagataki and Ingbar, 1986).
A  rise in plasma inorganic iodine causes a reduction in the rate of uptake of 
iodine into follicular cells. High concentrations of iodide also inhibit both iodination 
of TG and hormone synthesis (Gruffat et al, 1992). This is called the W olff- 
Chaikoff effect (McDougall, 1992). It is transient and in normal subjects usually 
only lasts for several days. Break-through from this protective m echanism  in 
patients is almost always due to the reduction in the rate of iodine transport. 
Therefore, there is no longer an excess of intracellular iodine and the thyroid cells 
can return to the normal rate of hormone production (McDougall, 1992).
W hen there is a deficiency of iodine, the transport rate of iodine into 
follicular cells increases. In man the resultant changes are not easy to separate from 
those caused by increased TSH and, indeed, iodine deficiency probably augments 
the TSH effects. There is an increase in formation of MIT and T3 ; therefore, the 
m ore active hormone w hich contains less iodine is produced preferentially 
(McDougall, 1992).
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Figure 1.3: Metabolism of thyroid hormones through deiodination of hormones.
1.1.3 Peptides In The Thyroid Gland
Nearly 70% of the cells o f the thyroid gland consist of thyrocytes. The 
rem ain ing  cells include endo thelia l cells, fib rob lasts, sym pathetic and 
parasym pathetic nerve cells, and parafollicular cells which produce calcitonin 
(Dumont et al, 1992).
D evelopm ent of goitre, with an increase in the number of thyrocytes and 
other cells in the thyroid, is not simply the effect of stimulation of the thyrocytes 
with TSH, or with TSAb in Graves' disease, but involves many other factors, 
including cell to cell signalling among the various populations of cells in the gland 
and environmental factors (Dumont et al, 1991; and 1992). It is known that growth 
factors such as EOF and FGF are present in the thyroid, and it is likely that growth 
of the gland is controlled by interactions between the various cell types, co­
ordinated by growth factors and other peptides.
A nother of the consequences o f disease is the generation o f new blood 
vessels and infiltration of a variety of mononuclear cells from peripheral blood 
which form aggregates or are diffusely distributed between and within the thyroid 
follicles (Nagataki and Eguchi, 1992). These cells are retained in the gland, by 
interaction with adhesion molecules, on other cells including thyroid epithelial cells. 
This interaction is influenced by the presence of cytokines released locally. The 
interaction of cytokines and growth factors with thyrocytes could also influence 
their functional pattern.
In addition, the thyroid gland is richly innervated by nerves of different 
types (adrenergic, cholinergic, and peptidergic) which terminate close to blood 
vessels and follicular cells (Ahrén, 1986 a; and 1991). It is likely, therefore, that 
neurotransm itters released locally may directly influence the activity o f the 
follicular cells (Ahrén, 1986 a; and 1991).
Peptides which have been shown to be present in the thyroid gland or are 
known to affect its function include endothelin, substance P and other tachykinin 
peptides, VIP, neuropeptide Y,‘ and pituitary adenyl cyclase activating peptide 
(PACAP). Substance P, vasoactive intestinal peptide (VIP), and neuropeptide Y 
(NPY) are found in nerves innervating the thyroid, while endothelin has been 
detected in thyroid epithelial cells. In addition, it is known that several cytokines 
associated with the immune response are present in thyroids from patients with 
autoimmune thyroid disease. These include interleukin-1 (IL-1), IL-6 , and tumour 
necrosis factor a  (TN F-a). It is likely that these affect both the growth pattern of 
the gland and the secretion of thyroid hormones, though only limited studies have 
been carried out, particularly on the possible effects of the neuropeptides.
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SECTION: TWO 
IMMUNITY
Nomnal immune responses are controlled by the reactivity of T lymphocytes 
to antigens. Since the pattern of responsiveness of these cells is determined by 
random combinations of T cell receptor genes, there is always a chance that some T 
cells will react with the body's own proteins. It is therefore necessary to develop 
tolerance to "self" antigens to allow normal growth, development, and maintenance 
of existence. When the integrity of self-tolerance is disturbed, an immune response 
to self may develop. This is term ed autoimm unity. W hile the presence of 
autoantibodies is a common finding, frank autoimmune disease only develops in a 
few individuals.
Thyroid autoimmune diseases, the subject of this thesis, are organ specific 
auto-immune diseases in which there is production of antibodies against different 
components of thyroid follicular cells including thyroglobulin, microsomes and the 
TSH receptor (Benjam ini and Leskow itz, 1992). Since some know ledge of 
immunological theory is required to discuss thyroid autoimmunity, a brief review of 
immunology and autoimmunity will be presented here.
1.2.1 Normal Immune Response
1.2.1.1 Macrophages
Although many cells such as lymphoid dendritic cells, B lymphocytes, and
1 1
The sequence of events in a normal immune response culminating in the 
production of antibody can be outlined as: uptake of antigen by antigen presenting 
cells; its processing and presentation to helper T lymphocytes (a subset of the T 
lymphocytes which mature in the thymus); stimulation of these T lymphocytes to 
multiply; and synthesis o f antibody by B lymphocytes (which develop in the bone 
marrow) under the influence of these helper cells (Benjamini and Leskowitz, 1992). 
Communication between these cells is carried out both by direct cell-cell interaction 
and by soluble peptide mediators called cytokines. This is a general term for a wide 
variety of growth factors and other active peptides produced by many different cell 
types, but the ones active in the immune response are primarily of the interleukin 
(IL) series. The actions of cytokines which are relevant to the regulation of the 
immune response will be discussed in this section, while their direct action on 
thyroid cells will be discussed in chapter 3.
endothelial cells (W eetm an, 1991) are able to present antigen to T cells, 
macrophages are still regarded as the classical antigen presenting cells.
A soluble foreign antigen may be taken up by phagocytosis or pinocytosis, 
but for the induction of a productive immune response, the antigen must enter the 
antigen presenting cell (APC) via a receptor such as those specific for mannose, 
complement, and the Fc fragment of immunoglobulin. This allows foreign antigens
■to be taken up in preference to potentially competing self antigens (Lorenz et al,
1990).
T lym phocytes only recognise peptide fragm ents of antigens. These
detemiinants, or epitopes, are around 1 0 - 2 0  amino acids in size, contrasting with the 
epitopes recognised by B cells which usually comprise conformational determinants 
depending on the tertiary structure o f the intact antigen. The APC must produce 
these peptide fragm ents by processing. The exact m echanism s involved in 
processing have not yet been identified, but lysosom es may be particularly 
important for phagocytosed antigens, whereas endosomes may contain proteases 
capable of degrading antigen taken up by receptor-mediated endocytosis (Weetman, 
1991). Fusion of endocytic vesicles with others capable of producing degradation is 
a further possibility (Lanzavecchia, 1990).
Antigenic peptides must be associated with molecules encoded by the major 
histocompatibility complex (MHO) before their recognition by the T cells. MHC 
molecules can be divided into two kinds: class I, encoded by the human leukocyte 
antigen (HLA) A, B, and C regions, and the MHC class II, encoded by the HLA- 
DR, DQ and DP regions (Benjam ini and Leskowitz, 1992). This dichotomy in 
antigen presenting molecules is reflected by the existence of two subsets of T cells 
identifiable by their surface markers: CDS cells, which recognise class I MHC, and 
CD4, which recognises class II. A fter uptake and processing, soluble antigens are 
bound to and presented exclusively by class II MHC molecules which are also 
called la  molecules (Weetman, 1991).
One of the key determinants for stimulation of CD4+ T cells is the amount 
of la  expressed by an APC. A number of factors influence la  expression by APC. 
Interferon-y (INF-y) derived from stimulated T cells is a key cytokine responsible 
for such effects (Steeg et al, 1982), though several other modulators of macrophage 
la expression have been identified. In particular, prostaglandins and hydrocortisone 
(Unanue, 1984) and IL-10 (Quesniaux, 1992) down-regulate la  expression.
1.2.1.2 T Lymphocytes
T lym phocytes m ature in the thym us and then m igrate to secondary 
lymphoid tissues such as lymph nodes. They recognise processed antigenic peptide
1 2
More than 90% of mature T cells in humans express a clone-specific T cell
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combined with an la molecule by means of a T cell receptor specific for both 
antigen and la. During their residence in the thymus, cells are selected positively for 
the ability to recognise peptides only in the presence of la  and those which 
recognise self antigens are removed by negative screening.
I
receptor comprising an a  and P glycoprotein chain in association with either CD4
.or CDS, while the remaining T cells express a receptor comprising y and ô chains 
(Weetman, 1991; Benjamini and Leskowitz, 1992; Janeway and Travers, 1994). 
The receptor is only triggered by peptide bound to a particular MHC molecule; 
class II molecules in the case of CD4+ T cells, or class I in the case of CDS. Both 
a(3 and yô forms of receptor are non-covalently linked to a complex of peptides 
with extracellular and intracellular domains termed CD3, which is responsible for 
signal transduction after receptor-ligand binding. (Weetman, 1991; Benjamini and 
Leskowitz, 1992; Janeway and Travers, 1994).
The m ajor activities o f T cells can be divided into helper functions, 
cytotoxicity and suppression.
Helper cells (TH) are required for the activation and differentiation of B 
cells and cytotoxic and suppressor T cells. There are two CD4+ subsets described in 
mice which produce discrete sets of cytokines. TH2 cells (stimulators of antibody 
production) produce IL-3, IL-4, IL-5 and IL-6 , whereas T H l cells (stimulators of 
the delayed type hypersensitivity response) produce IL-2, IL-3, interferon y (INF-y), 
lymphotoxin and TNF (Janeway and Travers, 1994). There is regulatory feedback 
between the two classes o f cells, w ith IL-4, IL-10, and IL-13 from  TH2 cells 
inhibiting the development of T H l cells. T H l cells are strongly promoted by IL-12, 
produced by APCs (Janeway and Travers, 1994).
It is not yet clear whether a similar dichotomy exists in man. Some clones 
with a similar pattern of cytokine release to the murine T H l and TH2 classes have 
been isolated, but many human and murine CD4+ T cell clones appear capable of 
producing a mixed pattern of cytokine release, so-called T H q (Janeway and Travers, 
1994). One possible explanation for this anomaly is that CD4+ T cells begin with 
one phenotype and function and that some of these mature to become one of several 
potential CD4+ subsets; the density of ligand binding to the T ceil receptor and the 
cytokine and hormonal environment could modulate this development (Weetman, 
1991).
As already mentioned, cytotoxic CD 8 + T cells recognise antigen presented 
by class I MHC molecules. The prime role of CDS"** T cells seems to be reactivity 
against intracellular antigens such as viruses. The viral antigens are partially 
degraded to peptides by a proteasome, a multisubunit protease complex which is 
situated near the endoplasmic reticulum (Janeway and Travers, 1994). The peptides
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derived from the foreign protein selectively pass through a complex of transport 
systems known as "transporters associated with antigen processing" (TAP-1 and 
TAP-2) to the lumen of the endoplasm ic reticulum , w here MHC class I is 
synthesised. Once expressed on the cell surface, this antigen/MHC class I complex 
is recognised by a specific CD 8 + T cell and the infected cell then is killed 
(Benjamini and Leskowitz, 1992; Janeway and Travers, 1994).
The phenomenon of T cell-mediated suppression is controversial, because 
the specificity and mechanism of action of suppressor T cells is unknown (Janeway 
and Travers, 1994). Experimentally it has been shown that the activity of CD4+ or 
CD8 + lymphocytes can be suppressed by a population of T cells. These cells are 
necessary for tolerance to self proteins and preventing tissue damage (Janeway and 
Travers, 1994), because depletion of suppressor T cells lead to aggravated responses 
to self antigen and grafts. A distinct suppressor cell growth factor derived from 
monocytes, possibly IL-10 or transforming growth factor p (TGF-(3), appears to be 
necessary for differentiation of human CD8 + suppressor cells (Webb et al, 1994), 
following their initial stimulation by CD4+ inducer cells and IL-2.
Antigen-specific CD 8 + suppressor cell clones have been established from 
patients with leprosy, capable of inhibiting CD4+ T cell proliferation induced by 
Mycobacterium leprae. These clones appear to use the normal a p  T cell receptor. 
Furthermore, the suppressor cells appear to recognise specific antigen in a MHC- 
restricted fashion, but their effect is not necessarily specific or MHC-restricted; they 
appear to induce inactivation or anergy in the CD4+ population by an unknown 
mechanism (W eetman, 1991). Other explanations for T suppressor cell effects 
include: (i) release of antigen-specific suppressor factors, (ii) cytotoxicity to helper 
cells and (iii) reactivity of the suppressor cells against the variable region (idiotype) 
of the T cell receptor on the target clone, thus behaving as anti-idiotypic cells. It is 
also apparent that either CD4+ or CDS"*' T cells may become suppressor cells, and 
that there is considerable leeway for changing function during development of an 
individual cell, depending on ambient conditions (Weetman, 1991).
1.2.1.3 B Lymphocytes
Each B lym phocyte expresses a surface im m unoglobulin or antibody, 
capable of unique binding to an antigen and generated by a variety of mechanisms 
to induce diversity. The regulation of B cell development, from a resting state to a 
plasma cell secreting immunoglobulin, generally depends upon antigen recognition 
(via surface im munoglobulin) follow ed by proliferation and differentiation in 
response to cytokines (W eetman, 1991). Activated human B cells proliferate in
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response to IL-4 and this is enhanced by INF-y; many other cytokines costimulate 
this, including IL-1, IL-2, IL-6 , TNF, and lymphotoxin. Differentiation seems 
primarily dependent on IL - 6  but this too is costimulated by IL-1, IL-2 and INF-y 
(Janew ay and Travers, 1994). Transform ing growth factor-(J inh ib its both
proliferation and differentiation (Weetman, 1991).
As mentioned earlier, B cells can act as APCs. They have been shown to
capture antigen by binding it to their specific im m unoglobulin receptors, to 
internalise and degrade the immunoglobulin-anti gen complexes, and then to re ­
express fragments of the antigen, on their surfaces in association with MHC class II 
molecules. Additionally, B cells express IL-1 and the membrane protein B7 to serve 
as second signals (Benjamini and Leskowitz, 1992).
1.2.1.4 Cytokines
The cytokines studied in the current work are IL-1, IL-2, IL-4, IL-6 , TN F-a, 
INF-y, andTG F-p.
1.2.1.4.1 Interleukin-1
Interleukin-1 is synthesised primarily by macrophages, although it is now 
recognised that most cells can make this molecule (Di Giovine and Duff, 1990). 
There are at least two species of interleukin-1, IL-1 a  and IL-1 p, with only limited 
sequence homology. They are non-glycosylated peptides with a relative molecular 
mass of 17500.
IL-1 is central to the activation of resting T cells, while those T cells already 
activated are dependent on other cytokines like IL-2, IL-4, INF-y (Janeway and 
Travers, 1994), and IL-12 (T rinchieri, 1993) for optimal differentiation and 
proliferation. Other T cell activities, such as cytokine release, may have less 
requirement for IL-1 (Di Giovine and Duff, 1990).
M acrophage IL-1 synthesis is stim ulated by phagocytosis of m icro­
organisms. Uptake of soluble protein antigens has no direct effect, but their 
presentation to the T cell leads to release of T cell cytokines such as tum our 
necrosis factor (TNF), w hich indirectly stimulate production of IL-1. There is 
evidence that T cell-APC contact is also stimulatory (Weaver et al, 1989).
Another member of the IL-1 family, known as the IL-1 receptor antagonist 
(IL -lra ), inhibits the action of IL-1 on its target cells (Svenson et al, 1993; 
Mandrup-Poulsen et al, 1993; Blakemore et al, 1995). IL-10 (Moore et al, 1993; 
Bogdan and Nathan, 1993), TGF-p (Bogdan and Nathan 1993; Ruscetti et al, 1993) 
and IL-4 (Bogdan and N athan, 1993), inhibit the production of IL-1 by
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macrophages.
1.2.1.4.2 lnîerleukin-2
1.2.1.4.3 lnterleukin-4
Interleukin-4 was previously known as B cell growth factor-1 (BCGF-1 or
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Interleukin-2 (IL-2) is a glycoprotein of relative m olecular mass 15500 
synthesised and secreted prim arily by activated T helper (CD4+) lymphocytes 
(Benjamini and Leskowitz, 1992). A t this level, IL-2 is an autocrine factor, driving 
the expansion of the antigen specific cells (Minami et al, 1993). The synthesis of 
IL-2 is enhanced by IL-1 produced by activated APC, while IN F -a  maintains an 
enhanced level of IL-2 niRNA in the activated cells (Holan et al, 1994).
IL-2 also acts as a paracrine factor. It enhances the proliferation and 
differentiation of both B cells (Rubin and Nelson, 1990) and cytotoxic T cells
'(Benjam ini and Leskow itz, 1992). IL - 2  also enhanced the production  of 
prostag landin  E2 by hum an m onocytes or m acrophages activated  w ith  
lipopolysaccharide (Valitutti et al, 1989).
Defects in IL-2 production have been reported in patients with systemic 
lupus erythematous (Horwitz et al, 1994), rheumatoid arthritis (M iyasaka et al,
1984), insulin-dependent diabetes mellitus (Zier et al, 1984), and Graves’ disease 
(Akasu et al, 1991; Eisenstein et al, 1988). The reason for this is unknown, but there 
are reports suggesting that excessive prostaglandin E2 production by activated APC
Ï
could be one of the causes (Eisenstein et al, 1994; Hilkens et al, 1995). The 
production of IL-2 was restored to normal after therapy.
The receptors for IL-2 were originally referred to as high, intermediate, and 
low affinity receptors. Now it is recognised that the high affinity receptor contains 
three distinct subunits, IL-2R(x, IL-2RP, and IL-2Ry, while the inteimediate affinity 
receptor contains two subunits, IL-2Rp and IL-2Ry. The |3 chain also binds IL-15 
(Grabstein et al, 1994), while the y chain is a common subunit for IL-4, IL-7, and 
IL-15 (Leonard et al, 1994; Voss et al, 1994).
It is known (Murakami et al, 1995; Murphy et al, 1994; Mariotti et al, 1992 
a, and 1994; Balâzs and Farid, 1991) that the concentration of a soluble form of the 
interleukin - 2  receptor is elevated in thyrotoxicosis and in many other diseases 
which are thought to have an immunological component. The soluble form of the 
receptor which has been described is an a  chain. This is a membrane glycoprotein 
of relative molecular mass 55000, capable of weak binding of IL-2 (Robb and 
Greene, 1983, Minami et al, 1993),
BSF-1) or B cell differentiation factor (BCDF) by virtue of its ability to costimulate 
B lymphocyte proliferation (Idzerda et al, 1990). It is prim arily produced by 
activated type 2 helper T cells and has diverse functions on a variety of cell types. 
The primary functions of IL-4 on B cells are activation, growth, induction of MHC 
class II, and production of immunoglobulins (Weetman, 1991; Benjamini and 
Leskowitz, 1992; Janeway and Travers, 1994). In the mouse, IL-4 preferentially 
induces class switching to IgG l and IgE, while it inhibits IgM, IgG3, and IgG2a 
production (Weetman 1991; Jane way and Travers, 1994). Its functions on T cells 
include induction of growth, promotion of survival, down-regulation of cytokine 
production by cytotoxic T cells (Janeway and Travers. 1994) and suppression of 
production of IL-2 and the p chain of IL-2R (Llorente et al, 1989; Linqvist et al,
1991). IL-4 also regulates the proliferation and differentiation of CD 8  cytotoxic 
cells synergistically with IL-2 (Hargrove et al, 1993).
IL-4 inhibits macrophage activation by down-regulation of IL-1 production 
(Bogdan and Nathan, 1993) or down-regulation of c-fos and c-jun mRNA (Dokter 
et al, 1993), but it induces monocyte-macrophage differentiation and expression of 
MHC class II (Te Velde et al, 1988).
1.2.1.4.4 Interleukin-6
IL - 6  is a multi-functional cytokine that is produced by a range of cells, 
including monocytes or m acrophages, T lymphocytes, and activated B cells 
(Janeway and Travers, 1994). Sources of non-hematopoietic origin include rat 
testicular cells (Syed et al, 1993), fibroblasts, endothelial cells (Bartalena et al, 1994 
a), and thyrocytes in autoimmune thyroid disease (Watson et al, 1994; Zheng et al,
1991) or stimulated in vitro (Kennedy et al, 1992; Iwamoto et al, 1991). It is also 
produced by many carcinoma cells such as carcinoma of kidney, colon, breast, and 
pancreas, and malignant melanomas (Gastl et al, 1993).
IL - 6  binds to a high affinity receptor complex consisting of two membrane 
glycoproteins (Baumann et al, 1990; Hibi et al, 1990). This consists of an IL - 6  
binding subunit (IL-6 R or CD 126) and a signal-inducing protein, known as gp l30  
or CDw 130, that is common for several cytokines, including IL - 6  and IL-11 (Yin et 
al, 1993). The IL - 6  receptor has been detected on monocytes, granulocytes, resting
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and activated CD4+ T cells, natural killer cells, and activated, but not resting, B 
lymphocytes (Wognum et al, 1993).
The effect of IL - 6  on B cells is to stimulate differentiation and antibody 
secretion (Weetman, 1991; Janeway and Travers, 1994). IL - 6  exhibits growth factor 
activity for mature thymic or peripheral T cells and enhances the differentiation of 
cytotoxic T cells in the presence of IL-2 or INF-y (Janeway and Travers, 1994). IL-
Ï
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6  stimulates production of acute phase proteins by hepatocytes, and the activity of 
hematopoietic stem cells (Weetman, 1991). It stimulates the growth of sarcomas, 
carcinomas, EBV-transformed B cells, kératinocytes, and mesangial cells (Hirano, 
1990; and 1992).
lL - 6  and IL-1 help to co-ordinate the body's responses to infection. IL - 6  
activates hepatocytes to synthesise acute phase proteins such as C-reactive protein 
(CRP), a process in which IL-1 co-operates by inducing IL - 6  production by Kupffer 
cells (liver macrophages). CRP acts as an opsonin, and this activity is augmented by 
enhanced recruitment of neutrophils from the bone marrow (Janeway and Travers, 
1994). Other acute phase proteins protect the body against proteases (e.g. alpha - 1 
antitrypsin) or bind toxic products released from cells (e.g. haptoglobin). A major 
effect of IL - 1  and IL - 6  is to act on the hypothalamus, altering the body's 
temperature regulation, and on muscle and fat cells, altering energy mobilisation to 
increase the body temperature, which may decrease bacterial and viral replication 
(Janeway and Travers, 1994).
1.2.1.4.5 Tumour Necrosis Factor
Tum our necrosis factor alpha (T N F-a) is predominantly produced by 
activated macrophages (Tracey and Cerami, 1994; Beyaert and Fiers, 1994), though 
several other cell types including activated T-cells (CD4+ and CD8 +), B-cells, NK 
cells, neutrophils, endothelial cells, and smooth muscle cells (Vilcek and Lee, 1991) 
can produce small amounts of this cytokine. The TNF fam ily includes two 
structurally and functionally related proteins, TN F-a or cachectin, and TNF-P or 
lymphotoxin (Tracey and Cerami, 1994; Beyaert and Fiers, 1994; Vilcek and Lee,
1991).
Under denaturing conditions, the relative molecular masses of human TN F- 
a  and TNF-(J were approximately 170CX) and 25090 respectively, while in native 
form both TN F-a and TNF-p are in trimers (Vilcek and Lee, 1991),
There are two distinct TNF receptors with relative molecular mass of 55000 
and 75000 (Gruss and Dower, 1995; Smith et al, 1994; Tartaglia et al, 1993; 
Tartaglia and Goeddel, 1992; Chouaib et al, 1991), known as TNF-Rl and TNF-R2 
respectively.
Both types of TN F receptors are present on the plasma membranes of 
virtually all nucleated cells (Tracey and Cerami, 1994; Tartaglia and Goeddel, 1992; 
Vilcek and Lee, 1991). In addition, cleaved fragments of both receptor types, also 
known as TNF-binding proteins, have been detected in the urine and serum of 
patients with a variety of diseases, including cancer, AIDS, and sepsis (Tracey and 
Cerami, 1994). They may inhibit the activity of TNF by preventing receptor-ligand
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interaction, or may delay clearance from serum (Tracey and Cerami, 1994).
Acute exposure to recombinantly derived human TNF caused a syndrome of 
shock and tissue injury which are virtually indistinguishable from septic shock 
syndrome (Tracey and Cerami, 1994; Tartaglia et al, 1993; Tartaglia and Goeddel,
1992), including tissue injury, capillary leakage syndrome, hypoxia, pulmonary 
edema, and multiple organ failure associated with a high mortality rate (Tracey and 
Cerami, 1994). On the other hand, the net effect of prolonged exposure to T N F -a  
by any route is the development of cachexia characterised by anorexia, weight loss, 
dehydration, and depletion of whole body protein and lipid (Tracey and Cerami, 
1994). In both cases, some of the effects are directly attributable to the cytokine 
itself, whereas others are the result of secondary factors triggered by TNF.
The production of TN F-a is increased by LPS (Haziot et al, 1994), and also 
by other stimuli like viruses and mitogens. Dayer and Burger (1994) considered that 
the direct contact of monocytes with activated lymphocytes was the most efficient 
stimuli for T N F-a production. This was caused by interaction with glycoproteins 
expressed on the surface of activated lymphocytes, particularly CD 1 1  and CD69. 
Prostaglandins and their precursors, such as dihom o-gam m a linolenic acid, 
arachidonic acid, and eicosapentaenoic acid, were shown to inhibit T-cell 
proliferation while increasing their ability to secrete T N F -a (Kumar and Das, 
1994).
The most active inhibitors of T N F -a  production by activated macrophages 
are IL-4 (Ranheim and Kipps, 1995), IL-13 (D'Andera et al, 1995), and ÏL-10 
(Ranheim  and Kipps, 1995; M archent et al, 1994). Granulocyte-m acrophage 
colony-stimulating factor (Rhoades et al, 1995), nitric oxide (Eigler et al, 1995), and 
noradrenaline (Van-Der-Poll et al, 1994) may also have some inhibitory effects.
1.2.1.4.6 Interferon- y
Interferons are produced by leukocytes and fibroblasts in response to viral 
infection. The family includes tliree members: IN F-a, INF-j3, and INF^y. INF-y has 
major effects on the immune system.
INF-y is produced by activated CD4+ T H l or CD 8 + cytotoxic cells 
(Nagataki and Eguchi, 1992). Its receptor, CD 119, is expressed by many cells 
including m acrophages, m onocytes, B cells (Janeway and Travers, 1994), 
endothelial cells, connective tissue cells (Evans and Whicher, 1993), and thyrocytes 
(Mariotti et al, 1992 b).
Interferons trigger the synthesis of several host-cell proteins that contribute 
to the inhibition of viral replication. One of these is the enzyme oligo-adenylate 
synthetase, which polymerises ATP into a series of 2'-5'-linked oligomers that
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activate an endoribonuclease that then degrades viral RNA. A nother protein 
activated by interferon a  and p is a serine/threonine kinase called PI kinase. This 
enzyme phosphorylates the eukaryotic protein synthesis factor (eIF2), thereby 
inhibiting translation of viral proteins. Interferons also increase expression of the 
MHC class I and TAP transporter proteins, enhancing the ability of virus-infected 
cells to present viral peptides to CDS T cells. They also activate NK cells (Janeway 
and T rav ers, 1994).
In addition to the above-m entioned functions of interferons, INF-y can 
induce the production of both classes of MHC on APCs (Mariotti et al, 1992 b; 
Janeway and Travers, 1994), and thyrocytes (Toda et al, 1992; Chiovato et al, 1994; 
Eguchi et al, 1995). MHC class 2 is not present on the surface of normal thyrocytes 
(Chiovato et al, 1994, Otsubo et al, 1988). It is also reported that INF-y acts as a 
macrophage activating factor and synergises with tumor necrosis factor to effect 
tumor cell lysis and inhibit cell proliferation (Evans and Whicher, 1993). INF-y also 
acts on proliferating CD4 T cells (THO) cells and causes them to differentiate into 
inflammatory (T H l) CD4+ T cells (Janeway and Travers, 1994).
1.2.1.4.7 Transforming Growth Factor Beta
Transforming growth factor-p (TGF-p) is a homodimeric protein of relative 
molecular mass 25000. The TG F-p family is a group of structurally and functionally 
related peptides that include at least five members, which are known as T G F -p i to 
5. Three are present in mammals. While specific receptors for these proteins have 
been found on almost all mammalian cells examined, the effect of the molecule 
varies depending on the cell type and growth conditions. Generally, TG F-p is 
stimulatory for cells of mesenchymal origin and inhibitory for cells of epithelial or 
neuroectodermal origin (Cirafici et al, 1992). TGF-p is released in a latent form, 
which must be activated proteolytically by enzymes such as plasmin before it can 
bind to its receptor.
TGF-P has been^shown to regulate the immune response. When produced by 
CD4+ helper (TH2) T cells, it inhibited growth of inflammatory CD4 T cells (TH l).
1.2.2 Autoiinmunity
Lymphocytes are prevented from reacting with normal tissues by several 
mechanisms. Those T cells which are capable of reacting with self antigens are 
deleted in the thymus by a process of negative selection. However, this mechanism 
is not complete, and self-reactive T lymphocytes may survive. To prevent damage, 
other mechanisms are active in peripheral tissues.
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The phenomenon of anergy occurs when a T cell encounters antigen without 
a second activating signal such as the presence of specific adhesion molecules 
(especially B7) and cytokines. The cell becomes incapable of responding to the 
antigen. This mechanism for T cell tolerance seems well suited for preventing T cell 
reactivity against peripheral tissues, which will express class I and II MHC antigens 
in response to inflammatory or cytotoxic cytokines and thus prevent the fortuitous 
activation of any non-deleted auto-reactive T cells in the vicinity (Weetman, 1991; 
Jane way and Travers, 1994).
Another mechanism to control thymically untolerised, self-reactive T cells 
could be the presence of active suppression. The action of T suppressor cells is 
essentially similar to that of peripheral tolerance, namely blocking a necessary 
second signal to helper cells (W eetman, 1991) by production of soluble factors, 
either antigen specific suppressor factors (TSFs) or non-specific inhibitors such as 
TGF-p.
The development and maturation of B cells take place in bone marrow. 
There are two mechanisms ensuring the tolerance to self antigens encountered by 
immature B cells: deletion and anergy. Immature B cells expressing only IgM are 
eliminated or inactivated if  they bind to abundant m ultivalent ligands in their 
environm ent, such as M HC antigens. These B cells are believed to undergo 
programmed cell death or apoptosis. The second mechanism takes place when 
immature B cells bind soluble self antigens. The cells are rendered unresponsive or 
anergic to the antigen. Only immature B cells that do not encounter antigen in the 
bone marrow at this stage of development can mature, express surface IgD and IgM 
and migrate from bone marrow to the peripheral lymphoid tissue (Janeway and 
Travers, 1994).
Autoimmune disease occurs when a specific adaptive immune response is 
mounted against self, or, in other words, the immune response has failed and 
reacted with self antigen. It is not known what triggers the autoimmune response, 
but many factors could be responsible:
1) Autoreactive cells fail to be deleted or rendered anergic.
2) Neonatally untolerised T cells fail to be kept in check by peripheral 
tolerance and suppression mechanisms in adult life.
3) C ross-reaction w ith foreign antigens induces a response against a 
normally 'silent' self antigen (e.g. drug-induced haemolytic anaemia or myocarditis 
after streptococcal infection in rheumatic fever).
There is evidence for all these possible mechanisms. It is now apparent that 
intrathym ic self tolerance for T cells is generally incomplete. Indeed neonatal 
thymectomy in mice results in organ-specific autoimmune disease by enhancing this 
imperfect clonal deletion.
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W hichever mechanism proves to be the most important, the production of 
cytokines by the activated lym phocytes is likely to be a crucial com m on 
mechanism. Their release could expand the population of non-tolerised, se lf­
reactive B cells and CDS'*" cytolytic T cells, and they may directly cause tissue 
damage.
SECTION: THREE 
AUTOIMMUNE THYROID DISEASE
Thyroid autoimmunity occurs mostly in middle aged females. It leads to 
several different disorders, comprising the commonest autoimmune diseases in the 
community. The three main disorders, autoimmune thyroidism (Hashimoto's 
thyroiditis and primary myxoedema). Graves’ disease, and postpartum thyroiditis 
share reactivity against the same thyroid components, albeit to varying extents 
(Weetman, 1991). Lymphocytes in the gland are thought to be the major site of 
production  o f an tithy rog lobu lin , antim icrosom al, and anti-TSH  recep to r 
autoantibodies in patients with these diseases (LiVolsi, 1994). No good animal 
models of thyrotoxic Graves’ disease have been developed, but several models of 
autoimmune thyroid disease are known, and these have provided invaluable insights 
into the aetiology and pathogenesis of different classes of thyroid autoimmunity. 
Generally, susceptibility to thyroid autoimmunity is polygenic, and there is a variety 
of possible endogenous and exogenous factors which modulate the effects of the 
genetic component (W eetman, 1991). The major diseases and the possible factors 
that could influence the development of thyroid autoimmunity are reviewed below.
1.3.1 Thyroid Pathology
1.3.1.1 Hashimoto's Thyroiditis
In Hashimoto's disease, there is chronic lym phocytic thyroiditis. The 
follicles are small and atrophic, and there is a marked lym phocytic infiltrate 
(LiVolsi, 1994). There may be fibrosis, and patients are usually hypothyroid.
Autoimmune hypothyroidism is common. In an extensive survey of a village 
in North-East England, the prevalence was at least 1% in women but less than 0.1% 
in men (Tunbrige et al, 1977). Thyroid auto-reactivity, that is, the presence of 
thyroid autoantibodies without thyroid dysfunction, was even more common, being 
found in 10.3 % of women and 2.7% of men, increasing with age in women only
I
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(Tunbrige et al, 1977). This frequency is related to the prevalence of focal 
thyroiditis, found at routine autopsy in 6 % of men and 2 2 % of women; there is a 
close association between the presence of such lym phocytic infiltration and 
circulating thyroid antibodies (Yoshida et al, 1978). Thus there is a high prevalence 
of thyroid auto-reactivity in the community which progresses to overt disease in 
around 5-10% of cases. The emergence of gland dysfunction is a slow process. For 
instance, overt hypothyroidism developed at a rate of 5% per year in subjects who 
had thyroid antibodies and an elevated TSH, but normal T 3  and T 4  at presentation, 
while the presence of thyroid autoantibodies alone had no impact over a four year 
period (Weetman, 1991).
Anti-microsomal (thyroid peroxidase, TPO) antibodies are found in about 
90% of patients w ith H ashim oto 's thyroiditis or prim ary m yxoedem a by 
haemagglutination assay (Kaufman et al, 1990). It is also possible that patients 
negative for circulating TPO antibodies could have sufficient intrathyroidal 
synthesis to mediate pathogenic effects (Baker et al, 1988).
TPO antibodies are important in tissue injury: they bind to thyrocytes in vivo 
and are cytotoxic in the presence of complement in vitro. However, in common 
with many nucleated cells, thyrocytes are relatively resistant to hom ologous 
complement. Sub-lethal membrane attack complex formation impairs thyroid cell 
function in vitro: sustained attack may well exhaust the cell metabolically and lead 
to lysis (Weetman et al, 1990). There is considerable evidence for immune complex 
form ation in Hashimoto's thyroiditis. Elevated levels of term inal com plement 
complexes are present in the circulation and these are also localised around the 
thyroid follicles (W eetman et al, 1989). In addition to this strong evidence for 
com plem ent-m ediated injury, a proportion o f TPO antibodies can inhibit the 
function of this key enzyme, which could also lead to thyroid dysfunction (Doble et 
al, 1988).
Thyroid  receptor blocking antibodies may contribute separately  to 
hypothyroidism in some patents. It was clear at an early stage that TSH receptor- 
binding antibodies occurred in  up to 14% of patients w ith autoim m une 
hypothyroidism (Mukhtar et al, 1975). Subsequent studies have found that blocking 
antibodies are present in both Hashimoto's thyroiditis and primary myxoedema 
(Kraiem et al, 1987).
1.3.1.2 Graves' Disease
Graves’ disease is caused by thyroid stimulating antibodies (TSAb) which 
bind to the TSH receptor and activate adenylate cyclase, resulting in thyrotoxicosis. 
There is a diffuse goitre, w ith some lym phocytic infiltrate and hyperplastic
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epithelium.
There are many features that are shared with autoimmune hypothyroidism, 
including the presence of thyroglobulin and TPO antibodies and lym phatic 
infiltration of the thyroid. Hyperthyroidism is common, affecting 1.9% of women 
and 0,16% of men surveyed in the North-East o f England (Weetman, 1991). The 
majority of these patients have Graves’ disease but exact diagnostic criteria have 
been variable. Others have single or multiple thyroid nodules. W hilst it is assumed 
that all patients with Graves' disease have TSAb, the detection of these antibodies 
depends on assay sensitivity. In 850 European patients with hyperthyroidism, the 
condition was defined by the presence of TSH receptor-binding antibodies and/or 
Graves' ophthalmopathy. Of these patients, 59.5% had Graves' disease while 31,3% 
remained unclassified (Reinwein et al, 1986). In UK the peak age for developing 
Graves' disease is between 40 and 60, and females dominate males in the ratio of 4 - 
8  to 1 (McDougall, 1992).
Treatment of Graves' patients in UK is initially with anti-thyroid drugs, such 
as carbimazole or propylthiouracil, for 6-18 months. Propranolol is used for some 
patients to control acute symptoms. If patients become hypothyroid as a result of 
drug treatment, they are given thyroxine replacement therapy. Patients who relapse 
on drug treatment may be offered treatment with radioactive iodine to ablate the 
gland or, if they are unsuitable for this, may be treated surgically.
1.3.2 Mechanisms Of Thyroid Autoiinmunity
1.3.2.1 Genetic Factors
Observations in experimental animals revealed that certain strains of mice 
were good responders and others poor responders to lesions developing after 
thyroglobulin immunisation. Hashimoto's disease was detected in half the siblings 
of good responders (Weetman, 1991). In humans, there is also evidence for genetic 
factors. Susceptibility to Graves' disease was 60% in monozygotic twins if one twin 
had the disease, in contrast to 3-9% in dizygotic twins (Weetman, 1991).
A relationship with HLA molecules has been detected in various types of 
thyroid  au to im m unity . G enetic  suscep tib ility  to au to im m une hypo or 
hyperthyroidism is related to HLA-DR3 (Santamaria et al, 1994; Yanagawa et ai, 
1994), while postpartum thyroiditis is related to HLA-DR4/5 (W eetman, 1991). 
Genetic susceptibility to Graves' disease is also related to HLA-DQA 1*0501 in 
Caucasian DR3 haplotypes, while Hashimoto's disease is related to DQB 1*0301 
(Santamaria et al, 1994),
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13.2.2 Immunological Mechanisms
1.3.2.2.1 Thyrocytes as Antigen Presenting Cells
MHC are now known to be essential components in the presentation of 
antigen, both self and non-self, to the T cell receptors of helper and suppressor T 
lymphocytes. While MHC class I antigens are widely expressed in many types of 
cells including thyrocytes (Nagataki and Eguchi, 1992; Davies et al, 1989), the 
MHC class II antigen has a more restricted degree of constitutive expression, 
principally within the immune system. It is now known that thyrocytes can express 
MHC class II molecules on their surface and act as an APC (Chiovato et al, 1994; 
Asakawa et al, 1992 a; Volpé, 1991). This led to the suggestion that this aberrant 
class II expression might initiate or perpetuate thyroid autoimmunity (Bottazzo et 
al, 1983). This was supported by the fact that in Graves' disease, thyroid follicular 
cells were able to present antigen through HLA class II to autologous T 
lymphocytes, derived from thyroid gland (Fukazawa et al, 1991; W eetman et al, 
1986 a). HLA class II is also present on the surface of thyrocytes in non-immune 
thyroid diseases such as non-toxic goitre, nodular goitre, and thyroid carcinoma 
(Grubeck-Loebenstein et al, 1988), but not on normal thyrocytes (Chiovato et al, 
1994; Otsubo et al, 1988) and its expression can be induced by INF-y (Chiovato et 
al, 1994). The HLA class II molecules on the surface of thyrocytes, from patients 
with Graves' disease are more efficient in stimulation and proliferation of both 
allogeneic and autologous peripheral blood mononuclear cells than those in non- 
toxic goitre (Grubeck-Loebenstein et al, 1988). When thyrocytes from patients with 
Graves' disease were incubated with autologous peripheral blood T cells the 
percentage of HLA-DR positive thyrocytes increased. Furthermore, addition of 
autologous peripheral blood monocytes to the above co-culture increased the cell 
expression of HLA-DR on both thyrocytes and T-cells (Otsubo et al, 1988). Tumour 
necrosis factor-a (TN F-a), which is principally produced by monocytes, is capable 
of enhancing the expression of HLA class I on thyrocytes (Nagataki and Eguchi,
1992), though the major stimulus may be INF-y produced by T H l lymphocytes.
The above findings indicate that expression of HLA class II on the surface 
of thyrocytes is influenced by cytokines that are produced by activated lymphocytes 
This is probably, however, a secondary effect of lymphocytic infiltration of the 
thyroid gland, but not sufficient by itself for the induction of thyroid autoiinmunity.
1.3.2.2.2 Defects in Lymphocytes
Examination of T cell infiltrates in thyroid tissue from patients with thyroid
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autoiinmunity has shown a marked accumulation of a variety of specific T cell 
subsets, in patients with Graves' disease, whereas the infiltrate cells of Hashimoto's 
disease have reflected the proportions in peripheral blood (Davies et al, 1992). 
Nagataki and Eguchi (1992) illustrated that the distribution of CD4'^ and CD 8 + 
cells differed in different regions of thyroid tissue in Graves' disease. CD4+ cells 
were mainly found in lymphoid aggregates, whereas CD8 + were scattered among 
the thyroid follicles. T heir report showed that activated T cells (H LA -D R+, 
CD25+/CD26+), helper and memory T cells (CD4^'CD29+) and cytotoxic cells 
(CD8 + C D llb “) were increased in the intra-thyroid fraction compared to peripheral 
blood, and that peripheral blood also had higher numbers than normal controls, 
while what they described as suppressor-inducer T cells, and is now thought to be 
the naive T cell population (CD4+CD45RA+), and natural killer cells were reduced.
Increases in the ratio of helper/suppressor cells led to the hypothesis that 
reduction of the fraction of suppressor T cells could be one of the predisposing 
factors for thyroid autoimmunity (Volpé, 1991). Unopposed action of helper T  cells 
would cause production of TSAb, which would directly stimulate the thyroid and 
also cause increased production of autoantigens.
While this hypothesis is plausible, the question remains as to the identity of 
the originating antigen. The existence and identification of specific suppressor cells 
have frequently been called into question (Martin and Davies, 1992), so this 
mechanism is still very controversial. However, there is no doubt that accumulation 
of different classes of activated lymphocytes in thyroid tissue leads to the local 
release of various cytokines. Activated CD4+ helper type 1 or CD 8 + cells are 
capable of producing IL-2 and INF-y, while T helper type 2 cells produce IL-4, IL- 
5, and IL-10, among others (Nagataki and Eguchi, 1992).
Thyroid infiltrating B cells from Graves’ patients are able to synthesise anti- 
thyroidal antibodies in vitro. M ost of these antibodies were IgG (Nagataki and 
Eguchi, 1992).
W hilst it is highly likely that the intrathyroidal T cells are capable of 
producing the cytokines necessary to stimulate B cell activation and differentiation, 
an additional source of a key cytokine in this progression, namely IL-6 , is the 
thyrocyte itself (Nagataki and Eguchi, 1992). Thyrocyte production of IL - 6  in vitro 
is enhanced by other cytokines known to be produced by infiltrating mononuclear 
cells, in particular INF-Y and TN F, as well as by TSH w hich is elevated in 
autoim m une hypothyroidism . Thus, the thyroid may contribute to its own 
destruction by release of IL - 6  that stim ulates intrathyroidal B and T cell 
proliferation and differentiation (Weetman, 1991).
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1.3.2.3 Non-Immune Factors
1.3.2.2.3 Cytokines
Hypothyroidism and transient thyrotoxicosis with elevated antimicrosomal 
antibody titres have been described in patients receiving IL-2 and lym phocyte 
activated killer cell therapy for advanced cancers (Atkins et al, 1988; Sauter et al,
1992). Similar findings have been reported in patients on long-term treatment with 
IN F-a (Gisslinger et al, 1992). It is postulated that the hypothyroidism may have 
been caused by unmasking sub-clinical autoimmune thyroiditis (Atkins et al, 1988; 
Gisslinger et al, 1992). These findings are good evidence that disordered production 
of cytokines could be a mechanism for initiating or maintaining autoimmune 
thyroid disease.
1.3.2.2.4 Infection
The role of infectious agents as précipitants is unclear. Analysis of 857 
British cases of Graves' disease over a 10 year period revealed no clustering of 
cases in time or space, indicating that infections behaving in an epidemic fashion 
are unlikely to be precipitating factors (Cox et al, 1989). Antibodies to Yersinia 
enterocolitica are found with increased frequency in Graves' disease and a 
saturable binding site for TSH was discovered in lysozyme-treated extracts of this 
organism (Weiss et al, 1983). Such a TSH receptor-like molecule could provoke the 
formation of cross-reactive TSAb (Weetman, 1991). Further investigations have 
suggested that antibodies against a plasmid-encoded protein in enteropathogenic 
strains of Yersinia are strongly associated with various form s of thyroid 
autoimmunity, although how this can be reconciled with the specific induction of 
Graves' disease is unclear (Wenzel et al, 1988; and 1990). Similar TSH receptor- 
binding material has been found in mycoplasma (Sack et ai, 1989). An exogenous 
retrovirus has also been implicated, based on hybridisation of an HIV-I gag probe 
with thyroidal DNA from  Graves' but not control subjects, although it is unclear 
where the virus is located and what it is (Ciampolillo et al, 1989).
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1.3.2.3.1 Hormones
Thyroid disease is commoner in females than in males. Observations of
autoimmune thyroiditis in animal models also show that female mice and rats
.develop m ore severe thyroid autoimm unity than males. High doses of fem ale 
hormones increased the risk, while high doses of testosterone could reverse the
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effect (Weetman, 1991).
Stimulation of the gland with TSH is immunomodulatory, since this leads to 
endogenous TG release and increases the expression of adhesion molecules and 
HLA class I and II on the surface of thyrocytes. High concentrations of T4  suppress 
both  thyro id itis and form ation o f TG antibodies, which may be a d irect 
immunological effect of the hormone (Volpé, 1994). Autoimmune thyroid disease 
also has been reported in individuals with hyperprolactinaemia (Walker et al, 1993).
1.3.2.3.2 Iodine
D ietary  iod ine is a m ajor environm ental determ inant in thyroid  
autoimmunity. Excess iodine tends to enhance disease, whereas a low iodine diet 
ameliorates it (Volpé, 1994). Several mechanisms might account for this, including 
direct thyroid cell toxicity with excess iodine. In the Obese strain (OS) chicken it is 
known that highly iodinated TG is more immunogenic than poorly iodinated forms 
(Weetman, 1991).
The increasing incidence of Hashimoto's thyroiditis in the mid-western 
states of the USA between 1920 and 1960 coincided with the introduction of iodine 
prophylaxis for endemic goitre and a careful 2 0  year follow-up of thyroidectomy 
specimens revealed a much higher frequency of lymphocytic infiltration after the 
introduction of iodisation (Harach et al, 1985). The introduction of iodised oil as 
prophylaxis on the island of C orfu resulted in the appearance o f thyroid 
autoantibodies in 43% of subjects six months later (Boukis et al, 1983).
Iodine-containing drugs can also be responsible. Iodine in cough medicine 
was responsible for goitre in asthm a patients, half o f whom had thyroid 
autoantibodies (Weetman, 1991).
1.4 BACKGROUND TO CURRENT STUDY
The aetiology of autoimmune thyroid disease remains unknown. Whatever 
the initial stimulus, however, an immune response involving T and B lymphocytes, 
macrophages and their soluble products is the result. The nature of the resultant 
damage is likely to depend on the particular form of the cellular response, such as 
whether there is primarily a type 1 or type 2 helper T cell reaction, or whether it is 
mixed. This will alter the pattern of cytokines which is produced and determines 
whether the predominant lesion is that of destruction or proliferation.
There is some information as to the effect of cytokines on the thyroid, but 
this is limited and incomplete. In addition, there is little information as to the likely 
modifying effects of the other peptides and growth factors which are known to be
1 '
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present in the thyroid gland.
In this study, the presence of soluble interleukin 2 receptors was studied in 
the blood of patients w ith Graves' disease. W hen abnormalities were found, the 
investigation was extended to study the release of the IL-2 receptor from samples of 
blood incubated in vitro, and then to the release of several other cytokines from the 
same preparations.
In parallel with this study, the effects of several cytokines, growth factors 
and neuropeptides were tested on thyroid cells in culture. The cell line which was 
used was the FRTL-5 rat thyroid epithelial cell line, which responds to stimulation 
by TSH and other growth modulators by changes in iodine uptake and growth rate. 
It is not capable of synthesising thyroid hormones.
The effects of several modulating factors were also studied. Since thyroid 
cells in patients with Graves' disease are under the combined stimulus of thyroid- 
stimulating antibodies and thyroid hormones, the experiments were repeated with 
both TSH and thyroid hormones in the culture medium. It has been suggested that 
cell-surface protease enzymes may modify the effects of peptide mediators, so 
attem pts w ere also m ade to inh ib it these enzymes w ith known inhibitory 
compounds.
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SECTION ONE 
INTRODUCTION
2.1.1 Interleukin-2 Receptor
The effects of interleukin-2 are mediated through interaction with specific 
receptors on the surface of target cells. The receptors for IL-2 were originally referred 
to as high, intermediate, and low affinity receptors. Now it is recognised that the high 
affinity receptor contains three distinct subunits, lL -2R a, IL-2Rp, and lL-2Ry, while 
the intermediate affinity receptor contains two subunits, 1L-2R(5 and lL-2Ry. Isolated 
IL-2Ra binds IL-2 with low affinity (Minami et al, 1993).
2.1.1.1 Interleukin-2 Receptor a  Chain
The human IL-2R a chain, originally described as the tac antigen, was 
identified as a membrane glycoprotein (p55) capable of binding IL-2 (Robb and 
Greene, 1983). It is a protein of 251 amino acids, with a signal peptide of 21 amino 
acids in length. The 219 amino acid residues of the amino-terminal constitute the 
extracellular region, while the next 19 amino acids form the membrane spanning 
region, and the cytoplasmic region involves the 13 amino acid residues of the 
carboxy-terminal (Minami et al, 1993). When the cloned human IL~2Ra cDNA was 
transfected into non lymphoid cells or lymphoid cells lacking IL-2 binding ability, it 
became evident that IL -2R a constitutes only the low affinity IL-2 binding form, a 
form that can not cause internalisation of IL-2 or signalling (Greene et al, 1985). 
However, when the human cDNA was introduced and expressed in murine T cell 
line, the high-affinity as well as the low-affinity 1L-2R were reconstituted on the 
surface, suggesting a contribution of the a-chain to the formation of the high affinity 
receptor (Robb, 1986). Mutational analyses have shown that the N-terminal 83 amino 
acid residues of IL-2Ra chain especially residues 1-6 and 35-43 are important for IL- 
2 binding (Robb et al, 1988).
2.1.1.2 lnterleukin-2 Receptor p Chain
The structure of IL-2Rp (p75) was elucidated through the expression cloning 
of the cDNA for human IL-2Rp (Hatakeyama et al, 1989). This is a protein of 551 
amino acids, with a signal peptide of 26 amino acids in length. The 214 N temiinal
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amino acids are extracellular, while the next 25 amino acids are membrane-spanning, 
and the C terminal 286 amino acids constitute the cytoplasmic regions (Hatakeyama et 
al, 1989). Deletion of the entire cytosolic protein of IL~2Rp abrogates all known IL-2 
dependent signalling and growth responses. This region is relatively rich in proline 
and contains two distinctive subdomains that are serine rich and acidic rich. Deletion 
of the serine rich region blocked IL-2 dependent growth responses, while deletion of 
the acidic region blocked IL-2 dependent activation of protein tyrosine kinases 
(Minami, et al, 1993). This indicates that some of the signalling functions of IL-2R are 
encoded by distinct sub-regions within the IL-2Rp.
2.1.1.3 Interleukin-2 Receptor y Chain
The finding that a  and p receptor chains were only capable of reconstituting 
low or intermediate affinity lL-2 receptors, and results obtained from studies of 
mutants of IL-2Rp led to discovery of IL-2Ry (Zu raw ski et al, 1990). The structure 
of IL-2Ry (p64) was elucidated by expression cloning (Takeshita et al, 1992). The 
human IL-2Ry is a protein of 369 amino acids with a signal peptide of 22 amino 
acids. The N terminal 232 amino acids are extracellular, while the next 29 amino 
acids are membrane-spanning, and the C terminal 8 6  amino acids constitute the 
cytoplasmic region (Takeshita et al, 1992). The presence of the IL-2Ry subunit is 
required for all IL-2R signalling functions (Takeshita et al, 1992). There is no 
measurable binding of IL-2 to the individual lL-2Ry subunit, but the presence of ÏL- 
2Ry augments the affinity of lL-2Rp binding and is necessary for formation of the 
high affinity IL-2Rapy complex (Gaulton and Williamson, 1994). IL-2Ry is also 
involved in internalisation of the IL-2/IL-2R complex (Voss et al, 1994).
A recent study shows that a mutation in the y chain of the 1L-2R complex is 
the cause of X-linked severe combined immunodeficincy (Voss et al, 1994; Leonard 
et al, 1994). The discovery points to a central role of the IL-2Ry chain in development 
and function of lymphoid cells (Voss et al, 1994),
The IL-2Rp and IL-2Ry chains have significant homologies with other 
cytokine receptors in the length and folding of their extracellular domains, while IL- 
2R a does not have any homology with other known cytokine receptors (Minami et 
al, 1993; Cosman, 1993). Furthermore, the y chain of 1L-2R is com mon to the 
receptors for IL-2, lL-4, and IL-7 (Leonard et al, 1994; Voss et al, 1994), while the 
p chain may be shared by the IL-2 and lL-15 receptors (Grabstein et al, 1994). It has 
been shown that circulating human neutrophils express IL-2Rp (Djeu et al, 1993) and 
IL-2Ry (Liu et al, 1994), but not IL-2Ra. Although these two receptor subunits on 
neutrophils could potentially interact with IL-2 with intermediate affinity and induce
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an intracellular signal, the absence of IL-2Ra suggests that this receptor may not be 
specific for IL-2, and may be a receptor for IL-15 (Grabstein et al, 1994). The above 
findings indicate that the a  chain may confer specificity for lL-2 although it does not 
have any part in intracellular signalling.
IL-2Rp and IL-2Ry stimulate at least two intracellular signal transduction 
pathways that lead to nuclear proto-oncogene induction (Shibuya et al, 1992). One 
pathway is linked to tyrosine phosphorylation events, mediated by a tyrosine kinase 
of the 5 rc-famiiy, which leads to activation of c-fos, c-jun, and other genes of this 
family. Another pathway leads to c~myc gene induction by an unknown mechanism 
(Minami et al, 1993). Other signalling events lead to a rapid increase in intracellular 
pH, as a result of the activation of Na+/R+ antiport (Gaulton and Williamson, 1994). 
For further information on this topic see the review of Gaulton and W illiamson 
(1994). The combination of three chains of IL-2R is shown in figure 2.1, while the 
binding affinity, association time, and signalling functions of each individual subunit 
of 1L-2R and their combinations are summarised in table 2.1.
2.1.2 So lub le  In te r le u k in -2  R ece p to r
2.1.2.1 Structure
Resting lymphocytes express only intermediate affinity lL-2 receptors. When 
T cells activated the expression of IL-2Rp is increased 5-10 fold, whereas IL-2Ry 
expression, is not changed. However IL-2R a is strongly induced and expressed out 
of proportion to the amount of lL-2Rp and IL-2Ry (Leonard et al, 1994), This leads 
to release of a soluble form of this chain into the plasma, after enzymatic cleavage 
from the membrane (Jacques et al, 1990; Robb and Kutny, 1987).
The relative molecular mass of the soluble interleukin-2 receptor (sIL-2R) is 
40-45000. It has most of the characteristics of the membrane-bound IL -2R a, 
including a low affinity for IL-2, but lacks 72 amino acids corresponding to 
transmembrane and intracytoplasmic regions of the IL -2R a (Rubin et al, 1985). 
Jacques and colleagues (1990) reported that naturally secreted sIL-2R is a non- 
covalently bound dimer, suggesting that the cell-bound IL-2R a receptor is also a 
dimer. This has not yet been confirmed.
Human monocytes and macrophages produce sIL-2R when stimulated with 
LPS (Kniep et al, 1992) or INF-y (Valitutti et al, 1989; Espinoza-Delgado et al,
1990); resting monocytes do not express IL-2Ra, but do express IL-2RP (Kniep et 
al, 1992) and IL-2Ry (Epling-Bumette, 1995; Bosco et al, 1994) on their surface. 
Resting human B cells, natural killer cells, and CD4+ and CD8 + T cells also express
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Figure 2.1: Schem atic o f the human IL-2 receptor. The functional receptor is 
composed of at least three Polypeptide chains, a ,  (3, and y. Numbered regions of the 
IL-2Ra chain represent protein domains encoded by exons 2, 3, and 4, respectively 
(copied from Kaempfer, 1994).
IL-2R a p Y ap Py apy
Binding affinity
(mol/l)
1 0 - 8 10-7 ? 1 0 - 1 0 10-5 10-11
Dissociation 35 s 1.6 min ? 18.5 min 255  mill 255  min
Internalisation No No ? ? Yes Yes
Signalling functions No ? No 7 Yes Yes
Table 2.1: Binding affinity for IL-2, time of association, and function of subunit of 
interleukin-2 receptor (IL-2R).
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IL-2Rp on their surface, but not IL-2Ra. After activation, newly synthesised lL -2R a 
appears on the surface of these cells (Ohashi et al, 1989), Recent studies indicate that 
the up regulation and expression of lL -2R a on stimulated B cells is enhanced by IL- 
10 (Itoh et al, 1994), and retinoic acid (Bhatti and Sidell, 1994). There is a report that 
indicates the expression of IL -2R a on CD4 and CD8  T cells are decreased in HIV 
infected patients, while expression of IL-2RP did not change compared to control 
(Vanham et al, 1994). This may indicate that the a  chain confers specificity for IL-2 
and is therefore regulated independently of the other chains of the receptor. 
Moreover, the high levels of sIL-2R found in many instances where IL-2 dependent 
function is impaired suggests that this molecule may act as an antagonist of IL-2 
mediated cell responses (Rubin and Nelson, 1990),
2.1.2.2 Clinical Applications
Increased concentrations of slL-2R have been reported in a wide variety of 
diseases. Some of the recent publications are described here in brief but only thyroid 
disease will be characterised in detail.
2 .1 .2 .2 .1  Malignant Disease
Serial measurement of sIL-2R levels was shown to be of clinical importance 
in adult T-cell leukaemia, because changes in the level of sIL-2R correlated with 
disease progression, especially in the early phase of adult T-cell leukaemia, where it 
is more useful then LDH (Kamihira et al, 1994).
The plasma sIL-2R was found to be significantly elevated in patients with 
primary myelofibrosis compared to poiycythaemia vera, while that of patients with 
polycythaemia vera was significantly higher than control. This may be secondary to 
T-cell activation resulting from autoimmune phenomena and myeloblast activation. In 
prim ary m yelofibrosis, plasm a slL-2R  concentrations were also found to be 
correlated to survival, circulating blast cell count and thrombocytopenia, but not to 
white blood cell counts, LDH levels, degree of marrow fibrosis or degree of 
splenomegaly (Wang and Wang, 1994).
Serum concentration of sIL-2 R was increased in females with advanced 
ovarian cancer (Gadducci et al, 1994); the increase was also detected in their ascitic 
fluid (Hurteau et al, 1994).
The level of serum sIL-2R in patients with gastric cancer with lymph node 
métastasés were higher than those patients that did not have lymph node métastasés 
(Murakami et al, 1994).
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2 .1.2.2.2 Autoimmune Disease
An association of high concentrations of serum sIL-2R with rheumatoid 
arthritis was shown by Polisson and co-workers (1994). The level decreased 
significantly during treatm ent, but there was no correlation of the sIL-2R  
concentrations w ith jo in t pain or tenderness (Ward et al, 1994). Cyclosporin A 
reduced the level of sIL-2R in patients with rheumatoid arthritis (Crilly et al, 1995).
Serum concentration of slL-R was significantly raised in patients with 
systemic lupus erythematous, coeliac disease and Crohn's disease (Srivatava et al, 
1995).
2 .1 .2 .2 .3  Infection
Serum concentrations of sIL-R were significantly elevated in patients with 
pulmonary tuberculosis; the slL-2R concentrations were still higher than control after 
treatment though they had decreased significantly, suggesting a delayed resolution of 
the inflammation in these patients (Chan et al, 1995).
Both neopterin (released from activated monocytes and macrophages) and 
slL“2R were identified as significant predictors of a state of shock caused by gram 
negative sepsis, but neither of them contributed any additional significant predictive 
information to standard measurements (Delogii et al, 1995).
2 .1 .2 .2 .4  Transplantation
During rejection of renal transplants, serum and urine sIL-2R concentrations 
are affected by both rejection episodes and infection. While Bock and co-workers 
(1994) claimed that serial measurement of sIL-2R excretion may be a useful adjunct 
to the diagnosis of rejection, Montagnino and colleagues (1995) did not find that 
measurement of sIL-2R concentration was superior to clinical diagnosis.
2.1.2.2.5 Thyroid Diseases
The serum  concentration of sIL-2R of patients previously treated for 
differentiated thyroid carcinoma by total thyroidectomy while they were off treatment 
with L-thyroxine was nearly half that in the control group (Mariotti et al, 1994). In 
contrast, highly variable circulating slL-2R concentrations were found in 49 patients
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■with untreated Hashimoto's thyroiditis and 22 patients with idiopathic myxoedema 
(Mariotti et al, 1992 a).
All publications agree that the serum or plasma concentrations of slL-2R are 
significantly increased in untreated patients with non-autoimmune hyperthyroid 
patients (single toxic adenoma) (Mariotti et al, 1992 a) or Graves' disease (Murakami 
et al, 1995; Murphy et al, 1994; Mariotti et al, 1992 a, and 1992 b; Balazs and Farid,
1991), but conflicting data have been published on production of SÏL-2R in treated 
patients,
Balazs and Farid (1991), who studied the sIL-2R of 20 patients with
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untreated Graves' disease, showed a strong correlation between slL-2R and TSAb 
(r=0.94). Weryha and co-workers (1991) have shown that untreated patients with 
Graves' disease had a strong correlation between T 3  and sIL-2R (r=0.93), but a 
lower correlation between TSAb and sIL-2R (r=0.74), while Mariotti's group (1992 
a, 1994) and M urakami's group (1995) could not detect any correlation between 
thyroid TSAb and sIL-2R. It is not clear why the reported correlation is so variable or 
why there is only a correlation between TSAb and sIL-2R, not microsomal or 
thyroglobulin antibodies.
Mariotti and co-workers (1992 a, 1994) have shown that treatment of both 
hypothyroid and hyperthyroid patients returned the concentration of sIL-2R to 
normal. They believed that the normalisation of thyroid hormones was responsible 
for this rather than any effect on the immune process itself. This statem ent is 
consistent with the results of Balazs and Farid (1991), but it is only based on indirect 
evidence, and requires confirmation.
Murphy and co-workers (1994) showed that sIL-2R concentrations decreased
'in patients treated with propylthiouracil, and did not return to norm al when 
euthyroidism was established, so it was in their opinion unlikely that anti-thyroid 
drugs could be responsible for the observed reduction of sIL-2R concentrations.
Volpé (1994) also stated that anti-thyroid drugs could not mediate any im m uno­
suppressive effect and suggested that the actions of anti-thyroid drugs were mediated 
only through modifying the function of thyrocytes. Balazs and Farid (1991) have 
shown the concentrations of slL-2R normalised earlier than other immunological and 
hormonal parameters, and believed that this was the effect of methimazole treatment, 
because after cessation of drug the concentration of sIL-2R increased. There is no 
direct evidence whether or not anti-thyroid drugs could affect the production of sIL- 
2R, and this needs further investigation.
T7
2.1.3 Soluble IL-2 Receptor And Cytokines In Blood
In the current study, the concentration of sIL-2 receptor in serum was 
measured in a group of patients with Graves’ disease before and during treatment. In 
addition, various experiments were carried out to investigate whether the observed 
increases could be accounted for by a direct effect of thyroid hormones and drug 
treatment on blood cells. To do this, samples of blood from nonnal volunteers were 
incubated with thyroid hormones, TSH and methimazole in the presence of standard 
stimulators of peripheral blood cells, and the concentrations of sIL-2R which were 
released into the medium were measured. This study was then extended to cover 
measurement of several other cytokines which could be of importance in the immune 
process of Graves’ disease. These were IL-2, IL-4, IL-6 , TN F-a, and INF-y.
In addition, similar stimulation experiments were carried out using blood from 
untreated patients with Graves' disease, without exogenous thyroid hormones, in 
order to compare the response of blood cells with the reference group.
Most groups who have studied the release of cytokines from blood cells have 
used various populations of isolated cells (monocytes, T or B lymphocytes), and 
stimulated them with mitogens or cytokines. It was decided to use peripheral whole 
blood (WB) as the test medium. The reasons for this decision are discussed below.
The separation of cells requires density centrifugation of blood and adherence 
of cells to tissue culture plastic to isolate monocytes, however, under these conditions 
of isolation, at least three variables potentially affect the separated cells. Firstly, the 
adherence step of monocyte purification is known to induce mRNA for TNF (Desch 
et al, 1989), and so it presumably also affects other cytokines which it is desirable to 
study. Secondly, it is difficult to avoid contamination of reagents and tissue culture 
medium by low levels of endotoxin. As monocytes are sensitive to picogram 
quantities of LPS, this can have a marked effect on results. Thirdly, the presence of 
heterologous serum may alter the effect of stimulators on cultivated cells.
Furthermore, removal of cells from their physiological environment (plasma) 
also uncouples cell to cell interactions and production of cytokines, both known and 
unknown, that orchestrate interactions between the different cells in vivo. There is 
evidence, for instance, that granulocyte macrophage colony stimulating factor (GM- 
CSF) could enhance the plasma level of sIL-2R of cancer patients treated with this 
cytokine (Crispino et al, 1993). In vitro stimulation of whole blood (diluted 1:1 or 
1:10 with medium) with LPS caused a significant release of TNF within the first 4-8 
hours of stimulation, while the same number of isolated monocytes only produced
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3one fifth o f the quantity of this cytokine after 24 hours (Stricter et al, 1990; De Groote 
et al, 1992).
Similar observations were made for other cytokines. The production of IL -ip  
was 8  times higher when whole blood was used as substrate and stimulated with LPS 
than when isolated cells were used (Allen et al, 1992). Expression of SÏL-2R w as 
minimally induced on surface of CD8  bright cells when whole blood was stimulated 
with CD3 monoclonal antibody, while all CDS bright cells expressed sIL-2R when 
isolated mononuclear cells were used (Janssen et al, 1994). Also, production of IL - 6  
and IL-2 were lower in whole blood than isolated peripheral mononuclear cells (De 
Groote et al, 1992). It seems likely, therefore, that isolation of cells significantly 
alters their responsiveness to stimulation in an unpredictable manner, and it may be 
preferable to use whole blood cultures in clinical situations.
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SECTION TWO 
METHODS
2.2.1 Blood Samples
2.2.1.1 Blood Samples for Study of Serum sIL~2 R
The required amounts (4-8 ml) of peripheral blood were collected by 
venepuncture from 17 healthy adults (11 females and 5 males) aged between 17 to 
57 years or from patients with Graves' disease into plain Vacutainer tubes, and 
serum was separated within 30 min by centrifuging the sample at 800 g. The sera 
were transferred into another tube and stored at -20“ C until assay for sIL-2R. 
Specimens for thyroid function testing were collected from  patients at the same 
time. Follow up samples were collected from these patients on their review visits to 
hospital.
2.2.1.2 Samples For Study Of Release Of sIL-2R From Whole Blood
The required am ounts (30 ml) of peripheral blood were collected by 
venepuncture from healthy adults aged between 25-40 years, into 3 plain Vacutainer 
tubes, and 500 pi of concentrated heparin solution (1000 U/ml) was injected into 
each tube immediately after collection. The experiment was set up within one hour 
after collection. Samples of 10 ml were collected using the same protocol from  
patients with untreated Graves' disease.
2.2.1.3 Samples For Study Of Release Of Cytokines From Whole Blood
Peripheral blood samples (4 ml x 4 tubes) were collected by venepuncture 
from healthy adults aged between 25-50 years, or from patients with untreated 
Graves' disease, into endotoxin free heparinized vacuum blood collection tubes 
(Endotubes).
2.2.2 Soluble IL-2 Receptor Production By Whole Blood In Vitix)
Heparinized blood samples were processed using two different protocols. 
All experiments were carried out in triplicate.
,:s;
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A portion of the sample was centrifuged at 800 g for 5 min. Plasma was 
stored at -20“ C until assay of sIL-2R. This plasma served as a pre-control.
2.2.2.1 Protocol 1 (undiluted)
Various amounts of concentrated LPS and PHA solution, and combinations 
of these, were mixed with medium immediately before use. 450 p\ of whole blood 
(WB) were transferred into each well of a 12-well plate. 50 pi of medium were 
added to triplicate control wells. To other sets of triplicate wells, 50 pil of medium 
containing LPS, PHA, or a mixture of LPS and PHA were added. The plate was 
incubated in a 37“ C incubator with 95 % air and 5 % CO 2 , for various periods.
A fter incubation, the plate was removed from the incubator, and blood from 
each well was transferred to tubes which were centrifuged at 500 g for 5 min. 
Plasmas were separated and saved at -20“ C, until assay of sIL-2R.
2.2.2.2 Protocol 2 (1:2 dilution)
0.5 ml of whole blood was transferred into each well of a 12-well plate. 0.5 
ml of medium with or without stimulators was added to triplicate wells as described 
above. The plate was incubated in a 37“ C incubator with 95 % air and 5 % CO 2 , for 
various periods. The remaining steps were the same as protocol 1.
2.2.3 D eterm ination o f Soluble IL-2 R eceptor
To determine the amount of sIL-2R in plasma, and cell culture supernatant, 
a kit manufactured by T Cell Diagnostics Inc. was used. The kit contained the 
following reagents and materials:
Anti-Human IL-2R Coated Microtitre plate: Each plate consists of twelve 8 - 
well strips precoated with murine monoclonal antibody to human 1L-2R.
Soluble IL-2R conjugate: Each vial contains horseradish peroxidase (HRP)- 
conjugated murine monoclonal antibody to human slL-2R in a buffered solution 
with bovine serum protein and thimerosal. This solution should be protected from 
light.
IL-2R Specimen Diluent: Each vial contains equine-derived serum proteins 
and thimerosal.
IL-2R standards: Each vial contains recombinant human IL-2R in a buffered 
solution with bovine derived serum proteins and thim erosal at the follow ing 
concentrations: 0, 200, 800, 1600, and 3200 U/ml, a unit bring defined by the
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m anufacturer from the content of a standard prepared from  PHA-stim ulated 
lymphocytes.
IL-2R controls: Each vial contains recombinant human IL-2R in a buffered 
solution with bovine derived serum proteins and thimerosal. The concentrations of 
each control differ from batch to batch. Usually they are approximately 500 and 
1200 U/ml.
Chromogen tablets: Contain 0-Phenyl en edi amine and fillers.
Substrate: A buffered solution containing 5.3 mmol/1 urea peroxide and 
thimerosal.
PBS salt: Each packet contains pre-measiired salts sufficient to make one 
litre of buffer.
Surfactant solution: Each vial contains a 50 % solution of surfactant.
Plastic plate sealers.
All reagents were stored at 2-8° C: One hour before use, they were brought 
out to room temperature.
Wash buffer salt was dissolved in one litre of distilled water, and one ml of 
surfactant solution was added to it. The shelf life of this solution is 30 days.
Chromogen substrate solution m ust be prepared only 10 min before use. For 
its preparation 4 chromogen tablets were transferred to 20 ml of substrate solution. 
They dissolved in 1-2 min if left undisturbed. The solution was mixed by swirling 
before use. The resultant solution m ust be colourless to pale yellow. A yellow- 
orange colour indicates chromogen deterioration and solution should be discarded.
Stop solution, which is 1 mol/l (2 normal) H 2 SO4 , is not provided in the kit. 
For preparation of this solution and other acid preparations, the following formula 
was used throughout this study.
Yolume of acid (ml) leqaiiad to   Molecular Maaa X 100
make one litre of Normal solution Specific gravity K Valency X purity
The assay was performed according to the m anufacturer’s instructions. 
Briefly, standards and samples (50 pX) were added to duplicate wells of a microtitre 
plate coated w ith m urine m onoclonal antibody to human SIL-2R, follow ed 
immediately by addition o f 1 0 0  p\ horseradish peroxidase conjugated m urine 
monoclonal antibody to human lL-2 R, leaving the first two wells empty as a blank. 
The plate was sealed and shaken on a plate shaker for 3 h.
Ten min before the end of the incubation, chromogen solution was prepared. 
The sealer was removed and discarded and the solution in each well was aspirated. 
Each well was washed at least 3 times with 350 pi of wash buffer. Excess of wash 
solution was removed from  the wells by inverting the plate over tissue paper.
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Immediately after washing, 100 /d  of a chromogen solution was added to all wells 
including blanks. The reaction was terminated by addition of 50 //I of stopping 
solution (2 Normal solution of H 2 SO4 ) to each well, and the plate was read at 490 
nm. All the tests were carried out in duplicate. Figure 2.1 shows an example of a 
standard curve for measurement of sIL-2R.
2.2.4 Cytokine Production by Samples of Whole Blood in Vitro
Three sets of triplicate sterile polypropylene tubes was labelled as control, 
LPS/PHA, and Ca/PMA. To all tubes of the second set, 25 //I of working solution of 
LPS/PHA, and to the third set 25 //I of working Ca ionophore ( 8  /ig/ml), and 25 /d  
of working PMA (0.24 /^g/ml) solution were added. To all tubes, 2 ml of p re­
warmed medium were added, followed by addition of 0 . 2  ml of w ell-m ixed 
heparinized whole blood from  either patients or reference controls. The tubes were 
capped and mixed. The caps were loosened, and the tubes were incubated in a 37° C 
incubator in 95 % air and 5% CO 2 , for periods of 4 ,24 , and 72 h.
At the end of each incubation time, one tube from each set was taken out of 
the incubator and centrifuged at 500 g for 5 min. Medium from  each tube was 
transferred to appropriate labelled tubes and stored at -2 0 ° C, till shipment to 
Medgenix Diagnostics (Fleurus, Belgium) for analysis of cytokines.
A portion of the original blood was centrifuged at 800 g for 5 min, and 
plasma was removed and transferred to a new tube. This tube was capped, and 
stored at -20° C till shipment of specimens. These plasmas served as untreated 
control. Soluble IL-2 receptors were also assayed by the T-Cell Diagnostics kit, but 
only on the samples incubated for 72 h.
For each reference sam ple, an additional three groups of 9 sterile 
polypropylene tubes were treated with thyroid hormones, TSH or an anti-thyroid 
drug (methimazole) in addition to the stimulators mentioned above. Either 23 pd of 
Methimazole solution (100 mmol/1), 23 pi\ of TSH solution (5 U/1), or a mixture of 
23 J4.Ï of T4  solution (100 /(mol/1) and 23 /d  of T 3  solution (1 /(mol/1) were added. 
To all tubes, 2 ml of pre-warmed medium were added, followed by 0.2 ml of well- 
mixed heparinized whole blood. Tubes were capped and mixed. The caps were 
loosened, and the tubes were incubated in a 37° C incubator in 95 % air and 5% 
CO 2 , for periods of 4, 24, and 72 h.
At the end of each incubation time, the samples were centrifuged and stored 
as above until they were sent to Medgenix Diagnostics for analysis. Soluble IL-2 
receptor assays were also carried out on the samples in tliis experiment using the T - 
Cell Diagnostics kit.
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Figure 2.2: Standard curve used for measurement of sIL-2R, in serum and cell culture 
supernatant.
2.2.5 M easurem ent o f T hyroid  Function Tests
Total T 4  was m easured using the A bbott IMx instrument. Free T 4  was 
measured using the Amerlex MAb kit and total T3  was measured using the Amerlex 
M kit manufactured by Amersham International. Thyroid receptor antibody (TRAb) 
was measured using the kit manufactured by RSR Ltd, Cardiff, UK. Thyroid 
microsomal and thyroglobulin antibodies were measured using the Thymune-M and 
Thymune T kits manufactured by Murex Diagnostic Limited, Dartford, England.
2.2.6 Statistical Analysis
Statistical analysis was carried out using the StatView computer package. 
Comparison of patients with controls at the same time point was carried out using 
unpaired t-tests, while analyses of the time course of stimulation and the effect of 
thyroid hormones, TSH, or methimazole were performed by analysis of variance 
(ANOVA), using the Bonferroni/Dunn criterion of significance.
The differences were defined as significant when the calculated critical 
difference as determined by the Bonferroni/Dunn criteria (5% significance level) 
was less than the mean difference (P< 0.05), while they are defined as highly 
significant when the calculated critical difference is less than half of m ean 
difference (P< 0.001).
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SECTION THREE 
RESULTS
2.3.1 Serum Soluble IL-2 Receptor in Graves' Disease
During the study period we received 24 samples from  patients with 
untreated Graves' disease. O f these, 18 were females, and 6  were males. The 
average age of these patients was 37.37 years (range of 17-77 years). Figure 2.3 
shows the age distribution of these patients. The histogram illustrates that the 
highest incidence of disease was between 20 and 50 years.
The m ean serum  concentration  and standard deviation of soluble 
Interleukin-2 receptor (sIL-R) for these patients were 2465 U/ml ± 833.
The thyroid function of the patients was evaluated by measurements of total 
T4 , T3 , TSH, and TSH receptor antibody (TRAb). Free T4, titre o f thyroid 
m icrosom al antibodies (M) and titre of thyroglobulin antibodies (T) w ere 
determined for some cases. The results of these tests were extracted from the case 
files of these patients.
23 out of 24 cases had increases in the serum level of T4 , ranging from 113 
to 453 nmol/1 (reference range in our laboratory is 55-145 nmol/1). The level of T 3  
was determined for 23 cases, ranging from 2.5 to 12.1 nmol/1 (reference range in 
our laboratory is 0.9-2.7 nmol/1). TSH was undetectable in almost all cases (<0.1 
mU/1). The highest value was 0.16 mU/l (reference range 0.4-5.0 mU/1). Thyroid 
receptor antibody (TRAb) was determined for 22 cases. Two of these cases were 
within the normal range ( < 1 0  %), a further two cases were borderline ( 1 0 - 2 0  %), 
and the remainder had increased level of thyroid antibody. Free T4  was determined 
for 1 1  cases, and all of them also had increased values for this parameter (reference 
range 11-24 pmol/1). The titre o f thyroid microsomal antibodies (M) was 
determined for 19 cases. Titres for six cases were undetectable or normal (at or 
below 1/100), and the remaining cases had increased titres ranging from 1/400 to 
1/102400. Finally the thyroglobulin antibody titre (T) was determined for 19 cases. 
Titres for 14 cases were normal (<1/10), and remaining cases had increased titres 
ranging from 1/80 to 1/5120. The summary of these data is shown in table 2.2. For 
the calculations, values of the titres of thyroid microsomal antibodies and of thyroid 
antibody were expressed as real numbers. The cases that had their titre of thyroid 
microsomal antibodies (M) below 1/100 were designated as 80, and cases that had 
their titre of thyroglobulin antibodies (T) below 1/10 were designated as 8 .
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Figure 2.3: Age distribution histogram of patients with untreated Graves’ disease. 
Numbers in the bars represent male cases.
Variable Mean Std. Dev. Count Minimum Maximum
Age 37.4 13.4 24 17 77
SIL-2R 2465 833 24 930 4250
T4  nmol/ 1 236.9 85.0 24 113 453
T3  nmol/ 1 6 . 6 2.3 23 2.5 1 2 . 1
FT4  pmol/1 61.2 2 2 . 1 1 1 36.1 1 1 0 . 2
TSH mU/1 0.103 0.103 2 2 0 . 1 0.16
TR Ab % 35.7 21.9 2 2 6 80
M 8513 23498 19 < 1 0 0 102400
T 325.9 1170.1 19 < 1 0 5120
Table 2.2: Results of investigations carried out on untreated patients with Graves' 
disease. M and T stand for thyroid microsomal antibody titre and thyroglobulin 
antibody titre. For calculation these titres were shown as real numbers.
Treatment for most patients was started by prescribing anti-thyroid drugs 
(20 mg carbimazole, twice a day, or propylthiouracil). All patients with elevated T 4  
orTh were also prescribed 40 mg propranolol, twice per day.
Follow up samples were collected on their review visits to hospital. Two 
patients did not have follow up samples, and five patients had only one follow up 
sample after one or two months of treatment. The remaining patients had at least 
two to four follow up samples. All together we received 49 further samples. An 
analysis of these samples is given in table 2.3. The results of thyroid function tests 
and the other related param eters that were carried out on the same date were 
extracted from patient files.
Generally, after first month of treatment, T 4  and T 3  concentrations decreased 
to within the reference range, as did the free T 4  concentration, but TSH was not 
brought into the reference range in 87 % of the patients. Titres of thyroid antibodies 
(TRAb, M, and T) were still above normal level. The concentration of sIL-2R was 
reduced compared to initial levels, but still above normal.
After two months of treatment, serum concentrations of T 4  and T3  (T4  53± 
34, n-10; T 3  1.5 ± 0.63, n~9) decreased to below the reference range. Patients were 
then started on L-thyroxine (0.1 mg per day). TSH was still abnormal, and thyroid 
antibodies (TRAb, M, and T) levels were starting to decrease. The level of serum 
sIL-2R was reduced again, but not to normal levels.
In the third month post treatment, the level of serum sIL-2R tended to 
increase again as the concentrations of thyroid hormones also rose with hormone 
replacement, although improvements were seen in TSH and thyroid antibodies 
levels. The concentration of serum SÎL-2R continued to fluctuate till eight months 
post treatment (figure 2.4).
The fluctuations in serum sIL-2R levels till eight months post treatment 
suggest that the concentration of this receptor in serum not only depends on the 
immune state of the patient, but also on the concentrations of thyroid hormones. 
This could be tested statistically by calculation of correlation coefficients for each 
hormone against slL-2R. However, the numbers of post treatment samples after the 
first 2  months were insufficient to carry out calculations for individual time points. 
Therefore all post treatm ent samples were combined for statistical purposes. A 
summary of the descriptive statistics for these data is given in table 2,4.
Statistical analysis of the values for serum sIL-2R of patients before and 
after treatment revealed a highly significant difference between groups. The serum 
concentration of sIL-2R in patients with Graves' disease, before treatment, is also 
significantly different from the normal subjects (327 ± 8 8  U/ml). The summaries of 
the statistical analysis are presented in figure 2.5.
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Period of treatment Number of cases Percentage of total
1 month 15 30.31
2  months 1 2 24.49
3 months 3 6 . 1 2
4 months 6 12.24
5 months 3 6 . 1 2
6  months 2 4.81
7 months 4 8.16
8  months 2 4.81
9 months 1 2.04
1 0  months 1 2.04
Total 49 1 0 0
Table 2.3: Number of follow up samples received after corresponding period of 
treatment.
I
Variable Mean Std. Dev. Count Minimum Maximum
Age 3 7 7 13.7 49 17 77
SIL-2R 1040 412 49 260 2050
T4  nmol/ 1 87.4 36.7 43 8 157
T3  nmol/ 1 1.82 0.55 37 0 . 6 3.1
FT4  pmol/1 12.45 7.20 1 2 1.3 27.4
TSH mU/1 3.17 6 . 1 48 0 . 1 26.2
TR Ab % 34.25 27.2 36 1 84
M 6444.5 18939.7 31 < 1 0 0 102400
T 62.1 136.1 31 < 1 0 640
Î
Table 2.4: Results of investigations carried out on treated patients with G raves' 
disease. M and T stand for thyroid microsomal antibody titre and thyroglobulin 
antibody titre. For calculation these titres were shown as real numbers. 1
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Figure 2.4: Serum level of sIL-2R after different periods of treatment. The bar 
represents the standard deviation, while numbers in the boxes (mean) represent the 
number of cases.
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Figure 2.5: Serum level of sIL-2R in patients with Graves' disease before and after 
treatm ent. Error bars represent one standard deviation, while the (*) shows 
significant differences compared to control subjects.
After treatment the serum level of SÎL-2R decreased significantly to 1040 ± 
412 U/ml. This could be a direct effect of drug treatment on the disease process or 
could be related to the decreases in thyroid hormones that took place during the 
same time interval. However, the serum level of SÏL-2R was still significantly 
different from the control group.
Regression analysis was carried out against sIL-2R for all m easured 
parameters before and after treatment. There was a highly significant correlation 
between T 4  and sIL-2R before treatm ent (r=0.684, P<0.001). The correlation 
between T3  and slL-2R before treatm ent was also highly significant (r=0.695, 
P<0.001). The correlation between free T 4  and corresponding slL-2R in untreated 
Graves' disease was lower (r=0.54) and not significant. This may be partly because 
of the lower number of cases. There were no significant correlation between the 
titres of thyroid microsomal antibodies, thyroglobulin antibody, or thyroid receptor 
antibody with sIL-2R. Summaries of the regression analyses and their plots are 
presented in figure 2 .6 .
Among 49 cases post treatment, 43 patients had results available for T 4 . 
There was no correlation between T 4  and sIL-2R post treatment (r=0.216, P>0.05). 
Only 37 post treatment cases had results for T 3 . The correlation between T 3  and 
sIL-2R was low but significant (r=0.507, P<0.01). Only 12 results were obtained 
for free T 4  post treatment. There was no significant correlation between this 
parameter and sIL-2R (r=8.96x 10^, P>0.05). Thyroid receptor antibody (TRAb) 
values were obtained for 36 cases post treatment. There was a significant correlation 
between TRAb and sIL-2R (i-0 .469, P<0.01).
TSH concentration of serum increased by the end of study in m ost cases. 
There were 29 cases below reference range, 10 cases within the range and 9 cases 
above the range. The mean value was 3.17 mU/1 ± 6 .1 . The correlation between 
TSH and sIL-2R was 0.350, p<0.05, after treatment.
Thyroid m icrosom al antibodies were measured on 31 occasions post 
treatment. Out of these, 11 cases had a normal titre, and the 20 increased values 
reported were scattered in a wide range, from 1/400 to 1/102400; there was no 
correlation between this parameter and sIL-2R. From 31 results for thyroglobulin 
antibody titre, only 8  cases had increased titre ranging from 1/80 to 1/640. There 
was no correlation between these parameters and sIL-2R in patients post treatment. 
Summaries of the regression analyses and their plots are presented in figure 2.7.
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Figure 2.6: Regression plots for serum concentrations of T4 , T 3 , FT4 , and TSH 
receptor antibody versus sIL-2R in untreated patients with Graves' disease.
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Figure 2.7: Regression plots for serum concentrations of T 4 , T3, TSH receptor 
antibody, and TSH versus sIL-2R in treated patients with Graves' disease.
2.3.2 Production Of siL-2R by Whole Blood
2.3.2.1 Preliminary Experiments
Blood was collected from healthy volunteers and prepared as described in 
section 2.2.1.2. Initial experiments were set up using whole blood (WB) diluted 
9:10 with RPM l medium containing stimulators. It was stimulated with 1 0  piglml of 
EPS, 10 ptglmX of PHA, or a mixture of them (10 /^g/ml of each one), for 24 h. 
Control wells contained medium in place of stimulator. Plasma separated from the 
blood immediately after collection served as pre-control.
In all incubated wells, the plasma level of sIL-2R increased significantly 
compared to pre-control (401 U/ml ± 3.0). The level of sIL-2R in the control group 
increased to 521 U/ml ± 12.2, while that in the group treated with EPS was 830 
U/ml ± 16.8. The level of sIE-2R for PHA stimulated cells was 724 ± 29.1 U/ml, 
while that for EPS/PHA mixture was 1247 U/ml ± 50.5.
The above data shows that the sum of the stimulatory effects of EPS and 
PHA is approximately the same as that for stimulation with the mixture of EPS and 
PHA. This suggests that either there are different receptors on the same cell for each 
of the stimulators used, or different stimulators act on a different population of 
cells.
This experim ent was repeated on three different occasions and sim ilar 
results were obtained.
2.3.2.2 Time Course Study
The optimal time course was investigated for each stimulator used. Three 
1 2 -well plates were set up as for the first experiment, using the same concentrations 
of stimulators. All plates were incubated as before. Every 24 h, one plate was 
removed from the incubator, and plasma from each well was separated as described 
in section 2.2.3.1.
The concentration of sIE-2R in control wells containing no stimulant was 
itself elevated after 24, 48 and 72 h compared to the pre control at 0  time. The 
concentration at 0 time was 583 U/ml ± 14.0, and at 24, 48 and 72 h the 
concentrations were 713 U/ml ± 20.4, 913 U/ml ± 41.0 and 963 U/ml ± 35.5 
respectively. There was a statistically  significant d ifference betw een the 
concentrations at 24 and 48 h, but not between 48 and 72 h.
The concentrations of sIE-2R in wells stimulated with EPS were 948 U/ml ±
23.4 at 24 h, 1422 U/ml ± 40.0 at 48 h and 1612 U/ml ± 30.6 at 72 h. These were 
highly significantly increased (p<0 .0 0 0 1 ) compared to the control cells at the same
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tim e points. There w ere statistically  significant d ifferences betw een the 
concentrations at 24 and 48 h and between 48 and 72 h.
The concentrations produced by cells stimulated by PHA were 1167 U/ml ± 
29.6, 2389 U/ml ± 23.0 and 2820 U/ml ± 106.7 at 24, 48 and 72 h. These were 
again highly significantly increased over control cells incubated for the same time. 
There were highly significant differences between the concentrations at 24 and 48 h 
and between 48 and 72 h.
Cells stimulated with 10 /fg/ml of PHA produced more slL-2R than those 
stim ulated with the same concentration of LPS, This difference was highly 
significant (p<0.0001) at all time points.
The concentrations of sIL-2R produced by cells stimulated by the mixture of 
LPS and PHA were 1520 U/ml ± 31.1, 3011 U/ml ± 54.2 and 4392 U/ml ± 46.7 at 
the three time points. These were highly significantly increased (p<0,0001) over 
control cells. The concentrations at 48 h were significantly higher than those at 24 h 
and those at 72 h were higher than at 48 h (p<0.0001).
2.3.2.3 Dose-Response Curves
To determine the optimal dose for each stimulator, three 12-well plates were 
set up by dispensing 450 pil whole blood into each well. To triplicate sets of wells in 
the first plate, 50 /d  of medium containing 0, 1, 5 or 10 jxg/ml of LPS were added. 
The stimulator used for the second plate was a series of identical concentrations of 
PHA, whereas the third plate was stimulated with a mixture of LPS and PHA. The 
plates were incubated for 72 h.
As had been found in the previous experiment, cells incubated w ithout 
stimulators still produced a certain amount of sIL-2R. The concentration in the 
combined control wells of the tliree plates was 907 U/ml ± 21.3, compared to 588 
U/ml ± 17.2 in the pre-control.
There were no significant differences between the amounts of sIL-2R 
produced by cells stimulated by 1, 5, or 10 /fg/ml of LPS, these being 1807 ± 69.29, 
1891 ± 48.52 and 1889 ± 52.88 U/ml respectively (figure 2.8). All were, however, 
significantly different from control ceils (907 ± 11.02 U/ml).
There was a significant dose-response curve for PHA. The concentrations at 
1, 5, and 10 pig/m\ were 906 ± 14.73, 1743 ± 22.28 and 2901 ± 48.14 U/ml 
respectively. The concentrations produced by 5 and 10 pig/ml of PHA were 
significantly different from control (903 ± 40.53 U/ml).
Once more, the concentrations of sIL-2R produced under the influence o f a 
mixture of LPS and PHA were equivalent to the sum of the individual stimulators. 
Summaries of these results are presented in figure 2.9.
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Figure 2.8: Soluble IL-2R produced by whole blood, when incubated with 10 fig/ml 
of LPS, PHA, or a mixture of LPS and PHA (10 pig/m\ of each) for various times. 
Stars show significant differences between value obtained for each stimulator at 
each time point, and value obtained for unstimulated cells (zero time point).
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Figure 2.9: Dose-response curve of sIL-2R produced by whole blood, when 
incubated with LPS, PHA, or a mixture of them for 72 hours. Stars show significant 
differences between value obtained for each stim ulator and the value of 
unstimulated cells (zero concentration).
23 .2 .4  Effect O f Dilution O f The Sample
In initial experiments, the minimal volume of stimulator was added to avoid 
dilution of whole blood in culture. However we always detected an increase in the 
level of sIL-2R for control sets. Some of this increase could be due to the activation 
of monocytes and macrophages by adhesion to the plate, or lack of movement for 
different groups of cells. It is also possible that part of this increase could be caused 
by dilution of blood by the medium. To investigate the effect of dilution in our 
protocol, we set up a new series of experiments. For this experiment the whole 
blood was diluted two fold with media as given in section 2 .23 .2 . The final 
concentration for LPS was selected as 1 /<g/ml, because in the previous experiment 
it was shown to be the lowest effective dose. The final concentration of PHA was 
selected as 10 piglml. T hree identical plates were set up using the above 
concentrations of LPS, PHA, and the combination. The plates were incubated as 
before. Every 24 h, one plate was removed from the incubator, and supernatant 
from each well was separated. To compare the result of the two protocols, all values 
were expressed as units per ml of whole blood rather than concentration in the 
wells.
As before, the control samples produced sIL-2R, and the amounts were 
comparable to those in undiluted blood. The pre-control was 727 ± 37.0 U/ml, and 
the concentrations at. 24, 48 and 72 h were 1039 ± 42.8, 1144 ± 62.4 and 1240 ±
32.4 U/ml. The concentration at 72 h was significantly greater than that at 24, but 
not 48, h. The concentration produced by cells stimulated with LPS was 2327 ±
77.3 U/ml at 24 h, 2588 ± 25.3 U/ml at 48 h and 3253 ± 109.1 U/ml at 72 h. These 
figures are markedly greater than the amounts secreted by undiluted cultures (see 
figure 2.10). The amounts produced by cells stimulated by PHA or by the mixture 
were also approximately doubled when cells were diluted 1:2. The concentrations 
produced under PHA stimulation were 2674 ± 267.0, 4523 ± 55.1 and 6047 ± 198.7 
U/ml and for the mixture were 4658 ± 349.1, 7064 ± 198.5 and 8991 ± 244.8 U/ml 
respectively.
Similar experiments were carried out with whole blood that was collected 
from healthy volunteers. The effect of Graves' disease on whole blood release of 
sIL“2R was investigated in a pilot experiment. For this, blood was collected from 
three patients with untreated Graves' disease. Samples were prepared as before, and 
experiments were set up within one hour after collection. Two 12-well plates were 
set up for each patient. The first plate was set up undiluted and the second plate was 
set up using samples diluted 1:2. The final concentration of LPS for both protocols 
was 1 pigiml, and that of PHA was 10 /fg/ml. The final concentrations of mixed
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Figure 2.10: Effect of dilution of whole blood on production of sIL-2R. W hole 
blood was stimulated under identical conditions, for various times, with different 
dilution factors. The final concentration of LPS was 1 /<g/l, while that of PHA was 
10 /ig/1. Stars show significant differences between value obtained for each 
stimulator at each time point, and value obtained for unstimulated cells (control), 
while (•) show significant differences between corresponding values in each set that 
were caused by change of dilution factor.
stimulators were 1 jiglxnl of LPS and 10 ptgjml of PHA. The incubation time for 
both plates was 72 h.
The concentration of sIL-2R in the pre-control sample of the patients was 
2040 ± 58.5 U/ml, considerably greater than that in normal subjects. In unstimulated 
wells, the concentration of SÎL-2R increased to 4319 ± 100,8 U/ml (undiluted 
samples) and 4400 ± 9 1 .6  U/ml (diluted 1:2). The absolute m agnitude of the 
increase and percentage change were also greater than those for healthy controls 
(112% compared to 65% for undiluted samples, and 116% compared to 70% for 
diluted samples). The results of this experiment are shown in figures 2.11 and 2.12.
The concentration of sIL-2R produced by cells stimulated by LPS was 6135 
± 56.9 U/ml (undiluted) and 6393 ± 123.4 U/ml (diluted). While these are not 
different from each other, in contrast to the results found with normal blood, they 
are clearly much greater than the levels produced by normal cells. The absolute 
magnitude of the increase over control was also greater, but only in the undiluted 
cultures (1816 compared to 650 U/ml). The increase was similar in both groups of 
subjects in the diluted cultures (1993 compared to 2013) and the percentage 
increase was actually considerably less in patients than in healthy controls because 
of the elevated initial concentrations (undiluted: 42.0% versus 67.5%; diluted: 
45,2% versus 162.3%).
Similar results were obtained in cultures stimulated with PHA or the mixture 
of PHA and LPS. The undiluted PHA cultures produced 7544 ± 125.8 U/ml in 
patients compared to 2820 ± 106.7 U/ml in healthy controls, while in diluted 
cultures, the values were 10923 ± 245.8 and &D41 ± 198.7 U/ml. In this case, there 
was a difference between patients and healthy controls in both culture systems. The 
absolute magnitudes of the increases over control were greater for patients than 
controls, but again the percentage increases were lower (undiluted: 74.6% versus 
192.8%; diluted: 148.2% versus 387.6%).
When both stimulators were used, the patients produced 9320 ± 30.5 U/ml 
(undiluted) and 17640 ± 244.3 U/ml (diluted). Again, the absolute magnitude of the 
increase compared to control cells was greater in patients, but the percentage 
increase was less (undiluted: 115.7% versus 356.07%; diluted: 300.9% versus 
625.0%).
Consistently, then, the response of blood cells from patients with Graves' 
disease was greater than that of normal control individuals. The difference in 
response was seen even in control cultures, though there was also a difference in the 
response to stimulation. This was particularly marked in the diluted cultures 
exposed to the combined stimulus (figures 2.11 and 2.12).
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Figure 2.11: Effect of dilution of normal and patient blood on production of sIL-2R, 
when stimulated by 1 //g/ml of LPS, 10 piglml of PHA, and mixture of them for 72 
hours. Stars show significant differences between value obtained for each stimulator 
and value of unstimulated cells (control) while (•) shows significant differences 
between corresponding values obtained for the reference and patient samples.
S1L-2R U/ml of whole blood
20000-g I I (lontrol 
H  IJ^ S
10 0 0 0 -B H  MIX
5 0 0 0 -
15000
Reference (9:10) Patient (9:10) Reference (5:10) Patient (5:10)
Figure 2.12: Increment in production of sIL-2R by whole blood of reference and 
patient samples after 72 hours stimulation with 1 piglml of LPS, 10 ;<g/PHA, or a 
mixture of them. All values were corrected by subtracting the values of pre-control 
from the results obtained for each set. Stars show significant differences between 
value obtained for each stimulator or control for the patients and corresponding 
values obtained for the reference group.
2.3.3 Production of SÏL-2R and Cytokines by Whole Blood
For a further set of experiments on the release of cytokines and sIL-2R by 
cultures of whole blood, we adopted a protocol provided by Medgenix Diagnostics.
This protocol was used for the following reasons:
This company agreed to carry out measurement of various cytokines on our 
samples if we followed a method which had been validated by De Groote and co- 
workers (1992), With this method whole blood was diluted 1:11 with the medium, 
which would allow us to examine the effect of higher dilution factors on sIL-2R 
release. An advantage of this protocol was that polypropylene tubes are used instead 
of plates, and cells were less liable to stick to these tubes than to the flat-well plates 
used previously.
W hole blood samples from reference group and patients with G raves' 
disease were obtained as described in section 2.2, and stimulated with a mixture of 
LPS/PHA or a mixture of Ca ionophore A 23187 and PMA for 4, 24, or 72 h as 
described in section 2.2.5. Because the values of cytokine production were highly 
skewed and the variances between the groups were greatly different, mean and 
standard deviation are mentioned in the text and graphs.
2.3.3.1 Soluble lL-2 Receptor
Soluble 1L-2R was determined in plasmas separated before incubation and 
in supernatants from LPS/PHA stimulated WB at 72 h only, since the preliminary 
experiments had indicated that production would be maximal at this time. Since the 
same volume of whole blood was used throughout this set of experiments, all values 
determined for supernatants are expressed in unit per ml of supernatant.
2.3.3.1.1 Reference range for plasma
A new reference range was detennined for slL-2R in heparinized plasm a 
(449 ± 134.35 U/ml). There was a significant difference (p=0.02) between this 
range and the previous reference range established for serum (326 ± 88.20 U/ml). 
Although the number of cases is small (n=6 for plasma, and n -1 6  for serum), this 
suggests that the plasma level of slL-2R may be higher than the corresponding 
value for serum.
The plasma level of slL-2R for patients with Graves' disease had a mean 
value of 2106 ± 983.46 U/ml. This was significantly different (p<0.001) from  the 
reference range. This result agreed with the findings for untreated Graves' patients 
that were reported in the previous section.
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2.3.3.1.2 Production from blood in vitro
W hen peripheral bloods of the reference group (n=6) were incubated 
without stimulation for 72 h, the amount of sIL-2R produced was 871 ± 36 U/ml 
(mean ± SD). Stimulation of the whole blood with a mixture of LPS and PHA 
increased the production of slL~2R to 1575 ± 25 U/ml, significantly different 
(P<0.0001) from the unstimulated group.
W hen peripheral bloods of the patients' group (n=16) were incubated 
un stimulated for 72 h, the production of sIL-2R was 881 ± 33 U/ml. Statistically 
there was no significant difference between the values obtained for supernatant 
separated from the unstimulated set of reference samples (871 ± 36 U/ml), and the 
patient samples.
The production of sIL-2R by blood samples of patients had a mean value of 
3200 ± 173 U/ml after stimulation with LPS and PHA, whereas the corresponding 
value for the reference samples was 1575 ± 25 U/ml. Statistically the difference was 
highly significant (P<0.0001). Furtherm ore, there was a significant difference 
between the values obtained for the stimulated cells of the patient group and its 
unstim ulated control (P<0.0001). This finding also m atched our previous 
experiments. Summaries of above results are presented in figure 2.13.
To determine the actual production of sIL-2R during the course of the 
experiment, the value of the pre-control was subtracted from values obtained for 
control and stimulated cells after incubation (after correction of values for dilution 
factor of 11) to determine the response of the cells to dilution and stimulation.
The mean production of sIL-2R by the WB cells of the reference group due 
to the effect of dilution alone (unstimulated wells) was 9136 ± 352 U/ml of whole 
blood, and the con'esponding value for patient samples was 7591+ 398 U/ml of 
whole blood. This indicates that dilution and incubation itself caused a significant 
increase of sIL-2R for both groups, when these values were compared to the pre- 
control. Production of sIL-2R by the reference group was significantly higher than 
that of the patient samples (p<0.05).
The recalculated results for stimulated whole blood (LPS/PHA) indicate that 
the production of sIL-2R by the cells of both groups was increased significantly 
when compared to their unstimulated controls. The mean value was 16883 ± 270 
U/ml of WB for the reference group, and the corresponding value for patient 
samples was 33098 ± 1881 U/ml of WB. There was a highly significant difference 
(p<0.0001) between these increases. This shows that the cells of patient group are 
more sensitive to stim ulation than the cells of reference group. Summaries of 
recalculated results are presented in figure 2.13.
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Figure 2.13: Effect of dilution (1:11; Medgenix protocol) and stimulation of whole 
blood of the reference (R, n -6 ) and patient samples (P, n=16) on production of sIL- 
2R. Upper graph: the m ean and standard deviation of sIL-2R obtained in 
supernatants of the cells when incubated for 72 hours. Lower graph: same values 
after recalculating the values as per ml of whole blood, and subtracting the values o f 
pre-control from each sample.
23.3 .2  Interleukin-2
2.3.3.2.1 Unstimulated
W hen peripheral bloods of the reference group (n=6) w ere incubated 
without addition of stimulators, the production of IL-2 was undetectable in 4  cases 
and reached a maximum level of 54 pg/ml in the remainder after 72 h. In the 
patients with Graves' disease, production of IL-2 without stimulation was also 
undetectable for 4 cases throughout the study. The mean production of IL-2 was 72 
± 38 pg/ml at 4 h, 157 ± 87 pg/ml at 24 h, and 201 ± 117 pg/ml at 72 h. The values 
obtained for each time point were not significantly different from each other. 
Furthermore, there were no significant difference between the values obtained for 
the reference group and the patient group at any of the three time points.
23.3.2.2 LPS/PHA
Stimulation of whole blood from control subjects with a mixture of LPS and 
PHA increased the production of IL-2. The mean values were 64 ± 59 pg/ml (mean 
± S #  after 4  h, 370 ± 59 pg/ml after 24 h, and 149 ± 38 pg/ml after 72 h. 
Statistically, the release of IL-2 at 24 h and 72 h was significantly different from the 
unstimulated controls (p<0.01 and <0.05). The production reached its highest level 
after 24 h. The value at this tim e point was significantly higher than at 4  h 
(P=0.001), and declined by 72 h to a level significantly lower (P<0.01) than at 24 h, 
while not significantly different from the value obtained for 4  h.
Stimulation of whole blood of the patients with a mixture of LPS and PHA 
increased the production of IL-2 to 120 ± 50 pg/ml after 4 h, 762 ± 141 pg/ml after 
24 h, and 986 ± 166 pg/ml after 72 h. The value obtained at 4  h was not different 
from the unstimulated control at the same time point, whereas the values obtained at 
24 h and 72 h were significantly higher than their controls (p<0.01). Furthermore, 
there were significant differences between the value obtained for 4 h and the other 
time points (p<0.001 between 4  and 24 h and <0.0001 between 4  and 72 h).
The pattern of IL-2 production by the patient group was different from that 
of the reference group. In the reference group, the production of this cytokine 
reached its highest level at 24 h and declined after this time, whereas in the patients' 
group its production continued after 24 h, and the highest level was detected after 
72 h stimulation. There was a significant difference between patients and controls 
after 72 h (p<0.01).
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Figure 2.14: Increases in production of IL-2 by whole blood of reference and patient 
samples after stimulation with a mixture of LPS and PHA, or a mixture of PMA and 
Ca ionophore, for different periods. The final concentrations were 22.5 mg/1 for 
LPS, 4.5 mg/1 for PHA, 89 pioJ\ for Ca ionophore, and 2.7 ;^g/l for PMA. The (*) 
shows significant increases compared to the self-control, and (•) shows significant 
differences.
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Figure 2.15: Increases in production of IL-4 by whole blood of reference and patient 
samples after stimulation with a mixture of LPS and PHA, or a mixture of PMA and 
Ca ionophore, for different periods. The final concentrations were 22.5 mg/1 for 
LPS, 4.5 mg/1 for PHA, 89 //g/1 for Ca ionophore, and 2.7 /^g/l for PMA. The (*) 
shows significant increases, compared to self-control.
2.33.2.3 Ca/PMA
Stimulation of, whole blood of controls with a mixture of Ca ionophore and 
PMA also increased the production of lL-2. The mean values were 15 ± 15 pg/ml 
after 4  h, 37 ± 20 pg/ml after 24 h, and 18 ± 11 pg/ml after 72 h. The value at 72 h 
was significantly different from its unstimulated control (P<0.05).
Stimulation of whole blood of the patients with a mixture of Ca ionophore 
and PMA increased the production of IL-2 to 201 ± 1 1 7  pg/ml after 4  h, 503 ± 186 
pg/ml after 24 h, and 420 ± 196 pg/ml after 72 h. The production of IL-2 at 4, 24, 
and 72 h was not different from the unstimulated controls at the same time point. 
There were no significant differences between the reference group and the patient 
group (figure 2.14).
2.3.3.3 Interleukin-4
2.3.3.3.1 Unstimulated
When peripheral bloods of the reference group (n -6 )  were incubated 
without stimulation no production of IL-4 was detectable at all three time points. 
Peripheral blood samples of the patients with Graves' disease (n=18) tended to 
release more IL-4 than the control group. The production of IL-4 was undetectable 
for 11 cases after 4  h incubation. The mean value obtained for this set was 141 ± 
109 pg/ml. The mean value obtained for the unstimulated cells after 24 h incubation 
was 136 ± 104 pg/ml. After 72 h, the value was 130 ± 98 pg/ml. Statistically, the 
values obtained at each time point were not significantly different from each other. 
Furthermore, there were no significant differences between the values obtained for 
the reference group and the patient group at any of the three time points.
2333.2LPS/PHA
Stimulation with a mixture of LPS and PHA increased the production of IL- 
4 from control cells slightly. The mean values were 3 ± 3 pg/ml after 4 h, 10 ± 2 
pg/ml after 24 h, and 13 ± 3  pg/ml after 72 h. Statistically, the values obtained at 24 
h and 72 h were significantly higher than their controls (p<0.05). Stimulation of the 
whole blood of the patients w ith a mixture of LPS and PHA increased the 
production of IL-4 to 141 ± 107 pg/ml after 4  h, 160 ± 104 pg/ml after 24 h, and 
206 ± 111  pg/ml after 72 h. Statistically, the values obtained at 24 and 72 h were 
significantly h igher than the unstim ulated controls (p<0.05). There was a
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significantly greater production of IL-4 from patients' samples than from the 
reference group at 72 h (p<0.05).
2 .3 .3 3 3  CalPMA
Stimulation with a mixture of Ca ionophore and PMA also increased the 
production of IL-4 slightly. The mean values were 1 ± 0.4 pg/ml after 4  h, 5 ± 1 
pg/ml after 24 h, and 11 ± 5 pg/ml after 72 h. The value obtained at 24 h was 
significantly different from its unstimulated control (p<0.05). The values obtained 
at each time point were not significantly different from each other.
Stim ulation of the whole blood of the patients with a m ixture of Ca 
ionophore and PMA increased the production of IL-4 to 143 ± 109 pg/ml after 4  h, 
166 ± 124 pg/ml after 24 h, and 135 ± 82 pg/ml after 72 h. Statistically, the values 
obtained for 4, 24, and 72 h were not different from their unstimulated controls. 
There were also no significant differences between patients and the reference group 
(figure 2.15).
2.3.3.4 Interleukin-6
2.3.3.4.1 Unstimulated
The production of IL-6 in the reference group (n=6) was either undetectable 
(n -5 ) or reached a maximum level of 9 pg/ml (n= l) after 72 h. Samples from 
patients with Graves' disease (n=18) released more IL-6 than the control group. The 
production of IL-6 from the unstimulated cells was undetectable for only 1 case 
after 4  h incubation. The mean value obtained for this group was 185 ± 105 pg/ml. 
The mean value obtained after 24 h incubation was 233 ±111 pg/ml, and after 72 h, 
it was 229 ± 128 pg/ml. There were no statistically significant differences between 
these values. There was a significantly greater production of IL-6 from patients' 
samples than from the reference group at 4  h (p<0.05), but not at 24 h or 72 h. ;
23.3 .4 .2  LPS/PHA
Stimulation of control cells with a mixture of LPS and PHA increased the 
production of IL-6 to 667 ± 212 pg/ml after 4  h, 7269 ± 2531 pg/ml after 24 h, and 
23623 ± 4564 pg/ml after 72 h. Statistically, the values obtained for all three time 
points were significantly different from their unstimulated controls at the same time 
point (p<0.05 at 4  and 24 h, <0.01 at 72 h). The value at 72 h was significantly 
higher than at 4  h (p<0.001) or 24 h (p<0.01).
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Figure 2.16: Increases in production of IL-6 by whole blood of reference and patient 
samples after stimulation with a mixture of LPS and PH A, or a mixture of PMA and 
Ca ionophore, for different periods. The final concentrations were 22.5 mg/1 for 
LPS, 4.5 mg/1 for PHA, 89 //g/1 for Ca ionophore, and 2.7 //g/1 for PMA. The (*) 
shows significant increase, compared to self-control, while (•) shows significant 
increases, compared to reference group.
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Figure 2.17: Increases in production of INF-y by whole blood of reference and 
patient samples after stimulation with a mixture of LPS and PHA, or a mixture of 
PMA and Ca ionophore, for different periods. The final concentrations were 22.5 
mg/1 for LPS, 4.5 mg/1 for PHA, 89 //g/1 for Ca ionophore, and 2.7 pigl\ for PMA. * 
shows significant increase, compared to self-control, while (•) indicates significant 
decreases, compared to the reference group. The (*) shows significant increase, 
compared to reference group.
Stimulation of blood from patients with a mixture of LPS and PHA also 
increased the production of IL-6. The mean values were 2472 ± 293 pg/ml after 4  h, 
9564 ± 2197 pg/ml after 24 h, and 17231 ± 2837 pg/ml after 72 h. Statistically, the 
values obtained for all three tim e points were significantly higher than their 
unstimulated controls (p<0.0001 at 4  h, <0.0005 at 24 h and <0.0001 at 72 h). 
A dditionally, the value obtained for 72 h was significantly higher than those 
obtained for 4  h (p<0.0001), and 24 h (p<0.05). The patient group produced 
significantly more IL-6 than the reference group at 4 h (p<0.0001) but not at later 
times.
2.3.3.4.3 CaJPMA
Stim ulation of the whole blood from  controls with a m ixture o f Ca 
ionophore and PMA increased the production of IL-6 to 55 ± 30 pg/ml after 4 h, 
123 ± 61 pg/ml after 24 h, and 199 ± 90 pg/ml after 72 h. The values obtained for 4, 
24, and 72 h were not different from their unstimulated controls at the same time 
point. Furtherm ore, there were no significant differences between the values 
obtained at each time point, although there was a trend towards a time-dependent 
increase.
Stimulation of patient samples with a mixture of Ca ionophore and PMA did 
not cause further production of IL-6. The mean values obtained were 226 ± 92 
pg/ml after 4  h, 848 ± 293 pg/ml after 24 h, and 675 ± 235 pg/ml after 72 h. 
Statistically, the values obtained for 4, 24, and 72 h were not significantly different 
from  their unstim ulated controls at the same time point. There were also no 
significant differences between corresponding values obtained for the reference 
group and the patient group. The summary of above data is presented in figure 2.16.
2.3.3.5 Interferon-Y
2.3.3.5.1 Unstimulated
The mean production from control samples was 488 ± 336, 452 ± 2 7 1 , and 
674 ± 268 pg/ml after 4, 24, and 72 h. The mean production of INF-y from the 
patients with Graves' disease (n=18) was 183 ± 1 1 2  pg/ml at 4  h, 126 ± 86 pg/ml 
after 24 h, and 151 ± 1 1 2  pg/ml at 72 h. The values obtained for the patient group 
were significantly lower than the corresponding values obtained for the reference 
group at 72 h (p<0.05), while there were no significant differences at the other two 
time points.
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23.3.5.2 LPS/PHA
Stimulation of the whole blood of controls with a mixture of LPS and PHA 
increased the production of INF-y at 24 h and 72 h. The mean values obtained for 
the stimulated cells were 365 ± 182 pg/ml after 4  h, 3142 ± 1473 pg/ml after 24 h, 
and 12466 ± 2725 pg/ml after 72 h. Only the value obtained at 72 h was 
significantly different from  its unstim ulated control (p<0.01). The increase in 
production of INF-y was time dependent, because the values obtained for 72 h were 
significantly different from the value obtained for 4 h (p<0.001), or 24 h (p<0.01).
Stimulation of the whole blood of the patients with a mixture of LPS and 
PHA increased the production of INF-y to 284 ± 136 pg/ml after 4 h, 5682 ± 898 
pg/ml after 24 h, and 117733 ± 36092 pg/ml after 72 h. Statistically, the value 
obtained at 4  h was not different from  its unstimulated control, while values 
obtained for 24 h and 72 h were significantly higher than their unstimulated controls 
(p<0.001, <0.01). Additionally, the value obtained for 72 h was significantly higher 
than the values obtained for 4  h (p<0.01), and 24 h (p<0.01). Statistically, the 
patients with Graves' disease secreted more INF-y than control subjects after 72 h 
(p<0.05).
2.3.3.5.3 CaJPMA
Stimulation of the whole blood of controls with a mixture of Ca ionophore 
and PMA also affected the production of INF-y. The mean values obtained were 
674 ± 408 pg/ml after 4  h, 6195 ± 3948 pg/ml after 24 h, and 4547 ± 3576 pg/ml 
after 72 h. Statistically, the values obtained for 4, 24, and 72 h were not different 
from their unstimulated controls at the same time points. Furthermore, there were 
no significant differences among the values obtained at each time point.
Stimulation of whole blood of the patients with a mixture of Ca ionophore 
and PMA caused release of 230 ± 83 pg/ml after 4 h, 1258 ± 399 pg/ml after 24 h, 
and 3784 ± 1585 pg/ml after 72 h. The values obtained for 24, and 72 h were 
significantly different from their unstimulated controls (p<0.05). The production of 
INF-y after 72 h was significantly higher than the value obtained for 4  h (p<0.05). 
There was a significant difference between release of INF-y between patients and 
controls after 24 h (p <0.05). The summary of above data is presented in figure 
2.17.
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23 .3 .6  Tumor Necrosis Factor-a
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Incubation of unstimulated peripheral bloods from the reference group (n=6) 
did not induce production of TNF. In 5 cases the level of TNF was undetectable 
throughout the study, and only one case had a detectable concentration of TNF, 
after 4  h incubation.
The mean production of TNF from unstimulated patient samples (n=18) was 
294 ± 168 pg/ml at 4  h, 218 ± 114 pg/ml after 24 h incubation and 249 ± 143 pg/ml
at 72 h. There were no significant differences between these values. The values 
obtained for the patient group were not significantly different from those obtained 
for the reference group.
Stimulation of the whole blood of controls with a mixture of LPS and PHA 
increased the production of TNF to 339 ± 94 pg/ml after 4  h, 3790 ± 493 pg/ml after 
24 h, and 7986 ± 1283 pg/ml after 72 h. These were significantly higher than their 
unstimulated controls at the same time points (p<0.05, <0,001, <0.01). Furthermore, 
the increase in production of TNF was time dependent, because the values obtained 
for 72 h were significantly different from the value obtained for 4  h (p<0.0001), or 
24h(p<0.01).
Stimulation of whole blood of the patients with a mixture of LPS and PHA 
increased the production of TNF to 1668 ± 237 pg/ml after 4 h, 2488 ± 343 pg/ml 
after 24 h, and 2731 ± 379 pg/ml after 72 h. Statistically, the values obtained for all 
three time points were significantly higher than their unstim ulated controls
(p < 0 .0 0 1 , < 0 .0 0 0 1 , < 0 .0 0 0 1 ).
A t 4 h, the production of TNF by the patient group was significantly higher 
than the reference group (p<0.0001). A t 24 h and 72 h, patients released less TN F 
than controls. This decrease ju st failed to reach significance at 24 h (p=0.06), but 
was significant at 72 h (p<0.0001). f
2.3.3.6.3 CaJPMA
Stimulation of the whole blood with a mixture of Ca ionophore and PMA 
also increased the production of TNF. The mean values were 19 ± 15 pg/ml after 4
I
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Figure 2.18: Increases in production of T N F -a  by whole blood of reference and 
patient samples after stimulation with a mixture of LPS and PHA, or a mixture of 
PMA and Ca ionophore, for different periods. The final concentrations were 22.5 
mg/1 for LPS, 4.5 mg/1 for PHA, 89 piglX for Ca ionophore, and 2.7 //g/I for PMA. 
The (*) shows significant increase, com pared to self-control, while x shows 
significant increases, and + indicates significant decreases, compared to reference 
group.
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Figure 2.19: Effect of M ethimazole, TSH, and thyroid hormones on whole blood 
production of sIL-2R, in presence (right side) and absence (left side) of a mixture of 
LPS and PHA for 72 hours. The (*) shows significant differences compared to self- 
control.
h, 26 ± 12 pg/ml after 24 h, and 30 + 7 pg/ml after 72 h. The value obtained for 72 h 
was significantly higher than its unstimulated control.
Stim ulation of the w hole blood of the patients with a m ixture of Ca 
ionophore and PMA caused production of TNF of 194 + 72 pg/ml after 4  h, 424 ± 
135 pg/ml after 24 h, and 261 ± 67 pg/ml after 72 h. Statistically, the values 
obtained for 4, 24, and 72 h were not significantly different from their unstimulated 
controls at the same time point, or from each other. The production of TNF was not 
significantly greater in patients than controls, at any time point. The summary of the 
above data is presented in figure 2.18.
2.3.4 Effects of Thyroid Hormones, TSH and Methimazole on Cytokine 
Praduction
As the concentration of thyroid hormones in blood altered during the 
treatm ent of the patients w ith Graves' disease studied in section 2.3.1, the 
concentration of sIL-2R appeared to change in parallel. It seemed possible that the 
thyroid hormones themselves might affect the concentration of cytokines. To test 
this hypothesis in vitro, blood from normal subjects was incubated with thyroid 
hormones, TSH, or carbimazole, the most commonly used anti-thyroid drug in this 
country, as described in section 2.2.5, and the production of cytokines was 
measured.
Only the 72 h specimen was assayed for sIL-2 R. A significant effect of 
treatment was seen for both the un stimulated cells and for the cells stimulated with 
LPS/PHA. In the unstimulated cells, this was caused by an increase in the cells 
treated with m ethim azole (957 + 40.6 U/ml). W hile this ju s t failed to reach 
significance when com pared to control (871.4 ± 35.7, p=0.06), the difference 
between methimazole and the cells treated with either thyroid hormones (820 ± 20.7 
U/ml) or TSH (825 + 24.1 U/ml) was significant at the level of p< 0.01.
When the cells were stimulated with LPS/PHA, the control value was 1575 
± 25.3 U/ml. There was a decrease in the cells stimulated with methimazole (1378 +
37.3 U/ml) which again ju s t failed to reach significance when tested by the 
Bonferroni-Dunn criterion (p=0.014, critical value p<0.008), but there was a 
significant increase in those treated with TSH to 2046 ± 71.3 U/ml and in those 
treated with thyroid hormones to 1859 ± 61.5 U/ml (figure 2.19).
The production of cytokines by the cells that were stimulated only with 
thyroid hormones, TSH, or methimazole were not significant compared to the 
control cells (unstimulated cells). These results were shown in figure 2.20 to 2.23. 
The cytokine production by the cells that were stimulated with thyroid hormones, 
TSH, or methimazole, in the presence of a mixture of Ca ionophore and PMA, was
i
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Figure 2.20: Production of IL-2 by whole blood (reference group) diluted 1:11 with 
the medium, and stimulated with methim azole (Im  mol/1), TSH (50 mU/1) or a 
mixture of T 4  (1 //mol/1) and T 3  (10 nmol/1), for different periods.
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Figure 2.21: Production of IL - 6  by whole blood (reference group) diluted 1:11 with 
the medium, and stim ulated with methimazole (Im  mol/1), TSH (50 mU/1) or a 
mixture of T 4  (1 //mol/1) andT s (10 nmol/1), for different periods.
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Figure 2 .2 2 : Production of INF-y by whole blood (reference group) diluted 1 : 1 1  
with the medium, and stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a 
mixture of T 4  ( 1  //mol/1) and T 3  ( 1 0  nmol/1), for different periods.
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Figure 2.23; Production of T N F -a  by whole blood (reference group) diluted 1:11 
with the medium, and stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a 
mixture of T 4  ( 1  //mol/1) and T 3  ( 1 0  nmol/1), for different periods.
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Figure 2.24: Production of IL-2 by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of PMA (2.7 //g/1) and Ca ionophore (89 
//g/l), and stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a mixture of 
T4  ( 1  //mol/1) and T 3  ( 1 0  nmol/1), for different periods.
PMA/Ca stimulated cellsIL-4 (pg/ml)
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Figure 2.25: Production of IL-4 by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of PMA (2.7 //g/1) and Ca ionophore (89 
//g/1), and stimulated with methimazole (Im  mol/1), TSH (50 mU/l) or a mixture of 
T4  (1 //mol/1) and T 3  (10 nmol/1), for different periods.
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Figure 2.26: Production of IL - 6  by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of PMA (2.7 //g/1) and Ca ionophore (89 
//g/1), and stimulated with methimazole (Im  moI/1), TSH (50 mU/1) or a mixture of 
T4  ( 1  //mol/1) andT s ( 1 0  nmol/1), for different periods.
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Figure 2.27: Production of INF-y by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of PMA (2.7 //g/1) and Ca ionophore (89 
//g/1), and stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a mixture of 
T4  (1 //mol/1) and T 3  (10 nmol/1), for different periods.
TNF (pg/ml)
PMA/Ca stimulated cells
60 n
E  2 4 h
Control MMI TSH T4,T3
Figure 2.28: Production of T N F -a  by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of PMA (2.7 //g/1) and Ca ionophore (89 
//g/1), and stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a mixture of 
T4  ( 1  //mol/1) and T 3  ( 1 0  nmol/1), for different periods.
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Figure 2.29: Production of IL-2 by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of LPS (22.5 mg/1) and PHA (4.5 mg/1), and 
stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a mixture of T 4  (1 
//mol/1) and T 3  ( 1 0  nmol/1), for different periods.
IL-4 (pg/ml)
25-1 4  h
2 0
15 -
LPS/PHA stimulated cells
1 0 -
Control MMI TSH T4,T3
Figure 2.30: Production of IL-4 by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of LPS (22.5 mg/1) and PHA (4.5 mg/1), and 
stimulated with methimazole (Im  mol/1), TSH (50 mU/1) or a mixture of T 4  ( 1  
//mol/1) and T 3  ( 1 0  nmol/1), for different periods.
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also not significantly different from control, when tested by the Bonferroni/Dunn t
criterion (figure 2.24 to 2.28).
For the cytokines, significant effects of thyroid horm ones, TSH , or 
methimazole were only seen in those samples which were stimulated with a mixture 
of LPS and PHA. There were no significant changes in the production of IL-2 
(figure 2.29) and IL-4 (figure 2.30).
After 4  h, methimazole, TSH and thyroid hormones decreased production of 
TNF from 339.3 ± 94 pg/ml to 48.8 ± 23.8 pg/ml, 129.8 ± 31.8 pg/ml and 47.1 ±
19.6 pg/ml respectively. The changes caused by methimazole and thyroid hormones 
were significant, while that caused by TSH just failed to reach significance by the 
Bonferroni-Dunn criterion (figure 2.33).
After 24 h, there were significant changes in both TNF and IL - 6  production.
TNF (figure 2.33) release was reduced from 3789 ± 493 pg/ml to 156 ± 35 pg/ml,
254 ± 40 pg/ml and 124 ± 12 pg/ml respectively. IL - 6  production was reduced from 
7269 ± 2530 pg/ml to 282 ± 82 pg/ml, 653 ± 360 pg/ml and 607 ± 354 pg/ml (figure 
2.31). All these changes were significant.
Finally, at 72 h, INF-y was also affected (figure 2.32). It was reduced from  
12466 ± 2724 ng/ml to 415 ± 3 1 8  ng/ml, 559 ± 3 1 8  ng/ml, and 1005 ± 445 ng/ml.
TNF was reduced from 7986 ± 1282 pg/ml to 89.5 ± 16.2 pg/ml, 174 ± 40.7 pg/ml 
and 147.6 ± 18 pg/ml. IL - 6  was reduced from 23623 ± 4563 ng/ml to 529 ± 209 
ng/ml, 936 ± 326 ng/ml, and 1180 ± 355 ng/ml. All of these alterations w ere 
significant.
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Figure 2.31: Production of IL - 6  by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of LPS (22.5 mg/1) and PHA (4.5 mg/1), and 
stimulated with methim azole (Im  m ol/1), TSH (50 mU/1) or a mixture of T 4  (1 
//mol/1) and T 3  (10 nmol/1), for different periods. The (•) shows significant 
decreases, compared to the control.
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Figure 2.32: Production of INF-y by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of LPS (22,5 mg/1) and PHA (4,5 mg/1), and 
stimulated with methim azole (Im  mol/1), TSH (50 mU/l) or a mixture of T 4  (1 
//mol/1) and T 3  (10 nmol/1), fo r different periods. The (*) shows significant 
decreases, compared to the control.
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Figure 2.33: Production of T N F -a  by whole blood (reference group) diluted (1:11) 
with the medium containing a mixture of LPS (22.5 mg/1) and PHA (4.5 mg/1), and 
stimulated with m ethim azole (Im  mol/1), TSH (50 mU/1) or a mixture of T 4  (1 
//mol/1) and T 3  (10 nmol/1), for different periods. The (•) shows the significant 
decreases, compared to control.
S E C T IO N  FO U R  
D IS C U S S IO N
2.4.1 Soluble IL  2 R e c e p to r  In  S e ru m
Soluble iîiterleukin-2 receptor is a protein with a molecular mass of 40-45000. 
It is an enzymatic cleavage product of the a  chain of the IL-2 receptor, and is present 
in plasma in healthy subjects. The basal plasma concentration of sIL-2R does not vary 
with age or sex (Giannitsis et al, 1991), but has a circadian rhythm with a peak value 
at 12:29 hour and a trough at 4:14 hour (Lemmer et al, 1992). The plasma level of 
this protein increases in many diseases including Graves' disease.
In the present study, the mean serum concentration of sIL-2R among the 
untreated patients was 7.5 fold higher than the value obtained for the healthy subjects 
who served as controls. This increase has also been reported by other investigators 
(Murakami et al, 1995; Murphy and Kallio, 1994; Mariotti et al, 1992 a; Weryha et al, 
1991; Balâzs and Farid, 1991), but the reasons for the increase in Graves' disease or 
other diseases listed in the introduction (section 2.1.5) are unknown.
In the present study, among untreated patients, the sIL-2R concentration in 
serum correlated with serum concentrations of T4 , T 3  and FT4 , but not with any of the 
thyroid antibodies. Significant correlations between the serum level of sIL-2R and 
either T 4  or FT4  in Graves' disease have been reported previously (Koukkou et al, 
1991). A correlation between T 3  and sIL-2R was also reported by other groups 
(Mariotti et al, 1992 a; W eryha et al, 1991; Koukkou et al, 1991), in agreement with 
the current results.
It is possible that part of the increase in the level of sIL-2R could be caused 
directly by the high concentration of thyroid hormones. This possibility is supported 
by the studies of Mariotti and colleagues (1994) who showed that the serum level of 
sIL-2R was decreased in patients with thyroid carcinoma who were treated with total 
thyroidectom y. The concentration was norm alised by L-thyroxine therapy. In 
addition, serum IL-2R is also increased in patients with non-im mune causes of 
hyperthyroidism, such as adenomas.
If thyroid hormones do induce sIL-2R, it is not clear whether T4  or T3  would 
be primarily responsible. Although T 4  acts primarily as a prohormone for cells that 
contain the 5'-deiodinase enzyme which converts it to T3  (Brent, 1994), the thyroid 
receptors also have affinity for T 4  and are usually occupied by 10-15% T 4  
(McDougall, 1992). It is not clear whether the immune cells that synthesise sIL-2R
----------------
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contain 5 '-deiodinase, leading to the local production of T 3 , which may be an inducer 
of sIL-2R. This needs further investigation.
Two different groups (Balâzs and Farid, 1991; Weryha et al, 1991) detected a 
highly significant correlation between the serum level of TRAb and slL-2R, while 
recent reports (Mariotti et al, 1992 a; and 1994; Murakami et al, 1995) showed no 
correlation between these two parameters in untreated patients with Graves’ disease. 
Moreover, none of these groups detected a correlation between the sIL-2R and the 
titre of thyroglobulin or microsomal antibodies. There was no correlation between 
sIL-2R and the titre of TRAb or other antibodies (T and M) in the present study, 
suggesting that the increase in sIL-2R is not directly related to that aspect of the
2.4 .2  S tudy  O f sIL -2R  R elease F ro m  W hole B lood
To explore further the possible mechanisms of the increased concentration of 
SÏL-2R in serum, it was decided to investigate whether it was possible to stimulate 
blood cells in vitro to release sIL-2R. To ensure that all relevant cell-cell interactions
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immune process.
Among the 49 samples collected after initiation of therapy, 30.3%  were
collected after one month, and 24.5% after two months of treatment. The remainder 
were collected between the third month and tenth month after initiation of treatment. 
The treatment of patients with : carbimazole reduced the serum level of SÏL-2R 
significantly, but it remained significantly higher than the control group. At this stage 
of the study, it could not be determined whether this decrease was a direct or indirect 
effect of the anti-thyroid drug on the immune system.
After initiation of treatment, there was no significant correlation between T 4  
(n=43) or FT4  (n -12 ) and the level of sIL-2R, while there was a significant 
correlation between sIL-2R  and T3  (n=37). There w ere significant negative 
correlations between sIL-2R and serum level of TSH and TRAb. The absence of 
correlation between T4  or FT4  and sIL-2R may be caused by the fact that T 4  returned 
to normal values, while the presence of a significant correlation between T 3  and sIL- 
2R supports the suggestion that it can modulate the serum concentration of sIL-2R 
(figure 2 .6 ).
The negative correlation between TSH and sIL-2R in treated patients may be 
simply a reflection of the correction o f the thyroid function abnorm alities, or 
methimazole may have a direct effect on IL-2R.
The negative correlation between sIL-2R and the titre of TRAb may also 
indirectly reflect a suppressive effect of m ethim azole on the im m une system. 
Furthermore, it shows that the serum level of sIL-2R normalised faster in the patients 
with higher litre of TR Ab rather than in patients with negative or low titre.
were preserved and to minimise disturbances to the system, unseparated whole blood 
was used.
For establishing the method heparinized whole blood of healthy volunteers 
was stimulated with LPS, PHA, or a mixture of them. Initial experiments indicated 
that sIL-2R production occurs not only from the stimulated whole blood cells (WB), 
but also from control WB that were treated with medium instead of stimulator. The 
29.7% increase that occurred after 24 h in the control set could be partly due to 
activation of monocytes or macrophages by attachment to the plastic plate. However, 
there was a marked response to both LPS and PHA stimulation.
There was continued release of sIL-2R up to at least 72 hours. The data 
obtained from the time course experim ent indicates that at least two distinct 
populations of cells responded to stimulation, because at all time points the response 
to LPS and PHA was additive. The dose-response study confirm ed this finding 
(figure 2 .8 ).
The population of cells that responds to LPS may consist of monocytes, 
which are known to produce IL-2 receptors when stimulated by LPS (Valitutti et al, 
1989; Kniep et al, 1992), while the dominant cells of the set responding to PHA may 
be T lymphocytes (Rieckmann et al, 1995; Kniep et al, 1992; Ohashi et al, 1989; 
Rubin et al, 1985). There is a possibility that other cells such as B-lymphocytes and 
natural killer cells also contribute to sIL-2R production, stim ulated by cytokines 
released by activated macrophages or T-lymphocytes. It has been shown that WB 
cells released different sets of cytokines under the influence of LPS and PHA, 
Stimulation by PHA induced production of IL-6 , TN F-a, IL-2, INF-y, and GM-CSF 
(De Groote et al, 1992), while stimulation by LPS caused production of IL -ip , TNF- 
a  (De Groote et al, 1992; Allen et al, 1992), and IL - 6  (De Groote et al, 1992).
The data obtained from the dose study experiments also revealed that the 
lowest dose of LPS which was tested ( 1  //g/m l) was sufficient to produce the 
maximum effect on release of sIL-R, whereas greater than 1 //g/m l of PHA was 
required to have any effect. This suggests that the production of IL-2R from  
macrophages is as sensitive to LPS as that of IL-1 or TNF.
2.4.2.1 Effect of dilution of whole blood
The emphasis in studies of the use of whole blood as a substrate has been to 
show that the method is reliable and to compare it to the use of separated cell 
populations. The critical variables of the methods have not been system atically 
studied. Various dilution factors were used by different investigators. Some used 
undiluted whole blood with only the minor dilution caused by addition of stimulator 
(D escheta l, 1989; Alien et al, 1992; Van-Deuren et al, 1993), while others used
I::;
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blood diluted in ratios of 1:1 (Stricter et al, 1990), 1:5 (Lyte, 1987), and 1:10 
(Ellaurieetal, 1991; De Groote et al, 1992; Elsdsser-Beile et al, 1994; Hornef et al, 
1995).
The release of SÏL-2R from whole blood has not previously been studied, so 
no protocols were available. For the initial series of experiments in this study, the 
dilution factor was 9:10, the minimum practical. When the time-course experiment 
was repeated with a dilution factor of 5:10, the production of SÎL-2R by the same 
volume of whole blood when stimulated was doubled compared to undiluted cells. 
The effect was less in the unstimulated controls.
The reasons for this increase are not certain. There may be inhibitory 
components of blood which are diluted out, such as cytokines produced by the cells, 
hormones, or other components of plasma.
When the experiments were repeated with both dilution factors (9:10 and 1:2) 
using WB samples collected from the patients with untreated Graves' disease (n=3), 
the pattern of results obtained was the same, but the release of sIL-2R into the 
medium was greater. Since it was necessary to compare this set of results with the 
previous results obtained from WB of the healthy reference sample, the values of pre- 
controls were subtracted from both the sets to allow assessment of the increase due to 
stimulation. The amount of sIL-2R released by the unstimulated cells from patients 
was higher than that produced by the reference samples. This indicates that immune 
cells in vivo are under the control of an endogenous stimulator, whose effect is not 
altered by dilution. Cells further stim ulated with LPS and PHA also showed an 
increased production compared to controls.
In addition, the effect of dilution was not detected with LPS stimulated cells, 
while it remained with the cells stimulated with PHA or the mixture of LPS and PHA. 
This may show that macrophages are insensitive to whichever inhibitor is present in 
serum, whereas the cells, presumably lymphocytes, which are sensitive to PHA are 
affected by it.
The increase in sIL-2R production is consistent with the findings of Nagataki 
and Eguchi (1992) who have shown in Graves' disease that the number of activated T 
cells (helper, memory and cytotoxic cells) is increased in peripheral blood compared 
to normal controls, while suppressor-inducer T ceils and natural killer cells were 
reduced.
2.4.3 Production Of Cytokines By Whole Blood In Vitro
The experiments using whole blood to investigate the release of sIL-2R from cells 
was extended to include the measurement of several other cytokines. The protocol
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was slightly different, with a higher dilution of blood and the use of a stimulation 
with PMA and calcium ionophore as well as LPS and PHA.
2.4.3.1 Interleukin-2
Incubation of diluted (1:11) whole blood of reference group did not cause a 
noticeable effect on lL-2 production. On the other hand, incubation of whole blood of 
the patients increased the production of lL-2, in an apparently time dependent fashion. 
In these sets of experiments, polypropylene tubes were used instead of plates, and for 
this reason the auto-activation of cells is less likely. It seems the unknown stimulator 
which was postulated to stimulate sIL-2R release also induced the production of lL-2 
in the patients with Graves' disease. This effect was more conspicuous when the 
blood was stimulated with a mixture of LPS and PHA, or a mixture of PMA and Ca 
ionophore (figure 2 .1 2 ).
Many factors could be responsible for the induction of IL-2 production. The 
synthesis of lL-2 is under complex regulation. It is enhanced after interaction of B7, 
on the surface of APC, with its counterpart on the surface of T-cells, CD28 (Paul and 
Seder, 1994), and by IL-1 produced by activated macrophages, in response to 
stimulation by LPS. IN F-a maintains an enhanced level of IL-2 mRNA in the 
activated cells (Holan et al, 1994). In addition, there is interaction between the 
populations of helper T cells. Activated CD4+ T H l cells are capable of producing ÏL- 
2, INF-y, and TN F-a, while TH2 cells produce IL-4, IL-5, IL-10, GM-CSF, and 
IL-13 (Paul and Seder, 1994). It is now clear that cytokines produced by either of the 
sets of helper cells influence the production of cytokines by the other group (Paul and 
Seder, 1994; Seder and Paul, 1994). It is clear that the number of activated immune 
cells in peripheral blood is increased as detected by Nagataki and Eguchi (1992).
Defects in IL-2 production have been reported in patients with Graves' disease 
(Eisenstein et al, 1988; Akasu et al, 1991), The reason for this reduction is unknown, 
but there are reports suggesting that excessive prostaglandin E2 production by 
activated APC could be one o f causes (Eisenstein et al, 1994; Hikens et al, 1995). 
The production of IL-2 was restored to normal after proper therapy. In the present 
study, the production of IL-2 was higher among these patients, when the whole blood 
was diluted 1:11. This could be due to dilution of the elevated thyroid hormones 
presented in the WB of untreated patients with Graves' disease, or cytokines 
produced by other cells. This needs further investigation.
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2.4.3.2 Interleukin-4
Incubation of diluted whole blood of reference group did not cause a 
detectable release of IL-4. On the other hand, the level of IL-4 in the incubated whole 
blood of the patients was apparently higher than in the reference group at the 4 h time 
point, follow ed by an apparently tim e dependent dim inution. Furtherm ore, 
stimulation of the whole blood of both groups (reference as well as patients) with a 
m ixture of LPS and PHA significantly increased the production of IL-4, which 
seemed to be time dependent. The mean value obtained for the patients' group was 
higher (nearly 15 fold) than the corresponding value obtained for the control group 
(figure 2.15). However due to the high degree of variability of the data, there were no 
significant differences between the values obtained for the patients and reference 
group after 4  or 24 hours. The patients' IL-4 release became significantly higher than 
the reference group after 72 h. This finding agrees with the report published by 
Hirooka et al, (1993), who demonstrated that peripheral blood mononuclear cells of 
patients with Graves' disease produced more IL-4 than the normal controls when 
stimulated with PHA.
The quantity of IL-4 produced was low and variable. This may reflect the fact 
that primary stimulation of resting T cells produces mostly IL - 2  rather than IL-4 
(Seder and Paul, 1994). Other cytokines like IL-4, TNF-p, INF-y, IL-10, and IL-12 
are required for differentiation of the resting lymphocytes to either T H l or TH2 cells 
(Seder and Paul, 1994). This process may take several days, and those patients who 
produce high levels of IL-4 at the start may go on to produce more IL-4 throughout 
the stimulation period.
Interleukin-4 is primarily produced by activated T helper type 2 cells, along 
with IL-5, IL-10 (Nagataki and Eguchi, 1992), GM-CSF, and IL-13 (Paul and 
Seder, 1994). It suppresses the production of IL-2 and the J3 chain of IL-2R (Llorente 
et al, 1989; Lindqvist et al, 1991; Seder and Paul, 1994). This could be one of the 
causes, of the increase in the plasma level of sIL-Ra, as it is shed from the cells, in 
the absence of the other chains of the IL-2 receptor, and the decrease in IL-2 
production which has been reported in patients with Graves' disease.
H elper cells which could produce IL-4 are present in the infiltrating 
mononuclear cells, in the thyroid gland of patients with autoimmune disease 
(Nagataki and Eguchi, 1992; Mariotti et al, 1992 b). Since it has been shown that IL- 
4 together with INF-y enhances the expression of MHC class II on endothelial cells 
(M asinovsky et al, 1990) and facilitates the m igration o f immune cells to the 
neighbouring tissue, elevated levels in the thyroid may contribute to the accumulation 
of cells within the gland.
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2.4.3,3 Interleukin-6
Incubation of diluted whole blood of the reference group for different periods 
did not cause a noticeable release of IL-6 . On the other hand, incubation of whole 
blood of the patients with Graves' disease released more IL - 6  into the medium than 
the reference group after 4  h, but not after 24 or 72 h. This could indicate an increase 
in the number of activated immune cells, in the peripheral blood of the patients with 
Graves' disease. The concentration of IL - 6  may also be higher in the plasma of these 
patients, as detected before (Hirano, 1992). Some of the IL - 6  in blood could come 
from activated immune cells, including monocytes or macrophages, T lymphocytes, 
and activated B cells (Janeway and Travers, 1994), or from thyroid follicular cells 
(Kennedy et al, 1991; Zheng et al, 1991; W atson et al, 1994). However, the 
apparently time dependent increase in the production of IL - 6  suggests that the primary 
source is the activated cells in blood.
Stimulation of whole blood of the reference group, with a mixture of LPS and 
PHA caused a time dependent increase in the production of IL-6 . This result 
corresponds with those reported before (Eggesbo et al, 1994; De Groote et al, 1992), 
and could be due to a combination of IL - 6  produced by monocytes or macrophages 
that respond to LPS, and IL - 6  produced by lymphocytes that respond to PHA.
The production of this cytokine by stimulated (LPS/PHA) whole blood of the 
patients with Graves' disease had a different pattern. In the first 24 h, production was 
higher than that of the reference group, while after 72 h, the production of this 
cytokines tended to be lower than from the reference group, although this did not 
reach significance.
There are many possible reasons for this change in the pattern of production. 
One could be the presence of high levels of thyroid hormones in the plasma of these 
patients, because it has been shown that high levels of thyroid hormones and other 
iodinated compounds enhance the ability of the monocytes to mature into cytologically 
and functionally characteristic veiled/dendritic cells (Mooij et al, 1994). This may lead 
to changes in the pattern of IL - 6  production. The higher level of thyroid hormone also 
suppressed the production of this cytokine as detected in this study. Other factors in 
the serum of patients, such as the presence of high levels of immunoglobulins 
(especially antibodies to TSH receptor, thyroglobulin, and thyroid peroxidase), may 
antagonise the induction of IL - 6  by stimulators, and the increased value detected after 
4  h may reflect the initial elevated level of this cytokine in vivo. Alternatively, the 
cultures may produce inhibitory cytokines after the first few hours in vitro.
Another possibility is that the activated immune cells become exhausted and 
can not respond to the stimulator, as happens in septic patients (Ertel et al, 1995). For 
the confirmation of these possibilities, further investigations are necessary.
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2 .4 3 .4  INF-y
Production of INF-y by d ilu ted  whole blood of the reference group 
(unstimulated) was higher than the whole blood of the patients with Graves' disease. 
This reduction was also observed by Akasu and co-workers (1991) in patients with 
Graves' or Hashimoto’s disease. They suggested this event takes place when there is 
an abnormal reactivity of the stimulator/inducer subset, and T cells proliferate in 
response to non-T cells. Such auto-activation of lymphocytes is referred to as the 
autologous mixed lymphocyte reaction, and has been detected in several other human 
autoimmune diseases (Akasu et al, 1991). In addition, elevated levels of IL-4 can 
suppress the production of INF-y by activated CD4+ cells (Seder and Paul, 1994). As 
mentioned before, the level of IL-4 was apparently higher at all three time points (4, 
24, and 72 h) among the patients with Graves’ disease.
Stimulation by LPS/PHA or PMA/Ca ionophore of diluted whole blood of 
both groups (patients and reference) caused significant and time dependent increases 
in INF-y production. W hen whole blood of the patients with Graves' disease was 
stimulated with a mixture of LPS and PHA, the production of INF-y was higher than 
the reference group after 72 h. On the other hand, when whole blood of Graves' 
patients was stimulated with a mixture of PMA and Ca ionophore, INF-y production 
was significantly lower than the corresponding value obtained for the reference group 
(at 24 h time point). These findings may indicate that the production of INF-y 
depends on the stimulator used, as suggested by Seder and Paul (1994). PMA and Ca 
ionophore are protein kinase agonists (Hershman and Pang, 1993), while LPS can 
activate macrophages, and PHA activates naive T cells.
INF-y is produced by activated CD4+ T H l or CD8 + cytotoxic cells (Nagataki 
and Eguchi, 1992), and blocks the growth of TH2 cells (Janeway and Travers, 
1994). On the other hand, it is also known that undifferentiated T cells (THO) can 
produce IL-2, ÏL-3, IL-4, and INF-y (Seder and Paul, 1994) after primary activation. 
The finding of both IL-4 and INF-y in supernatants of stimulated whole blood cells 
may indicate that both sub-types of lymphocytes, or undifferentiated THO cells, are 
present among the activated immune cells, in the peripheral blood of the patients with 
Graves' disease.
2 .4 3 .5  TN F-a
The level of T N F -a, in the supernatant of unstimulated whole blood of the 
reference group was undetectable for the first 72 h. On the other hand, the level of 
T N F -a was variably detectable in the supernatant recovered from the unstimulated
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whole blood of the patients with Graves' disease, without noticeable differences 
between the three time points.
Factors responsible for this increase in TNF production could include the 
presence of high levels of thyroid hormones or other cytokines in blood, and the 
increase in the number of activated cells in vivo (Nagataki and Eguchi, 1992). It is, 
however, unlikely that thyroid hormones could be involved directly, since their effect 
was to suppress release of TNF in vitro. There are no data on the level of this 
cytokine in the plasma of untreated patients with Graves' disease, though there are 
reports (Mooradian et al, 1990; Pang et ai, 1989 a; Van-Der-Poll et al, 1990) showing 
a negative correlation between the plasm a level of T N F-a and thyroid hormones 
(especially T3 ).
Stimulation of whole blood with a mixture of LPS and PHA caused a time 
dependent increase in the production of TN F-a. The increase in production of T N F-a 
was significantly higher in patients than controls after 4  h. However, there was no 
significant difference between the values obtained for the reference group and the 
patients' group after 24 h, and by 72 h, T N F-a release was significantly lower than 
from the reference group.
The elevation of TN F-a production after 4  h shows that this cytokine is one 
of the group of cytokines that is synthesised and released early in response to 
stim ulation. Tum or necrosis factor is predom inantly produced by activated 
macrophages (Tracey and Cerami, 1994; Beyaert and Fiers, 1994), though several 
other blood cells including activated T-cells (CD4+, and CD 8 +), B-cells, natural killer 
cells, and neutrophils (Vilcek and Lee, 1991) can produce small amounts. The higher 
early release of this cytokine detected in the patients with Graves’ disease could be a 
reflection of the increase in the number of activated immune cells of these patients. 
The failure to continue the initial rate of increase could be due to production of other 
down-regulatory cytokines, to inhibitory substances in plasma or to cell exhaustion as 
suggested for IL-6 ,
Another possibility is that the release of cleaved fragm ents of the TN F 
receptors (also known as TNF-binding proteins) may be increased in the supernatants 
recovered from the stimulated cells of the patients after 72 h and may interfere with 
the immunoassay which was used. The assay is, however, claimed to be free of such 
interference.
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2.4.4 Effects Of Methimazole, Thyroid Hormones, And TSH On 
Cytokine Production
In the study of sIL-2R in serum, it was observed that there was a positive 
correlation between the serum concentration of sIL-2R and thyroid hormones. In 
addition, there was a negative correlation between sIL-2 R and TSH or TRAb. 
Weetman (1986 b) reported that methimazole enhances IL-2 production by peripheral 
blood mononuclear cells in vitro. In the present study, the effects of these compounds 
on cytokine release from blood cells were determined, using WB of the reference 
group, stimulated with these compounds with or without a mixture of LPS and PHA, 
or Ca ionophore and PMA.
Stimulation of WB with thyroid hormones, TSH, or methimazole in the 
absence of any stimulator did not affect cytokine production. In addition, in the 
presence of a mixture of Ca ionophore and PMA, these compounds also failed to alter 
cytokine production significantly. However, in the presence of a mixture of LPS and 
PHA, they did effect the pattern of production of sIL-2R, IL-6 , INF-y, and TN F-a.
Both TSH and thyroid hormones caused an increase in sIL-2R production, 
while there was a tendency to a decrease in the presence of methimazole. These 
changes are in agreement with the increase seen in vivo and the prompt decrease on 
treatment. The increase in the presence of thyroid hormones alone may also explain 
the increase in serum sIL-2R seen in cases of adenomas, which are presumed to have 
little or no immune component.
There was a tendency for the changes in IL-2 release to be reciprocal to those 
of the receptor, though they did not reach significance. This may point to a role for 
IL-2, in control of the synthesis of its own receptor, but the evidence is weak. 
Weetman (1986 b) reported that methimazole enhanced IL-2 production by peripheral 
blood mononuclear cells in vitro, but Eisenstein and colleagues (1988) did not see any 
effect of anti-thyroid drugs. In addition Volpé (1994), in a review of the actions of 
anti-thyroid drugs, denied that anti-thyroid drugs could m ediate any im m uno­
suppressive effects and claimed that their action was m ediated only through 
modifying the function of thyrocytes.
Against this, the present results indicate that methimazole itself can suppress 
the cytokine production of immune cells, especially IL-6 , INF-y, and T N F-a. This 
confirms the observation of Weetman (1986 b). The mechanism is not known, but 
methim azole is known to effect thyroid function through inhibition of thyroid 
peroxidase. It may also affect oxidative functions in monocytes or lymphocytes. This 
needs further investigation.
The present study is not the first report on the effect of TSH on immune 
system. Komorowski et al, (1993) have shown that stimulation of lymphocytes with
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TSH (maximum dose used 25 mU/1), in the presence of PHA (10 /fg/ml) could 
increase the production of ÏL-2. The negative results obtained in the present study 
could be due to differences in the concentration of PHA, or the use of whole blood. 
The influence of TSH on the immune system, and the detection of the TSH beta 
subunit gene in human lymphocytes (Peele et al, 1993) and cloned lymphocyte cell 
lines (Harbour et al, 1989) indicate that TSH can modulate the activity of immune 
cells. To determine the role of TSH in the immune system, further study is necessary.
IL-1 (Van-Haasteren et al, 1994; M andrup-Poulsen et al, 1996), IL - 6  
(Stouthard et al, 1994; Bartalena et al, 1994 c; Van-Haasteren et al, 1994), and TNF- 
a  (Pang et al, 1989 a; Van-Der-Poll et al, 1990; Mandrup-Poulsen et al, 1996) are 
known to suppress the production of TSH. Infusion of large amounts of IL - 6  in 
humans (Stouthard et al, 1994; Bartalena et al, 1994 b; Hashimoto et al, 1994) and 
rats (Bartalena et al, 1994 c; Van-Haasteren et al, 1994) were associated with a 
decrease in thyroid hormones and TSH. It has been shown here that high levels of 
thyroid hormones and TSH suppress the production of IL-6 , INF-y, and T N F -a 
from  blood cells. This suggests that a feedback system may operate in vivo. It 
remains to be proved whether the action of thyroid hormones is through direct action 
on the cells that produce these cytokines, or through the induction of inhibitory 
cytokines like IL-10 and IL-13.
In Graves' disease, it is therefore likely that the combined increase in thyroid 
horm ones and TRAb, sim ulating TSH, will cause a functional defect in the 
production of IL-6 , INF-y, and T N F-a. The early increases seen in vitro in the 
patients in this study may then not simply be due to activation of cells within the 
patients, but be caused by release of inhibition in culture when the blood is diluted.
C h a p t e r  T h r e e
Bioactive Peptides 
A nd  
Thyroid Function
i
■;E
S
. 'in,
SECTION ONE 
INTRODUCTION
About 70% of the cells in the thyroid gland are follicular epithelial cells. 
Among the rest are stromal cells, vascular endothelial cells and nerve cells (Dumont et 
al, 1992). All these are capable of releasing factors which may affect the function and 
growth patterns of the gland in health and disease. In this section, the effects on the 
thyroid gland are discussed of the growth factors, cytokines, and other peptides that 
may be released locally during autoimmune thyroid diseases by.infiltrating cells or by 
other cells in the gland and which were studied in the current work.
3.1.1 Growth Factors
3.1.1.1 Insulin-Like Growth Factor
Insulin-like growth factors IGF-1 and IGF-II (previously known as 
somatomedin-C and Multiplication Stimulating Activity) are nonglycosylated, single 
chain peptides that are structurally related to insulin (Saji et al, 1987).
IGF-1 plays a central role in development. It is primarily synthesised by the 
liver under the control of growth horaione (Delafontaine and Lou, 1993). IGF-1 is 
also expressed in a variety of tissues and by different cell types including thyroid 
fo llicular cells (Dumont et al, 1991; and 1992). The production of IGFs are 
considered to have m ajor autocrine/paracrine effects on growth and protein 
metabolism (Delafontaine and Lou, 1993).
The expression of IGF-II is high in most fetal tissues and declines after birth, 
except in neural tissue (Gluckman and Ambler, 1993). Thyroid epithelial cells can 
produce IGF-1 when stimulated with TSH or growth hormone (Bachrach et al, 
1988), while they can synthesise IGF-II when stimulated with IGF-1 (Dumont et al, 
1991; and 1992).
The IGFs in blood and other biological fluids occur are complexed with 
specific binding proteins (Yang et al, 1989). The six identified IGF binding proteins 
(IGFBPs) transport the IGFs in plasma and across capillary membranes, and control 
the interaction of the IGF with receptors. It has been shown that IGFBP-1 is present 
in the normal and carcinomatous thyroid gland, while IGFBP-2 and IGFBP-3 were 
detected only in medullary carcinomas (Van-Der-Laan et al, 1995).
IGF-1 produces its effect through the IGF type-1 receptor, which is related to 
the insulin receptor, while insulin can use the same receptor, with lower affinity (Saji
et at, 1987); IGF-II has its own receptor (type 2), which is the same as the mannose- 
6 -phosphate receptor (Gluckman and Ambler, 1993). Both types of receptors are 
present on the surface of thyrocytes (Bachrach et al, 1988) and their expression can 
be increased by administration of growth hormone (Nanto-Salonen et al, 1993; 
B achrach et al, 1988), w hile TSH  dow n-regulates the receptor fo r IGF-1 
(Tramontane et al, 1988 a).
Both insulin (Smith et al, 1986; Bachrach et al, 1988; Takahashi et al, 1990) 
and IGF - 1  (Tramontano et al, 1986; ïsozaki et al, 1987; Santisteban et al, 1987; 
Maciel et al, 1988; Pang et al, 1990 a; Takasu et al, 1989; Takada et al, 1990) can 
increase the growth of animal thyroid cells when combined with TSH. Both are also 
required for synthesis of prostaglandin E2 by FRTL-5 cells (Tahara et al, 1991). The 
transport of amino acids is increased in presence of IGF-1 (Villone et al, 1993). IGF- 
1 can also induce production of thyroglobulin mRNA by FRTL-5 cells (Isozaki et al, 
1987; Santisteban et al, 1987).
Iodine uptake by thyroid cells is believed to be controlled by intracellular 
cAMP, which itself is increased by TSH. Tram ontano and colleagues (1988 a) 
showed a slight increase in cAM P when FRTL-5 cells were stimulated with a 
combination of TSH and IGF-1, but Pang and co-workers (1990 a) have shown a 
decrease in iodine uptake of the same cell line. Although it is plausible that excessive 
concentrations of IGF-1 could be implicated in goitre formation, there is sufficient 
conflict in the experimental results for further experimentation to be necessary. In 
particular, none of the studies was carried out in the presence of thyroid hormones, 
which might be expected to have an influence on hyperthyroid goitres.
3 .1 .1 .2  Transforming Growth Factor-p
TGF-(3 is produced by both normal and diseased thyroid glands (Grubeck- 
Loebenstein et al, 1989; Cowin and Bidey, 1994; and 1995), and its synthesis is 
regulated by intra-thyroid iodine concentration (Yuasa et al, 1992; Cowin and Bidey, 
1994; and 1995). The concentration of TGF-p mRNA was found to be lower in 
thyrocytes of patients with iodine-deficient non toxic goitre than in Graves' disease 
(Grubeck-Loebenstein et al, 1989).
Reduction in growth of human (W idder et al, 1991; Taton et al, 1993) or 
animal (Morris III etal, 1988; Tsushima et al, 1988; Pang et al, 1992; Cirafici et al,
1992) thyroid cells under the influence of TG F-p is well documented. TGF-p 
inhibited the growth of medullary thyroid carcinoma (Khosla et al, 1994), several 
thyroid cancer cell lines derived from the primary tumour and lymph node and lung 
métastasés of a single patient (Hotting et al, 1994), and a papillary carcinoma cell line 
(Usa et al, 1994).
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Besides this inhibitory effect, the presence of TGF-P influenced the 
morphological changes induced by TSH on thyroid cells. Addition of TGF-P to the 
culture medium of thyrocytes caused cells to enlarge and stick to the plate more 
firm ly. This was shown to be caused by a striking effect of TG F p on actin 
microfilaments, which counteracted the actions of TSH (Garbi and Nitsch, 1989). It 
also inhibited the migration of carcinoma cell lines significantly by enhancing the 
adhesion of cells to collagen (Holting et al, 1994).
A down-regulatory effect of TGF-p was also shown on thyroid peroxidase 
production (Widder et al, 1991; Taton et al, 1993) without effecting cAMP induced 
by TSH (Taton et al, 1993). TGF-p was shown to decrease the iodine uptake induced 
by TSH in porcine thyroid cells (Tsushima et al, 1988), and rat FRTL-5 cells (Pang 
et al, 1992). On the other hand, Morris and colleagues (1988) demonstrated that in 
the presence of TSH, TGF-p had a stimulatory effect on iodine uptake of FRTL-5 
cells.
3 .1 .1 .3  Fibroblast Growth Factor
Fibroblast growth factors are a family of polypeptides that play a crucial role 
in normal development, in the maintenance of tissues and in wound healing and repair 
(Gospodarowicz et al, 1987). They act on cells of meso-, ecto- and endodeim origin, 
and cause changes in migration, morphology and function, as well as proliferation 
(Isozaki et al, 1992). The fam ily includes nine members which show 30-50% 
sequence identity at the amino acid level and conservation of the positions of two 
cysteine residues. The factors are designated FGF-1 through 9, though the names 
FGF acidic and basic are used for FGF-1 and FGF-2, respectively.
Acidic and basic FGF, the prototypical members of this family, were named 
for their differing isoelectric points. They have sim ilar m olecular masses and 
biological activities, and show approximately 55% amino acid identity but with 
different genes located on chrom osom e 4 (acidic FGF) and 5 (basic FGF) 
(Gospodarowicz et al, 1987). FGFs bind to heparin, and most of extracellular FGF is 
sequestered by binding to heparan sulphate in the extra-cellular matrix, where it can 
be released by heparin-like molecules and by heparan sulphate-degrading enzymes. 
Their binding to heparin causes a conformational change that protects FGF from 
proteolysis and dénaturation.
The receptor for bFGF is detected on many cells and many cells produce 
bFG F, in contrast to aFGF, which has a more restricted cellular distribution. FGF is 
thus a fundamental regulatory molecule, acting by both autocrine and paracrine 
mechanisms (Logan et al, 1992).
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Normal human thyrocytes (Taylor et al, 1993) and those of normal animals 
(Bechtner et al, 1993; Logan et al, 1992), and human carcinoma cell lines (Eggo et al, 
1995; M atsuo et al, 1993; Daa et al, 1993) can synthesise basic FGF, although 
another potential source could be the endothelial cells in the gland. The amount 
produced was shown to correlate with the degree of malignancy in human thyroid 
cancer (Shingu et al, 1994) and hyperplasia of thyroid in rat (Becks et al, 1994).
It has been shown that both the acidic (De Vito et al, 1992; Chanoine et al,
1992) and basic (Emoto et al, 1991; Black et al, 1990) forms of FGF increase the 
growth or DNA synthesis of thyroid cells. The increase in growth is accompanied 
after a delay by an alteration in some of the functions of thyrocytes, including a 
decrease in iodine uptake induced by TSH (Hill et al, 1994; Emoto et al, 1991). 
Furthermore, down-regulation of 5' deiodinase is also reported to be an effect of 
FGF (Tang et al, 1994).
The enlargement of the gland during goitre formation is always accompanied 
by angiogenesis. FGFs are potent angiogenic factors, so they may be involved in this 
process in Graves' disease.
3.1.2 Cytokines
3.1.2.1 Interleukin 1
In several animal models it has been demonstrated that interleukin 1 (IL-1) can 
affect thyroid function in vivo. Daily injection of mice with recombinant IL-1 a  (1-15 
pig) for seven days decreased the serum concentration of T 4  to undetectable levels 
(Enomoto et al, 1990), primarily by blocking release of T4  by the thyroid. Daily 
injection o f rats with 2-4 piglkg of recom binant IL -Ip  also resulted in the 
development of lymphocytic thyroiditis and hypothyroidism (Vertrees et al, 1991; 
Hermus et al, 1992). IL - la  also affected the hypothalamic-hypophysial-thyroid axis. 
Continuous infusion of IL-1 a  decreased hypothalamic pro-TRH mRNA by 73%, and 
reduced hypophysial mRNA for the p-chain of TSH by 62% (Van-Haasteren et al, 
1994). The reduction in the hypophysial TSH p chain mRNA occurred before the 
reduction in the mRNA for hypothalamic pro-TRH.
It is not clear whether reduction of TSH or direct interaction of IL-1 with 
thyrocytes is more important for development of hypothyroidism in these animals. 
The serum concentration of IL-1 and the period of the experiment could potentially 
both influence results. In a recent report it was shown rats given two injections of IL- 
l a  or IL -lp  in  a single day did not develop hypothyroidism, but the growth of 
thyrocytes increased when IL - 1  was infused (Zerek-Melen et al, 1994).
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mIn vitro experiments are more contradictory. Zeki and co-workers (1993) 
dem onstrated that the growth of a human thyroid carcinoma cell line (NIM 1) 
increased when the cells were incubated with 10 /^g/L of IL-1 a  or IL-1 p. They 
showed that this cell line produced IL-1 which acted as an autocrine growth factor.
On the other hand, Kimura and co-workers (1992) and Yip and colleagues (1995) 
reported that both IL-1 a  and IL -lp  suppressed DNA synthesis in at least some 
thyroid carcinoma cell lines.
It was shown that both IL-1 a  and IL -ip  inhibited the incorporation of 
radioactive iodine and iodothyronine release in human thyrocytes (Sato et al, 1990). It 
was also shown that IL -lp  (10 U/L) inhibited basal and TSH-stimulated iodine 
uptake and organification in porcine thyroid cells, while it did not influence their 
growth (Nolte et al, 1994). A low dose of IL - la  has, however, been reported to 
increase iodine uptake of porcine thyroid cells, though this changed to inhibition if 
cells were preincubated with IL-1 for 42 hours (Westermark et al, 1990).
IL - la  or IL -lp  on their own did not affect the morphology of rat thyroid 
follicles cultured as sem i-organs, but they reduced the effects of TSH on 
morphological changes (elongation of microvilli and formation of reabsorbed colloid 
droplets). This action depended on the dose and time of exposure to IL-1 (Asakawa et 
al, 1991 a). In the absence of TSH, the growth and cAMP production of rat thyroid 
cells (FRTL-5) which were incubated with IL - la  or IL -lp  was increased, while in 
the presence of TSH both growth and cAMP production were decreased (Zeki et al, 
1991; Mine et al, 1987). On the other hand Rasmussen and co-workers (1989; 1990) 
have shown that in the presence of IL -lp , the growth of FRTL-5 cells decreased, 
while cAMP production was not affected. Pang and colleagues (1990 b) showed that 
IL-1 increased growth of this cell line, while decreasing iodine uptake, but there was 
no effect on production of cAMP. They claimed that the site of IL-1 action is distal to 
the production of cAMP. Since the conditions of the experiments were different in 
these studies, it is difficult to reach a conclusion, but it is clear that IL-1 affects the 
function of thyroid cells.
3 .1 .2 .2  Interleukin4
Helper cells are present among the infiltrating mononuclear cells in the thyroid 
gland of patients with autoimmune disease (Nagataki and Eguchi, 1992; Mariotti et al, 
1992 b). Interleukin 4  (IL-4) not only induced the expression of adhesion molecules 
on endothelial cells but markedly enhanced expression stimulated by IL -lp  or INF-y 
(Masinovsky et al, 1990). Adhesion of lymphocytes to these cells is the requisite first 
elem ent in the multi-step process of transm igration from blood across the post 
capillary venules, so IL-4 may affect the accumulation of immune cells in the thyroid.
75
Hirooka and colleagues (1993) demonstrated that when peripheral blood 
mononuclear cells of patients with Graves' disease were stimulated with PHA, IL-4 
production was significantly higher than in normal controls. A recent study shows 
that mouse spleen cells pre-treated with murine thyroglobulin (mTG) and IL-4 exhibit 
slightly decreased proliferative responses and increased cytotoxic responses toward 
mTG-pulsed macrophages compared with mTG-stimulated cells cultured in the 
absence of cytokine. The injection of mTG-activated spleen cells, cultured in the 
presence of IL-4, into irradiated CBA/J mice reduces circulating anti mTG antibody 
significantly (Godefroy et al, 1995). These findings suggest that there is release of 
IL-4 during the development of autoimmune thyroid disease and that IL-4 could 
potentially modify the immune response, but w hether this cytokine can affect
functions of thyrocytes is not known.
3 .1.2.3 Interleukin6
Increased serum interleukin 6  (IL-6 ) concentrations have been reported in 
many diseases, including autoimmune diseases of thyroid gland (Hirano 1992) and 
sub-acute thyroiditis (Bartalena et al, 1994 a).
Increases in serum concentration of IL - 6  among patients with non-thyroidal 
illness may also influence thyroid function. Rats injected with rIL - 6  for different 
periods developed hypothyroidism with low T4  and T 3  (Bartalena et al, 1994 c; Van- 
Haasteren et al, 1994). A reduction of TSH was reported after a week, though 
without detectable change in mRNA, while Van-Haasteren co-workers (1994) did not 
detect any changes in serum TSH after one day. Administration of rIL - 6  in patients 
with renal cancer caused a significant decrease in serum TSH and T 3 , while it induced 
an increase in reverse T 3  (rTs), but did not affect the total or free T4  concentration 
(Stouthard et al, 1994). These findings are similar to those reported in patients with 
non-thyroidal illness.
In vitro experim ents showed that IL - 6  inhibited TSH-induced mRNA 
expression for thyroid peroxidase in human thyrocytes dispersed from G raves’ 
thyroid tissue, while in the absence of TSH the cytokine did not affect expression 
(Tominaga et al, 1991). It was also demonstrated that the combination of TSH and 
IL - 6  stimulated DNA synthesis in FRTL-5 cells (Nishiyama et al, 1993; and 1994) 
while it did not modulate cAMP accumulation in the presence or absence of TSH 
(Nishiyama et al, 1993). The in vitro studies are limited, and further experiments are 
required to determine the role of IL - 6  in autoimmune thyroid diseases.
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3.1 .2 .4  Tumour Necrosis Factor
In vivo experiments showed that the serum concentration of TSH^ T 4 , T 3 , 
free T4 , and hypothalamic TRH decreased significantly after injection of rats with 
T N F -a (Pang et al, 1989 a). The same group also reported that the decrease in TSH 
was due to a reduction of TRH production, as well as a reduction in mRNA for the p- 
subiinit of TSH. The injection of T N F -a into humans also caused the same effect 
(Van-Der-Poll et al, 1990). The low level of thyroid hormones and TSH resembles 
the condition of sick euthyroid syndrome. However, there is no significant difference 
between the plasma level of T N F-a o f healthy controls and patients with non- 
thyroidal illness, hypothyroidism, or hyperthyroidism (Chopra et al, 1991).
At the same time, different groups have shown that thyroid epithelial cells 
possess the receptors for TNF (Pang et al, 1989 b; Buscema et al, 1989; Deuss et al,
1992). Pang and co-workers (1989) showed a 3 fold increase in the number of TNF 
receptors, after treatment of the cells with TSH. The group of Buscema (1989) also 
showed that the number of the receptors for INF-y increased when the human thyroid 
cells were exposed to TNF-a.
W hile low doses of T N F -a  increased the growth of hum an and rat 
thyrocytes, high doses were less effective (Deuss et al, 1992; Patwardhan and 
Lombardi, 1991; Pang 1990 b; Zakarija and McKenzie, 1989 b). In addition, the 
TSH-stimulated iodine uptake of both human and rat thyrocytes was decreased by 
TN F-a (Pang 1990 b; Zakarija and McKenzie, 1989 b; Sato et al, 1990). Synthesis 
of thyroglobulin (Tang et al, 1995; Rasmussen et al, 1994), thyroid peroxidase (Tang 
et al, 1995), and 5'-deiodinase (Ongphiphadhanakul 1994) were also reduced by 
T N F-a. All of this data clearly indicates that T N F-a can directly alter various 
functions of thyroid follicular cells.
3 .1 .2 .5  Inteiferon-y
INF-y has been recognised to possess diverse non-immunological effects on 
epithelial cells such as alterations in growth and differentiation state. In vitro, besides 
the expression of HLA-DR on the surface of thyrocytes, other effects of INF-y on 
human or animal thyrocytes are usually inhibitory. INF-y inhibits TSH induced 
m orphological changes such as elongation o f m icrovilli and appearance of 
pseudopods in human (Asakawa et al, 1991 b; Kung et al, 1992) and mouse 
thyrocytes (Asakawa et al, 1990). Addition of INF-y to the medium of human 
thyrocytes resulted in marked degeneration with shrinkage of the cell membrane, 
vacuolation of cytoplasm, swollen mitochondria and presence of lysosomal granules
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(Kung et al, 1992). ït  also reduced the number of actin filaments in mouse thyrocytes 
(Asakawa et al , 1990).
INF-y decreased the growth of human thyroid cells as measured by 
thymidine incorporation into cellular DNA and cell counts (Kraiem et al, 1990; Huber 
and Davies, 1990; Yip et al, 1995). In the presence of TSH, the growth of FRTL-5 
cells was also reduced (Zakarija and McKenzie, 1989 b; Misaki et al, 1988).
INF-y caused reduction of TG production in presence of TSH by human 
(Rasmussen et al, 1994; Kung et al, 1992; Kung and Lau, 1990; Huber and Davies,
1990) and FRTL-5 thyrocytes (Misaki et al, 1988; Zakarija and McKenzie 1989 b; 
Graves et al, 1989; Tang et al, 1995), and inhibited TG gene transcription in the 
absence of TSH (Kung et al, 1992). It also reduced TPO production by human 
(Asakawa et al, 1992 b; Chiovato et al, 1994) and rat (Tang et al, 1995) thyrocytes.
INF-y has also been reported to influence iodine uptake and cAMP production 
in human and rat thyrocytes, but the results are conflicting. Iodine uptake has been 
reported to be decreased in human thyrocytes in the presence of TSH (Kraiem et al, 
1990; Sato, 1990), but increased in FRTL-5 cells (Misaki et al, 1988; Zakarija and 
M cKenzie, 1989 b). Production of cAMP by human thyrocytes was reduced 
(Rasmussen et al, 1994), while it was increased in  FRTL-5 cells (Zakarija and 
McKenzie, 1989 b).
3.1.3 Neuropeptides
3.1.3.1 Pituitary Adenylate Cyclase Activating Polypeptide
Pituitary adenylate cyclase activating polypeptide (PACAP), originally 
isolated from ovine hypothalamus, is a neuropeptide considered to be a member of 
the family of peptides including vasoactive intestinal peptide (VIP), glucagon, 
secretin, and growth hormone-releasing hormone (Kononen et al, 1994; Joumot et al,
1994), Two forms of PA CAP, PACAP38 and PACAP27, which have 38 and 27 
amino acids respectively, have been demonstrated in the rat hypothalamus (Dow et al, 
1994; Joumot et al, 1994). Hannibal and co-workers (1995) recently detected a third 
member of the PA CAP family in the rat hypothalamus called PACAP-related peptide 
(PRP), but the function of this new member is not known. PACAP27 corresponds to 
the 27 N-terminal amino acids of PACAP38, and it is also 68% identical to VIP 
(Tatsuno et al, 1992). Although certain bioactivities of PACAP are similar to those of 
VIP, there are considerable qualitative and quantitative differences (Tatsuno et al, 
1992; Arimura, 1992).
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PACAPs are present in the central nervous system as well as in peripheral 
organs and tissues such as pituitary, lung, liver, gastro-intestinal tract, adrenal 
m edulla, and testes (Journot et al, 1994). PACAP38 is present in h igher 
concentrations in nervous tissue than PACAP27. In the pituitary, PACAP was shown 
to induce or to potentiate release of GH, prolactin, ACTH, LH, FSH, and a-M SH , 
and to stimulate accumulation of cAMP (Arimura, 1992; Dow et al, 1994).
There are two different receptors for PACAPs. The type I PACAP receptor 
has a much higher affinity for both PACAP27 and PACAP38 than VIP (Arimura,
1992), whereas the type II receptor does not discriminate efficiently between these 
two peptides (Kononen et al, 1994). The type I receptor predominates in the central 
nervous system, while the type II receptor is higher in other tissues like liver, lung, 
digestive tract, prostate gland, and testis (Arimura, 1992; Joumot et al, 1994). Both 
types of receptors have been detected on the rat medullary thyroid carcinoma cell line 
6/23 (Vertongen et al, 1994).
Since PACAP and VIP are neuropeptides and not circulating hormones, they 
may directly influence thyroid function only if they are locally released from nerve 
endings or if they act as autocrine or paracrine regulators. Nerves containing PACAP 
have not yet been described in the thyroid gland, but PACAP was found to increase 
T4  production in porcine thyroid cells in vitro (Chen et al, 1993). It was also shown 
that presence of PACAP could inhibit the binding of labelled TSH to thyroid 
membranes, while increasing cAMP production (Chen et al, 1993).
3.1.3.2 Neuropeptide Y
Neuropeptide-Y (NPY) is synthesised and released by adrenergic nerves 
(Ahrén, 1991). NPY is w idely distributed in central and peripheral neurones 
including peripheral sympathetic nerve fibres, where it co-exists with noradrenaline 
(Grundemar and Hâkanson, 1994). The NPY family includes the hormones peptide 
YY and pancreatic polypeptide.
NPY produces a multitude of biological effects in the brain and periphery. 
NPY and peptide YY are among the most powerful stimulants of eating known. NPY 
also controls mood, and regulates central autonomic functions. In the periphery, 
sympathetic NPY plays a role as a vasopressor and vasoconstrictor (Grundemar and 
Hâkanson, 1994). NPY from the hypothalamus enhances the FSH and LH secretory 
responses to LH releasing hormone in vivo (Freeman, 1993).
Adrenergic nerve fibres containing NPY have been detected in the thyroid 
gland of mouse, rat, guinea pig, cat, dog, sheep, pig, calf, and man (Grunditz et al, 
1984). In the anterior pituitary gland of the rat, it seems that the concentration of T4  
controls the release of NPY. M oderate and low concentrations of T 4  induced its
release from nerve fibres (Jones et al, 1994), though higher concentrations failed to 
have an effect. In vivo, it has been shown that a combination of TSH or VIP with 
NPY caused increased release of thyroid hormones in mice compared to the use of 
single hormones (Grunditz et al, 1984). In another in vivo study, it was shown that 
intravenous administration of antiserum against NPY in normal rats increased thyroid 
blood flow after one hour without affecting thyroid hormone or TSH concentrations 
(Michalkiewicz et al, 1993). The effect on NPY on the function of isolated thyroid 
cells has not been studied.
3.1.3.3 Vasoactive intestinal peptide
Vasoactive intestinal peptide (VIP) is a 28 amino acid peptide that functions as 
a neurotransmitter in the brain and peripheral nervous system (Metwali et al, 1993). 
Since the concentration of VIP in various brain areas changes markedly with 
development, it has been suggested that this neuropeptide is involved in maturation, 
growth, and maintenance of neurones (Gozes and Brenneman, 1993). VIP is also a 
m ediator of water and anion secretion by pulm onary, intestinal and pancreatic 
epithelia, and causes relaxation of gastrointestinal, bronchial and uterine smooth 
muscle, and vasodilatation of cerebral, peripheral and pulmonary blood vessels 
(Sreedharan et al, 1993). During investigation of the vasodilatory actions of VIP, it 
was shown that VIP was an inducer of NO synthesis in gastric muscle cells (Murthy 
et al, 1993), rat pinealocytes (Spessert 1993) and many other cells like smooth 
muscle (Grider et al, 1992) and blood vessels (Murthy et al, 1993).
VIP belongs to a family of regulatory peptides including secretin, growth 
hormone-releasing hormone (GHRH), glucagon, gastric inhibitory polypeptide and 
PACAP. It has been reported that the secretion of VIP in the adrenal gland is 
associated with catecholamines (Wakade et al, 1991).
Apart from the well-described cross reaction with PACAP type I and II 
receptors, VIP has two specific receptors (Usdin et al, 1994; Lutz et al, 1993). These 
receptors are present in liver, lung, and intestine as well as in several regions of the 
brain (Lutz et al, 1993).
The first neuropeptide demonstrated in thyroid nerves was VIP (Ahrén, 1986 
a). The VIP-containing nerves were shown to exist around and close to the follicular 
cells, and subsequent experiments with denervation and retrograde tracing have 
shown that the intrathyroid VIP nerves are intrinsic, originating in a thyroid ganglion 
(Ahrén, 1991). It has also been extracted from human parathyroid glands along with 
other peptides like substance P, gastrin-releasing peptide, and calcitonin (Weber et al,
1991).
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Intracellular cAMP increased when the cells of normal and hyperplastic 
hum an thyroids from patients with Graves* disease (Toccafondi et al, 1984; 
Siperstein et al, 1988) or guinea-pig thyroid sections (Ealey et al, 1985) were 
incubated with VIP, but the cAMP concentration was lower than that produced by 
TSH (Siperstein et al, 1988).
There is a negative correlation between the serum concentration of T4  and 
intrathyroid VIP concentration in rats (Jones et al, 1994). It has also been shown that 
while VIP alone did not affect the 3H  thym idine uptake of rat thyroid lobes, it 
increased the uptake produced by TSH (Karbownik et al, 1995). The activity of 
thym idine kinase, an enzyme involved in the supply o f precursors for DNA 
synthesis, was increased in homogenates of rat thyroid lobes incubated in vitro in the 
presence of low concentrations of VIP (lO -^L io - 9  mol/1), while high concentrations 
of VIP (10 '^ -10"-5 mol/1) had the reverse effect (Karbownik et al, 1995). On the other 
hand, when anti-VIP antibodies were administered to normal and iodine deficient 
rats, there was no alteration in blood flow  or thyroid horm one production 
(Michalkiewicz et al, 1993).
3 .1 .3 .4  Neuromedin U
Neuromedin U (NmU), a peptide originally isolated from porcine spinal cord, 
stimulates uterine smooth muscle contraction and causes selective vasoconstriction 
(Lo et al, 1992). This neuropeptide family includes two members, NmU 8  and NmU 
25. NmU 25 has 25 amino acids, having an identical C-terminus to NmU 8  (Lo et al,
1992). NmU has been found to have a widespread distribution extending throughout 
the mammalian central nervous system and in the gastrointestinal tract, particularly in 
the ileum, genitourinary tract, hypothalamus, spinal cord, thyroid, and the endocrine 
cells of pituitary gland (Bookman et al, 1989; Domin 1990; Lo et al, 1992). Although 
the NmU 25 separated from rat is two amino acids shorter and contains nine 
substitutions compared with porcine NmU 25, the five amino acids at the C-terminal 
of the peptide are totally conserved among different species (Lo et al, 1992). The 
receptor for NmU has not been cloned yet. Nandha and colleagues (1993) showed 
that a specific receptor for these peptides is present in the rat uterus, and suggested 
that the receptor is coupled to a G-protein.
NmU immunoreactivity occurs in corticotrophs of all species including human 
(Steel et al, 1988; Cimini et al, 1993). NmU immunoreactivity was significantly 
increased when rats were subjected to adrenalectomy (Cimini et al, 1993). NmU is 
also detected in some thyrotroph cells (Domin et al, 1989; Cimini et al, 1993), and 
oral administration of TRH to a euthyroid animal evoked a five fold increase in 
peptide content of anterior pituitary (Domin et al, 1989). The effect was caused by
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changes in circulating levels of thyroid hormone, since administration of TRH to a 
thyroidectomized animal failed to show a similar effect.
Domin et al, (1990) showed that there is a significant am ount (331+ 67 
fmole/gland) of NmU in the thyroid gland of the rat, and treatm ent of rats for two 
weeks with anti thyroid drugs caused a significant decrease in its content; 
thyrotoxicosis induced by exogenous T 4  failed to alter the thyroid content of this 
peptide. No studies have been published on its effect on isolated thyroid cells.
3 .1 .3 .5  Tachykinins
Substance P (SP) is a member of the tachykinin family of peptides. These are 
peptides with a common C-terminal sequence that were isolated from equine brain 
and gut in 1931 by Von-Euler and Gaddum, but only sequenced 40 years later 
(Maggi et al, 1993). The mammalian members of this tachykinin family include 
substance P, neurokinin A (also called substance K, neurokinin a, or neuromedin L), 
and neurokinin B (also called neurokinin p, or neuromedin K) (Maggi et al, 1993; 
Mussap et al, 1993). Other members of the tachykinin family are synthesised from 
alternative splicing of mammalian tachykinin mRNAs, followed by differential post 
transcriptional processing, including N-terminally extended forms of neurokinin A. 
These peptides are neurokinin A (3-10), neuropeptide K, and neuropeptide y (Helke 
et al, 1990; Mussap et al, 1993). The non-mammalian members of the tachykinin 
family include physalaemin, eledoisin and kassinin, isolated from amphibian skin 
(Regoli and Nantel, 1991; Maggi et al, 1993).
The term tachykinin was introduced to describe members of this peptide 
fam ily because of their relatively rapid initiation of smooth muscle contraction 
compared with the slower acting bradykinin. Tachykinins possess the common C- 
terminal sequence Phe-X-Gly-Leu-Met-NH 2  , where X represents either Phe, Tyr, 
He, or Val (Mussap et al, 1993; Maggi et al, 1993). Among the tachykinin peptides, 
substance P, neurokinin A, neurokinin A (3-10), and neuropeptide y are produced 
from a single preprotachykinin gene as a result of differential RNA splicing and 
posttranslational processing, while neurokinin B is produced from a separate 
preprotachykinin gene (Krause et al, 1989; Helke et al, 1990; Regoli and Nantel 
1991; Mussap et al, 1993; Maggi et al, 1993).
Substance P and neurokinins were found to be present in both the central 
nervous system and in peripheral organs (Mussap et al, 1993). Neurones are the 
m ajor source of tachykinins both in the central nervous system and in peripheral 
organs, but tachykinin-like immunoreactivity has also been found in other cell types, 
such as certain endocrine cells of the gut, principal parenchymal cells in the carotid 
body, chrom affin cells in the adrenal gland, cells of the anterior pituitary.
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eosinophils, cells in pig skin, and vascular endothelial cells. There is no firm 
evidence that their synthesis occurs in these non-neuronal elements (Maggi et al,
1993). Intrinstic neurons of the gut and peripheral endings of primary afferent 
neurons are the primary peripheral source of tachykinins (Maggi et al, 1993).
Substance P and other members of the tachykinin family interact with one (or 
more) of three receptors, which are known as neurokinin (NK) receptors (Krause et 
al, 1989; Helke et al, 1990; Regoli and Nantel 1991; Mussap et al, 1993; Maggi et al,
1993). Since there are three receptors and cross reactivity of several members of the 
tachykinin family with more than one receptor has been detected; it was necessary to 
develop specific agonists or antagonists for each receptor. There are many synthetic 
agonists and antagonists of these peptides now available that recognise one of the 
three receptors (Maggi et al, 1993, Mussap et al, 1993).
Substance P and other members of the tachykinin family produce different 
effects in different organs because of the presence of different proportions of the three 
receptors. Results of various experim ents indicate that N K l, NK2 and NK3 
receptors are present in the central nervous system, but the number of NK2 receptors 
is less than that of the other two (Maggi et al, 1993). All three receptors also have 
been detected in peripheral tissues with NK2 dominating the other two (Helke et al, 
1990; Maggi et al, 1993). The affinity for N K l is in the order substance P >  
neuropeptide y ^ neurokinin A = neuropeptide K >  neurokinin B, while for NK2 it is 
neuropeptide K = neuropeptide y > neurokinin A >  neurokinin B > substance P, and 
for NK3 it is neurokinin B > neurokinin A > substance P (Helke et al, 1990).
Tachykinins produce numerous actions, including contraction of urinary, 
respiratory, and gastrointestinal smooth muscle, increased salivary, respiratory, and 
gastrointestinal secretion, both contraction and endothelial-dependent relaxation of 
vascular smooth muscle, plasma extravasation and histamine release (Mussap et al,
1993).
Substance P (Ahrén et al, 1983) and neurokinin A (Grunditz et al, 1987) have 
been detected in the thyroid gland by immunoreactivity. There is a report that mRNA 
for substance P is expressed by the thyroid carcinoma cell line 6/23, which is a C cell 
line (Cremins et al, 1992). It has been reported that in the dog substance P stimulated 
thyroid hormone secretion, whereas in the mouse it had no effect (Ahrén, 1991). It 
has also been reported that the concentration of substance P in the rat anterior pituitary 
gland is inversely proportional to the concentration of serum T 4  (Jones et al, 1994). 
Although substance P has been reported to be present around the follicular cells and 
blood vessels (Ahrén, 1991) its direct influence on thyroid cells has not been studied. 
In this study, along with other neuropeptides, the effects of substance P and specific 
agonists for the N K l, NK2, and NK3 receptors on the iodine uptake and growth of 
thyroid cells were investigated.
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3.1.3.6 Endothelin
Endothelins are a family of three bicyclic 21-amino acid peptides, which are 
constrictors of vascular smooth muscle (Inoue et al, 1989). The most potent member 
of the family, endothelin-1 (ET-1), was originally isolated from the supernatant of 
porcine aortic endothelial cells (Kennedy et al, 1993). Endothelin-2 (ET-2) has two 
and Endothelin-3 (ET-3) has six (Haynes and Webb, 1993; Cody and Doherty, 1995) 
am ino acid differences from ET-1. They also have structural resemblance with 
sarafotoxins isolated from the venom of the Israeli burrowing asp (Haynes and 
W ebb, 1993).
Immunoreactive ET-1, or expression of mRNA of preproendothelin-1 can be 
detected in a wide variety of tissues including blood vessels, lungs, pancreas, spleen, 
kidney (Haynes and Webb, 1993), rat parathyroid epithelial cells (Fujii et al, 1991), 
and human (Tseng et al, 1993), rat (Colin et al, 1992; and 1994) and porcine (Colin 
et al, 1992; Isozaki et al, 1993) thyroid follicular cells. The ET concentration in the 
plasm a is between 0.25 and 20 ng/1, which is below the concentration generally 
associated with biological effects, and mainly consists of ET-1 and ET-3 (Kennedy et 
al, 1993; Haynes and Webb, 1993). ET-1 and ET-2 are predominately produced in 
endothelial cells and act in an autocrine or paracrine manner, whereas ET-3 
predominates in the central nervous system and anterior pituitary (Haynes and Webb,
1993).
Two endothelin receptor subtypes have been cloned (Cody and Doherty,
1995). These are termed ETa , which is selective for ET-1 and ET-2 over ET-3, and 
ETb , which is non selective for the ET isopeptides. An E T c  receptor subtype, 
selective for ET-3, has been reported, but has not been fully characterised (Kennedy 
et al, 1993; Cody and Doherty, 1995). The endothelin receptor subtypes are widely 
distributed in several tissues and appear to vary in function in different species (Cody 
and Doherty, 1995). Receptor for ET has been detected in human thyroid cells 
(Jackson et al, 1992; Tseng et al, 1993), and there is indirect evidence for its presence 
on the surface of thyroid cells from other species like pig (Isozaki et al, 1993) and rat 
(Miyakawa et al, 1992).
There are many reports that ET-1 may influence the growth or the functions of 
thyroid cells. It was shown by Jackson and co-workers (1992) that ET-1 decreased 
the release of TG by human thyroid cells w ithout affecting growth or cAMP 
production, while Eguchi and colleagues (1993) showed an increase in growth of 
human thyrocytes measured by ^H thymidine incorporation into DNA as well as by 
cell count assessed by the trypan blue method. On the other hand, it was shown by
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Miyakawa and colleagues (1992) that stimulation of FRTL-5 cells with ET-1 alone 
increased c-fos mRNA expression without affecting growth, while in the presence of 
TSH or IGF it caused a decrease or an increase in the growth of cells respectively. 
ET-1 also decreased the iodine uptake of porcine thyroid cells without affecting 
cAMP production (Tsushima et al, 1994).
Goitre formation is characterised not only by hypertrophy and hyperplasia of 
thyrocytes, but also by rapid and organ-specific increase in blood flow, and 
endothelial cell proliferation (Colin et al, 1994). The increase in the number of small 
capillaries is partly due to local release of ET-1 which is synthesised by thyrocytes 
and endothelial cells in the thyroid gland.
It was shown by Yoshizumi and colleagues (1990) that IL-1 increased the 
production of ET-1 by endothelial cells. Furthermore sodium iodide (Nal) increases 
the production of ET-1 mRNA by porcine thyroid cells (Isozaki et al, 1993), while 
other investigators have shown that human thyroid cells stimulated withTGF-|3 could 
synthesise a significant amount of ET-1 and release it into the medium (Tseng et al,
1993). IL-1, iodine, and TGF-(3 are known to be involved in thyroid autoimmunity, 
so it is likely that FT is also of importance.
3.1.4 Model Systems Of Thyrocyte Function
In vitro studies of thyroid function have either used primary cell cultures 
derived from humans or from a wide variety of animals, or used established cell lines 
like the rat FRTL-5 cell line or other cell lines developed from thyroid carcinomas.
There are many problems associated with the use of human thyrocytes. It is 
not common for thyroids to be removed in most centres, since Graves' disease can be 
controlled medically. The tissue which is available is not strictly speaking normal, 
and it is difficult to purify the epithelial cells in the presence of large numbers of other 
cells, particularly fibroblasts, which grow actively in culture.
Normal animal thyroid glands are easily collectable from a slaughterhouse or 
from laboratory animals, but other problems like bacterial or fungal contamination 
and the presence of other cells beside thyrocytes are still serious. Moreover, neither 
human nor animal cells separated as mentioned above grow well under laboratory 
conditions. Furthermore, to carry out many experiments as was intended for this 
study, many different batches of cells would be needed. This m ight cause 
unreproducible results due to treatments carried out on different patients, including 
anti thyroid therapy or radiation of the gland, before removal of the gland by surgery. 
If small animals such as rats were used, the low number of cells available in each 
gland would be limiting.
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A very useful model for the functional study of thyroid cells in vitro is the 
FRTL-5 cell line, a line of normal differentiated rat thyroid cells. This cell line was 
originally derived from  thyroid follicu lar cells of the Fisher rat by Am besi- 
Impiombate, Parks and Coon in 1980 and named FRTL. The original cell line had a 
doubling time of 7-10 days, but subsequent cloning gave rise to the FRTL-5 cell line, 
which grows in the presence of 5% serum and a mixture of six hormones with a 
doubling time of only 31 hours (Bidey et al, 1988; Tramontano, 1990). The only 
draw-back of this cell line is that though the cells are capable of transport of iodine 
and production of cAMP, they incorporate iodine very inefficiently into thyroglobulin 
and do not produce thyroid hormones. In spite of this, they are comparatively easy to 
use and give reproducible results, at least within individual laboratories.
I
3.1.5 Aim Of Study
The aim of this section of the study was to investigate the effects of cytokines, 
growth factors and neuropeptides on the function of thyroid cells. The FRTL-5 cell 
line was used as the experimental model, and iodine uptake and growth rate were 
measured.
The effect of certain combinations of mediators which are likely to occur in 
vivo was also studied. Since the disease of interest, Graves' disease, causes an 
excess of thyroid hormone in the blood, the effect of addition of thyroid hormones 
was investigated. Finally, since it is known that cell-surface proteases can modify the 
effect of peptides in some investigative systems, inhibitors of these enzymes were 
included in some experiments.
i.
I
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SECTION TWO: METHODS
3.2.1 G row th Of FRTL-5
FRTL-5 cells were grown in C oon’s m odified H am ’s F-12 medium  
supplemented with 5% heat inactivated foetal calf serum and six hormone mixture 
(6 H).
2x10^ cells were added to an 80 cm^ flask, and 20 ml of freshly filtered 6 H 
medium were added. Every 3 days the medium was changed till the cells had grown 
to confluence. Usually this time was about two weeks. The growing area of the flask 
was never fully covered by cells, because the cells tended to form follicles and grew 
over each other (Figure 3.1 and 3.2).
3,2 .1 .1  Cell Passage
After the cells had grown to confluence, they were passaged. The medium of 
the flask was removed and the cells were washed with 10 ml of the HBSS without 
calcium and magnesium. Then the HBSS was removed and replaced by 5 ml of 
freshly filtered CTC medium. The flask was incubated at 37“ C in 95% air and 5% 
CO2  for 10 min. After this time the cells had separated from the flask, but were in 
clumps. To separate them, the medium was sucked into a 10 ml pipette and blown out 
into the flask several times, and then 5 ml of freshly filtered stopping medium was 
added to the flask and incubated at 37“ C for a further 15 min. After this second 
incubation, the cell suspension was removed and transferred to a 50 ml sterile conical 
tube. The flask was washed with 5 ml of freshly filtered 6 H medium, and the wash 
was transferred to the same tube. The tube was centrifuged at 120 g for 5 min, after 
which the supernatant was discarded and the cells were immediately resuspended in 
1 0  ml of growth (6 H) medium. Cells were separated from each other by sucking in 
and out of an 18 gauge needle and syringe. At this stage a small aliquot (50 /d) of cell 
suspension was transferred to an Eppendorf tube, followed by addition of the same 
volume of trypan blue solution (4 g/1 in the PBS). The numbers of live cells per ml of 
cell suspension were determ ined visually in an im proved N eubauer counting 
chamber. The concentration of the cells was adjusted according to the requirement for 
the particular experiment.
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Figure 3.1: FRTL-5 cells cultured in 6 H medium. Top picture shows over-confluent 
cells in the 6 H medium forming follicles and growing over each other after 10 days. 
Lower picture indicates initiation of follicle formation after one week in 6 H 
medium.
Figure 3.2: FRTL-5 cells grown for 5 days in 5H (top picture) or 6 H (lower picture) 
media, after initial growth in 6 H medium for 3 days.
3.2.1.2 Recovery of Frozen Cells
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To recover cells from liquid nitrogen, the vial was washed in a beaker of 70% 
ethanol, and quickly thawed at 37“ C. The vial then was transferred to a laminar flow 
cabinet and the ethanol was allowed to evaporate. The vial was mixed slowly and 
opened carefully. The cells were removed by pipette, care being taken not to touch the 
edge of the tube, and then transferred to a 16 ml sterile tube, followed by addition of 
10 ml of 6 H medium. The cell suspension was centrifuged at 120 g for 5 min. The 
supernatant was discarded and cells were suspended in 5 ml of fresh 6 H medium. 
The suspension was transferred to a 80 ml flask with a pipette, and another 15 ml of 
6 H medium was added. The flask was incubated at 37° C in an incubator under an 
atmosphere of 95% air and 5% CO 2 . It was left for 2  days undisturbed, to allow cells 
to attach to the flask.
I
3.2.1.3 Preservation of Cells
To preserve stocks of cells, cells were suspended in freezing medium at 
2x10^ cells/ml and 1 ml of cell suspension was added to each Cryotube (Nunc). The 
tubes were sealed and transferred to a polystyrene foam box. The box was sealed and 
kept at -20° C for 3-4 h. After this period the box was transferred to a -70° C freezer 
for 24 h. This procedure is necessary for cooling the cells at 1-3 degree per min. 
After 24 h at -70° C, tubes were taken out of the box and immediately transferred to 
liquid nitrogen.
3 .2 .1 .4  Experimental Procedure
To study the effects of different cytokines or growth factors, the cells were 
grown in 12 or 24-well plates. For a 24-well plate, 0.5-0.8 xlO^, and for a 12-well 
plate, 1x10^ cells were dispensed in each well, followed by addition of 0.5 or 1 mi of 
medium (6 H) respectively. The plate was incubated at 37° C for 3 days, to allow the 
cells to attach to the plate and start growing. This time is sufficient for at least a two 
fold increase in cell number. After the first incubation, the medium was removed, the 
ceils were washed with 2 ml of the HBSS, and 0.5 or 1 ml of 5H medium with 5% 
serum was added. The plate was incubated at 37° C for at least five days, with one 
change of medium after 3 days.
The cells were now ready for the experiment. At this stage, the cells were 
washed, the concentrated solution of stimulator was added to the required volume of 
freshly filtered 5H or 6 H medium containing additional amino acids and 0.5% FCS, 
and this was added to appropriate wells.
3.2.2 Protocol For Iodine Uptake
3,2.3.2 Protocol For MTT Assay
After stimulation, and without disturbing the cells, 100 /d  (for 24-well plate) 
or 150 fil (for 12-well plate) of MTT stock solution were added to each well. The 
plate was incubated at 37“ C in an atmosphere of 95% air and 5% CO2  for one h. The 
yellow colour of the MTT dye changed to black spots around the cells. The plate was 
centrifuged at 800 g for 10 min, to sediment any suspended formazan. The medium 
was carefully aspirated, and any remaining medium was removed from the wells by 
inverting the plate over tissue paper. To dissolve the formazan formed, 1 ml of
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A fter stim ulation of cells for the required time, the medium containing 
stimulator was aspirated from the wells, and the cells were washed twice with the 
HBSS.
For a 12-well plate one ml of iodine uptake medium and for a 24-well plate 
0.5 ml was added to each well. The plate was incubated at37^C for 2 0  min. A fter the 
incubation period, the medium was aspirated from the well and discarded. Each well 
was given a quick wash (5-10 sec) with ice cold HBSS and the plate was dried 
over tissue paper. The cells were overlaid with 1 ml of ice cold ethanol and the plate 
was incubated at -20° C for 30 min. The ethanol was removed from each well and 
transferred to a tube for counting the activity with a Y counter.
3.2.3 Measurement Of Cell Growth Using The MTT Assay
3 .2 .3 . 1  Principle Of Assay
f
The cleavage of the tétrazolium salt MTT into a blue or purple coloured 
product (formazan) by the mitochondrial enzyme succinate-dehydrogenase (Slater et 
al, 1963) is used for assaying cell survival and proliferation. The conversion takes 
place only in living cells and the amount of formazan produced is proportional to the 
number of cells present. The fact that this enzyme is not present in serum (Landegren, 
1984) allowed the development of a rapid and simple assay by Mosmann (1983). 
Denizot and Lang (1986) and Carmichael and co-workers (1987) m odified the 
original method. Companies such as Sigma and Bio-Rad have also produced kits 
based on these m odified m ethods. However, the m ethod required fu rther 
modification to be applicable as a tool for measurement of cell growth under the 
conditions of these experiments.
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DMSO was added to each well of a 12-well plate (500 fi\ for a 24-well plate). To 
assist quick and complete dissolution, the plate was agitated on a plate shaker for 5 
min. A 100 pà aliquot of the pink solution wliicli developed was tiansferred to a 96 
well plate in duplicate and the absorbance was measmed with a plate reader at a 
wavelength of 450 run and a background conection at 780 nm.
3 .2 .4  P ro te in  A ssay
Iodine uptake tvas coixected for the number of cells present by measuiing the 
protein contents of each w ell and results were calculated as cpm per ;ag of protein.
The protein assay was carried out using a kit mimufacuu'ed by Bio-Rad. Tliis 
method is a dye binding assay based on the observation that the absorbance maxiimmi 
for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 
mn when binding to protein occurs. It requires a single reagent and an incubation time 
of 5 min.
The protocol for protein measurement was modified to obey B eer's Law over 
a range of 0  to 1 0 0  /fg/ml.
For a standard solution, a protein solution of 400 //g/m l was used. This 
solution was diluted with physiological saline to give protein concentrations of 2 0 , 
40, 60, 80, and 100 /fg/ml for constinction of a standard curve. Figure 3.3 shows an 
example of a standard ciuve for protein measiuement.
To measur e the protein concentration in  each well, the cell remnants that were 
still adlierent to the plate after iodine uptake weve solubilised in 0.5 ml (24-well plate) 
or 1.0 ml (12-well plate) of 0.2 mol/1 NaOH. The plates were sealed and incubated at 
room temperatme overnight. Next day, the solution was resuspended by shaking the 
plate on a plate shaker. Then, the contents of each well were mixed thoroughly at 
least 4  times, using a one rnl automatic pipette. M iquots of 20 pd of samples and 
standar ds were transferred to a 96-well plate in duplicate, followed by addition of 200 
pd of stock dye reagent, using the first two wells as blank. Tire plate was mixed on a 
plate shaker for 5 miir. The-absorbance of the solution was detenniiied usmg a plate 
reader, with a filter of 595 mn, against a solution 20 of pd of distilled water and 2 0 0  
pd of reagent as reagent blank.
3 .2.5 E x trac tio n  O f cAIMP F rom  F R T L -5  Cells
Into each well of a 6 -well plate, 10 xlO^ cells were seeded, followed by 
addition of 2.5 ml of 6 H medium containing 10 U/1 of TSH. Two different protocols 
were mvestigated for extractiorr of cAhdP using separate plates.
9 0
0 .1 5
0 . 10-
0 . 0 5
0.00
0 2 5 5 0 7 5 100 1 2 5
jwg protein/ml
Figure 3.3: Standard curve used for measurement of cellular protein.
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-Plates were incubated at 37° C in on atmosphere of 95% air and 5% CO? for 3 
days. After tills time, the mediimi was removed from each well, and cells were 
washed twice with the HBSS. To each well, 2.5 ml of freshly filtered 5H medium 
were added, and plates were incubated for a fuither 5 days (medium w-as changed 
once after three days). A fter this second incubation, the medium of all wells was 
removed, and the cells were washed using the HBSS. One plate was used for each 
extraction protocol.
3.2.5.1 Protocol 1
After washing the cells, 2.5 ml of HBSS containing 2 g.l BSA and 0.5 
mmoi/1 IBN'IX (3-isobut)d-methyl xantliine) were added to all wells. Tlnee wells 
served as control and to another 3 wells a concentrated TSH solution was added to 
give a final concentration o f 10 U/i. The plate was irrcubated at 37° C. A fter 3 h 
irrcubation, nredia from all wells were aspuated and discarded. To each well 2.5 nil of 
ice-cold absolute ethanol were added, and the plate was incubated at -20° C 
overnight. The alcohol from each well was removed and transfeiTed to appropriate 
labelled tubes, and lyophilised. Immediately before cAAfl? assay, 2.5 rid of cAAlP 
buffer were added to each control tube, and 5 ml to tubes containing the extract of 
stimulated cells, to reconstitute the samples for assay.
3 .2 .5.2 Protocol 2
The buffer used for tins protocol was low sodium salt (composition of this 
solution is given in table 3.1). Tliis buffer causes diffusion of cAhfP out of the cells. 
To each well of the second plate, 2.5 ml of low sodrimi buffer contahiing 2 g/1 BSA 
and 0.5 nunol/1 IBAIX were added. Three wells served as control arrd to another 3 
wells a concentrated solution of TSH was added to give a final corrcentration of 10 
U/1. The plate was incirbated at 37° C. After 3 h incubation, media fronr all wells 
were aspirated arrd tr airsferred to appropriate labelled tubes. Tubes were kept at -20° 
C imtil they were assayed. To tirbes corresponding to stimrdated wells 2.5 ml o f 
assay buffer were added.
To dissolve the cells remairdng in the weds of both plates, 3 ml of 0.2 rnol/1 
NaOH were added to each well, and plates were incubated at room ternperatirre 
overnight. Protem assay was carried out as described above.
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Ingredient mmol/l M.W. gA
KCI 5.00 74.55 0 3 7 5
C aC l2 .2 H 2 0 1.30 147.0 0.191
M gS04 0.40 120.5 0.048
N a2H P04 0.34 142.0 0.048
K H 2 P O 4 0.44 136.1 0.060
Glucose 5.55 180.2 1 . 0 0 0
H EPES 1 0 . 0 238.3 2.383
BSA - - 1 . 0 0 0
Table 3.1: Ingredients of buffer solution with low sodium, pH 7.4.
3.2.6 D eterm ination of cAMP
3.2.6.1 Piindples of the Assay
To detenTiine the amount of cAAIP in cell culture supernatants, a commercial 
kit (Amei-sham Life Sciences) was used. Tins kit method is based upon competition 
between unlabelled cAlVIP and a fixed quantity of peroxidase-labelled cAMP for a 
hmited number of binding sites on a cAAfP specific antibody. Witli fixed amoimts of 
antibody and peroxidase-labelled cAMP. the amount of peroxidase-labelled ligand 
bound by the antibody will be inversely proportional to the concentration of added 
unlabelled ligand.
The rabbit anti-cAhdP antibody is immobihsed on to polyst^nene microtitre 
wells precoated with second antibody (Donkey anti rabbit IgG). Tlius any unbound 
ligand can be removed from the well by washing.
The amount of peroxidase labelled cAMP bound to the antibody is deteiiuined 
by addition of a tetramethylbenzidiiie (TVIB)/hydi'ogen peroxidase substrate. The 
reaction is stopped by addition of acid, and the resultant colour read at 450 mn in a 
microtitm plate spectrophotometer.
The kit contained the reagents and materials listed below.
Microtitre plate: Plate containing 8  x 12-well strips coated with donkey anti­
rabbit IgG, ready for use.
Peroxidase conjugate: 11 ml diluted assay buffer were added to the contents 
of a vial of lyoplrilised c.ANTP-hor’semdish peroxidase.
Standard: To one vial of lyopliiHsed cAM P standard containing 64 pmol 
cAh/fP, 2 ml distilled water were added. The vial after reconstitution contained 32 
nmol/1 of cAMP in 0.05 mol/1 acetate buffer and 0.01 % (w/v) thimerosal.
Eight working standards were prepaied by serial dilution of the stock standard 
of 32 mnol/l with the assay buffer. The fmal concentrations mnged from 0.125 to 16 
mirol/1 .
Antiserum: 11 ml distilled water \rere added to the contents of a vial of rabbit 
anti cAMP. The solution contained anti-cAAIP senun in 0.05 mol/1 acetate buffer pH  
5.8, 0.5 % (w/v) bovine serimr albumin and 0.01 % (w/v) tliimerosal.
TKTB Substrate: One bottle of enzyme substrate was provided, containing 22 
ml solution of 3,3%5,5'-tetramethylbenzidine (ThTB)/hydrogen peroxide, ready for 
use.
Assay buffer: One bottle was provided, containing 10 ml. This was made up 
to 500 ml with distilled water. Tire diluted buffer contained 0.05 mol/1 sodium acetate 
buffer pH  5.8, 0.02 % (w/v) bovine seium albmnin and 0.005 % (w/v) thimerosal.
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Wash buffer: One bottle was provided, containing 12.5 ml. This was made up 
to 500 ml with distiUed water. The diluted buffer contained 10 mmol/l phosphate 
buffer pH 7.5, md 0.05 % (w/v) tliimerosal.
3 .2 .6 .2 Piotocol for Measmement of cAhIP
Before assay all reagents and samples were left to equihbrate to room 
temperatme. All steps of the protocol were perfomied according to the manufactuier’s 
instiuctions.
The required numbers of microtitre strips vrere fixed on the frame provided. 
Two wells n-ere used as blank and another two as non-specific binding (NSB), and 
200 /d  of assay buffer were added to tliese in place of standard or samples. To 
another two wells (Bq), 100 /d  of assay buffer were added. From each working 
standaid or sample, 1 0 0  /d  were transferred into the appropriate duplicate wells of the 
microtitre plate. To all wells except blanlc and NSB wells, 100 /d  of antisemm were 
added. The plate was sealed, gently mixed, and incubated for exactly 2 h over 
cmshed ice.
After incubation, the plate sealer was removed, and to all wells except the 
blank, 50 /d  of cAhfP-peroxidase conjugate were added. The plate was sealed, gently 
mixed, and incubated over cmshed ice for another hour.
After tiie second mcubation, the plate sealer was removed, and the nulls nure 
decanted by inveiting the plate. The weds were washed 5 times with 400 /.d of wash 
buffer and chied by placmg the inverted plate over tissue paper. Iimnediately after- 
washing, 150 pA of enzyme substrate were dispensed into aU wells. The plate was 
sealed again and mixed on a microtitre plate shaker for one h at room temperature. 
The reaction was stopped with 100 pA of 1 mol/1 H 2 SO4  and absorbance was 
measrned at 450 mn. The final colour' was stable for 30 rnin.
To construct the standard curve and determine results, the average optical 
density of each standard or sample was converted to percentage of bound labelled 
cAAIP, using following for-mida:
E Àtijortaiio*: of 5tan*irii\ior55iiipk3_Àtsof'haiv.*:*! of HSB  __%  —  =  ---------------------------------   X 1 U0g A-bsortaacfl of Ec*~ Atfc-fl'aMC of USE
A n example of standard curve for cAhTP assay is presented in figure 3.4.
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Figure 3.4: Standard curve used for measurement of cAMP.
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3.2.7 Acrylaniide Gel Preparation And Electrophoresis
For poh'aciyianiide gel prepai'atiou, and electrophoresis an electrophoresis set 
(Protean II Slab Cell) manufactured by Bio-Rad was used. Electrophoresis was 
canied out as stated in tire manufacturer’s instmctions.
The required volume of stock aciylamide/Bis for prepar ation of 50 ml of 
solution was calculated. This is equal to 12.5 ml for a 7.5 % gel. This was 
transferred to a beaker that contained 24.25 nil of distilled water, followed by 
addition of 12.5 ml of 1.5 mold Tiis-HCl buffer (pH 8 .8 ). The solution was mixed 
thoroughly and was transferred to a filtration unit (Corning, \4icuum  Filtration 
System), connected to a vacumn pump. The pmnp was started, and the solution was 
filtered. After filtration, the pump was tun for a fuither 20 min to remove air trapped 
in the solution.
lATiile the reagents were being filtered, the apparatus u'as set up as described 
in the Bio-Rad manual.
After de-aerating the monom er solution, 500 /rl of freshly prepaied 10% 
solution of ammonium persulphate were added, followed by rapid addition of 50 pi\ 
of TEhTED (N,N,N’,N'-tetrainethylethylenediamine) to initiate polymerisation. The 
solution was mixed quickly with a pipette. By using a 30 ml syringe and a needle, 22 
ml of monomer solution were transfeiTed to the gel sandwich assembly, between the 
glass plates. Cam was taken not to hap any air bubbles. Immediately, the monomer 
solution was overlaid with 1 ml of water. The assembly ^vas left undistuihed for 1 h 
to allow gel fomiation to take place.
During polymerisation of the separatmg gel the stacking gel solution was 
prepared. 10 ml of 4% stacking monomer solution was prepared by addition of 1.3 
ml of stock aciylamide/Bis solution (30% T, 2.67% C), and 2.5 ml of 0.5 mol/1 Tris- 
HCl buffer, pH  6 .8 , to 6 . 2  ml of distilled water in a beaker. This was filtered and 
de-aerated, as described above.
TiTien polymerisation was complete, the liquid was removed from the top of 
the gel and the smface of the gel was dried with filter paper. Then, a d 0-toothed well 
comb was placed between the glass plates in such a way as to make an angle of 15- 
20° with the smface of the miming gel. This prevents air being happed under the 
comb teeth wliile pomiiig the monomer solution. The assembly was then ready for 
introduction of the stackhig gel.
The stacking gel solution was prepai'ed by addition of 50 pi\ of 10% 
am monium persulphate solution to the stacking m onom er solution, follow ed 
himiediately by 50 pâ of TEhlED. Tliis was pomed with a 10 ml syringe and needle, 
’^ dien all teeth had been covered by the solution, the comb was pushed down and 
ahgned. Then more solution was added to fill the sandwich completely. It was left
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undisturbed for 1 h for the gel to polymerise. Gently, the comb was removed by 
pulling it straight up. The sandwich assembly was attached to the cooling system of 
the tank. An acrylic dam was used to form the upper buffer chamber. The lower 
buffer chamber was filled with the required volume of diluted running buffer ( 1 . 2  1).
Then the cooling system and attached gel were put in place and the cooling system 
was connected to a w ater tap. The upper buffer chamber was filled with running 
buffer (approxim ately 350 ml). The lid of the tank was put in place, and the 
apparatus leads were connected to the power supply. The system was run w ithout 
sample at a constant current of 15 mA for 0.5 h. Then the power supply was 
disconnected.
During the above period, the samples for electrophoresis were prepared by 
addition of 60 ja.1 of sample buffer to 20 /d  of sample in an Eppendorf tube. The 
contents of the tube were mixed by vortexing. Using an automatic pipette with a 
narrow tip, 30 pi\ of this mixture were transferred to each well. The lid of the tank 
was replaced, and the run was carried out at constant current of 18 mA for 2 h. W hen 
the dye had entered the separating gel, the current was reduced to 5 mA and the 
system was run overnight. W hen the dye (BPB) reached the end of gel, the electric 
supply was disconnected.
The gel was removed carefully from the glass plates and was immediately 
transferred to the staining tray, which contained 1 0 0  ml of stain solution, and left for 
30 min, with occasional shaking. The stain was discarded from the tray and was 
replaced by 50 ml of destaining solution. The gel was washed thoroughly in this 
solution. The solution was removed and discarded, and was replaced by another 100 
ml of destaining solution. This changing of destaining solution was carried out every 
30 rain, with shaking every 5 min until the gel was clear.
3.2.8 Statistical Analysis
The FRTL-5 cells used for this study were between the 14^^ and 19^^ 
passage. The experiments for this part of the work were repeated at least twice, and in 
some cases up to five tim es. The results presented for growth are fo r the 
measurement of cellular protein, and are the mean ± standard deviation of triplicate 
results obtained in one set of experiments. Statistical analysis was carried out using 
the StatView computer package. Data were analysed by factorial analysis of variance 
(ANOVA). The Bonferroni/D unn criterion was used to determ ine significant 
differences in multiple comparisons.
The P value is m entioned in the text w herever necessary. Significant 
differences are shown in the graphs by (*), while in text they are defined as 
significant or highly significant. I$95 i
The differences were defined as significant when the calculated critical 
difference as detemiined by the Bonfenoni/Dunn criteria (5% significance level) was 
less than the mean difference (P< 0.05), wliile they are defined as highly significant 
when the calculated critical difference is less than half of mean difference (P< 0.001).
■Sf-
9 6
.        . __________
SECTION THREE: RESULTS
3,3.1 Characterisation of FRTL-5 Cells
The ability of the FRTL-5 cells to respond to TSH was confirm ed by 
determination of cAMP production, iodine uptake and growth.
3.3.1.1 cAMP Production
For extraction of cAMP from the cells, two different protocols were quoted in 
the literature, using either ethanol or hypotonic saline solution. To compare these, 
two parallel 6 -well plates were set up as given in methods' sections (3.2.1.4). The 
mean value of cAMP extracted by ethanol in the control group was 15.71 fm ol//ig 
protein, compared to 549.8 fmol///g protein when cells were stimulated by 10 U/ml 
of TSH for 3 h. When hypotonic saline solution was used, the mean value obtained 
for control wells was 15.70 fmol//<g protein, and for stim ulated cells was 528.4 
fmol/jwg protein. Statistically there were no differences between the two extraction 
methods for either controls or stimulated cells. These results confirmed that the cells 
were capable of responding to TSH by increasing cAMP production and showed that 
there was no difference in efficiency between the extraction methods.
3 .3 .1 .2  Growth Measurement
The MTT assay has not been used previously for growth measurement of 
FRTL-5 cells, so its suitability was tested. Two 24-well plates were seeded with 
IxKB to 1x10^ FRTL-5 cells in 0.5 ml of medium, either without TSH or containing 
10 U/1 of TSH. Plates were incubated at 37° C for 24 h, and the MTT assay was then 
carried out as described in section 3.2.3,
The graph of absorbance versus number of cells (figure 3.5), was a straight 
line passing through the origin. This shows that the MTT assay is a reliable method 
for m easurement of growth for this cell line. The mean value of the ratio of 
absorbance of stimulated cells versus unstimulated cells at 24 h was 1.626 ± 0.043.
3.3.1.3 Iodine Uptake
Since several protocols for uptake of iodine into FRTL-5 cells have been 
published, optimal conditions were investigated.
9 7
_______
■V, '
Absorbance X 1000
2000
5H
6H
1500
1000-
5 0 0 -
100 20  3 0  4 0  50  60 70 80 90 100
No of cells ( IX  104)
Figure 3.5: Growth of FRTL-5 cells as assessed by the MTT assay. D ifferent 
numbers of FRTL-5 cells were seeded in 5H and 6 H media for 24 h, and MTT assay 
was performed.
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Figure 3,6: Association of radioactive iodine with albumin. A dose of 0.5 piCi of 
in 10 nmol/1 KI was incubated with albumin at pH 7.35. P rotein was 
precipitated with TCA and radioactivity was counted.
3.3.1.3.1 EjfectofpH
Salt solutions with and without additional buffering in the form of HEPES 
were compared as iodine uptake media. Two 12-well plates were seeded with 
approximately 1x10^ cells per well. The ceils were incubated for 3 days in 6 H (TSH 
2 U/1), followed by 5 days in 5H medium. The medium of 6  wells from each plate 
was changed to 5H and the other 6  wells to 6 H (TSH 500 mU/1). The plates were 
incubated for a further 3 days. In one plate the HBSS containing bicarbonate buffer 
was used (pH 7.4), and in the second plate the HBSS containing 1 0  mmol/l of 
HEPES, pH 7.4. To these buffers, KI and radioactive iodine were added to final 
concentrations of 1 pmoMX and 0.2 /Æ i/m l respectively. Iodine uptakes were 
performed for 30 min at 37° C. The pH of the first medium changed to 6.3-6.4 
during this incubation, as assessed by the colour change of the phenol red indicator.
The uptake of iodine into TSH-deprived cells incubated in HEPES was 
494.42 ± 48.17 cpm//tg protein, and for TSH-stimulated cells was 631.46 ± 39.64. 
The stimulatory effect o f TSH was significant (P<0.01). The values obtained for 
iodine uptake of the cells incubated in medium not containing HEPES was 716.73 ± 
24.23 cpm//fg protein when unstimulated, and 735.85 ± 46.43 cpm//^g protein when 
stimulated by TSH. There is no significant difference between these values. This 
shows that adequate buffering of the medium is essential for the cells to respond to 
TSH.
3 .3 .1 .3 .2  Ejfect of albumin
Incubation media described in the literature sometimes, but not always, 
contain albumin. It is possible that albumin may bind to iodine and act as a carrier, 
thus modifying the uptake characteristics of the cells. Experiments were carried out to 
assess the extent of uptake of radioactive iodine by albumin in solution, in the 
absence of cells. Different concentrations of albumin ranging from 0 to 10 g/1 were 
prepared in HBSS with 10 mmol/l of HEPES (pH 7.35). A mixture of radioactive 
iodine (0.5 (xCi/ml) and non-radioactive iodine (10 nmol/1 potassium iodide) was 
added to the solutions. They were incubated in a 37° C water bath for 30 min. For 
each concentration of albumin four replicate tubes were prepared. One ml from each 
solution was transferred to a tube containing 1.0 ml of 10% TCA. After incubation 
for 10 min in ice, the tubes were centrifuged at 1500 g, the supernatants were 
discarded, and the precipitates were washed once with TCA, before measurement of 
their radioactivity in a y  counter.
The mean value obtained for four tubes without albumin was considered to be 
non-specific binding and was subtracted from the remaining values. The results are
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presented in figure 3.6. There is a direct relation between concentration of albumin 
and bound iodine.
To investigate, whether the association of albumin and iodine was saturable, 
the experim ent was repeated with a fixed concentration of albumin (5 g/1) and 
radioactive iodine (0.5 pCi/ml) and various concentrations of KI ranging from 10 
nmol/1 to 10 mol/1. Increasing the concentration of KI caused a decrease in 
association of albumin and radioactive iodine, implying competition for a saturable 
binding site (figure 3.7).
To investigate the time course for association to albumin, the above 
experiment was repeated using a fixed concentration of albumin ( 2 0  g/1) and iodine 
(10 nmol/1 of KI and 0.5 /iCi/ml of radioactive iodine), and various incubation times 
ranging from 15 seconds to 60 min. There were no differences between values 
obtained for each time point. This suggests that the association of iodine and albumin 
was instantaneous.
To identify the carrier of iodine in serum, blood was taken from 8  healthy 
adults (4 males, 4  females). After separation of serum, 10 pCi radioactive iodine (1 
pi) was added to 50 pi of each sample, and the sera were prepared for polyacrylamide 
gel electrophoresis as described in section 3.2.7. After the destaining step, the gel 
was cut into strips, one for each sample. Each strip was further cut into 8  segments. 
The radioactivity of each segment was counted in a y counter.
Approximately 15 % of the total count of the radioactive iodine was attached 
to the pre-albumin band, 37.5 % to albumin, and 12.5 % to the last band in the 
gamma globulin region, although some was also found in other bands (figure 3.8).
The results from the above experiments suggest that inorganic iodide is bound 
to proteins, especially pre-album in and albumin, by a strong bond that is not 
disrupted by protein precipitation. Both pre-albumin and albumin are known to carry 
thyroid hormones, and this evidence suggests that the same proteins may also be 
carriers for inorganic iodine.
3.3.1.3.3 Optimisation Of Iodine Uptake Buffer
1x10^ FRTL-5 cells were seeded in each well of four 12-well plates, and 
incubated as described in section 3.2.1.4 (3 days in 6 H, 5 days in 5H, and 2 days in 
6 H). For the iodine uptake step, two sets of solutions of HBSS buffer w ith 10 
mmol/l HEPES were prepared. Both contained concentrations of KI ranging from 0.1 
/tmol/1 to 200 //mol/1, keeping the ratio of radioactive iodine to KI constant (50 
mCi/mmol of KI). The second buffer also contained 5 g/1 of albumin. Iodine uptake 
was carried out for 5 min according to the protocol given in section 3.2.2, using one 
concentration of KI for each set of triplicate wells.
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Figure 3.7: Effect of KI on association of fixed amount of radioactive iodine (0.5 
//Ci) to protein in a solution of 5 g/1 of albumin.
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Figure 3.8: Binding of radioactive iodine to serum proteins. The bands extended 
from pre-albumin (I) through albumin (2), and gamma globulin (7), to the material 
that was excluded from the gel (8 ). Serum was separated on a non-denaturing 
polyacrylamide gel (7.5 %)
The result of this experiment is presented in figure 3.9. At all concentrations 
of iodine, the iodine uptake was greater in the presence of albumin than its absence.
The curves for both media demonstrated saturable kinetics.
The data were used to determ ine Km and Vmax of iodine uptake in the 
presence and absence of 5 g/1 albumin by plotting as a Lineweaver-Burk plot (figure 
3.10). The Km was 52.6 //mol/1 in the absence of albumin, and was 27.0 //moI/1 
when albumin was present in the iodine uptake buffer. The corresponding values of 
Vmax were 3.57 and 2.70 pm ol///g protein/min. This indicates that the presence of 
albumin in the iodine uptake medium caused a decrease of 50 % in the value of Km, 
and decreased the value of Vmax by 0.87 pmol///g protein/min.
To ensure that measurements were made in the approximately linear section of 
the response curve, a concentration of KI of 10 //mol/1 was used. Albumin (5 g/1) 
was also included in the buffer.
To determine the optimal incubation time, 1x10^ FRTL-5 cells were seeded 
per well of eight 1 2 -well plates, and incubated as given in methods' section 3.2.1.4.
For iodine uptake two different HBSS buffers with 1 0  mmol/l HEPES (pH 7.38) 
were prepared. Both contained 10 //mol/1 of KI and 0.5 //Ci/ml of radioactive iodine,
(50 mCi/mmol of KI). The second buffer contained 5 g/1 of albumin in addition. For 
iodine uptake, 6  wells from each plate were filled with one ml of buffer alone, and the 
other 6  wells were filled with buffer that contained albumin. Each plate was incubated 
for a different period ranging from 7 to 56 min.
At all time points the amount of iodine taken up by cells in the presence of 
albumin was higher than when it was absent. When albumin was absent from the 
buffer, iodine uptakes increased significantly with time up to 35 min, but after 35 min 
there were small, non significant increases up to 56 min (figure 3.11). The iodine 
uptakes at successive time points in the presence of albumin were significantly 
different from each other up to 21 min. After this time, there were small and non 
significant increases up to 56 min. An incubation time of 20 min was chosen.
3 .3 .1 .3 .4  Optimal Concentrations Of TSH And Serum
The recommended concentration of TSH in the original paper (Kohn and 
Valente, 1989) was 10 U/1 in 6 H medium. Many other investigators used different 
concentrations of TSH in the range of mU/1 to U/1. With high concentrations of TSH 
(10 U/1), small effects of other stimulators may be difficult to detect. Zakarija and 
McKenzie (1989 a) showed that the concentration of serum or its replacement with 
albumin could also change the pattern of iodine uptake and growth of cells. In the 
present study, FRTL-5 cells did not grow (nearly 10 % of the cells survived) when 
serum was replaced by albumin or if the concentration of serum was less than 0.5%.
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Figure 3.9: Iodine uptake of FRTL-5 cells. Cells were incubated with various 
concentrations of iodine in presence and absence of albumin for 5 min. The specific 
radio-activity of iodine was 50 mCi radioactive iodine/mmole KI.
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Figure 3.10: Lineweaver-Burk plot of iodine uptake of FRTL-5 cells. The specific 
activity of iodine was 50 m Ci/m m ole in the presence and absence of 5 g/1 of 
albumin. The time of exposure of cells to iodination medium was 5 min.
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Figure 3.11: Time course of iodine uptake of FRTL-5 cells in presence and absence 
of albumin. The concentration of iodine was 10 //mol/1 and the specific activity was 
50 mCi/mmole.
To determine the most suitable concentrations of TSH and serum for iodine 
uptake and growth, two 24-well plates were seeded with approximately IxlCP cells 
per well. The plates were incubated as given in section 3.2.1.4. For stim ulation, 
media containing different concentrations of serum (0.5 to 5 %) and TSH (0 to 2U/1) 
were used. Each set of triplicate wells had a different combination of serum and TSH . 
The plates were again incubated for a further 3 days. The iodine uptake assay and 
protein measurements were carried out as given in sections 3.2,2 and 3.2.4,
The iodine uptake of cells incubated in the absence of TSH (5H) did not 
change when the serum concentration was changed from 0.5 to 5%. W hen the cells 
were stimulated with a constant concentration of TSH (0.5, 1 , or 2 U/I), and serum 
concentration was changed from  0.5 to 5 %, the iodine uptake decreased. 
Statistically, the uptake obtained at a serum concentration of 2% was significantly 
decreased compared to values at 0.5 %. The decrease was highly significant when 5 
% serum was used (figure 3.12). The cells were most sensitive to changes in TSH 
concentration when the serum content in the medium was 0.5 % and least sensitive 
when the serum content of the medium was 5 %. At a serum content of 5%, there 
was no significant response to changes in TSH concentrations between 0.5 and 2.0 
U/1.
Since the highest iodine uptake was seen at 2 U/1 of TSH and serum content 
of 0.5 %, these concentrations were used in further experiments.
Cell growth in the absence of TSH did not change significantly when the 
serum content was changed from 0.5 to 5 %. A t a constant concentration o f TSH, 
growth increased as serum concentration was changed from 0.5 to 5% (figure 3.13). 
Statistically, values obtained for 2 and 5% were significantly greater that those at 
0.5%.
Since optimal growth required high serum concentrations, but optim al 
response of iodine uptake to TSH required low concentrations, additional amino acids 
were added to the medium to provide the requirements for growth. To do this, 10 ml 
of 50 X concentrated MEM amino acids solution with L-glutamine (Sigma), and 10 ml 
of 100 X concentrated MEM nonessential amino acid solution (Sigma) were added per 
litre of 5H medium containing 0,5% heat inactivated FCS.
3.3.2 T h y ro g lo b u lin  P ro d u c tio n  By F R T L -5  Cells
The activation of the thyroglobulin gene of FRTL-5 cells, in response to 
thyrotropin stimulation have been reported (Graves and Davies, 1993; Kamikubo et 
al, 1990; Bone et al, 1986 b; Van-Heuverswyn et al, 1984), but there is less 
information on the production of iodinated protein.
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Figure 3.12: Effect of serum content of medium and concentration of TSH on iodine 
uptake of FRTL-5 ceils after 72 h.
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Figure 3.13: Effect of serum content of medium and concentration of TSH  on 
growth of FRTL-5 cells after 72 h.
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To determ ine w hether the FRTL-5 cells were capable o f producing 
thyroglobulin, one 6 -weIl plate was seeded with approximately 5xlCP cells per well. 
The plate was incubated for 3 days with 6 H medium and 5 days with 5H medium. At 
this stage, the medium was changed to either fresh 5H medium or 6 H medium (2 U/1 
TSH) containing 0.5 % FCS, additional amino acids, 0.5 ^mol/1 KI, and 0.5 mCi/1 
radioactive iodine. The plate was incubated for a further 72 h.
After the final incubation, the medium from each well was transferred to 
appropriate labelled tubes, the cells were washed twice with ice-cold HBSS, and their 
iodine content was extracted with 1 ml of ethanol and counted with a Y counter. The 
protein content of each well was measured as given in section 3.2.4. The protein in 
the media was precipitated by 2.5 ml of 10 % TCA for 10 min, follow ed by 
centrifuging at 1500 g. The precipitates were washed twice, each with 1 ml of TCA, 
and counted.
The activity of radioactive iodine bound to protein in the m edium  of 
unstimulated cells (5H medium) was 143811 ± 9374 cpm, whereas the value for 6 H 
medium was 245083 ± 22565 cpm, a 70.4 % increase. W hen those data were 
corrected for number of cells, the activity of radioactive iodine bound to proteins in 
the 5H medium was 1168.60 ± 47.80 cpmlpig cell protein, while the value for 6 H 
medium was 1400.13 ± 77.18 cpm/j2 g cell protein. There is a significant difference 
between these values, which represents either newly synthesised protein or binding 
of iodine to serum components.
To determine whether there was synthesis of protein at the expected molecular 
mass of thyroglobulin, the distribution of iodine bound to protein was studied by 
electrophoresis. The experiment was repeated, under similar conditions. A t the last 
stage the media were concentrated, using Centriflo membrane filter cones (CF-25). 
The concentrated proteins were diluted twice with 2 ml of the HBSS and concentrated 
again, to remove any unbound radioactive iodine. The final volum es of the 
concentrated protein solutions were adjusted to 50 //I. To each tube 50 pi\ of sample 
buffer was added, and all 1 0 0  pci was used for non-denaturing polyacrylam ide 
electrophoresis.
After electrophoresis of the media, most of the radioactivity was shown to be 
bound to serum proteins, and only a small fraction was present in the high molecular 
mass band that was assumed to contain thyroglobulin. The average activity in this 
band for the media from unstimulated cells was 413.00 ± 87.07 cpm (corrected for 
background), whereas the corresponding value for stimulated cells was 1145.67 ± 
114.73 cpm. The values corrected for protein content of the media were 3.35 ± 0.63 
cpm/peg protein for 5H and 6,54 ± 0.32 cpm/jwg protein for 6 H. Statistically, the 
difference between these values was significant (p=0.0054). This indicates that the
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Figure 3.14: Thyroglobulin production by FRTL-5 cells. Cells were incubated for 72 
h in media that contained 0.5 % FCS, additional amino acids, 0.5 //mol/1 KI and 0.5 
mCi/1 radioactive iodine. A: Activity of iodine bound to the protein in the medium. 
B: Activity of iodine bound to the thyroglobulin that was released to the m edium 
(measured by electrophoresis). C: Activity of iodine remaining in the cells. D: 
Growth of cells.
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FRTL-5 cells were capable of responding to stimulation with TSH by increasing the 
production of a high molecular mass iodinated protein, presumably thyroglobulin.
The absolute amounts were, however, small. A summary of this experim ent is 
presented in figure 3.14.
3.3.3 Effect Of Inorganic Iodide On Growth
Endemic goitre is an adaptive disease that develops in response to an 
insufficient supply of dietary iodine (Studer and Gebel, 1986), and administration of 
iodine is known to affect the size of the goitre of Graves' disease acutely. It is 
therefore possible that iodine concentration could effect the growth of thyroid cells in 
vitro. To investigate the effect of inorganic iodine on growth of FRTL-5 cells, 
approximately 1 xlO^ cells were seeded in each well of four 12-well plates. The plates 
were incubated as above. W hen preparation of the cells was completed, the medium 
in triplicate wells of two plates was replaced by 5H medium containing 5 % FCS and 
concentrations of KI ranging from 0.01 to 1000 //mol/1. The medium of the other two 
plates was changed to 6 H medium (2 U/1 of TSH) containing similar concentrations 
of KI and FCS. The plates were incubated for a further 72 h. A fter the final 
incubation, the growth of cells was measured using the MTT assay.
The results of this experiment ai'e presented in figure 3.15. In the presence of 
TSH, growth decreased as the concentration of KI present in the medium increased 
above 1 pmol/1. The growth in the presence of 1 //mol/1 of KI was 8.43 % less than 
the value obtained for zero concentration. The growth in 10 //mol/1 of KI was 14.7 % 
less than zero concentration, and a greater decrease in growth was caused by 1 0 0 0  
//mol/1 of KI. These results indicate that optimal growth of FRTL-5 cells requires the 
absence of inorganic iodine in the medium.
In the absence of TSH, the FRTL-5 cells do not grow detectably, so there 
was no apparent effect of KI. However, the highest concentration of 1 mmol/l was 
toxic, and caused a 13.08 % decrease in the number of live cells.
3 .3 .4  Thyroid Hormones
Thyroid hormones may affect the function of thyroid cells directly (Akiguchi 
et al, 1992). To investigate the effect of these hormones on FRTL-5 cells, 
approximately 1x10^ cells were seeded per well of four 12-well plates. The cells were 
prepared for stimulation as given in section 3.2.1.4. Stimulation was carried out with 
5H or 6 H (2 U/L of TSH) medium that contained 0.5 % FCS, additional amino acids 
and different concentrations of thyroid hormones as given in table 3.2 for 72 h. Cells 
with only 5H or 6 H medium served as control.
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M edium T 4  nmol/1 T 3  nm ol/1
control 0 . 0 0 . 0
M l 50 0.5
M2 1 0 0 1 . 0
M3 250 2.5
M 4 500 5.0
M5 750 7.5
M 6 1 0 0 0 1 0 . 0
Table 3.2: Concentrations of T 4  and T 3  that were added to 5H or 6 H medium to 
study the effect of thyroid hormones on iodine uptake and growth of FRTL-5 cells.
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Figure 3.15: Effect of different concentrations of KI on growth of FRTL-5. MTT 
assay was performed after incubation for 72 h, in presence and absence of 2 U/1 of 
TSH.
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Figure 3.16: Effect of different concentrations of thyroid hormones on iodine uptake 
of FRTL-5 cells. The concentrations of T4  and T3  represented by M 1-M 6 are 
presented in table 3.3. Cells were incubated in the presence or absence of 2U/1 of 
TSH for 72 h.
The mean iodine uptake of the cells incubated in 5H without thyroid 
hormones was 108.36 ± 6.27 cpm/;<g protein. The addition of thyroid honnones 
caused a significant increase in iodine uptake of 19.83 % at the highest dose (1 /<mol/i 
T4  and 10 nmol/1 T 3 ) only.
In the presence of 2 U/1 of TSH (6 H), the iodine uptake of cells incubated 
without thyroid hormones was 331.95 ± 11.36 cpm/;<g protein. Thyroid hormones 
caused significant decreases in iodine uptake of cells, at concentrations of M3 (250 
nmol/1 T 4  and 2.5 nmol/1 T 3 ) and above. The maximum decrease was 27.01 % at a 
concentration of 1 jwmol/l T 4  and 10 nmol/1 T3 . These results are summarised in 
figure 3.16.
In the absence of thyroid hormones and TSH, the protein content of cells was 
30.97 ± 2,29 p i g  protein/well. There was a significant increase in the growth of cells 
(17.1 % )  when the concentrations of T 4  and T3  in the medium were 1 p i m o \ / \  and 10 
nmol/1  respectively.
In the presence of 2 U/1 of TSH (6 H), the protein content of control cells was 
63.50 ± 1.46 p i g  protein/well. Here also the highest dose of thyroid hormones 
produced a significant increase in growth of cells (9.89%). These results are 
presented in figure 3.17.
3 .3 .5  Insulin L ike Growth Factor-1 And Insulin
Insulin like growth factor - 1 (IGF-1) is known to affect iodine uptake and 
growth of FRTL-5 cells (Pang and Hershman, 1990 a; Saji et al, 1987). Therefore 
IGF-1 was used to verify our protocols. Since insulin and IGF-1 may bind to the 
same receptor, the two w ere com pared directly. For this purpose approximately 
1x10^ cells were seeded per well of four 12-well plates. The plates were incubated 
for 3 days with 6 H and for 5 days with 4H (no TSH or insulin) containing 5 % FCS. 
After this, the medium of one set of triplicate wells was changed to 4H containing 0.5 
% FCS (control). The medium of the other wells of two plates was changed to 4H 
containing 100 ng/ml of IGF-1, 10 p i g / m l  of insulin or a mixture of the two. The 
medium of the other two plates was changed to 4H containing TSH (2 U/1 of TSH) 
and sim ilar concentrations of other stimulators. The plates were incubated for a 
further 72 h. The iodine uptake and protein measurement were carried out on one 
plate from each set as given in the methods' sections 3.2.2, and 3.2.4. The growth of 
cells was measured on the remaining two plates using the MTT assay.
The mean value obtained for iodine uptake of the control set was 320 ± 14.07 
cpm//ig protein. When the cells were stimulated with insulin, the iodine uptake was 
increased by 5.64 %, whereas IGF-1 produced an increase of 7.71 %. Neither of 
these increases was significant. When the cells were stimulated with the mixture of
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insulin and IGF-1 there was an increase of 16.95 %. This was significant when 
compared with the control set, but not significant when compared to values obtained 
for Insulin or IGF-1. .
The mean value obtained for iodine uptake of cells that were stimulated with 
TSH in 4H medium was 571.15 ± 27,93 cpm/pig protein. This was 78.33 % higher 
than unstimulated cells and was highly significant (p<0 .0 0 1 ).
The effect of insulin on TSH-stimulated cells was not significant, but that of 
IGF-1 and the mixture of IGF-1 and insulin was (increases of 15.81% and 20.96% 
respectively). The effect of the combination of IGF-1 and insulin was significantly 
greater than that of insulin alone, but not than that of lGF-1 (figure 3.18).
The pattern of results as measured for growth as assessed by the MTT assay 
was similar to that assessed by protein measurement on the cells remaining after 
iodine uptake (figure 3.19). Since results obtained from both protocols were the 
same, the protein content of the cells was used in the remaining experiments.
The protein content of cells after incubation in 4H medium was 26.20 ± 0.70 
pig protein/well. Insulin alone significantly increased the protein content of cells to
29.84 ± 0.73 pig protein/well, 13.89 % higher than the control. IGF-1 alone also 
significantly increased protein by 42.82 %. The mixture of insulin and IGF-1 caused 
an increase in growth of 80.31 %, more than the sum of the effects of individual 
stimulators.
TSH caused a.highly significant increase in protein content to 58.51 ± 0.73 
pig protein/well, 123.32 % higher than the control (4H medium). Addition of insulin 
caused a further significant increase of 26.58 %, as did IGF-1, of 47.58 %. W hen 
insulin and IGF-1 were combined, the protein content increased by 53.94 % (figure
3.19).
3.3.6 Stimulation Of FRTL-5 Cells By Bioactive Peptides
A series of experiments was carried out to investigate the effect of selected 
cytokines, growth factors and neuropeptides on the function of FRTL-5 cells. Iodine 
uptake and growth rate, as assessed by protein content of the cells, were measured. 
Stimulators were used singly and in a limited number of combinations.
First, a dose response curve was measured for each stimulator. An effective 
dose was chosen from this, to investigate the effect of pro tea se inhibitors or thyroid 
hormones.
B esta tin  is an inh ib ito r of neutral endopeptidase (CDIO/NEP) and 
am inopep tidase  N (C D 13/A PN ), w hile D L -th iorphan is an inh ib ito r of 
aminopeptidase A (BP-1/6C3/APA). These glycoprotein enzymes are type II integral 
membrane proteins that are associated with peptide hormone receptors on the surface
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Figure 3.17: Effect of different concentrations of thyroid hormones on growth of 
FRTL-5 cells. Cells were incubated as described in figure 3.16.
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Figure 3.18: Iodine uptake of FRTL-5 cells in 4H medium stimulated with insulin, 
IGF-1, TSH, or combination of them. Cells were incubated for 72 h in 4H medium 
containing 0.5 % FCS, additional am ino acids, and TSH, insulin, IG F - 1  or 
combinations of them. The final concentrations of the stimulators used were 2 U/1 of 
TSH, 10 mg/1 of Insulin, and lOO^g/1 of IGF-1.
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Figure 3,19: Comparison of estimation of growth rate by MTT assay and protein 
content. Cells were incubated as described in figure 3.18. Significant differences 
from control without growth factors are denoted by (*).
of lymphoid progenitor cells, monocytes, granulocytes, renal proximal tubular 
epithelial cells, small intestinal epithelium, biliary canaliculae, and certain solid 
tumour cell lines. In some experim ental systems, they down regulate cellu lar 
responses to the peptide substrates (Shipp and Look, 1993). The inhibitors were used 
to test whether these proteases are present on the thyrocytes or not, and if present, 
inhibitions of them have a significant effect on the responses of FRTL-5 cells.
In Graves' disease, thyroid cells are under the influence of both thyroid 
hormones and thyroid stimulating antibodies, but few studies have tested the effects 
of thyroid hormones on stim ulation of thyroid cells in vitro. Experiments were 
therefore planned to test stimulators in the presence of thyroid homiones.
The protocol was similar for all the experiments to be described below. Cells 
were incubated in 1 2 -well plates for 3 days in medium containing TSH and then 
deprived of TSH for 5 days. They were incubated for 48 h in stimulation medium 
containing 0.5 % FCS and amino acids, with or without 2 U/1 of TSH and thyroid 
hormones. After third incubation, cells were stimulated for 48 h with m ediators, in 
stimulation medium containing 0.5 % FCS, additional amino acids, TSH ( 2  U/1), 
with or without thyroid hormones (1 ptmol/l T4  and 10 nmol/1 T 3 ) .
Although it had been shown that IGF-1 was capable of stimulating the cells in 
the absence of insulin, insulin was included in the medium at a concentration of 1 0  
mg/1. Wells without stimulator were used as controls. Iodine uptake and protein 
content were assayed,as described in sections 3.2.2 and 3.2.4.
Experiments using Protease inhibitors and thyroid hormones used a single 
dose of stimulator. Protease inliibitors (1 each of bestatin and thiorphan) were
included only at the stimulation stage, while thyroid hormones (1 //mol/1 T 4 , 10 
nmol/1 T 3 ) were preincubated with TSH-stimulated cells for 48 h, before stimulation 
with a mixture of thyroid hormones and TSH.
3.3.6.1 Insulin Growth Factor-1
3.3.6.1.1 Dose study
Doses of 1 to 1000 pg/m l w ere used. A dose of 500 //g/m l (h ighest 
significant effective dose, in dose study experiment) was used for studies o f 
inhibitors and thyroid hormones.
Doses of 50 //g/1 of IGF-1 and above increased iodine uptake significantly in 
the absence of TSH, to a maximum of 18.5 % more than control at a concentration of 
1000 pg/ml. There were no significant differences between successive doses from  10 
to 1000 jug/l of IGF-1. Doses above 5 pg/ml also caused a significant increase in
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growth rate, to a maximum of 24.8 % more than control at the highest dose (figure
3.20).
In the presence of 2 U/1 of TSH, doses of IGF-1 of 50 //g /l and above 
increased iodine uptake significantly, to a maximum of 38.7 % more than control at 
1 0 0 0  fxg/ml. All doses above 5 //g/1 also caused a significant increase in growth of 
cells. The highest increase of 16.1 % was caused by 500 //g/1 of IGF-1. There were 
no significant differences among increases in growth caused by successive doses 
above 1 0  //g/1 .
3 .3 .6 .1 .2  Protease Inhibitors
The inclusion of bestatin and thiorphan alone or with TSH failed to effect 
iodine uptake or growth of cells. The effects of these inhibitors on iodine uptake and 
growth of FRTL-5 cells were repeated on at least 35 different occasions during the 
stimulation experiments, and similar results were obtained.
The protease inhibitors did not alter the effect of IG F-1 on either iodine uptake 
or growth, either in the presence or the absence of TSH. The summaries of these 
results are presented in figure 3.21.
3.3.6 .1 .3  Thyroid Hormones
In the presence of T 4  and T 3 , IGF-1 failed to increase iodine uptake 
significantly. In the absence of thyroid hormones the same dose of IGF-1 produced 
an increase of 37.29 % in the rate of iodine uptake (figure 3.22). On the other hand, 
there was no significant change in the stimulation of growth caused by IGF-1 when 
thyroid hormones were added (17.33 % increase compared to 16.10 % when thyroid 
horm ones were absent). This indicates that the thyroid horm ones partially  
antagonised the effect of IG F-1.
3.3 .6 .2  Transforming Growth Factor-p (TGF)
3 .3 .6 .2.1 Dose Study
Doses of 1 to 100 //g/1 were used. A dose of 50 pg/1 was chosen for further
study.
TGF- p increased iodine uptake at all doses in the absence of TSH when 
compared with control. The increase associated with 2,5 jigtX of TGF- p was 18.2 %
1 0 7
__
Iodine uptake (cp m /u g protein)
500“
10 50 100 500 1000
IGF-1 ( ug/i)
Growth (ug protein/well)
5 10 50 100 500 1000
□  5H
6H
□  5H
IGF-1 (/vg/l)
Figure 3.20: Effect of IGF-1 on iodine uptake and growth of FRTL-5 cells. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by *.
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Figure 3.21: Effect of protease inhibitors on stimulation of FRTL-5 cells with IG F- 
1 . Cells were incubated as before, without IGF-1 (C), with 500 pg/î of IGF - 1  (S), or 
with a mixture of 1 //mol/1 of bestatin and 1 //.mol/l of thiorphan in the absence (E) 
or the presence of IGF-1 (S+E),
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Figure 3.22: Effect of thyroid hormones on stimulation of FRTL-5 cells with IGF-1 
and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, w ithout 
IGF-1 (C), with 500 //g/1 of IGF-1 (S), or stimulated in the 6 H medium containing 
0.5 % FCS, additional amino acids, 1 //mol/l of T4  and 10 nmol/1 of T 3 , 48 h before 
and 48 h after addition of IGF-1 [S (T4 ,T3 )]. The cells that were stimulated only 
with thyroid hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant 
differences between presence and absence of thyroid homiones are shown by *.
higher than control, while the maximum increase was seen with 50 //g/1 of TGF- p,
28.0 % more than control. However, a clear dose-response curve could not be 
demonstrated. TGF-p had no effect on growth rate (figure 3,23).
In the presence of TSH, all doses of TGF- p caused a significant increase in 
iodine uptake. At 2.5 //g/1 of TGF- p, the increase was 18.5 %, while the maximum 
increase of 64.4 % was associated with 50 //g/1. All doses of TGF- p also decreased 
the growth of cells. At 5 //g/1 of TGF- p, the decrease was 11.4 %. The maximum 
decrease in growth of 27.7 % was associated with 50 //g/1 of TGF- p.
3 .3 .6 .2.2 Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effect of TGF- p on 
iodine uptake by the cells in the absence of TSH and did not alter the effects on 
growth rate either in the absence or the presence of TSH (figure 3.24). However, 
bestatin and thiorphan caused a significant (p<0.05) reduction in the effect of TGF-p 
on iodine uptake (40.0 % decrease compared to 59.4 %).
3 .3 .6 .2.3 Thyroid Hormones
Thyroid hormones significantly (p<0.01) suppressed the increase in iodine 
uptake in the presence of TGF-p. The effect was reduced from an increase of 64.4 % 
to only 27.5 %. The effect on growth was also antagonised (figure 3.25).
3 .3 .6 .3 Basic Fibroblast Growth Factor (bFGF)
3.3 .6 .3 .1  Dose Study
Doses of bFGF from 1 to 100 //g/1 were used. A dose of 10 [xg/l was chosen 
for further study.
Doses of bFGF from  2.5 //g/1 significantly decreased the iodine uptake 
compared to unstimulated cells in a dose dependent manner. The decrease caused by 
2.5 //g/1 of bFGF was 27.3 %. The maximum decrease was 45.4 % lower than the 
control, at 25 p.g/1 of FGF, and there were no further decreases with higher doses. 
Addition of bFGF also caused an increase in growth of cells. A dose of 2.5 //g/1 
caused an increase of 29.6 %, and the maximum increase in growth was observed 
with a concentration of 10 //g/1, 53.9 % more than control. At higher concentrations, 
the effect was less than at 1 0  p.g/1, but still significant.
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Figure 3.23: Effect of TG F-p on iodine uptake and growth of FRTL-5 cells. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences are shown by *.
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Figure 3.24: Effect of protease inhibitors on stimulation of FRTL-5 cells with TG F- 
p. Cells were incubated as before, without TGF-P (C), with 50 //g/1 of TGF-p (S), or 
with a mixture of 1 //moI/1 of bestatin and 1 //mol/l of thiorphan in the absence (E) 
or the presence of TGF-p (S+E). Significant differences caused by inhibitors are 
represented by (*).
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Figure 3.25: Effect of thyroid hormones, on stimulation of FRTL-5 cells with TG F- 
p and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, without 
TGF-P (C), with 50 //g/1 of TGF-p (S), or stimulated in the 6 H medium containing 
0.5 % FCS, additional amino acids, 1 //mol/l of T4  and 10 nmol/1 of T 3 , 48 h before 
and 48 h after addition of TGF-p [S (T4 ,T3 )]. The cells that were stimulated only 
with thyroid hormones for 96 h sensed as control [C (T 4 ,T3 )] for this set. Significant 
differences between the presence and the absence of thyroid hormones are shown by 
(*)-
3 .3 .6 .3 .3  Thyroid Hormones
Thyroid hormones did not significantly alter the effects of bFGF on either 
iodine uptake or growth rate of the cells (figure 3.28).
3 .3 .6 .4 Endotheiin-1 (ET-1)
3 .3 .6 .4.1 Dose Study
'■3i
In the presence o f TSH, all doses greater than 1 pg/1 caused a significant 
decrease in iodine uptake. The maximum decrease of 39.1 % was caused by 10 //g/1 
o f bFGF (figure 3.26). All doses of bFGF increased the growth of cells, to a | f
maximum of 18.5 % at 100 //g/1. Statistically there were no differences between the 
growth rates at 2.5 //g/1 of bFGF and above. |
I3.3.6.3.2 Protease Inhibitors
I,3
The inclusion of bestatin and thiorphan in 5H or 6 H medium did not alter the 
effect of bFGF on iodine uptake of cells (figure 3.27), However, they antagonised :
the effects of FGF on growth of the ceils unstimulated with TSH. The growth 
stimulation was only 19.5 % compared to 51.6 % in the absence of inhibitors. In the 
presence of TSH, the antagonistic effect failed to reach significance (7.7 % increase 7
compared to 16.3 %).
I
The final concentrations used ranged from 0.5 to 100 nmol/1, A dose of 50 
nmol/1  was chosen for further study.
Addition of Endothelin-1 to medium without TSH did not change iodine 
uptake or growth rate of cells at any concentration (figure 3.29).
In the presence of 2 U/1 of TSH, concentrations of 50 nmol/1 and above 
caused a significant increase in the iodine uptake of stimulated cells. The maximum 
increase of 15.07 % above control occurred at a concentration of 100 nmol/1. There 
were no significant differences among the values obtained for doses over 25 nmol/1. s|
Endothelin-1 also caused a significant increase in growth at concentrations of 
25 nmol/1 and above. The maximum increase of 9.78 % over control occurred at a 
concentration of 100 nmol/1. There were no significant differences between values 
obtained for doses of 25, 50, and 100 nmol/1.
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Figure 3.26: Effect of basic FGF on iodine uptake and growth of FRTL-5 cells. 
Cells were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences are shown by *.
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Figure 3.27: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
bFGF. Ceils were incubated as before, without bFGF (C), with 10 //g/1 of bFGF (S), 
or with a mixture of 1 //mol/l of bestatin and 1 //mol/l of thiorphan in the absence 
(E) or the presence of bFGF (S+E). Significant differences caused by inhibitors are 
represented by (*),
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Figure 3.28: Effect of thyroid hormones, on stimulation of FRTL-5 cells with bFGF 
and TSH. Cells were stimulated in 6 H medium ( 2  U/1 of TSH) as before, without 
bFGF (C), with 10 //g/1 of bFGF (S), or stimulated in the 6 H medium containing 0.5 
% FCS, additional amino acids, 1 //mol/l of T 4  and 1 0  nmol/1  of Tg, 48 h before and 
48 h after addition of bFGF [S (T 4 ,Tg)]. The cells that were stimulated only with 
thyroid hormones for 96 h served as control [C (T 4 ,Tg)] for this set.
3 .3 .6 .4 .2 Protease Inhibitors
Inclusion of bestatin and thiorphan in 5H medium did not alter the effect of 
Endothelin-1 on iodine uptake or growth rate of the cells.
In the presence of 2 U/1 of TSH (6 H), bestatin and thiorphan completely 
suppressed the stimulatory effect of endothelin - 1  on the iodine uptake of cells (figure 
3.30) but did not affect growth.
3 .3 .6 .4.3 Thyroid Hormones
Thyroid  horm ones significantly  (p<0.05) antagonised the effect of 
Endothelin-1 on iodine uptake. The rate of uptake was decreased slightly (4.0 %) 
compared to an increase of 15.1 % in the absence of thyroid hormones. Thyroid 
hormones also antagonised the effect of Endothelin on growth (figure 3.31). There 
was a 3.5 % decrease in protein content compared to an increase of 9.2 %.
3 .3 .6 .5  Interleukin-1 (IL -lp)
3 .3 .6 .5.1 Dose Study
The final concentrations of IL-1 used ranged from  0.5 to 20 //g/1.
Concentrations of 1 pg /1  and 2 0  pg/1 were chosen for further study. 7
IL-1 did not alter the iodine uptake or growth rate of cells incubated in the 
absence of TSH at any dose.
In the presence of TSH, all doses of IL-1 above 2.5 //g/1 decreased iodine 
uptake significantly (p<0.001). The maximum decrease, at 20 //g/1 of IL-1, was
29.84 %. This decrease was highly significant (figure 3.32). IL-1 did not affect 
growth rate.
3 .3 .6 .5.2 Protease Inhibitors
The inclusion of bestatin and thiorphan did not alter the iodine uptake or 
growth of cells incubated in 5H or 6 H media containing 1 or 20 //g/1 of IL-1 (figure 
3.33). g
3 .3 .6 .5 .3  Thyroid Hormones
Thyroid hormones caused a significant (p<0.01) increase (23.6 %) in the rate 
of iodine uptake in the presence of 1 //g/1 of IL-1, compared to a non-significant
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Figure 3.29: Effect of Endothelin-1 on iodine uptake and growth of FRTL-5 cells. 
Cells were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by
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Figure 3.30: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
Endothelin-1. Cells were incubated as before, without Endothelin-1 (C), with 50 
nmol/1 of Endothelin-1 (S), or with a mixture of 1 /fmol/1 of bestatin and 1 /rmol/1 of 
thiorphan in the absence (E) or the presence of Endothelin-1 (S+E). Significant 
differences caused by inhibitors are represented by *.
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Figure 3.31: Effect of thyroid hormones, on stimulation of FRTL-5 cells with 
Endothelin-1 and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as 
before, without Endothelin-1 (C), with 50 nmol/1 of Endothelin-1 (S), or stimulated 
in the 6 H medium containing 0.5 % FCS, additional amino acids, 1 //mol/l of T 4  and 
10 nmol/1 of T 3 , 48 h before and 48 h after addition of Endothelin-1 [S (T4 ,T3 )]. The 
cells that were stimulated only with thyroid hormones for 96 h served as control [C 
(T4 ,Ts)] for this set. Significant differences that occurred in the presence and the 
absence of thyroid hormones are shown by
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Figure 3.32; Effect of IL-1 on iodine uptake and growth of FRTL-5 cells. Cells were 
incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and additional 
amino acids for 48 h. Significant differences between stimulated and unstimulated 
cells (control or zero concentration) are shown by
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Figure 3.33: Effect of protease inhibitors, on stimulation of FRTL-5 cells with IL-1. 
Cells were incubated as before, without IL-1 (C), with 1 (left) or 20 (right) /<g/l of 
IL-1 (S), or with a mixture of 1 /^mol/l of bestatin and 1 /nnol/l of thiorphan in the 
absence (E) or the presence of IL-1 (S+E).
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Figure 3.34: Effect of thyroid hormones, on stimulation of FRTL-5 cells with IL-1 
and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, without 
IL-1 (C), with 1 (S-1) or 20 (S-2) //.g/1 of IL-1, or stimulated in the 6 H m edium 
containing 0.5 % FCS, additional amino acids, 1 //mol/l of T 4  and 10 nmol/1 of T3 , 
48 h before and 48 h after addition of IL-1 [S-1 (T 4 ,Ts), and S-2 (T4 ,Tg) 
respectively]. The cells that were stimulated only with thyroid hormones for 96 h 
served as control [C (T 4 ,T3 )] for these sets. Significant differences that occurred in 
presence and absence of thyroid hormones are shown by *.
increase of 6.15% in the absence of thyroid hormones. IL-1 at 20 //g/1 did not affect 
iodine uptake in the presence of hormone, but it produced a significant decrease of 
26.49 % in their absence. Therefore, in the presence of thyroid hormones, the iodine 
uptake of cells was higher (figure 3.34). Thyroid hormones did not affect the growth 
of cells.
3.3.6 . 6  Lipopolysaccharide (LPS)
3 .3 .6 .6 .1 Dose Study
The final concentrations of LPS used ranged from  0.1 to 1 0  mg/1. 
Concentrations of 0 .1 and 10 mg/1 were chosen for further study.
LPS caused significant decreases in iodine uptake of cells in the absence of 
TSH at concentrations of 2.5 mg/1 and above. The maximum decrease of 25,1 % was 
obtained at a concentration of 10 mg/1. There were no significant differences among 
the doses of 2.5 to 10 mg/1. LPS did not affect growth rate.
In the presence of TSH, O.I mg/1 of LPS caused a significant increase of 
19.15 % in iodine uptake. On the other hand, significant decreases in iodine uptake 
occurred at concentration of 7.5 mg/1 and 10 mg/1. The maximum decrease of 24.62 
% occurred at a concentration of 10 mg/1 (figure 3.35). Concentrations of 2.5 mg/1 of 
LPS and above increased the growth rate significantly (p<0.05). The maximum 
significant increase of 19.1 %, occurred at a concentration of 10 mg/1. There were no 
significant differences between the growth rates of cells stimulated with 5, 7.5 or 10 
mg/1 of LPS.
3 .3 .6 .6 .2 Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effect of LPS on 
either iodine uptake or growth, either in the presence or the absence of TSH (figure 
3.36).
3 .3 .6 .6.3 Thyroid Hormones
Thyroid hormones did not significantly change the effects of LPS on iodine 
uptake, but completely suppressed the effect of 10 mg/1 on growth (figure 3.37).
111
Iodine uptake (cpm/A/g protein)
6 0 0 “
500
400“
300”
2 0 0  “
100 “
0 0 . 1  0.5
□  5H
LPS (mg/l)
Growth ( j jg protein/well)
LPS (mg/l)
0 ! 0.1 0-5
□  5H
Figure 3.35: Effect of LPS on iodine uptake and growth of FRTL-5 cells. Cells were 
incubated in 5H or 6 H (2U/1 of TSFl) medium containing 0.5 % FCS and additional 
amino acids for 48 h. Significant differences between stimulated and unstimulated 
cells (control or zero concentration) are shown by
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Figure 3.36: Effect of protease inhibitors, on stimulation of FRTL-5 cells with LPS. 
Cells were incubated as before, without LPS (C), with 0 . 1  (left) or 1 0  (right) mg/l of 
LPS (S), or with a mixture of 1 //mol/l of bestatin and 1 //mol/l of thiorphan in the 
absence (E) or the presence of LPS (S+E).
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Figure 3.37: Effect of thyroid hormones, on stimulation of FRTL-5 cells with LPS 
and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, without 
LPS (C), with 0.1 (S-1) or 10 (S-2) mg/l of LPS, or stimulated in the 6 H medium 
containing 0.5 % FCS, additional amino acids, 1 //mol/l of T4  and 10 nmol/1 of T3 , 
48 h before and 48 h after addition of LPS [S-1 (T 4 ,T3 ), and S-2 (T4 ,T3 ) 
respectively]. The cells that were stimulated only with thyroid hormones for 96 h 
served as control [C (T4 ,T3 )] for these sets. Significant differences between the 
presence and absence of thyroid hormones is shown by *.
33.6 .1  Interleukin-4 (IL-4)
3.3.6.7.1 Dose Study
The final concentrations o f IL-4 used ranged from  0.5 to 20 //g/1. A 
concentration of 2 0  p^ g/1  was chosen for further study.
In the presence or absence of TSH, the iodine uptake of cells did not change 
when IL-4 was added. IL-4 also had no effect on growth in the absence of TSH, but 
did cause decreases in growth in the presence of TSH. The maximum decrease was
23.6 %, at 20 pg/1 (figure 3.38).
3 .3 .6 .7 .2  Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effects of IL-4 on 
either iodine uptake or growth, either in the presence or the absence of TSH (figure 
3.39).
3 .3 .6 .7 .3  Thyroid Hormones
Exposure of cells to thyroid hormones did not change the rate of iodine 
uptake, but prevented.IL-4 from decreasing the growth rate (figure 3.40).
3 .3 .6 . 8  Interleukin-6 (IL-6 )
3 .3 ,6 .8 .1  Dose Study
The final concentrations of IL - 6  used ranged from  0.5 to 20 //g/1. A 
concentration of 2 0  fig/1  was chosen for further study.
In the absence of TSH, iodine uptake and growth rate of cells increased 
significantly only at 20 //g/1 of IL-6 . These increases were 17.0 % and 26.6 % 
respectively.
In the presence of TSH, the iodine uptake of stimulated cells increased 
significantly (p<0.01) with the doses of IL - 6  above 10 //g/1. The highest increase was 
caused by 20 //g/i of IL-6 , that was 33.4 % higher than the control. There were no 
significant differences between the values obtained for iodine uptake of doses above 
10 //g/1 when they were compared with each other (figure 3.41). IL - 6  did not produce 
any changes in the growth of cells.
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Figure 3.38: Effect of IL-4 on iodine uptake and growth of FRTL-5 cells. Cells were 
incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and additional 
amino acids for 48 h. Significant differences between stimulated and un stimulated 
cells (control or zero concentration) are shown by *.
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Figure 3.39: Effect of protease inhibitors, on stimulation of FRTL-5 ceils with IL-4. 
Ceils were incubated as before, without IL-4 (C), with 20 ptg/l of IL-4 (S), or with a 
mixture of I /rmol/1 of bestatin and 1 pimoMi of thiorphan in the absence (E) or the 
presence of IL-4 (S+E).
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Figure 3.40: Effect of thyroid hormones, on stimulation of FRTL-5 cells with IL-4 
and TSH, Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, without 
IL-4 (C), with 20 //g/1 of IL-4 (S), or stimulated in the 6 H medium containing 0.5 % 
FCS, additional amino acids, 1 //mol/l of T 4  and 10 nmol/1 of T 3 , 48 h before and 48 
h after addition of IL-4 [S (T4 ,T3 )]. The cells that were stimulated only with thyroid 
hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant differences 
between the presence and absence of thyroid hormones is shown by
Iodine uptake (cp m /p g protein)600-
IL-6 (pg/1)
Growth (/L/g protein/well)
0 0.5 1 2.5 10 15 20
IL-6 (pg/l)
□  5H 
■  6H
□  SH
Figure 3.41: Effect of IL - 6  on iodine uptake and growth of FRTL-5 cells. Cells were 
incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and additional 
amino acids for 48 h. Significant differences between stimulated and un stimulated 
cells (control or zero concentration) are shown by
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Figure 3.42: Effect of protease inhibitors, on stimulation of FRTL-5 cells with IL-6 . 
Cells were incubated as before, without IL - 6  (C), with 20 //g/1 of IL - 6  (S), or with a 
mixture of 1 //mol/l of bestatin and 1 //mol/l of thiorphan in the absence (E) or the 
presence of IL - 6  (S+E), Significant differences caused by inhibitors are represented 
by *
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Figure 3.43: Effect of thyroid hormones, on stimulation of FRTL-5 cells with IL - 6  
and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as before, without 
IL - 6  (C), with 20 //g/1 of IL - 6  (S), or stimulated in the 6 H medium containing 0.5 % 
FCS, additional amino acids, 1 //mol/l of T 4  and 1 0  nmol/1 of T3 , 48 h before and 48 
h after addition of IL - 6  [S (T4 ,T3 )J. The cells that were stimulated only with thyroid 
hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant differences 
between the presence and the absence of thyroid hormones is shown by *.
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3 3 .6 .8 .2  Proteose Inhibitors
Enzyme inhibitors had no significant effect on the iodine uptake of cells 
incubated without TSH, but amplified the growth effect of IL-6 . The stimulation was
41.0 % compared to 20.7 % (figure 3.42).
In the presence of TSH, the inhibitors suppressed the effect of IL - 6  on iodine 
uptake. The increase was only 16.6 % compared to 36.4 %. In the presence of 
inhibitors, the growth rate increased significantly by 37.3 % in the presence of IL-6 , 
an effect which was not present in their absence.
3 .3 .6 .8.3 Thyroid Hormones
Thyroid hormones did not alter the effect of IL - 6  on iodine uptake of cells 
significantly. They did, however, stimulate growth of cells by 9.9 %, whereas the 
same concentration of IL - 6  had no effect in their absence (figure 3.43).
3 .3 .6 .9 Interferon Gamma (INF-y)
3 .3 .6 .9.1 Dose Study
The final concentrations of INF-y used ranged from  1 to 1000 ytg!\. A 
concentration of 1 0 0  p,g/l was chosen for further study.
The addition of INF-y to cells in the absence of TSH caused a significant 
increase in iodine uptake at concentrations of 50 //g/l and above. The maximum 
increase of 21.23 % over control occurred at a concentration of 1000 pigl\. INF-y had 
no effect on growth rate.
In the presence of TSH, INF-y caused a significant increase in iodine uptake 
at concentrations of 10 //g/1 and above. The maximum increase was 75.65 % at 1000 
pigH (figure 3.44). INF-y also caused decreases in growth rate at concentrations of 1 
jig/1 and above, with the maximum effect at 1000 /ig/1 (36.0 %)
3 .3 .6 .9.2 Protease Inhibitors
The inclusion of bestatin and thiorphan did not alter the effects of INF-y on 
either iodine uptake or growth, in the presence or absence of TSH (figure 3.45).
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Figure 3.44: Effect of INF-y on iodine uptake and growth of FRTL-5 cells. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences are shown by *.
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Figure 3.45: Effect of protease inhibitors, on stimulation of FRTL-5 cells with INF- 
y. Cells were incubated as before, without INF-y (C), with 100 pig/l of INF-y (S), or 
with a mixture of 1 pimoVl of bestatin and 1 /<mol/l of thiorphan in the absence (E) 
or the presence of INF-y (S-fE).
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Figure 3.46: Effect of thyroid hormones, on stimulation of FRTL-5 cells with INF-y 
and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, w ithout 
INF-y (C), with 100 /rg/1 of INF-y (S), or stimulated in the 6 H medium containing 
0.5 % FCS, additional amino acids, 1 //mol/l of T4  and 10 nmol/1 of T 3 , 48 h before 
and 48 h after addition of INF-y [S (T4 ,T3 )]. The cells that were stimulated only 
with thyroid hormones for 96 h served as control [C (T 4 ,T3 )] for this set. Significant 
differences between the presence and absence of thyroid hormones are shown by
f
r
3 .3 .6 .93  Thyroid Hormones
In the presence of thyroid hormones, the increase in iodine uptake caused by 
INF-y was 33.35 %, In the absence of thyroid horm ones this increase was 
significantly less, 66.70 %. Thyroid hormones also partially antagonised the effect of 
INF-y on growth. The decrease in growth rate was 19.9 % compared to 28.5 %.
3.3.6.10 Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)
3.3.6.10.1 Dose Study
The final concentrations o f PACAP used ranged from 1 to 500 nmol/1. A 
concentration of 250 nmol/1 was used for further studies.
Inclusion of PACAP in 5H medium did not change the rate of iodine uptake 
or growth.
In the presence of TSH, all doses of PACAP caused an increase in iodine 
uptake, up to a concentration of 250 nmol/1, which caused the maximum increase of
28.5 %. A t a concentration of 500 nmol/1, iodine uptake was less than that at 250 
nmol/1 (figure 3.47). PACAP had no effect on growth.
3 .3 .6 .10 .2  Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effect of PACAP on 
either iodine uptake or growth, either in the presence or the absence of TSH (figure
3.48).
3 .3 .6 .10.3 Thyroid Hormones
Thyroid hormones antagonised the effect of PACAP on iodine uptake (figure
3.49). The increase in the presence of hormones was 11.3 %, compared to 28.5 % in 
their absence. There were small, non-significant changes in growth rate.
3.3.6.11 Neuropeptide Y (NPY)
3.3.6.11.1 Dose Study
The final concentrations of NPY used ranged from 10 to 2000 nmol/1. A 
concentration of 500 nmol/1 was chosen for further study.
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Figure 3.47: Effect of PACAP on iodine uptake and growth of FRTL-5 cells. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by *.
'' I'-'-" >..4 .
Iodine uptake (cp m /u g protein)
400-1
300-
2 0 0 -
100 -
îlrÆ iÆ Î
5H 6 H
80-
6 0 -
40-
2 0  —
Growth (pg protein /w ell)
r3&| {-3&t r3E
5H 6 H
Figure 3.48: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
PACAP. Cells were incubated as before, without PACAP (C), with 250 nmol/1  of 
PACAP (S), or with a mixture of 1 }imol/\ of bestatin and 1 of thiorphan in
the absence (E) or the presence of PACAP (S-l-E).
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Figure 3.49: Effect of thyroid hormones, on stimulation of FRTL-5 cells w ith 
PACAP and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, 
without PACAP (C), with 250 nmol/1 of PACAP (S), or stimulated in the 6 H 
medium containing 0.5 % FCS, additional amino acids, 1 //mol/1 of T 4  and 1 0  
nmol/1 of T 3 , 48 h before and 48 h after addition of PACAP [S (T 4 ,Tg)]. The cells 
that were stimulated only with thyroid hormones for 96 h served as control [C 
(T4 ,Ta)] for this set. Significant differences that occurred in presence and absence of 
thyroid hormones are shown by
Iodine uptake of cells increased significantly (p<0.05) at concentrations of 
500 nmol/1 and above in the absence of TSH. The maximum increase of 12.30 % 
occurred at a concentration of 2 //mol/1. There were no significant differences among 
values obtained for iodine uptake of doses above 500 nmol/1 (figure 3.50).
In the presence of TSH, the iodine uptake of stimulated cells increased 
significantly (p<0.05) with doses of NPY above 250 nmol/1. The maximum increase 
was caused by a concentration of 2 //mol/1, 11.59 % higher than the control. There 
were no significant differences between the value obtained for iodine uptake of doses 
above 250 nmol/1 and above when their values were compared with each other.
The inclusion of NPY in 5H or 6H medium did not alter the growth of cells 
significantly at any concentration.
3 .3 .6 .11 .2  Protease Inhibitors
Bestatin and thiorphan did not alter the effect of 500 nmol/1 of NPY on iodine 
uptake or growth of cells in the absence of TSH (figure 3.51).
Addition of bestatin and thiorphan to the medium containing TSH prevented 
the stimulatory effect of 500 nmol/1 of NPY on iodine uptake but did not affect 
growth.
3.3.6.11.3 Thyroid Hormones
Thyroid hormones did not alter the effects of NPY (figure 3.52).
3 .3 .6 .12  Vasoactive Intestinal Peptide (VIP)
3.3.6.12.1 Dose Study
The final concentrations of VIP used ranged from 10 to 2000 nmol/1. A 
concentration of 500 nmol/1 was chosen for further study.
VIP increased the iodine uptake in the absence of TSH significantly at 
concentrations of 500 nmol/1 and 1 //mol/1, while the value obtained for 2 //mol/1 was 
not different from control. The maximum increase of 14.2 % over control occurred at 
a concentration of 1 //mol/1 (figure 3.53). VIP had no effect on growth rate.
In the presence of TSH, the iodine uptake of stimulated cells increased 
significantly (p<0.05) at concentrations of 10 nmol/1 and above. The m axim um  
increase of 48.9 % above control was obtained for 500 nmol/1. The values obtained 
for iodine uptake at concentrations of 1 and 2  //mol/1  were significantly lower than the 
corresponding value for 500 nmol/1, although both values were significantly higher
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Figure 3.50: Effect of NPY on iodine uptake and growth of FRTL-5 cells. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by
  _ _ _ __________________
than control. VIP caused significant increases in growth at concentrations of 10 and 
50 nmol/1 , while it caused a significant decrease at a concentration of 2  /<mol/l (figure 
3.53).
3 .3 .6 .12 .2  Proteose Inhibitors
Inclusion of bestatin and thiorphan in 5H medium did not alter the effect of 
VIP on iodine uptake or growth of the cells.
In the presence of 2 U/l of TSH (6 H), the inhibitors significantly (p<0.05) 
reduced the effect of VIP on iodine uptake from 30.1 % to only 19.9 %, but did not 
affect growth (figure 3.54).
3 .3 .6 .12.3 Thyroid Hormones
Thyroid hormones antagonised the effect of VIP on iodine uptake. The 
increase of 48.9 % in their absence was reduced to 2.0 % (figure 3.55). Thyroid 
hormones also slightly increased the growth of cells. The increase was 6 . 6  % in their 
presence, compared to a decrease of 3.7 % in their absence.
3.3.6.13 Neuromedin U-25
3.3.6.13.1 Dose Study
The final concentrations used ranged from 5 to 1000 nmol/1. A concentration 
of 250 nmol/1 was chosen for further study.
In the presence or absence of TSH, the iodine uptake and growth rate of cells 
did not change when cells were incubated with Neuromedin U (figure 3,56).
3 .3 .6 .13 .2  Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effects of Neuromedin 
on either iodine uptake or growth, either in the presence or the absence of TSH 
(figure 3.57).
3.3 .6 .13.3  Thyroid Hormones
The only effect o f including thyroid hormones in the medium was a slight 
increase in growth rate of 14.1 % (figure 3.58).
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Figure 3.53; Effect of VIP on iodine uptake and growth of FRTL-5 cells. Cells were 
incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and additional 
amino acids for 48 h. Significant differences between stimulated and unstimulated 
cells (control or zero concentration) are shown by while • shows significant 
decrease compared to control.
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Figure 3.51: Effect of protease inhibitors, on stimulation of FRTL-5 cells with NPY. 
Cells were incubated as before, without NPY (C), with 500 nmol/1 of NPY (S), or 
with a mixture of 1 |/.mol/l of bestatin and 1 /imol/1 of thiorphan in the absence (E) 
or the presence of NPY (S+E). Significant differences caused by inhibitors are 
represented by
Iodine uptake (cpm/jug protein)
1201
-æ-
100 ■TBr
8 0 -
60
40
2 0
c_i «10
1 2 0
1 0 0
BOH
60
40
2 0
0
Growth {f jg protein/well)
-3E~
O
K)
£to
Figure 3.52; Effect of thyroid hormones, on stimulation of FRTL-5 cells with NPY 
and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, without 
NPY (C), with 500 nmol/1 of NPY (S), or stimulated in the 6 H medium containing 
0.5 % FCS, additional amino acids, 1 /^mol/1 of T4  and 10 nmol/1 of T 3 , 4S h before 
and 48 h after addition of NPY [S (T4 ,T3 )]. The cells that were stimulated only with 
thyroid hormones for 96 h served as control [C (T 4 ,T3 ) 1  for this set.
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Figure 3.54: Effect of protease inhibitors, on stimulation of FRTL-5 cells with VIP. 
Cells were incubated as before, w ithout VIP (C), with 500 nmol/1 of VIP (S), or 
with a mixture of 1 //mol/1 of bestatin and 1 //mol/1 of thiorphan in the absence (E) 
or the presence of VIP (S+E). S ignificant differences caused by inhibitors are 
represented by
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Figure 3.55: Effect of thyroid hormones, on stimulation of FRTL-5 cells with VIP 
and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, without 
VIP (C), with 500 nmol/1 of VIP (S), or stimulated in the 6 H medium containing 0.5 
% FCS, additional amino acids, 1 //mol/1 of T 4  and 10 nmol/1 of T 3 , 48 h before and 
48 h after addition of VIP [S (T 4 ,T3 )]. The cells that were stimulated only with 
thyroid hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant 
differences between the presence and absence of thyroid hormones are shown by 
(*).
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Figure 3.56: Effect of Neuromedin-U on iodine uptake and growth of FRTL-5 cells. 
Ceils were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h.
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Figure 3.57: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
Neuromedin-U. Cells were incubated as before, without Neuromedin-U (C), with 
250 nmol/1 of Neuromedin-U (S), or with a mixture of 1 //mol/1 of bestatin and 1 
//mol/1 of thiorphan in the absence (E) or the presence of Neuromedin-U (S+E).
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Figure 3.58: Effect of thyroid hormones, on stimulation of FRTL-5 cells w ith 
Neuromedin-U and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as 
before, w ithout Neuromedin-U (C), with 250 nmol/1 of Neuromedin-U (S), or 
stimulated in the 6 H medium containing 0.5 % FCS, additional amino acids, 1 
//mol/1 o f T4  and 10 nmol/1 of T 3 , 48 h before and 48 h after addition of 
Neuromedin-U [S (T 4 ,T3 )J. The cells that were stim ulated only with thyroid 
hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant differences 
between the presence and absence of thyroid hormones is shown by *.
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3.3 .6 .14  Substance P(SP)
3.3.6.14.1 Dose Study
The final concentrations of substance F used ranged from 10 to 2000 nmol/1. 
A concentration of 250 nmol/1 was chosen for further study.
SP increased the iodine uptake of cells at concentrations of 100 and 250 
nmol/1 in the absence of TSH. The maximum increase of 26.2 % above control 
occurred at 250 nmol/1. There were no significant increases at higher doses. SP did 
not affect growth (figure 3.59).
In the presence of TSH, the iodine uptake of cells increased significantly 
(p<0.05) at concentrations of 100 nmol/1 and above. The maximum increase was 
associated with 250 nmol/1 of SP; this was 14.55 % higher than control. SP did not 
affect growth.
3 .3 .6 .14 .2  Proteose Inhibitors
Protease inhibitors prevented SP from stimulating iodine uptake, both in the 
absence and presence of TSH (figure 3.60). The increase in the presence of inhibitors 
was only 7.3 % in 5H medium compared to 32.8 %, and 7.1 % compared to 17.1 % 
in 6 H medium. The inhibitors had no effect on growth rate.
3.3.6.14.3 Thyroid Hormones
N either iodine uptake nor growth of the cells was affected by thyroid 
hormones (figure 3.61).
The above experiments indicate that the iodine uptake of cells increases when 
stimulated with SP. Since SP binds to more than one of the neurokinin receptors, the 
experiments were repeated using a specific agonist for each of the three known 
receptors.
3.3.6.15 [Sar9 ,M et(0 2 )^i]-Substance P(SM O-SP)
3.3.6,15.1 Dose Study
[Sar^, M et(0 2 )^^]“Substance P (SMO-SP) is a specific agonist fo r the 
Neurokinin 1 receptor. Its final concentrations ranged from 10 to 2CXX) nmol/1. A 
concentration of 5(X) nmol/1 was chosen for further study.
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Figure 3.59: Effect of substance P on iodine uptake and growth of FRTL-5 cells. 
Cells were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated ceils (control or zero concentration) are shown by *.
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Figure 3.60: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
substance P. Cells were incubated as before, without substance P (C), with 250 
nmol/1 of substance P (S), or with a mixture of 1 //mol/1 of bestatin and 1 //mol/1 of 
thiorphan in the absence (E) or the presence of substance P (S+E). Significant 
differences caused by inhibitors are represented by *.
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Figure 3.61: Effect of thyroid hormones, on stimulation of FRTL-5 cells with 
substance P and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as 
before, without substance P (C), with 250 nmol/1 of substance P (S), or stimulated in 
the 6 H medium containing 0.5 % FCS, additional amino acids, 1 //mol/1 of T 4  and 
10 nmol/1 of T 3 , 48 h before and 48 h after addition of substance P [S (T 4 ,Tg)]. The 
cells that were stimulated only with thyroid hormones for 96 h served as control [C 
(T4 ,T3 )] for this set.
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Figure 3.62: Effect of SMO-SP (agonist for NK-1 receptor) on iodine uptake and 
growth of FRTL-5 cells. Cells were incubated in 5H or 6 H (2U/1 of TSH) medium 
containing 0.5 % FCS and additional amino acids for 48 h. Significant differences 
between stimulated and unstimulated cells (control or zero concentration) are shown 
by *.
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Figure 3.63: Effect of protease inhibitors, on stimulation of FRTL-5 cells with 
SMO-SP. Cells were incubated as before, without SMO-SP (C), with 500 nmol/1 of 
SMO-SP (S), or with a mixture of 1 /^mol/1  of bestatin and 1 pimo\/\ of thiorphan in 
the absence (E) or the presence of SMO-SP (S+E).
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Figure 3.64: Effect of thyroid hormones, on stimulation of FRTL-5 cells with SM O- 
SP and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, without 
SM O-SP (C), with 500 nmol/1 of SMO-SP (S), or stimulated in the 6 H medium 
containing 0.5 % FCS, additional amino acids, 1 /tmol/1 of T 4  and 1 0  nmol/1 of T 3 , 
48 h before and 48 h after addition of SMO-SP [S (T 4 ,Ts)]. The cells that were 
stimulated only with thyroid hormones for 96 h served as control [C (T 4 ,T3 )] for this 
set.
3 3 .6 .1 5 .2  Protease fnh ibi tors
Concentrations of 250, 500 and 1000 nmol/1 caused significant increases in 
iodine uptake of the cells incubated in 5H medium. The maximum increase of 29.1 % 
above control was detected at a concentration of 500 nmol/1 (figure 3.62). SMO-SP 
did not affect the growth of the cells at any concentration.
In the presence of TSH, SMO-SP at concentrations of up to 500 nmol/1 
increased the iodine uptake of cells. The maximum increase was 27.0 %. The iodine 
uptake at concentrations of 1000 and 2000 nmol/1 was significantly less than at 500 
nmol/1. A significant increase of growth rate of 12.3 % occurred at a concentration of 
2  //m ol/1 .
Ji'
Protease inhibitors reduced the stimulatory effect of SMO-SP from 23.3 % to 
9.8 % in the absence of TSH, and from 19.0 % to 9.8 % in the presence of TSH 
(figure 3.63). They had no effect on growth.
3.3.6.15.3 Thyroid Hormones
Thyroid hormones reduced the stimulatory effect of SMO-SP from 26.7 % to 
10.9 %, but did not affect growth rate (figure 3.64).
3.3.6.16 a-Neurokinin Fragm ent4-10 (NK)
3.3.6.16.1 Dose Study
a-Neurokinin fragment 4-10 (NK) is a specific agonist for the Neurokinin 2 
receptor. Its final concentrations ranged from 10 to 2000 nmol/1. A concentration of 
250 nmol/1 was chosen for further study.
NK significantly (p<0.05) increased iodine uptake in the absence of TSH at
concentrations of 100 and 250 nmol/1. The maximum increase of 21.16 % was 
detected at a concentration of 250 nmol/1. The value obtained for iodine uptake was 
significantly lower at a concentration of 2000 nmol/1 than at 250 nmol/1.
In the presence of TSH, NK increased the iodine uptake of cells significantly at all 
concentrations. The maximum increase was caused by 250 nmol/1 of NK, 26.25 % 
higher than control (figure 3.65).
Addition of NK did not affect the growth of the cells at any concentration, 
either in the presence or the absence of TSH.
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Figure 3.65: Effect of NK (agonist for NK-2 receptor) on iodine uptake and growth 
of FRTL-5 cells. Cells w ere incubated in 5H or 6 H (2U/1 of TSH) m edium  
containing 0.5 % FCS and additional amino acids for 48 h. Significant differences 
between stimulated and unstimulated cells (control or zero concentration) are shown 
by while • shows a significant decrease.
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Figure 3.66: Effect of protease inhibitors, on stimulation of FRTL-5 cells with NK. 
Cells were incubated as before, without NK (C), with 250 nmol/1 of NK (S), or with 
a mixture of 1 jimoVl of bestatin and 1 ^mol/1 of thiorphan in the absence (E) or the 
presence of NK (S+E). Significant differences caused by inhibitors are represented 
by (*).
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Figure 3.67: Effect of thyroid hormones, on stimulation of FRTL-5 cells with NK 
and TSH. Cells were stimulated in 6 H medium ( 2  U/l of TSH) as before, without 
NK (C), with 250 nmol/1 of NK (S), or stimulated in the 6 H medium containing 0.5 
% FCS, additional amino acids, 1 //mol/l of T 4  and 10 nmol/1 of T 3 , 48 h before and 
48 h after addition of NK [S (T 4 ,T3 )]. The cells that were stimulated only with 
thyroid horm ones for 96 h served as control [C (T4 ,T3 )] fo r this set.
3.3 .6 .16.2  Protease Inhibitors
Protease inhibitors did not alter the effect of NK on iodine uptake in the 
absence of TSH, but reduced its stimulatory effect in the presence of TSH from  21.5 
% to 11.4 % (figure 3.66). They did not alter the effect of NK on growth of cells 
incubated in 5H medium, but caused a slight but significant increase in growth rate of 
8.7 % in the presence of TSH.
3.3.6.16.3 Thyroid Hormones
Thyroid hormones moderately suppressed the effect of NK on iodine uptake 
(figure 3.67). The increase was 16.5 % compared to 25.1 %. Thyroid hormones did 
not alter the growth of cells stimulated with NK.
3.3.6.17 Succinyl-[Asp^, N-Me-Phe^]-Substance P (S-SP)
3.3.6.17.1 Dose Study
Succinyl-[Asp^, N-Me-Phe^]-Substance P is a specific agonist for the 
Neurokinin 3 receptor. Its final concentrations ranged from 10 to 2000 nmol/1. A 
concentration of 250 nmol/1 was chosen for further studies.
S-SP increased the iodine uptake significantly at concentrations of 250 and 
500 nmol/1 in the absence of TSH. The maximum increase of 12.68 % was detected 
at a concentration of 250 nmol/1. S-SP did not affect the growth of cells.
In the presence of TSH, S-SP increased the iodine uptake of cells at 
concentrations of 10 to 500 nmol/1. The maximum increase was associated with 250 
nmol/1 of S-SP, 16.29 % higher than control (figure 3.68). A t concentrations 
between 250 and 1 0 0 0  nmol/1, S-SP increased growth rate, by a maximum of 7.8 % 
at 500 nmol/1.
3.3.6.17.2 Protease Inhibitors
Protease inhibitors inhibited the effect of S-SP on iodine uptake significantly 
in the absence of TSH. The increase was only 6.2 % compared to 21.4 % (figure 
3.69).
In the presence of TSH, the inhibitors also inhibited the effect of S-SP on 
iodine uptake. The uptake was increased by 7.1 % compared to 19.9 %.
Addition of bestatin and thiorphan did not alter the effect of S-SP on growth 
of cells incubated in 5H or 6 H medium.
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Figure 3.68: Effect of S-SP (agonist for NK-3 receptor) on iodine uptake and 
growth of FRTL-5 cells. Cells were incubated in 5H or 6 H (2U/1 of TSH) medium 
containing 0.5 % FCS and additional amino acids for 48 h. Significant differences 
between stimulated and unstimulated cells (control or zero concentration) are shown 
by while • indicates significant decreases.
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Figure 3.69: Effect of protease inhibitors, on stimulation of FRTL-5 cells with S-SP. 
Cells were incubated as before, without S-SP (C), with 250 nmol/1 of S-SP (S), or 
with a mixture of 1 pimol/l of bestatin and 1 //mol/1 of thiorphan in the absence (E) 
or the presence of S-SP (S+E). Significant differences caused by inhibitors are 
represented by *.
1 2 0
105
90
75
60
45
30
15
0
Iodine uptake (cpm/jug protein) 
   -*-  -----
Growth (/jg protein/weli)
+
£O
•kTI—ij)
1 2 0  — 
1 0 0  
80 
60 
40 4  
2 0  
0
O
KJ
CO
Figure 3,70: Effect of thyroid hormones, on stimulation of FRTL-5 cells with S-SP 
and TSH. Cells were stimulated in 6 H medium (2 U/l of TSH) as before, without S- 
SP (C), with 250 nmol/1 of S-SP (S), or stimulated in the 6 H medium containing 0.5 
% FCS, additional amino acids, 1 //mol/1 of T 4  and 10 nmol/1 of T 3 , 48 h before and 
48 h after addition of S-SP [S (T4 ,T3 )]. The cells that were stimulated only with 
thyroid hormones for 96 h served as control [C (T4 ,T3 )j for this set. Significant 
differences between the presence and the absence of thyroid hormones is shown by 
(*).
3.3.6.17.3 Thyroid Hormones
Thyroid hormones reduced the effect of S-SP on iodine uptake from an 
increase of 16.3 % to 6.5 % (figure 3.70). Thyroid hormones did not alter the growth 
of cells stimulated with S-SP.
3.3.6.18 Noradrenaline (NA)
3.3.6.18.1 Dose Study
The final concentrations of ± noradrenaline ranged from 0.05 to 20 jwmol/1. A 
concentration of 2 0  p,mol/l was chosen for further study.
Inclusion of noradrenaline in 5H medium did not change the rate of iodine 
uptake or growth.
In the presence of TSH, the iodine uptake of stimulated cells increased 
significantly with all doses of noradrenaline. The highest increase was associated 
with 20 //mol/1 of noradrenaline, 93.9 % higher than the value obtained for the 
control (figure 3.71). Growth was unaltered.
3.3.6.18.2 Proteose Inhibitors
The inclusion of bestatin and thiorphan did not alter the effect of noradrenaline 
on either iodine uptake or growth, either in the presence or the absence of TSH  
(figure 3.72).
3.3.6.18.3 Thyroid Hormones
Thyroid hormones increased the effect of noradrenaline on iodine uptake but 
not growth (figure 3.73). The increase in uptake was 121.1 % compared to 93.9 %.
3.3.6.19 S-Nitroso-N-Acetyl Penicillamine (SNAP)
3.3.6.19.1 Dose Study
SNAP is a stable donor of nitric oxide and releases it into the medium during 
the incubation. The final concentrations of SNAP used ranged from 1 to 10 //mol/1.
SNAP decreased the iodine uptake of cells significantly at concentrations of 5 
and 10 //mol/1 in the absence of TSH. The decreases were 12.6 and 30.4 % low er 
than control. The difference between values obtained for iodine uptake of cells at
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Figure 3.71: Effect of ± noradrenaline on iodine uptake and growth of FRTL-5 cells. 
Cells were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by *.
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Figure 3.72: Effect of protease inhibitors, on stimulation of FRTL-5 cells with ± 
noradrenaline. Cells were incubated as before, without ± noradrenaline (C), with 2 0  
/miol/1 of ± noradrenaline (S), or with a mixture of 1 /fmol/1 of bestatin and 1 jimoVl 
of thiorphan in the absence (E) or the presence of ± noradrenaline (S+E).
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Figure 3.53: Effect of thyroid hormones, on stimulation of FRTL-5 cells with ± 
noradrenaline and TSH. Cells were stimulated in 6 H medium (2 U/1 of TSH) as 
before, w ithout ± noradrenaline (C), with 2 0  of ± noradrenaline (S), or
stim ulated in the 6 H medium containing 0.5 % FCS, additional amino acids, 1 
//mol/1 of T 4  and 10 nmol/1 of T 3 , 48 h before and 48 h after addition o f ± 
noradrenaline [S (T 4 ,T3 )]. The cells that were stim ulated only with thyroid 
hormones for 96 h served as control [C (T4 ,T3 )] for this set. Significant differences 
between the presence and the absence of thyroid hormones is shown by
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Figure 3.74: Effect of SNAP on iodine uptake and growth of FRTL-5 ceils. Cells 
were incubated in 5H or 6 H (2U/1 of TSH) medium containing 0.5 % FCS and 
additional amino acids for 48 h. Significant differences between stimulated and 
unstimulated cells (control or zero concentration) are shown by while • shows 
significant decreases compared to control.
____
concentrations of 5 and 1 0  //m ol /1  was significant (figure 3.74). SNAP increased 
growth significantly at concentrations of 5 //mol/1 and above, to a maximum of 22.82 
% at a concentration of 1 0  //m ol/1.
In the presence of 2  U/1 of TSH (6 H), SNAP decreased the iodine uptake of 
cells significantly at a concentration of 2.5 //mol/1, while it increased uptake 
significantly at a concentration of 1 0  //m ol/1. The decrease was 11.1 %, and the 
increase was 9.1 %. SNAP did not change the growth of cells at any concentration.
3.3.6.20 Interleukin-1 And Insulin Like Growth Factor-1
The final concentration of IL - 1  was 1 or 20 /fg/1, while that of IG F-1 was 500
//g/1 .
In 5H medium, addition of IL-1 did not alter the effect of IGF-1 on iodine 
uptake. A concentration of 20 pg/1 of IL-1 did reduce the growth effect of IGF-1 
from 22.4 % to 10.2 %, but 1 pg/1 had no effect (figure 3.75).
In the presence of TSH, IL-1 at a concentration of 1 //g/1 did not alter the 
effect of IGF-1 on iodine uptake. At a concentration of 20 //g/1 of IL-1 the effects of 
IGF-1 and IL-1 were additive, IGF-1 causing an increase of 38.6 %, IL-1 causing a 
decrease of 23.8 %, and the combination resulting in a 7.8 % increase. Both 1 //g/1 
and 20 //g/I of IL-1 reduced the effect of IGF-1 on growth. The increase was reduced 
from 18.6 % to 1 1 . 0  % by the lower and to 8 . 6  % by the higher dose.
3.3.6.21 Interleukin-1 And Interferon-y
The final concentration of IL-1 was 20 //g/1, while that of INF-y was 100
/^g/1-
In 5H medium, IL-1 did not alter the increase in iodine uptake of 27.1 % 
caused by INF-y (figure 3.76), and neither altered growth rate.
In the presence of TSH, the effects of IL-1 and INF-y on iodine uptake were additive. 
IL-1 decreased it by 23.77 %, INF-y caused an increase of 73.08 %, and the mixture 
of IL-1 and INF-y caused an increase of 31.35 % in iodine uptake. IL-1 did not 
significantly change the decrease of 31.9 % in growth rate caused by INF-y.
3.3.6.22 Interleukin-1 And Neuropeptide Y
The final concentration of IL-1 was 1 or 20 //g/1, while that of NPY was 500
nmol/1.
In 5H medium, neither IL-1 at concentrations of 1 or 20 //g/1 nor NPY 
affected iodine uptake of the cells significantly in isolation, but the mixture of 1 //g /1
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Figure 3.75: Effect of combining IL-1 and IGF-1 on FRTL-5 cells. Cells were 
stimulated for 48 h as before, with single stimulator or combination of them  as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
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Figure 3.76: Effect of combining IL-1 and INF-y on FRTL-5 cells. Cells w ere 
stimulated for 48 h as before, with single stimulator or combination of them  as 
labelled in the colum ns. U nstim ulated cells served as control. The final 
concentrations were 2 U/1 of TSH, 20 //g/1 of IL-1, and 100 //g/1 of INF-y. The 
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of IL-1 and NPY caused a significant increase of 16.49 %. A non significant 
decrease of 7.63 % occurred in iodine uptake of cells stimulated with a mixture of 20 
//g/1 of IL-1 and NPY (figure 3.77).
In the presence of TSH, a mixture of 1 //g/1 of IL-1 and NPY caused an 
increase of 14.08 % in iodine uptake, greater than that for NPY alone (9.8 %). The 
mixture of 20 //g/1 of IL-1 and NPY caused a significant decrease of 27.82 %, similar 
to that obtained with 20 //g/1 of IL-1 alone. In the presence or the absence of TSH , 
neither IL-1 nor NPY nor the mixture affected the growth of cells.
3.3.6.23 Interleukin-1 And Noradrenaline
The final concentration of IL-1 was 1 or 20 //g/1, while that of ± noradrenaline 
(NA) was 20 //mol/1.
In 5H medium, neither IL-1 at a concentration of 1 or 20 //g/1, NA alone, nor 
their combination affected iodine uptake of the cells (figure 3,78).
In the presence of TSH (6H), NA caused a significant increase of 64.8 %. 
The mixture of 1 //g/1 of IL-1 and NA caused an increase of significantly lower 
magnitude, 53.1 %. The mixture of 20 //g/1 of IL-1 and NA also caused a sm aller 
increase, 42.10 %, than NA alone. This indicates that IL-1 antagonised the effect of 
NA on iodine uptake. In the presence or the absence of TSH, neither the individual 
stimulators nor their combination affected the growth of cells.
3.3.6.24 Interleukin-1 And Vasoactive Intestinal Peptide
The final concentration of IL-1 was 1 or 20 //g/1, while that of VIP was 500
nmol/1.
In 5H medium, IL-1 at concentrations of 1 or 20 //g/1 did not alter the increase 
in iodine uptake caused by VIP (figure 3.79). Stimulation of the cells with 1 or 20 
//g/1 of IL-1 did not alter the effect of VIP on growth.
In the presence of TSH (6H), IL-1 a concentration of 1 //g/1 did not affect the 
iodine uptake caused by VIP, but a concentration of 20 pg/1 antagonised the increase. 
The increase caused by VIP alone was 42.3 %, while that in the presence of IL-1 was
11.2 %. Neither of the stimulators IL-1 nor VIP, nor their combination, affected the 
growth of cells.
1 2 2
1 3 5 -
120-
105
9 0 4  
75  
60 — 
45 
30  
15 
G
Iodine uptake (cpm/pg protein)
★
Iodine uptake (cp m /p g protein)
II
S.
g
3
Oi
1i3-
S.
+ 5“
1 3 5 -
120-
1 0 5 -
90
7 5 -
6 0 -
45
30
15
0 J
g
I
III
X
cr.=L
=!+y-
§
5H 6H
1 2 0 - 1
100
8 0 -
6 0 -
4 0 -
20-
0
Growth {pg  protein/well)
<3 I.
can=1
g
=d
I
3 -k
r î n r î n
Ç
sII=!+
120
100
80
6 0 -
4 0 -
20-
0
Growth {pg  protein/well)
æ-ir-æ
o
Oi
=4
gI
g
+
I
5H 6H
Figure 3.77: Effect of com bining IL-1 and NPY on FRTL-5 cells. Cells were 
stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Un stimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
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Figure 3.78: Effect of combining IL-1 and ± noradrenaline on FRTL-5 cells. Cells 
were stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
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Figure 3.79: Effect of com bining IL-1 and VIP on FRTL-5 cells. Cells were 
stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
3.3.6.25 Interleukin-1 And [Sar^, MetCOg)^ i]-Substance P
The final concentration of IL-1 was 1 //g/1, while that of [Sar^, Met(02)^ ^]- 
Substance P (SMO-SP) was 250 nmol/l.
In 5H medium, the increase caused by the mixture of IL-1 and SMO-SP was
30.4 %, significantly higher than the corresponding values obtained for IL-1 and 
SMO-SP alone (figure 3.80). In the presence of TSH, IL-1 had no effect on the 
increase of 19.6 % caused by SMO-SP on iodine uptake. In the presence or absence 
of TSH, neither of the stimulators nor their combination affected the growth of cells.
3.3.6.26 Interleukin-1 And a-Neurokinin
The final concentration of IL-1 was 1 //g/1, while that of a-N eurokinin (NK) 
was 250 nmol/l.
IL-1 did not alter the effects of NK on iodine uptake, either in the presence or 
absence of TSH (figure 3.81). Neither IL-1 nor NK nor their combination affected 
the growth of cells.
3.3.6.27 Interleukin-1 And Succinyl-[Asp^,N-Me-Phe8]-Substance P
The final concentration of IL-1 was 1 //g/1, while that of Succinyl-[Asp^,N- 
Me-Phe^j-Substance P (S-SP) was 250 nmol/l.
IL-1 did not significantly affect the increase in iodine uptake caused by S-SP 
alone either in the presence or absence of TSH (figure 3.82). Neither IL-1 nor S-SP 
nor their combination affected the growth of cells.
3.3.6.28 Selective Agonists Of Neurokinin Receptors
The final concentration of each agonist was 250 nmol/l.
The iodine uptake of the cells stimulated with 5H medium containing any one 
of the agonists was significantly increased. The increases above control were 18.8 % 
for SMO-SP, 20.0 % for NK, and 11.9 for S-SP. The increases above control when 
two agonists were added simultaneously were 26.4 % for a mixture of SMO-SP and 
NK, 29.3 % for a mixture of SMO-SP and S-SP, and 27.2 % for a mixture of NK 
and S-SP. Stimulation of the cells with medium containing all 3 agonists increased 
the rate of iodine uptake by even more, 34,0 %.
None of the increases caused by combinations of two agonists was significant 
when compared with the value obtained for each individual stimulator, while the
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Figure 3.80: Effect of combining IL-1 and SMO-SP on FRTL-5 cells. Cells were 
stimulated for 48 h as before, with single stimulator or combination of them  as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
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Figure 3.81: Effect of com bining IL-1 and NK on FRTL-5 cells. Cells w ere 
stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control.
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Figure 3.82: Effect o f combining IL-1 and S-SP on FRTL-5 cells. Cells were 
I stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
value obtained for the mixture containing 3 agonists was significantly higher than the 
iodine uptake of each individual agonist (figure 3.83).
The iodine uptake of the cells stimulated with TSH containing any one of the 
agonists was significantly increased. The increases above control were 19.6 % for 
SMO-SP, 20.1 % for NK, and 14.9 for S-SP. Stimulation of cells with 6H m edium 
containing two agonists also increased the rate of iodine uptake significantly. The 
increases above control were 36.9 % for a mixture of SMO-SP and NK, 30.7 % for a 
mixture of SMO-SP and S-SP, and 37.7 % for a mixture of NK and S-SP.
Stimulation of the cells with 6H medium containing all 3 agonists increased 
the rate of iodine uptake by 37.0 %.
All of the increases caused by combinations of two agonists were significant 
when compared with the value obtained for each individual stimulator, but the value 
obtained for the mixture containing 3 agonists was not different from the result 
obtained for the mixture containing two agonists (figure 3.83).
In the presence or absence of TSH, none of the stimulators affected the 
growth of cells, alone or in combination.
3.3.6.29 Noradrenaline And Insulin Like Growth Factor-1
The final concentration of ± noradrenaline (NA) was 10 //mol/1, while that of 
Insulin like growth factor-1 was 500 //g/1.
NA did not alter the effect of IGF-1 on iodine uptake or growth rate in 5H 
medium (figure 3.84).
In the presence of TSH, the mixture of IGF and NA caused an increase of 
96.9 % in iodine uptake. NA alone caused an increase of 64.8 %, while IGF caused 
an increase of 38.6 %. The effects of the stimulators were additive. NA did not alter 
the increase in growth rate caused by IGF.
3.3.6.30 Noradrenaline And Vasoactive Intestinal Peptide
The final concentration of ± noradrenaline (NA) was 10 //mol/1, while that of 
Vasoactive Intestinal Peptide (VIP) was 500 nmol/l.
In the absence of TSH, NA did not alter the significant increase in iodine 
uptake caused by VIP (figure 3.85). However, in the presence of TSH, the m ixture 
of 500 nmol/l of VIP and NA caused an increase of 94.5 %, compared to 64.8 % and
42.4 % for the single stimulators.
In the absence of TSH, NA did not affect the increase in growth caused by 
VIP. In the presence of TSH, 10 //mol/1 of NA or 500 nmol/l of VIP for 48 h did not
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Figure 3.83: Effect of combining agonists of tachykinin receptors on FRTL-5 cells. 
Cells were stimulated for 48 h as before, with single stimulator or combination of 
them as labelled in the columns. Unstimulated cells served as control. The symbol 
(*) shows significant differences compared with individual stimulator.
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Figure 3.84: Effect of combining ± noradrenaline and IGF-1 on FRTL-5 cells. Cells 
were stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol shows 
significant differences compared with individual stimulator.
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Figure 3.85: Effect of combining ± noradrenaline and VIP on FRTL-5 cells. Cells 
were stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
 ^ f-:
affect growth, while stimulation of the cells with a mixture of VIP and NA caused a 
significant increase of 25.4 %.
3.3.6.31 Noradrenaline And Neuropeptide-Y
The final concentration of ± noradrenaline (NA) was 10 //mol/1, while that of 
Neuropeptide-Y (NPY) was 500 nmol/l.
In 5H medium, 10 //mol/1 of NA or 500 nmol/l of NPY did not affect iodine 
uptake individually, while the iodine uptake of the cells stimulated with their 
combination increased significantly, by 15.0 % above control (figure 3.86).
In the presence of TSH, the mixture of 500 nmol/l of NPY and NA caused an 
increase of 76.0 % in iodine uptake, compared to 9.8 % and 64.8 % for the 
individual stimulators. This indicates that NPY and NA act independently (figure 
3.86).
In the absence of TSH neither of the stimulators affected the growth of cells 
individually, but in combination, the increase in growth was 12.88 % above control, 
a significant increase. N either the individual stimulators nor their com bination 
affected growth in the presence of TSH.
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Figure 3.86: Effect of combining ± noradrenaline and NPY on FRTL-5 cells. Cells 
were stimulated for 48 h as before, with single stimulator or combination of them as 
labelled in the columns. Unstimulated cells served as control. The symbol (*) shows 
significant differences compared with individual stimulator.
SECTION FOUR: DISCUSSION 
3.4.1 Characteristics Of FRTL-5 Thyroid Follicular Ceil
The FRTL-5 cell line is an established, continuously growing line that 
responds to TSH in culture medium. In our hands, exposure of the cells to TSH for 
two or three days after a period of deprivation of five days caused an increase of 
nearly two fold in growth and in iodine uptake. Confluency was not achieved because 
the cells grow over each other to form follicle-like structures (figure 3.1). The 
production of cAMP by the cells also increased 33 fold following exposure to TSH 
for 3 h after a period of five days deprivation. These observations are in agreement 
with the previously reported characteristics for this cell line (Bidey et al, 1988; Kohn 
and Valente, 1989; Tramontane, 1990).
Deprivation of TSH for 5 days caused the cells to swell, and re-exposure to 
TSH reversed this process (figure 3.2). TSH has a trophic effect on thyroid follicular 
cells. TSH deprivation in vivo such as that caused by hypophysectomy or Tg and T 4  
treatment induces several changes in follicular cell morphology (Nitsch et al, 1989). 
In medium deprived of TSH, FRTL-5 cells do not grow (Kohn and Valente, 1989; 
Tramontano, 1990) and undergo a dramatic modification in cell shape (Nitsch et al, 
1989). Nitsch and co-workers (1989) reported that incubation of FRTL-5 cells in 5H 
medium caused actin filaments to reassemble in thick bundles, and the cells lost rough 
endoplasmic reticulum after 7 days. The morphological changes detected during the 
present study could be due to these changes.
3.4.2 Iodine Influx
It was found that adequate buffering was essential for there to be a response 
of iodine uptake to TSH. In the presence of phosphate and HEPES buffers, there was 
an increase of nearly two fold in iodine uptake, while in phosphate/bicarbonate 
buffer, there was no response and the uptake rate was high even in the absence of 
TSH. The pH in this buffer fell to 6.2-6.4 during the time of the uptake experiment, 
which may have had a direct effect on the permeability of the cells or on the 
transporter.
In support o f this suggestion, W eiss and co-workers (1984 b) reported an 
increase at pH 6.5 in both iodine influx measured at 5 min and efflux measured at 40 
min. The present result was obtained in a 30 rain incubation and may include a 
smaller component of the efflux process. This result suggests that iodine uptake 
requires a pH difference between the extra-cellular and cytoplasmic spaces. It is 
known that activation of these cells is accompanied by an increase in cytoplasmic pH
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which could be caused by an electroneutral, amiloride-sensitive Na+/H+ exchanger 
that is present , on the surface (Bidey et al, 1988).This may then be responsible for 
iodine accumulation through an active Na+/I’ symporter and an iodine channel 
(Carrasco, 1993).
3.4.3 Plasma Carrier For Iodine
There is disagreement in the literature whether it is necessary to include 
protein in the uptake medium as a carrier for iodine or whether it is adequate to use 
carrier-free solutions. There is very little published work describing the presence of 
carrier proteins for inorganic iodine in serum, most workers having concentrated on 
the carriers for thyroid horm ones (U nderwood, 1977; Parsad, 1978). W e 
investigated whether inorganic iodine bound to serum protein to a significant extent 
and whether any binding which might be present could affect the rate of iodine 
uptake.
The present results indicate that iodine bound to albumin immediately at 37°
C, and this association is dose dependent and saturable (figure 3.6 and 3.7). 
Electrophoresis of serum incubated with radioactive iodine showed that it was mostly 
carried by pre-albumin and albumin, with a certain amount carried by other proteins.
The iodine associated with pre-albumin amounted to 15 % of the total counts and that 
associated with albumin was 37.6 %. The concentration of pre albumin in the plasma 
is approximately 160 times lower (250 mg/1) than the concentration of albumin (40 
g/1), so pre-albumin carries the highest amount of inorganic iodine per molecule. 
Thrall and co-workers (1992) showed in rats that 63% of injected radioactive iodine 
(U) or iodide(U) was associated with albumin, globulin, and lipids. They did not 
measure the iodine associated with pre-albumin, but showed that the largest amount 
was associated with lipids (43%). Our present work has also identified two bands 
(figure 3.8, bands 7 and 8 ) at the extreme end of gel with could be accounted for by 
lipoproteins which did not enter the gel. The sum of the activity associated with these 
two bands (22.5%) was less than that found by Thrall and co-workers. These results 
suggest that there is a carrier system for inorganic iodine in vivo.
3 .4 .4  Effect Of Albumin In Iodine Uptake Medium
The effect of including albumin as a carrier of iodine was examined. The rate 
of iodine uptake was measured at 5 rain to avoid the effect of the efflux pathway, and 
Michaelis-Menten parameters were calculated using a Lineweaver-Burk plot. The K„i 
was found to be 52.6 //mol/1 and the Vmax of iodine uptake was 3.57 pm ol///g 
protein/min. The value of Km found in the present study is higher than the study of
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Weiss and co-workers (1984), in which the K ^ fo r iodine uptake of this cell line was 
reported to be 31 //mol/1. Values for V^ax have not been reported previously.
Inclusion of 5 g/1 of albumin as an iodine carrier in the iodine uptake medium 
caused decreases in both Km and Vmax of iodine influx. The Km was nearly halved 
(27.0 //mol/1), while Vmax decreased by 0.87 pmol///g protein/min. This value for 
Km was much closer to previously reported values.
Since there is both influx and efflux of iodine in thyroid cells, transport 
eventually reaches steady state when these are equal. It has been previously reported 
that iodine transport reached steady state by 40 min when the iodine uptake medium 
included 10 //.mol/1 of iodide, but not albumin (Weiss et al, 1984; Kohn and Valente, 
1989). In the present study steady state was reached between 35 and 42 min in 
carrier-free medium. Inclusion of 5 g/1 of albumin in the medium reduced the time to 
steady state to 21 min when the concentration of iodine was 10 pmol/1. This is 
presumably a complex effect of the observed changes in initial uptake rate and in 
efflux rate, which was not measured directly in these studies.
3.4.5 Effect Of Serum In Medium
In the presence of a constant concentration of TSH, an increase in serum 
concentration from 0.5 to 5% in the medium of growing cells caused a significant 
decrease in iodine uptake, while it produced a significant increase in growth. The 
results presented here correspond with previous results obtained for human (Roger et 
al, 1988; Kraiem et al, 1991) or FRTL-5 (Di M arino et al, 1989; Zakarija and 
M cKenzie, 1989 a) thyroid cells, although their experimental conditions were 
different from the present study. The interpretation of each group was different and 
corresponds to the experimental condition applied.
Roger and co-workers (1988) compared the effects of TSH on human thyroid 
cells in the presence and absence of serum and claimed that treatment of cells with 
medium containing 1% serum induced TSH effects which were responsible for 
morphological changes and growth increases, while inhibiting the action of TSH on 
iodine uptake. The group of Kraiem (1991), who grew cells on collagen gel in the 
absence or presence of 1 0 % serum, showed that higher amounts of iodine uptake, 
organification and T3  synthesis were obtained when cells were stimulated with TSH 
in the absence of serum. Di Marino and co-workers (1989) reported that serum itself 
did not have any growth activity on FRTL-5 cells and only prevented other growth 
factors from sticking to plastic substrates. They believed that the IGF-1 present in 
serum was responsible for the increases in growth which they obtained with different 
concentrations of serum at a constant level of TSH. On the other hand, Zakarija and
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McKenzie (1989 a) claimed that serum did not contain a sufficient concentration of 
IGF-1 to induce growth.
In the present study, some of the cells died (nearly 90 %), when serum 
content of 5H was replaced with 2 g/1 bovine serum albumin, while 0.5 % of serum 
was sufficient to keep the cells healthy. This indicates that the albumin content of 
serum alone is not sufficient to maintain the cells, because the quantity of albumin 
which was used was m uch higher than the protein content of 0.5%  serum , 
approximately 400 mg/1. Other components of serum must be necessary for growth 
of thyroid follicular cells.
One possible factor in serum which might cause these effects is inorganic 
iodine. Two different groups (Heldin et al, 1987; Kasai et al, 1992) have provided 
evidence for effects of iodine on thyroid cells. Heldin and co-workers ( 1987) showed 
that iodine increased c-myc mRNA and incorporation of ^H thymidine 30 to 36 h 
after its addition to the medium of porcine thyroid cells, while Kasai and colleagues
(1992) shown that addition of Nal to the medium increased T 3  formation.
The receptor for thyroid hormones is present in FRTL-5 cells (Akiguchi et al, 
1992). T3  alone increased ^H thymidine incorporation at concentrations below 1 
nmol/l, while in combination with TSH or IGF-1 the increase was 1.5-2.2 fold 
higher. T 3  also induced 5'-deiodinase in FRTL-5 cells (Toyoda et al, 1992), thus 
providing a mechanism for increasing its own levels in the presence of T 4 . These 
observations clearly show that T3  and T 4  in serum may also cause growth effects.
The synthesis of cell m embranes requires the synthesis of new lipids, 
including cholesterol. The low density lipoprotein receptor is present on the surface 
of FRTL-5 cells (Aloj, 1989). Although thyrocytes are able to synthesise cholesterol 
and other lipids which are necessary for the synthesis of new cell membranes, the 
presence of this receptor indicates a need for an external source of lipids. Obviously 
the external source in vitro is serum, and this could be another factor responsible for 
the growth effect of serum in the presence of stimulators such as TSH or IGF-1.
It is also possible that there are peptide growth factors in serum in addition to 
IGF-1 which may be necessary for growth. FGF, for example is known to have a 
pow erful effect on growth of thyroid cells while sim ultaneously reducing 
differentiated functions such as iodine uptake, exactly the effect of serum which was 
seen in these experiments.
3.4.6 Thyroglobulin Production By FRTL-5
Most previous reports measured the increase in mRNA of thyroglobulin 
induced by TSH, or insulin or IGF-1 (Bone et al, 1986 b; Santisteban et al, 1987; 
Kamikubo et al, 1990; Graves and Davies, 1993), or used radioactive labelling
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(Chambard et al, 1987) of the protein synthesised. Two different groups measured 
the actual protein production using porcine thyroid cells on porous bottom chambers 
(Grufft et al, 1992), and FRTL-5 cells in monolayers (Ossendorp et al, 1989). In the 
present study, iodinated thyroglobulin that was released to the medium was measured 
using 7.5% polyacrylamide gel electrophoresis as described in section 3.3.4.
The results obtained correspond to previous reports, and showed that FRTL-5 
cells are able to synthesise and iodinate at least some thyroglobulin in the presence of 
adequate (0.5 mol/1) iodine in the medium. In the absence of TSH for 8  days, the 
production was half of that when the cells were stimulated with 2 U/L of TSH for 72 
h. Part of the basal production in the absence of TSH could be due to the influence of 
insulin (Bone et al, 1986 b; Santisteban et al, 1987; Isozaki et al, 1989; Kamikubo et 
ai, 1990; Graves and Davies, 1993) or other honnones present in the medium, while 
some might be induced by iodine uptake of the cells.
Graves and Davies (1993) reported that there are two genes for thyroglobulin 
in rats, which they named rTg-1 and rTg-2. The rTg-1 gene is independent of TSH 
but is insulin and IGF-l dependent. However, cells deprived of insulin, TSH, and 
serum still showed a background thyroglobulin mRNA production (Bone et al, 1986 
b; Ossendorp et al, 1989). On the other hand, the presence of thyroglobulin protein 
does not guarantee iodination. The production of H2 O2  is partially impaired (Bidey et 
al, 1988) in FRTL-5 cells, so that organification does not take place or is at a 
minimum level. This defect may be partly due to the absence of iodine in the culture 
medium, because the present results indirectly show that newly synthesised TG 
molecules are iodinated when adequate inorganic iodine is present in the medium. 
This suggestion is supported by a recent study of Corvilain and co-workers (1994), 
who have shown that a low level of iodine induces production of H2 Q2  by thyroid 
cells.
3.4.7 Effect Of Inorganic Iodine On Growth
In the present study, it was shown that inclusion of concentrations of 
inorganic iodine above 1 //mol/1  to the medium of growing cells reduced their growth 
dose dependency, while 1 mmol/1 of iodine started to cause cell damage in 5H 
medium containing 5% serum. These results correspond with previously reported 
results (Saji et al, 1988; Many et al, 1992), but using a wider range of concentrations 
and different methods.
An excess of iodine in vitro causes a chain of events which are possibly 
related to the W olff-Chaikoff effect observed in vivo. They take place in successive 
order. The excess iodine results in more iodine entering the cell than normal. This 
causes a reduction in cAM P (Saji et al, 1988), followed by reduction in H 2 O2 , a
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necessary substrate for organification of iodine (Corvilain et al, 1994). This is 
accompanied by reduction of thyroglobulin synthesis (Gruffat et al, 1992) and finally 
by reduction in hormone synthesis (Gruffat et al, 1992). These processes are 
transient in the presence of moderate doses ( 1  //mol/1 - 1 0  pm ol/l) of iodine and in 
normal subjects usually only last for several days. B reak-through from  this 
mechanism in patients is usually due to a protective mechanism reducing the amount 
of iodine entering the cell. Therefore, there is no longer an excess of intracellular 
iodine and the iodination can return to the normal rate (McDougall 1992). Excess 
inorganic iodine (I mmol/1  and above) has a direct acute toxic effect on thyroid 
follicular cells, inducing a necrosis of the cells followed by deletion or apoptosis, a 
physiological cell death (Many et al, 1992).
If the thyroid is under negative regulation when iodine concentrations are 
nonnal, these findings could explain the increased growth seen in endemic goitre 
caused by iodine deficiency. On the other hand, autoimmune thyroid diseases are 
more common among inhabitants of south east Asian countries who eat large 
quantities of sea food, a rich source of inorganic iodine. The amount of iodine in the 
diet varies in western countries, but there are other sources of iodine such as 
medications and antiseptics which suddenly provide many orders of magnitude of 
iodine more than is required for normal function. The development of thyroid 
autoimmune disease among people with high iodine intake is more common (Harach 
et al, 1985; Boukis et al, 1983; W eetman, 1991), consistent with the idea that 
fluctuation in iodine supply causing episodes of thyroid damage may initiate thyroid 
autoimmunity.
3.4.8 Effect Of Thyroid Hormones On Iodine Uptake And Growth
The present study showed a dose dependent decrease in iodine uptake of cells 
stimulated with 2U/1 of TSH and a mixture of T 4  and T3  at concentrations which are 
higher than those circulating in normal subjects. This result confirmed previous 
reports (Akiguchi et al, 1992) with an extended dose range. Furthermore, the present 
work also showed for the first time apparent increases in iodine uptake of cells that 
had been deprived of TSH for 8  days, which became significant (18.9 % above 
control) at a dose of 1 //mol/I of T4  and 10 nmol/1 of T3 . These effects could form an 
autoregulatory loop in Graves' disease. Thyroid cells in this disease would be 
expected to accumulate large quantities of iodine under the continuous stimulation of 
TSH-receptor antibodies. The elevated concentrations of thyroid hormones could then 
limit further iodine uptake and prevent thyroid function from completely escaping 
from hormonal control.
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In the present study, there were an apparent increase in growth rate of cells 
that were stimulated with thyroid hormones, which became significant at the highest 
dose only (1 //mol/1 of T 4 , and 10 nmol/1 of T3 ). The increases at this concentration 
were 17.1 % for 5H and 9.9 % for 6 H medium. These results contrast with the 
results reported by Akiguchi et al, (1992) who detected an increase at a concentration 
o f 0.1 nmol/1 o f T3 . The difference could be in their methodology, because they 
m easured thym idine incorporation, while in the present study growth was 
assessed by protein measurement and by MTT assay. Furthermore, their medium did 
not contain any additives, whereas medium used for present work contained 
additional amino acids and 0.5 % FCS. Kamikubo and co-works (1992) showed that 
mRNA for the alpha thyroid hormone receptor was increased by withdrawal of TSH, 
insulin, and serum from the medium without affecting mRNA for the beta receptor. 
Addition of TSH reduced the numbers of receptors to its previous level after 24 h, 
while insulin acted at a slower rate. We found that the growth stimulation in the 
absence of TSH was higher than in its presence, which is consistent with a negative 
regulatory effect of TSH on receptors.
These results may indicate that part of the abnormal growth of cells in patients 
with toxic goitres may be caused by the elevation in thyroid hormones themselves, 
though TSH may modify the effects.
3 .4 .9  In su lin
Insulin is included in both 5H and 6 H media. To investigate the effect of IGF- 
1 on functions of thyroid follicular cells most investigators have omitted insulin from 
the culture medium, because they believed that insulin would cross-react with the type 
I receptor for IG F-l (Smith et al, 1986; Saji et al, 1987; Bachrach et al, 1988; Becks 
et al, 1992). This may be true, but it does not reflect the situation in vivo, because a 
basal concentration of insulin is present in the plasma of all healthy individuals, and 
omission of insulin from culture medium could lead to reduction of glucose entry 
along with other unknown consequences. Furthermore, it has been shown that the 
synthesis of prostaglandin by thyroid cells needs the presence of TSH and either 
insulin or IG F-l in the medium (Tahara et al, 1991). In this work, the effects of IGF- 
1 were studied both in the presence and absence of insulin.
The results indicate that both in the presence or the absence of TSH, the 
effects of insulin and IGF-l on iodine uptake of cells were apparently independent of 
each other, since the cells that were stimulated with a mixture of both hormones 
demonstrated an increase in iodine uptake that was approximately equal to the sum of 
the increases elicited by the individual hormones. This increase in iodine uptake was 
consistent with the results reported by Becks and co-workers (1992), while it
1 3 2
contrasts with the results reported by Pang and colleagues (1990 a), who measured 
the iodine uptake at steady state. Tramontane and co-workers (1988 a) detected a 
slight increase in cAMP production by cells stimulated with IG F-l, which could 
account for the small increases in iodine uptake detected in the current study. 
Moreover, both IG F-l and insulin can increase intra-cellular Ca^+ concentration 
(Takada et al, 1990). Influx of extracellular Ca^+ and amino acids (Takasu et al, 
1989; V illone et al, 1993) may lead to the alkalisation of cytoplasm ic pH or 
acidification of extra-cellular medium, both of which can contribute to an increase in 
iodine uptake.
The results obtained for growth in the presence of insulin and IGF-1 also 
seemed to be additive both in presence or the absence of TSH, and confirmed the 
report of Tramontano (1989). In the presence of TSH the growth responses produced 
by each hormone were greater than when TSH was absent. These results are in 
accordance with earlier reports (Isozaki et al, 1987; Saji et al, 1987; Bachrach et al, 
1988; Tramontano et al, 1988 a; Pang et al, 1990 a; Takahashi et al, 1990; Becks et 
al, 1992; Villone et al, 1993). Since the present results showed that the presence of 
insulin does not interfere with the effect of IG F-l, other experiments were carried out 
in the presence of the standard concentrations of insulin in the medium normally 
required for optimal growth of the cells.
3.4.10 In su lin  L ike  G ro w th  F a c to r-1
IG F-l stimulated both the iodine uptake and growth of cells when it was 
applied for 48 h in either 5H or 6 H medium. The minimum effective dose for iodine 
uptake was 50 //g/i, while that for growth was 10 jug/1. The highest dose tested was 
500 jigtX. Inclusion of bestatin and thiorphan, which are inhibitors of cell surface 
proteinases (Shipp and Look, 1993), did not alter the effects of IG F-l on either 
iodine uptake or growth, whereas treatment of cells before and during stimulation 
with thyroid hormones (1 //mol/1 of T 4 , and 10 nmol/1  of T3 ) reduced the iodine 
uptake, without affecting the increase in growth. This is the first time the effect of 
IGF-l has been reported in the presence of insulin or thyroid hormones.
The present data shows that the growth effect of IGF-l in the absence of TSH 
is greater than when TSH is present. These results agree with the results reported by 
Isozaki and co-workers (1987), who used a single dose of IG F-l (100 //g/1) and with 
the results reported by Tram ontano and colleagues (1988 b) who have shown that 
TSH down-regulates the receptors for IGF-l. On the other hand, they are in contrast 
with work that was carried out in the absence of insulin and showed that the effect of 
TSH and IG F-l together was much greater than the sum of individual responses 
(Tramontano et al, 1986 and 1988 a; Takahashi et al, 1990).
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IG F-l is mainly produced by liver (D elafontaine and Lou, 1993), but 
thyrocytes can also synthesise and secrete it (Dumont, 1991; and 1992). It acts as an 
autocrine factor for growth of thyroid cells or a paracrine factor to induce the growth 
of endothelial or fibroblast cells. Thyroid epithelial cells can produce IGF-I when 
stimulated with TSH or growth hormone (Bachrach et al, 1988), and IGF-II when 
stimulated with IG F-l (Dumont, 1991; and 1992), or TSH in the absence of IG F-l 
(Maciel et al, 1988). Recently it was shown that thyroid hormones could induce IGF- 
1 mRNA in an osteoblast cell line (MC3T3-E1) (Varga et al, 1994), and increase the 
synthesis of growth hormone, the inducer of IGF-l production in many cells (Nanto- 
Salonen 1993).
In Graves' disease, thyroid stim ulating antibodies, which act like TSH 
(Gafny et al, 1992; Leedman et al, 1992; Shoda et al, 1993), may induce the 
production of IGF-l by thyroid cells, or the excess of thyroid hormones may induce 
IGF-l production by other cells. The increase in IGF-l could partly contribute to the 
growth of the thyroid gland and development of goitre. On the other hand, continued 
stimulation of thyrocytes with TRAb and IG F-l will down-regulate the receptors for 
both TSH and IG F-l and prevent further growth of the gland. Furthermore, the 
presence of a high level of thyroid hormones will tend to suppress iodine uptake and 
prevent further formation of thyroid hormones in such patients.
3.4.11 T ran sfo rm in g  G ro w th  F ac to r-p
T ransform ing grow th fac to rs  have diverse effects on grow th and 
differentiation of the thyroid follicular cells of human and other species. T G F-a has a 
growth promoting effect on thyrocytes (Holting et al, 1995; Aral et al, 1995), while 
TGF-p has a negative effect. In the present study, TGF-p produced an increase in 
iodine uptake both in the presence or absence of TSH, while it reduced the growth 
induced by TSH dose dependently.
Previous studies have reported various results for the iodine uptake of 
thyrocytes when stimulated with TGF-p. A decrease in iodine uptake was reported 
for human (Taton et al, 1993) and porcine (Tsushima et al, 1988) thyroid cells. An 
increase was reported by Morris and co-workers (1988) in FRTL-5 cells, while Pang 
and colleagues (1992) showed a significant decrease.
Several factors may have caused such contrasting results. The concentration 
of TSH used may be one. The concentration of TSH used in the experiments of the 
group of Morris (1988) and the present study, who both found an increase in uptake, 
was higher ( 1 0  U/1 and 2 U/1 respectively), than the concentrations used by others 
who detected a decrease [Pang et al, (1992) 11.1 mU/1; Tsushima et al, (1988) 1 U/1; 
and Taton et al, (1993) 250 mU/1]. However, this is unlikely fully to explain the
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3.4.12 Fibroblast Growth Factor
. I#
results. In the pilot experiments carried out for the present work TGF-p caused a 
decrease of 6.2% in the presence of 10 U/1 of TSH when cells were grown in a
medium containing 5% serum, and stimulated with 10 //g/1 of TGF-P for 72 h.
A second factor could be the serum concentration in the medium, which could | |
provide the cells with both iodine and growth stimulators. This factor may be less
important for freshly isolated cells, which are exposed to serum in the culture medium
for a shorter time. ;In this study it was shown that TGF-P was a potent growth inhibitor for g
TSH-stimulated rat thyroid cells. Down-regulatory effects of TGF-P on growth of 
thyroid follicular cells have been previously reported for human (Taton et al, 1993), | |
porcine (Tsushima et al, 1988) and FRTL-5 cells (Morris et al, 1988; Pang et al,
1992), using different methodologies. It has also been shown that TGF-p is involved 
in induction of apoptosis in certain epithelial cells (Bursch et al, 1993). In the present 
study, neither reduction in growth nor cell death occurred, even in the presence of a 
high dose of TGF-p (100 //g/1), when cells were grown in 5H medium. TGF-p could 
only reduce the growth induced by other growth factors such as TSH, IG F -l, and 
FGF (Pang et al, 1992), and does not decrease the number of quiescent cells in short 
term culture. : I
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Basic FGF decreased the iodine influx, while it increased the growth of
FRTL-5 cells. These effects w ere independent of TSH. M inim um  effects were
detected at a concentration of 2.5 //g/1, while the m axim um  effects were at a 
concentration of 10 //g/1. The effects of concentrations greater than 10 mg/1 were gl
lower, though still significant.
The reduction in iodine influx of the cells reported in this study confirmed a 
previous report (Isozaki et al, 1992) for the FRTL-5 cell line. Similar results were 
also obtained by other groups in porcine (Emoto et al, 1991) or sheep (Hill et al, ■iîl
1994) thyroid cells. A wider range of concentrations was used in this study, showing 
that doses above 1 0  //g /1  are less effective.
Basic FGF increased the growth of the cells. In the present study, growth of 
the cells was measured as the protein content of the cells. The present results are also 
in agreement with previous reports for FRTL-5 cells (Black et al, 1990; Isozaki et al,
1992) and other thyroid cells, such as porcine (Emoto et al, 1991), sheep (Hill et al,
1994), or human (Taylor et al, 1993) thyroid cells.
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3.4.13 Endothelin-1
Immunoreactive ET-1 or expression of mRNA of preproendothelin-1 has 
been detected in a wide variety of tissues including human (Tseng et al, 1993), rat 
(Colin et al, 1992; and 1994) and porcine (Colin et al, 1992; Isozaki et al, 1993) 
thyroid follicular cells, though it is predominately produced in endothelial cells and 
used locally in an autocrine or paracrine manner (Haynes and W ebb, 1993). Receptor 
for ET has been detected in human thyroid cells (Jackson et al, 1992; Tseng et al,
1993), and there is indirect evidence that at least one form of receptor is present on 
the surface of thyroid cells (Isozaki et al, 1993; Miyakawa et al, 1992).
In the presence of TSH (2U/1), 50 and 100 nmol/1 of endothelin-1 increased 
iodine influx, but it had no effect in the absence of TSH. This result contrasts with 
the work of Tsushima and co-workers (1994) who detected an inhibition of the iodine 
uptake induced by TSH when they stimulated porcine thyrocytes with doses as low 
as 100 pmol/1. The difference could be due to the species difference or to the 
differences between cell line and primary cultures.
ET-1 at a dose of 25 nmol/1 significantly increased the growth rate of cells, 
but only if they were stimulated with TSH. The effect plateaued above this. These 
results correspond with the results obtained by Eguchi and co-workers (1993) who 
detected an increase in growth of human thyrocytes by measuring ^H thymidine 
incorporation into DNA as well as by cell count assessed by trypan blue, but not with 
the results of M iyakawa’ group (1992) on FRTL-5 cells. They showed that ET-1 
alone increased c-fos mRNA expression without affecting growth, w hile in the 
presence of TSH or IGF it caused a decrease or an increase in the growth of cells 
respectively. The difference might be due to the concentration of TSH used, since the 
concentration of TSH in the present study was 2 U/1, while M iyakawa’ group used 
10 mU/1 TSH. It is also surprising that the combination of ET with IG F-l and TSH 
should give opposite effects, since all three act through the inositol phosphate/calcium 
pathway, causing increases in c-fos and c-jun (Kennedy et al, 1993; Corvilain et al, 
1994; Takazawa et al, 1995).
3.4.14 Interleukin-ip
Interleukin-1 is synthesised and secreted by many cells including monocytes, 
macrophages, B cells, dendritic cells (W eetman, 1991; Benjamini and Leskowitz, 
1992; Janeway and Travers, 1994), endothelial cells (Miyazaki et al, 1989; Asakawa 
et al, 1991 a; Rasmussen et al, 1993), and thyrocytes (Zheng et al, 1991; Nagataki 
and Eguchi, 1992; Zeki et al, 1993; W atson et al, 1994). The presence of so many 
possible sources of production within the gland suggest that this cytokine may
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influence the functions of thyrocytes in an autocrine or paracrine m anner during 
inflammatory diseases.
IL-1 had no effect on iodine uptake or growth in the absence of TSH. TSH- 
stimulated cells demonstrated a significant decrease in uptake at high doses, 5 to 20 
pg/1. There was a suggestion of an increase in uptake at a concentration of 1 //g/1, but 
this did not reach significance.
The current results are in agreement with those of Rasmussen and co-workers 
(1989), who found no change in the cAMP production of FRTL-5 cells stimulated 
with IL-1 in the absence of TSH. On the other hand, Pang and colleagues (1990 b) 
demonstrated a decrease in uptake in FRTL-5 cells, and Zeki and co-workers (1991) 
demonstrated an increase in cAMP production when cells were stimulated with IL-1. 
It is difficult to explain these differences, because variables such as the stimulation 
time and cell line were the same. The only clear differences in protocol were the 
concentration of serum in the medium and the duration of deprivation of cells of 
TSH. The studies of Rasmussen and Zeki both used 5 % serum in the medium and 
four days of deprivation, while Pang used medium containing 0.1% serum and 0,5 % 
albumin and 24 h deprivation. In the present study, the medium used contained 0.5 % 
serum and additional amino acids, while cells were deprived of TSH for 5 days. It is 
unclear whether any of these in vitro findings actually corresponds with the in vivo 
condition. There is evidence (Hermus et al, 1992; Van-Haasteren et al, 1994) 
indicates that continuous infusion of rats with IL-p for one week decreased the 
plasma concentration of TSH and thyroid hormones. These results indicate that the 
finding of no effect or a decrease in iodine uptake is more likely to reflect the in vivo 
situation than a stimulation of activity.
The decrease in iodine uptake observed in TSH-stimulated cells is m ore 
consistently in agreement with results obtained for human (Sato et al, 1990), porcine 
(Westermark et al, 1990; Nolte et ai, 1994), and FRTL-5 cells (Pang et al, 1990 b). 
The tendency towards an increase that occurred at a concentration of 1 //g/1 was also 
found by Rasmussen and co-workers (1994). This shows that IL-1 released by 
infiltrating cells or by cells within the thyroid could suppress the function of thyroid 
epithelial cells in inflam m atory diseases, possibly contributing to the dam age 
occurring in autoimmune thyroiditis or sub-acute thyroiditis.
In the present study, it was found that IL-1 (3 did not affect the growth of cells 
either in the presence or the absence of TSH. These results agree with the results 
obtained by Nolte and co-workers (1994) in porcine thyroid cells. However, other 
workers have shown an increase in the growth of FRTL-5 cells stimulated in 5H 
medium (Pang et al, 1990 b; Zeki et al, 1991), and a decrease in growth of cells in 
6 H medium (Pang et al, 1990 b; Zeki et al, 1991; Rasmussen et al, 1989; and 1990). 
In these studies, growth was measured by ^H thymidine incorporation into DNA.
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.This method is more sensitive than protein measurement, but is indirect and subject to 
interference from factors such as DNA repair synthesis which could be taking place 
within the cells. Details of experimental protocols were also variable between the 
various groups.
3.4.15 L ip o p o ly sacch a rid e  (LPS)
LPS is a major constituent of the cell wall of gram negative bacteria that can 
elicit a wide range of immune responses, including stimulation of release of cytokine 
such as IL-1 from macrophages. In the present study, stimulation of thyroid follicular 
cells with LPS increased iodine uptake at a low dose (100 //g/1 in 6 H medium), while 
it decreased iodine uptake at concentrations above 2.5 mg/1 (in 5H medium), or 7 .5  
mg/1 (in 6 H medium). Furthermore, LPS increased the growth of cells in 6 H medium 
at doses above 2.5 mg/1. The increases were dose dependent.
The pattern of decreases in iodine uptake that occurred in 6 H m edium  
resemble the results obtained for IL-1, while the decreases seen in 5H medium did 
' not. Moreover, the LPS produced a dose dependent increase in the growth of ceils 
that did not occur with IL-1. These findings indicate that the changes in the 
proliferation and iodine influx are caused by LPS directly and not by an autocrine 
action of IL-1 that may be induced by LPS. This suggestion is supported by a recent 
study carried out by Van-Der-Poll and co-workers (1995). They have shown that the 
injection of endotoxin into humans was associated with significant decreases in the 
plasma concentrations of T4 , free T4 , T3 , TSH and a rise in reverse T3 . They also 
showed that these changes are independent of IL-1.
This is the first report that shows effects of LPS on the proliferation and 
iodine influx of thyroid epithelial cells. The reduction in iodine influx and increase in 
growth may contribute to the in vivo changes (reduction in thyroid hormones with no 
change in TSH concentration) that occur in patients suffering from the euthyroid sick 
syndrome.
3 .4.16 In te r le u k in -4
In the present study, stimulation of the FRTL-5 cells with various doses of
IL-4 (0.5 to 20 //g/1) did not affect iodine influx, while it caused a dose dependent 
decrease in the growth of cells induced by TSH.
During the development of autoimmune thyroid diseases, im mune cells 
migrate into the thyroid gland, so it is possible that IL-4 may be produced in the gland 
by TH2 helper T cells.
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Inhibitory effects of IL-4 on m egakaryocytes (Sonoda et al, 1993), 
myeloblasticleukaemic cell lines (Imai et al, 1991), or growth of monocytes (Dokter 
et al, 1993) induced by LPS have been reported previously. Although there are 
reports (Lowenthal et al, 1988; Idzerda et al, 1990; Beckmann et al, 1992) that 
indicate that epithelial cells do have receptor for IL-4, there is no previous report to 
show the effect of this cytokine on proliferation of non-hematopoietic cells. These 
results may indicate that high concentrations of IL-4 may down-regulate the growth 
of thyroid follicular cells in patients with hypothyroidism and high concentrations of 
TSH.
3.4.17 In te r le u k în - 6
There are many recent reports (Stouthard et al, 1994; Hashimoto et al, 1994; 
Bartalena et al, 1994 a, b and c; Bartalena et al, 1995) indicating that elevated IL - 6  
may be responsible for the alterations in thyroid function in patients with non- 
thyroidal illness. Rats injected with rIL - 6  for different periods developed a low serum 
T4  and Tg (Bartalena et al, 1994 c; Van-Haasteren et al, 1994). A reduction of TSH  
was reported by Bartalena et al (1994 c), and Van-Haasteren et al (1994) after a 
week, though without detectable changes in mRNA. These in vivo findings m ay 
explain the reduction of thyroid hormones in patients with non-thyroidal illness, but 
are insufficient to show a direct action of cytokine on thyroid follicular cells.
In the present study, it was found that stimulation of cells that were deprived 
of TSH with IL - 6  increased iodine influx at a concentration of 20 //g/1 (17.0% above 
control). Furthermore, the iodine influx increased significantly at doses above 10 //g/1 
when the cells were stimulated in 6 H medium, Tominaga and co-workers (1991) 
found that IL - 6  inhibited thyroid peroxidase gene expression induced by TSH (5U/1) 
in human thyrocytes. This inhibition was dose dependent. These findings result in a 
pattern of increased iodine uptake and reduced thyroid hormone fonnation which has 
resemblances to the W olff-Chaikoff effect, the suppression of thyroid horm one 
release by excessive iodine. They are also consistent with the involvement o f IL - 6  in 
the suppression of thyroid hormone synthesis in non-thyroidal illness or subacute 
thyroiditis. IL - 6  could be produced by the thyroid cells in an autocrine manner 
(Kennedy et al, 1992; Zheng et al, 1991; W atson et al, 1994), by other cell types 
within the gland or could arise from increases in the serum concentration.
The growth of thyroid follicular cells was also slightly effected by IL-6 . IL - 6  
increased the growth rate o f the cells in 5H medium, but only at the highest 
concentration tested. In contrast, Nishiyama and co-workers (1993) have shown a 
dose dependent increase in the growth of FRTL-5 cells that were stimulated with 
TSH (10 mU/1) and IL-6 . The difference between the present results and the one
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obtained by this group may be explained by the medium used by this group, which 
did not include the standard 5 hormone supplement or serum, and the very low 
concentration of TSH which was used.
3.4.18 Interferon-y
Interferon-Y (INF-y) is synthesised and secreted by activated CD4+ helper 
cells and CD8+ cytotoxic cells (Nagataki and Eguchi, 1992), During the development 
of thyroid autoimmunity, these cells migrate into the thyroid gland. The local release 
of INF-y contributes to morphological changes in thyroid follicular cells that include 
production of class 1 and 2 of MHC on the surface of cells (Toda et al, 1992; 
Chiovato et al, 1994; Eguchi et al, 1995). Additionally, INF-y also inhibits TSH  
induced morphological changes such as elongation of microvilli and appearance of 
pseudopods in human as well as animal thyrocytes (Asakawa et al, 1990; and 1991b; 
Kung et al, 1992).
In the present study, it was found that stimulation of FRTL-5 cells with doses 
above 50 piglX (5H) or 10 //g/1 (6H) of INF-y increases the iodine influx. The 
increases detected in 5H medium were apparently dose dependent, while in the 6H 
medium (2U/I of TSH) the increases detected for doses of 10, 50, and 100 jigH were 
not significantly different for each other. On the other hand, stimulation of the cells In 
5H medium did not affect the growth at any concentration, while it decreased the 
growth induced by TSH at all concentrations (1-1000 piglX). These decreases were 
also dose dependent.
The results obtained for the iodine uptake in this study correspond with 
previous results obtained for the FRTL-5 (Misaki et al, 1988; Zakarija and Mckenzie 
1989 b) while they oppose the results obtained for human thyroid cells (Kraiem et al, 
1990; Sato et al, 1990). Furthermore, the decrease obtained for the growth in present 
study corresponds with the previous reports for the FRTL-5 cell line (Misaki et al, 
1988; Zakarija et al, 1989 b) as well as for human thyroid follicular cells (Huber and 
Davies, 1990; Kraiem et al, 1990; Yip et al, 1995).
The opposite results for iodine uptake in human and rat may be due to species 
differences or to the fact that human cells are usually isolated from glands of patients 
who have already been treated with drugs affecting the thyroid.
INF-y suppresses other thyroid functions like TSH  induced thyroid 
peroxidase synthesis (Asakawa et al, 1992 a; Chiovato et al, 1994; Tang et al, 1995) 
and thyroglobulin production (Misaki et al, 1988; Graves et al, 1989; Huber and 
Davies, 1990; Kung and Lau, 1990; and 1992; Graves and Davies, 1993; Rasmussen 
et al, 1994; Tang et al, 1995) in both human and rat, leading to the reduction of 
thyroid hormone synthesis (Kraiem et al, 1990). In a similar way to IL-6, the action I
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of INF-y on iodine uptake of the thyroid ceils could be compared to the W olff- 
Chaikoff effect. The increase in the intracellular concentration of iodine may lead to 
depression of thyroid peroxidase, thyroglobulin synthesis, and thyroid hormones 
production.
3.4.19 Pituitary Adenylate Cyclase Activating Polypeptide
Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) is a novel 
hypothalamic peptide that is widely distributed in neurones (Portbury et al, 1995), but 
there are no reports of its presence in the thyroid gland. On the other hand, both types 
of PACAP receptors were detected on the surface of rat medullary carcinoma of the 
thyroid cell line 6/23 (Vertongen et al, 1994). Furthermore, there is a report (Chen et 
al, 1993) indicating that both PA CAP-27 and PACAP-38 increased cAMP production 
by porcine thyroid cells. In the present study in the absence of TSH, stimulation of 
the FRTL-5 with PACAP-27 (1-500 nmol/1) did not affect the iodine influx or the 
growth of cells; whereas in the presence of 2U/1 of TSH, stimulation of the cells with 
PA CAP-27 did increase the iodine influx without affecting the growth. This data is 
the first report that shows a direct effect of PACAP on iodine influx of the FRTL-5 
cell line.
Two different receptors for PACAP has been identified (Arimura 1992; 
Joumot et al, 1994). The type I receptor predominates in the central nervous system, 
while type II receptors are distributed in other organs including liver, lung, digestive 
tract, prostate gland, and testis (Arimura 1992: Joumot et al, 1994). The interaction 
of PACAP with the type I receptor increases intracellular cAMP and phospholipase 
C, while the type II receptor causes increases of only cAMP (Kononen et al, 1994). 
Since the growth o f FRTL-5 cells is stim ulated through activation o f the 
phosphatidylinositol-Ca2+ pathway (Dumont et al, 1991; Corvilain et al, 1994; 
Takazawa et al, 1995), the absence of growth in the present study favours the 
presence of type II receptors. This would be consistent with the results of Chen and 
co-workers (1993) who detected an increase in cAMP of porcine thyroid follicular 
cells, or increase in the senim T4  after injection of rat with PACAP.
3.4.20 Neuropeptide Y
Adrenergic nerve fibres containing Neuropeptide Y (NPY) have been detected 
in the thyroid gland of several mammals, including man (Grunditz et al, 1984; Ahrén, 
1986 a; and 1991). These fibres occur around blood vessels and follicles in the gland
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(Grunditz et al, 1984), and T 4  can induce the production and release of NPY from 
them (Jones et al, 1994).
In the present study, stimulation of cells with NPY produced an increase in 
iodine influx without affecting growth. The increases in iodine influx were also TSH 
independent. The 10 ± 4 % increase in iodine influx detected at a concentration o f 500 
nmol/1  was consistently found in repeated experiments.
These minor increases in the iodine influx suggest that this neuropeptide is not 
expressly involved in thyroid functions, and local release of this neuropeptide may 
regulate the blood flow of the thyroid as observed by Michalkiewicz and colleagues
(1993).
3.4.21 V asoactive  In te s tin a l P ep tid e
Vasoactive intestinal peptide (VIP) was the first neuropeptide demonstrated in 
thyroid gland (Ahrén, 1986 a). The VIP-containing nerves were shown to exist 
around and close to the follicular cells, and subsequent experiments with denervation 
and retrograde tracing have shown that they are intrinsic, originating in a thyroid 
ganglion (Ahrén, 1991). Apart from the well-described cross reaction with PACAP 
type I and II receptors, VIP has two specific receptors, named VIPi and VIP2  (Usdin 
et al, 1994; Lutz et al, 1993). These receptors are present in liver, lung, and intestine 
as well as in several regions of the brain like cerebral cortex and hippocampus (Lutz 
et al, 1993), The interaction of VIP with its receptors stimulated cAMP production 
(Lutz et al, 1993; Sreedharan et al, 1993; Usdin 1994; Fatatis et al, 1994). It has also 
been shown that VIP increases intracellular calcium (Spessert, 1993; Murthy et al, 
1993; Fatatis et al, 1994).
In the present study, VIP increased the iodine influx of cells that w ere 
deprived of TSH for 5 days, at concentrations of 500 and 1000 nmol/1. In the 
presence of TSH, VIP increased the iodine influx at concentrations from 10 nmol/1  to 
2 0 0 0  nmol/1 , but the increases detected at concentrations of 1 0 0 0  and 2 0 0 0  nmol/1  
were significantly lower than the value obtained for 500 nmol/1, These results may be 
related to the increase in the intracellular concentration of cAM P of hum an 
(Toccafondi et al, 1984; Siperstein et al, 1988) or mouse thyrocytes (Ahrén, 1986 a; 
and 1991) caused by VIP. Ealey and co-workers (1985) also showed that stimulation 
of guinea-pig thyroid section with VIP increases p-naphthylamidase activity in the 
thyroid cells. Toccafondi and colleagues (1984) have shown that stim ulation of 
human thyroid cells with VIP increases the production of T 4 . On the other hand, 
Jones and colleagues (1994) have shown that intrathyroid release of VIP is inversely 
correlated with the serum concentration of T4 . In vivo, M ichalkiewicz and co­
workers (1994) did not detect any changes in blood flow or production of thyroid
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hormone after immunisation of rats against VIP. This difference may be due to an 
insufficient dose of anti-VIP serum used by this group or may show that the influence 
of VIP is minor in vivo.
Stimulation of cells that were deprived of TSH for 5 days with VIP did not 
affect their growth. On the other hand, stimulation of cells in the 6 H medium (2U/1 of 
TSH) with low doses of VIP (10 and 50 nmol/1) increased growth, whereas the doses 
of 100 to KXX) nmol/1 did not alter it. Furthermore, growth of the cells decreased at a 
concentration of 2000 nmol/1. These data correspond with the results obtained by 
Karbownik' group (1994 and 1995) who used rat thyroid lobes, but used different 
methodology. The growth of thyroid cells is controlled through the Ca^+/protein 
kinase C pathway (Dumont et al, 1991; Corvilain et al, 1994; Takazawa et al, 1995), 
which is consistent with the known actions of VIP on calcium transport (Spessert 
1993; M urthy et al, 1993; Fatatis et al, 1994). All these findings suggest that 
intrathyroidal VIP nerves have a stimulatory function on thyroid hormone secretion 
and growth, because the intrathyroidal concentration of VIP may never reach 2 /rniol/I 
which was associated with a decrease in growth in vitro. Local release of VIP could 
also contribute to the stimulation of thyroid function pathologically in the presence of 
TSH or thyroid stimulating antibodies.
3.4.22 Neuromedin U-25
Neuromedin U (NmU), a peptide originally isolated from porcine spinal cord 
(Lo et ai, 1992), and has been found to have a widespread distribution extending 
throughout the mammalian central nervous system, or in the gastrointestinal tract, 
particularly in the ileum, genitourinary tract, hypothalamus, spinal cord, thyroid, and 
the endocrine cells of pituitary gland (Bockman et al, 1989; Domin 1990; Lo et al, 
1992).
A large number of regulatory peptides initially identified in the brain and gut 
have subsequently been localised in the thyroid gland where they have been proposed 
to act as local transmitters or paracrine regulators. In the present study, stimulation of 
the FRTL-5 in 5H or 6 H medium with different doses of NmU-25 (5 to 1000 nmol/1) 
did not affect the iodine influx or the growth of cells.
3.4.23 Tachykinins
Tachykinins or neurokinins comprise a family of closely related peptides that 
participate in the regulation of diverse biological processes. The tachykinin peptides 
substance P, neurokinin-A, neurokinin-A (3-10), neuropeptide K, and neuropeptide y 
are produced from a single preprotachykinin gene as a result of differential RNA
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splicing and posttranslational processing. Another tachykinin, neurokinin B, is 
produced from a separate preprotachykinin gene (Krause et al, 1989; Helke et al, 
1990; Regoli and Nantel, 1991; Mussap et al, 1993; Maggi et al, 1993).
Substance P and neurokinins were found to be present in both the central 
nervous system and in peripheral organs (Mussap et al, 1993) including thyroid gland 
(Ahrén, 1991). Neurones are the m ajor source of tachykinins both in the central 
nervous system and in peripheral organs, but tachykinin-like immunoreactivity has 
also been found in other cell types, such as certain endocrine cells including the 
medullary thyroid carcinom a cell line 6/23 (Crem ins et al, 1992), principal 
parenchyma] cells in the carotid body, chromaffin cells in the adrenal gland, cells of 
the anterior pituitary, eosinophils, cells in pig skin, and vascular endothelial cells 
(Maggi et al, 1993).
Substance P and other members of the tachykinin family produce their actions 
through interaction with one (or more) of three receptors, which are known as 
neurokinin or NK receptors (Krause et al, 1989; Helke et al, 1990; Regoli and 
Nantel, 1991; Mussap et al, 1993; Maggi et al, 1993). Since there are three receptors, 
and cross-reactivity of members of the tachykinin family with more than one receptor 
has been detected, it is necessary to use different specific agonists to identify the 
presence of each receptor. [Sar^, Met(0 2 )  ^^-Substance P (S M O -S P ) is a specific 
agonist for the N K l receptor, a-N eurokinin Fragment 4-10 (N K  4-10) is a specific 
agonist for the NK2 receptor, and succinyl-[Asp^, N-Me-Phe^]-Substance P (S -S P )  
is a specific agonist for the NK3 receptor, although they all do cross-react with other 
receptors with lower affinity (Maggi et al, 1993; Mussap et al, 1993).
Substance P (Ahrén et al, 1983) and neurokinin-A (Grunditz et al, 1987) have 
been detected in the thyroid gland when assessed by immunoreactivity. It is also 
reported that in the dog substance-P stimulated thyroid hormone secretion, whereas in 
the mouse it had no effect (Ahrén, 1991). Results of various experiments indicate that 
N K l, NK2 and NK3 receptors are present in the central nervous system, but the 
number of NK2 receptors is less than that of the other two (Maggi et al, 1993). All 
three receptors also have been detected in peripheral tissues with NK2 dominating the 
other two (Helke et al, 1990; Maggi et al, 1993).
In this study, stim ulation of the FRTL-5 cells with different doses of 
substance P in the absence of TSH increased the iodine influx at concentrations of 
100 and 250 nmol/l, without affecting growth. When this experiment was repeated 
using specific agonists for each receptor as stimulators, the same pattern was 
obtained. These data indicate that any member of the tachykinin family can increase 
the iodine influx of this cell line at concentrations ranging between 100 to 250 nmol/l, 
and it is possible that all three receptors are present on the surface of this cell line.
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However, it is not clear whether the concentrations of any of the peptides in vivo 
reach those required to show biological effects.
The increase in the iodine influx may lead to an increase in the production of 
thyroid hormones, as detected in the dog (Ahrén, 1991). Additionally, among the 
patients with Hashimoto's disease, the reduced concentration of T 4  may increase the 
local release of substance P as it could do in the anterior pituitary gland (Jones et al, 
1994). This increase would lead to an increase in the iodine influx, followed by an 
increase in the production of thyroid hormones. Furthermore, the present study also 
indicates that local release of other member of the tachykinin family (neurokinin A, 
neuropeptide K, and neuropeptide y or neurokinin-B) could also increase the iodine 
influx or increase the production of thyroid hormones.
Stimulation of the cells in 6 H medium (2U/1 of TSH) with substance P caused 
increases in the iodine influx, without affecting growth. The increases in iodine influx 
occurred at concentrations ranging from 1 0 0  to 2000 nmol/l. Stimulation with SMO- 
SP caused a bell-shaped response-curve, with increases detected at concentrations 
ranging from 250 to 1000 nmol/l, while there was no change in the iodine influx of 
the cells stimulated with 2 //mol/1. Furthermore, there was an apparent increase in the 
growth of the cells. On the other hand, stimulation of the cells with a-neurokinin 
(N K  4-10), the specific agonist for the NK2 receptor, caused increases at all 
concentrations ranging from 10 to 2000 nmol/l, without affecting the growth. Finally, 
stimulation of cells with the NK3 receptor agonist succinyl-[Asp^, N-Me-Phe^]- 
Substance P (S-SP) produced increases at concentrations ranging from 10 to 500 
nmol/l, and no effect at concentrations above 500 nmol/l. Beside the increases in the 
iodine influx, S-SP also increased the growth of cells at concentrations ranging from 
250 to 1000 nmol/l.
The increases in the iodine influxes obtained for the low doses of NK 4-10 
and S-SP suggest strongly that NK2 and NK3 receptors are present on the surface of 
the FRTL-5 cells, and local releases of neuropeptide y, neurokinin-A, neuropeptide 
K, or neurokinin-B may increase the synthesis of thyroid hormones. On the other 
hand, the N K l receptor may not be present, because neither substance P nor SMO- 
SP could increase the iodine influx at low concentration (10-100 nmol/l), and the 
increases in the iodine influxes obtained at higher concentrations could be caused by 
the cross-reaction of these peptides with other receptors (NK2 and NK3). O ther 
experiments carried out in the present study showed that stimulation of the cells with 
a mixture of three agonists did not increase iodine uptake to a higher level than 
stimulation with two, though this effect could also be caused by desensitisation of the 
receptors or by the concentrations reaching the descending portion of the dose- 
response curve.
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3.4.24 Noradrenaline
The presence of adrenergic nerves in the thyroid gland has been known for 
more than 20 years (Ahrén, 1986 b). Electron auto-radiography has demonstrated, 
both in human and rodent tissue, that adrenergic nerve terminals occur in close 
connection with the follicular cells (Ahrén, 1991). A species variation exists with 
regard to the abundance of adrenergic innervation of the thyroid gland: human, mice, 
and sheep have a rich supply of adrenergic nerves within the thyroid in contrast to 
rats, dogs, and pig; and it seems that the density of adrenergic terminals in thyroid 
gland declines with age (Ahrén, 1986 b).
Noradrenaline is the classical adrenergic neurotransm itter, and the a l  
adrenergic receptor mediates its action. There is evidence that both synthesis and 
appearance of the a l  adrenergic receptor on the surface of thyrocytes are regulated by 
TSH through a cAMP/protein kinase-A dependent mechanism (Bone et al, 1986 a; 
Corda et al, 1 ^ 9 ; Meucci et al, 1994).
In the present study, it was found that thyroid follicular cells that were 
deprived of TSH for five days did not respond to noradrenaline (50 nmol/l to 20 
//mol/1  of ± Arterenol), although there was a tendency to an increase in iodine influx. 
This may indicate that the number of a  1 adrenergic receptors on the cell membranes 
was reduced by deprivation of TSH. On the other hand, stimulation of the cells in the 
presence of TSH increased iodine influx, without affecting the growth. These 
increases were dose dependent.
There are reports indicating that noradrenaline increases the synthesis of 
thyroid hormones by increasing iodine influx (M arcocci et al, 1987) and its 
incorporation into thyroglobulin (Rani and Field, 1988). On the other hand, there are 
contrasting reports that show noradrenaline does not change (Taguchi and Field, 
1988; Oda et al, 1993), or reduces (Cochaux et al, 1982; Ahrén et al, 1986 b) the 
intracellular concentration of cAMP induced by TSH and the production of thyroid 
hormones.
The changes of iodine influx caused by noradrenaline could be caused by the 
activation of phospholipase A2 (Marcocci et al, 1987) consequent to increases in the 
free cytosolic concentration of calcium and inositol phosphates (Philp and Grollman, 
1 ^ 6 ;  Marcocci et al, 1987; Grollman et al, 1989; Bizzarri and Corda, 1994; Meucci 
et al, 1993; 1994; and 1995). The increase in the intracellular concentration of calcium 
may also increase the intracellular pH and induce the influx of iodine through iodine 
channel.
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3.4.25 S-Nitroso-N-Acetyl Penicillam ine
S-Nitroso-N-acetyl penicillamine (SNAP) is a compound that slowly releases 
nitric oxide (NO) into solution. In the present study, this compound was used to 
investigate the effect of NO on the iodine influx and growth of FRTL-5 cells. The 
iodine influx of cells that were deprived of TSH for five days decreased after 
incubation for 48 h in medium containing 5 or 10 //mol/1 of SNAP, while there were 
increases in growth. On the other hand, in the presence of TSH, iodine influx 
decreased at a concentration of 2.5 //mol/1. At 5 //.mol/1 there was no change, and 
there was an increase at a concentration of 10 //mol/1. In the presence of TSH, growth 
of the cells was not affected by any concentration of SNAP.
These results are the first report that shows a direct effect of nitric oxide on 
the iodine influx and growth of thyroid follicular cells. An action of NO on thyroid 
follicular cells of humans (M illatt et al, 1993), and thyroid slices from  the dog 
(Esteves et al, 1992) has been shown indirectly  in the presence of sodium  
nitroprusside, which breaks down to NO and stim ulates cGM P production. 
However, stimulation of thyrocytes for 48 h with sodium nitroprusside had no effect 
on the release of Tg. Esteves and co-workers (1992) also showed that the increase in 
cGMP is caused by activation of the PIP2 /calcium cascade.
These reports show that NO can influence the intercellular signalling of 
thyroid follicular cells. The increases in the cytosolic concentrations of calcium, 
PIP2, and cGMP may lead to the decreases in the iodine influxes and increases in 
growth detected in the absence of TSH. The reasons for the biphasic response in the 
presence of TSH are not clear, and require further investigation.
One of the sources for local release of NO is the endothelial cell. Since the 
thyroid gland is extensively vascularised, NO released by these cells may influence 
the iodine uptake of the thyroid follicular cells. Additionally, the m acrophages 
infiltrating the gland in autoimmune thyroid diseases could be a second source of 
local release of NO. VIP is an inducer of NO synthesis in gastric muscle cells 
(Murthy et al, 1993), rat pinealocytes (Spessert, 1993) and many other cells such as 
smooth muscle (G rider et al, 1992), intestinal, sphincteric, visceral, corpora 
cavernosa, and cerebral vessels (Murthy et al, 1993). There is a possibility that the 
VIP released in the gland also induces the synthesis of NO by thyroid follicular cells.
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3.4.26 M ultiple Stimulators
3.4.26.1 Combination with Interleukin-1
Since IL-1 is an important cytokine released by antigen presenting cells after 
activation and during development of autoimmune diseases, this cytokine was used in 
combination with other stimulators.
The addition of IL-1 at a concentration of 1 //g/1 had little effect on other 
stimulators. At a concentration of 20 //g/l in the presence of TSH, the effects o f a 
mixture of IGF-l and IL-1 were approximately additive, IL-1 significantly reducing 
the effect of IG F-l. Similarly, IL-1 significantly decreased the growth effect of IGF- 
1, particularly in the presence of TSH.
IL-1 at 20 //g/1 also inhibited the increase in iodine uptake caused by INF-y. 
The effects of INF-y and IL-1 in the presence of TSH were additive. IL-1 itself had 
no effect on growth rate, and did not modify the inhibitory effect of INF-y.
IL-1 decreased the effects of NPY, VIP and noradrenaline on iodine uptake. 
Only the lower concentration was tested in combination with the tachykinins, and this 
had no effect, as would be expected.
In general, therefore, the effects of IL-1 were inhibitory. This may have 
implications for the situation in autoimmune disease or inflammation, where there is 
evidence for the presence of IL-1 within the gland. The effects were greater in the 
presence of TSH, so IL-1 may act to limit the growth and activity of the thyroid in 
both Hashimoto's and Graves' diseases.
3 .4 .26.2  Combination with Noradrenaline
Noradrenaline is known to be present within the thyroid gland and is thought 
to be responsible for many of the symptoms of hyperthyroidism. It has also been 
shown to share neurones with other mediators such as NPY.
NA significantly increased the stimulatory effects of IG F-l, VIP and NPY on 
iodine uptake in the presence of TSH. Surprisingly, there were also growth- 
stimulatory effects of NA in the presence of VIP and NPY, even when the individual 
compounds had no effect. This implies that noradrenaline may be directly involved in 
the pathogenic m echanism s of hyperthyroidism , and not ju s t in causing the 
symptoms.
1 4 8
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3.4.27 Protease Inhibitors
The cell-suiface protease inhibitors bestatin and thiorphan had no effect on 
either unstimulated or TSH-stimulated iodine uptake or growth rate. They did, 
however, partially inhibit the stimulation of iodine uptake caused by TG F-p, 
endothelin, IL-6 , NPY, VIP and the tachykinins, particularly in the presence of TSH. 
This effect was surprising. In other systems, it has been generally assumed that the 
effect of the proteases is to degrade the peptides, and the inhibitors were added in 
order to protect them and potentiate their actions. From these results, it seems more 
likely that activation of iodine uptake itself involves the cleavage of a protein, 
possibly to activate the transporter or associated molecules, and that this process was 
inhibited by bestatin or thiorphan. Clearly, more work is required before the 
mechanism of action can be clarified.
There was also a stimulatory effect on growth, but this was seen only in the 
cases of IL - 6  and the tachykinins. This effect would correspond more closely to what 
might be expected if the proteases were involved in degradation of these particular 
peptides.
3.4.28 Thyroid Hormones
The addition of thyroid hormones to medium containing TSH considerably 
modified the activity of the stimulators. In most cases the hormones antagonised the 
action of the peptides. The stimulatory effects of IG F -l, TGF-P, endothelin-1, 
interferon-y, PACAP and VIP on iodine uptake were all reduced. In addition, thyroid 
hormones prevented the inhibitory effects of IL-1 and LPS. However, there was a 
large potentiation of the increase in iodine uptake caused by noradrenaline.
The actions on growth rate were similar. The stim ulatory effects of 
endothelin-1 and LPS were reduced, as were the inhibitory effects of TGF-|3, IL-4 
and interferon-y. The only exceptions were slight growth stimulatory effects in the 
presence of VIP and neuromedin-U.
These results call into question the role of growth factors and peptides in 
hyperthyroidism. Only FGF and the tachykinins were completely unaffected by 
thyroid hormones. The effects of the others were greatly reduced to an extent that 
they may be of little importance in vivo. In autoimmune hypothyroidism, however, 
the absence of thyroid hormones may allow the peptides to act fully and they may 
contribute to goitre formation under those circumstances.
The most striking finding was the increase in iodine uptake in the presence of 
noradrenaline. Coupled with the fact that noradrenaline increased the effect of IG F-l, 
NPY and VIP on iodine uptake and also caused growth-stimulatory effects, it seems
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that it is the single most important influence on the metabolism of thyroid cells in the 
hyperthyroid state.
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CHAPTER FOUR 
CONCLUSION
The initiating cause of autoimmune hyperthyroidism or Graves' disease is 
unknown. However, the result is an immune response involving macrophages, T and 
B lymphocytes, and their soluble products, leading to the development of goitre. 
Local release of cytokines by infiltrating immune cells, growth factors by thyrocytes 
or other cells in the gland, and neuropeptides released by nerves could influence the 
functions of the thyroid follicular cells.
The purpose of this study was to investigate the relationship between thyroid 
disease and cytokine production. Initially, the level of SÏL-2R was investigated in 
samples of serum collected from patients with Graves' disease before and after 
treatm ent. The study was extended by stimulating whole blood samples from 
untreated patients with Graves’ disease, to assess the production of sIL-2R and other 
cytokines in vitro, and the results were compared with those obtained from blood 
collected from healthy control subjects. Then, FRTL-5 rat thyroid epithelial cells were 
used as a model to investigate the effects of these cytokines and various other peptides 
that would be expected to be present in the thyroid and influence its activity. Finally, 
the effects of these bioactive peptides were investigated in the presence of TSH and 
thyroid hormones, that could resemble the in vivo circumstances of Graves' disease.
4.1 SOLUBLE IL-2 RECEPTOR AND CYTOKINE PRODUCTION IN 
GRAVES' DISEASE
The present study confirmed that there are high levels of sIL-2R in serum of 
patients with untreated Graves' disease. The reasons for this abnormality are not 
clear. Increases in serum sIL-2R have been previously ascribed to a general activation 
of the immune system. There have also been suggestions that the concentrations of 
thyroid hormones could directly affect its production, because release correlated with 
thyroxine use in patients with total thyroidectomy, and increases are also found in 
patients with non-immune thyrotoxicosis. The effect of thyroid hormones and anti- 
thyroid drugs (methimazole) were directly studied on preparations of blood cells. 
Effects were detected, though only in stimulated cells. The production of sIL-2R was 
increased by thyroid hormones and TSH, while that of IL-6 , TN F-a and INF-y was 
markedly reduced by both the hormones and methimazole. This gives some support 
to the suggestion that thyroid hormones and the drugs used in the treatment of thyroid
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disease can directly affect the production of sIL-2R and several cytokines from blood 
cells. This could imply an aberrant inflammatory response in both untreated and 
treated patients with thyroid disease.
The source of the sIL-2R could not be identified in this study, since the 
decision was taken to use unseparated blood cells to avoid possible artefacts caused 
by the procedures used to separate the cells. However, the fact that the cells 
responded to both LPS and PHA suggests that there are contributions from  
monocytes and lymphocytes, as would be expected from previous work.
The pattern of production of cytokines by whole blood of the patients' group 
was also different from that obtained for the control group. The abnormalities in the 
release of other cytokines did not appear to fit the hypothesis of separate sets of T H 1 
and TH2 cells. Both INF-y and IL-4 were released, though the amount of INF-y was 
much greater. PMA and Ca ionophore were much weaker stimuli than LPS and PHA, 
possibly because of direct effects on monocytes and release of stimulatory cytokines. 
Overall, the pattern suggested that there were both T H l and TH2 cells present. 
However, the amount of IL-4 released in patients was more than in controls, and the 
amount of INF-y was less. This may imply a degree of switching towards a TH2 
phenotype, but it is clearly not complete. The marked effect of varying the dilution of 
blood also suggests that care must be taken to avoid the effect of interfering 
substances in blood plasma.
Recent reports (Achiron et al, 1994; W olf et al, 1994; Yentis et al 1994) have 
also shown that elevated levels of immunoglobulin (IgG and IgA) could down- 
regulate the release of inflammatory cytokines. The presence of antibodies against 
TSH receptor, thyroglobulin or TPO among the patients with autoimmune thyroid 
disease could be one of the reasons for change in the pattern of cytokines production 
detected in the presence study.
Whether the abnormalities seen in blood cells reflect the activities of the cells 
in the thyroid itself is open to question. It is possible that blood may be depleted of 
certain populations of lymphocytes which are retained in the thyroid. However, it is 
known that there is an increased number of activated blood cells, in the blood of 
patients with G raves’ disease, so this is unlikely. It is not known whether this 
represents an epiphenomenon or is part of the pathogenesis of the disease. The facts 
that patients treated with IL-2 and INF-y tend to develop autoimmune phenomena 
w ould, however, tend to suggest that abnormalities in cytokine production are 
connected with the presence of disease.
Stimulation of whole blood of the reference group with a mixture of LPS and 
PHA, in presence of high concentrations of TSH, thyroid hormones, or methimazole 
significantly reduced the production of IL-6 , INF-y, and T N F -a. These findings 
indicate that the change in the pattern of cytokine production detected among the
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patients with Graves' disease could be the consequence of elevated thyroid hormones 
or TRAb, while among the patients with Hashimoto's disease, high levels of TSH 
could change the pattern of cytokine production. Since this is the first report that 
shows • r-c these compounds could influence the cytokines production, it is too early 
to reach a conclusion, and further experiments are necessary. It may suggest that the 
increase in the number of TH2 and decrease in the number of T H l or suppressor T 
cells reported previously could be due to the influence of elevated thyroid hormones 
or TRA b. In addition, these results also indicate that m ethim azole has an 
immunological effect, but do not show whether this effect is a direct effect on the 
synthesis of cytokines, or an indirect effect through induction of other cytokines. The 
answers to these questions need further investigation.
4.2 CARRIER PROTEINS FOR INORGANIC IODINE IN SERUM
Because of disagreements in the literature whether it is necessary to include 
protein in the uptake medium as a carrier for iodine or whether it is adequate to use 
carrier-free solution, it was decided to investigate whether there was a carrier for 
inorganic iodine in serum. In this study, it was shown that iodine bound to albumin 
immediately at 37'* C, and this association is dose dependent and saturable (figure 3.6 
and 3.7). Follow up experiments showed that more than 50 % of inorganic iodine 
was carried by pre-albumin and albumin, while the remainder was carried by other 
proteins especially lipoproteins.
Inclusion of albumin as a carrier for iodine decreased both the Kni and the 
Vjnax of iodine uptake of FRTL-5 cells. These results suggest that there is a carrier 
system for inorganic iodine in vivo, as is true for other trace elements. The thyroid 
gland has a reservoir of thyroid hormones in the form of colloid inside the follicles, 
and there are carrier proteins, including pre-albumin and albumin, that carry 15-30 % 
of thyroid hormones in the serum. Since the same proteins carry both iodine and 
thyroid hormones, the question arises is whether excess of inorganic iodine in the 
serum could compete with thyroid hormones, and release them from their binders. If 
so, an excess of iodine could change the normal pattern of cytokine production, and 
be an initial step in development o f autoimmune thyroid disease. The answer to this 
question needs further investigation, though there are reports (Harach et al, 1985; 
Boukis et al 1983; W eetman 1991) indicating that high iodine intake could lead to 
thyroid autoimmune diseases.
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4.3 THYROID HORMONES AND THYROID FUNCTION
In this study, it was shown that thyroid hormones also could control the 
function of thyroid follicular cells. The stim ulation of FRTL-5 cells w ith high 
concentrations of thyroid horm ones and TSH increased the growth of thyroid 
follicular cells, while it reduced the iodine influx. These effects could form an auto- 
regulatory loop in Graves' disease. Thyroid cells in this disease would be expected to 
accumulate large quantities of iodine under the continuous stim ulation of TSH- 
receptor antibodies. The elevated concentrations of thyroid hormones could then limit 
further iodine uptake and prevent thyroid function from completely escaping from 
hormonal control.
On the other hand, in the absence of TSH, stimulation of the cells with high 
concentration of thyroid hormones increased growth as well as iodine uptake. These 
results may indicate that part of the abnormal growth of cells in patients with toxic 
goitres may be caused by the elevation in thyroid hormones themselves, though TSH 
may modify the effects.
4.4 BIOACTIVE PEPTIDES AND THYROID FUNCTIONS
In this study, effect of some bioactive peptides on iodine uptake and growth 
of thyroid follicular cells were investigated. Some of these peptides could be 
synthesised and released by infiltrating immune cells, or cells in the gland, and act in 
a paracrine manner, while others such as IGF-1 and IL - 6  may be synthesised and 
released by the thyroid follicular cells themselves and act in an autocrine manner. In 
addition, the effects of these peptides were investigated in the presence of protease 
inhibitors to found out the presence of cell-surface proteases might affect the action of 
mediators. Finally, for the first time, the effects of these peptides on the thyroid 
follicular cells were investigated in conditions which resemble that found in Graves' 
disease (TSH and high concentration of thyroid hormones), to determine the effect of 
these peptides in such patients. The summary of the results obtained in this study is 
presented in table 4 .1.
The effects of IGF-1, TGF-(3, bFGF, IL -l, INF-y, and noradrenaline were 
mostly in agreement with previous reports, as was discussed in chapter three. The 
results obtained for the remaining stimulators are reported in this study for the first 
time. Most of the peptides did have some effect on the cells, though often weak.
The addition of thyroid hormones to medium containing TSH considerably 
modified the activity of the stimulators. In most cases the hormones antagonised the 
action of the peptides. The stim ulatory effects of IGF-1, TG F-p, endothelin-1, 
interferon-y, PACAP and VIP on iodine uptake were all reduced. In addition, thyroid
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Condition 5H 6 H 5H +P.I 6 H+P.I Graves' disease
Peptide I G I G I G I G I G
IGF-1 NE + + 4" NC NC NC NC NE +
TGF-P + NE + - NC NC - NC 4 NE
bFGF - + - 4 NC NC NC - 4
ET-1 NE + NE 4 NC NC , - NC NE NE
IL-l: high  dose NE NE - NE NC NC NC NC NE NE
IL-l: lo w  d ose NE NE NE NE NC NC NC NC 4 NE
IL-4 NE NE NE - NC NC NC NC NE NE
IL - 6 -f- + ■f NE NC 4 - 4 4 4
INF-Y + ' NE + - NC NC NC NC 4 *-
LPS: high  d o se - NE - 4 NC NC NC NC NE NE
LPS: lo w  d ose NE NE + NE NC NC NC NC NE NE
PACAP NE NE + NE NC NC NC NC 4 -
NPY 4- + NE NE NC NC - NC NE NE
VIP: high  d ose + NE + - NC NC - NC NE 4
VIP; lo w  d o se NE NE 4- 4 ND ND ND ND ND NID
N eurom edin NE NE NE NE NC NC NC NC NE 4
SP + NE + NE - NC - - 4 NE
SMO-SP + NE 4- 4 NC NC NC NC 4 4
NK + NE 4- NE NC NC 4 4 NE
S-SP + NE 4- 4 - NC - NC NE 4
NA NE NE 4- NE NC NC NC NC 4 NE
SNAP - + ± NE ND ND ND ND ND ND
Table 4.1; Effect of different bioactive peptides on iodine uptake (I) and growth (G) 
of FRTL-5 cells, in different experimental conditions. The media containing protease 
inhibitors (bestatin and thiorphan) are shown by P.L, while stim ulation with 6 H 
medium containing thyroid hormones is referred to as Graves' disease. NE stands for 
not affected, and ND means not determined. In the column dealing with the effect of 
protease inhibitors, the + or - sign shows significant increases or decrease 
respectively compared to controls w ithout protease inhibitors. NC indicates no 
changes compared with the corresponding response in the absence of protease 
inhibitor.
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hormones prevented the inhibitory effects of IL -1 and LPS. However, there was a 
large potentiation of the increase in iodine uptake caused by noradrenaline.
The actions on grow th rate w ere sim ilar. The stim ulatory effects of 
endothelin-1 and LPS were reduced, as were the inhibitory effects of TGF~p, IL-4 
and interferon-y. The only exceptions were slight growth stimulatory effects in the 
presence of VIP and neuromedin-U.
These results call into question the role of growth factors and peptides in 
autoim m une hyperthyroidism . Only FGF and the tachykinins were com pletely 
unaffected by thyroid hormones. The effects of the others were greatly reduced to an 
extent that they may be of little importance in vivo. In autoimmune hypothyroidism, 
however, the absence of thyroid hormones may allow the peptides to act fully and 
they may contribute to goitre formation under those circumstances.
The most striking finding was the increase in iodine uptake in the presence of 
noradrenaline. Coupled with the fact that noradrenaline increased the effect of IG F-1, 
NPY and VIP on iodine uptake and also caused growth-stimulatory effects, it seems 
that it is the single most important influence on the metabolism of thyroid cells in the 
hyperthyroid state.
The results obtained in this study may show that in Graves' disease, when the 
thyroid follicular cells are under continuous stim ulation by TRAb and high 
concentration of thyroid hormones, local release of TGF-p, IL - l,  IL-6 , INF-y, 
PACAP, noradrenaline, and tachykinins, or the presence of LPS could increase the 
iodine uptake of the cells, while bFGF could decrease the iodine uptake. The 
concentration of noradrenaline in the glands of these patients is another factor that can 
influence the outcome. Because most of these peptides could increase the iodine 
uptake, wliich may increase the intracellular concentration of this element, this may 
lead to inhibition of thyroid hormone synthesis through the Wolff-Chaikoff effect. On 
the other hand, noradrenaline not only increases the iodine uptake but also increases 
the efflux of iodine, that may lead to an increase in the production of thyroid 
hormones.
Goitre formation in Graves' disease could be the consequence of the local 
release of IGF-1, bFGF, IL-6 , VIP, neuromedin-U, and tachykinins, while down- 
regulation of growth could be the result of local release of INF-y and PACAP. There 
is a possibility that a down-regulatory effect could be produced by a combination of 
TGF-p and IL-4. This possibility could be a starting point for follow up experiments.
The cell-surface protease inhibitors bestatin and thiorphan had no effect on 
either unstimulated or TSH-stim ulated iodine uptake or growth rate. They did, 
however, partially inhibit the stim ulation of iodine uptake caused by TGF-(3, 
endothelin, IL-6 , NPY, VIP and the tachykinins, particularly in the presence of TSH. 
This effect was surprising. It seems more likely that activation of iodine uptake itself
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involves the cleavage of a protein, possibly to activate the transporter or associated 
molecules, and his process was inhibited by bestatin or thiorphan. Clearly, more 
work is required before the mechanism of action can be clarified.
There was also a stimulatory effect on growth, but this was seen only in the 
cases of IL - 6  and the tachykinins. This effect would correspond more closely to what 
might be expected if the proteases were involved in degradation of these particular 
peptides.
Since IL -l is an important cytokine released by antigen presenting cells after 
activation and during development of autoimmune diseases, this cytokine was used in 
combination with some of the stimulators. The results obtained indicated that the 
effects of IL -l were inhibitory. This may have implications for the situation in 
autoimmune disease or inflammation, where there is evidence for the presence of IL-l 
within the gland. The effects were greater in the presence of TSH, so IL -l may act to 
lim it the growth and activity  of the thyroid in both Hashim oto's and Graves' 
diseases.
Noradrenaline is known to be present within the thyroid gland and is thought 
to be responsible for many of the symptoms of hyperthyroidism. It has also been 
shown to share neurones with other mediators such as NPY.
NA significantly increased the stimulatory effects of IGF-1, VIP and NPY on 
iodine uptake in the presence of TSH. Surprisingly, there were also growth- 
stimulatory effects of NA in the presence of VIP and NPY, even when the individual 
compounds had no effect. This implies that noradrenaline is directly involved in the 
pathogenic mechanisms of hyperthyroidism, and not just in eliciting the symptoms.
These studies have shown that several peptides have direct effects on thyroid 
cells. Abnormalities have been shown in production of the same peptides in tliyroid 
disease. This gives strong support to the proposal that abnormalities in cytokine 
production are central to the abnormalities found in autoimmune disease. Much more 
work is needed in patients, however, to prove which of these peptides are important 
in vivo and what their role is in human disease.
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APPENDIX 1
LIST OF ABBREVIATIONS
4H: 4  hormone medium
5 H : 5 hormone medium
6 H  : 6  hormone medium
MSH ; Melanocyte stimul ating hormone
ACTH: Adrenocorticotropic hormone
AP A ; Ami nopeptidase A, also called B P-1 or 6C3
AP C : Antigen presenting cell
ATP ; Adenosine triphosphate
BCGF-1 : B cell growth factor-1, an older term used for IL-4
Bis : N,N'-methylene-bis-acrylamide
BSA: Bovine Serum Albumin
B S F -1 : B cell stimulatory factor-1, an older term used for IL-4
BSF-2: B cell stimulatory factor-2, an older term used for IL - 6
Ca: Calcium
C cells: Parafollicular cells
CD: Cluster of Differentiation
CD3 : T cell receptor complex
CD4: Surface protein characterising helper T cells
CD8  : Surface protein characterising cytotoxic T cells
CDIO: Neutral endopeptidase (NEP)
CD I I  : a  subunit of integrin LEA-1
CD 13: Aminopeptidase N (APN)
CD 18: Equivalent term for LEA-1 or CD 11a
CD 19 : Co-receptor for B cells that forms complex with CR2
CD21 : Receptor for complement component or CR2
CD25 : Soluble interleukin-2 receptor, and a  chain of IL-2 R
CD27 : Equivalent term for member of tumour necrosis growth factor super­
family on the surface of T cells 
CD28: Adhesion molecules, on the surface of T cells
CD40 : Equivalent term for member of tumour necrosis growth factor super­
family on the surface of B cells, and monocytes 
CD44 : Binds hyaluronic acid, mediates adhesion of leukocytes
CD45 : Equivalent term for leukocyte common antigen
CD50 : Adhesion molecules, equivalent term for ICAM-3
I
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CD54: Equivalent term for ICAM -1
CD69 : Activation inducer molecule on the surface of activated lymphocytes,
and monocytes
CD80: Adhesion molecules, on the surface of APC, equivalent term for B7-1
CD 8 6 : Adhesion molecules, equivalent term for B7-2
CD 102: Adhesion molecules, equivalent term for ICAM-2
CD118: Receptor for interferon a  and p
CD 119 : Receptor for interferon-y
CD 126 : One of the subunits of IL - 6  receptor
C D w  130: One of the subunits of IL - 6  receptor also called gp 130
cAMP: Cyclic adenosine monophosphate
CRP : C-reacti ve protein
CTC: Chicken serum-trypsin-col 1 agenase solution
DIT : Diiodotyrosine
DMSG: Dimethyl Sulfoxide
EDTA : Ethylene diamine-tetra-acetate
eIF2 : Eukary oti c protein synthesi s factor-2
ELISA: Enzyme linked immunosorbent assay
ET -1 : Endothelin-1
E T  a : Endothelin receptor
E T b : Endothelin receptor
Fc : Fragment of antibody without antigen sites
FCS : Foetal calf serum
FGF: Fibroblast growth factor
FRTL-5 : A line of normal differentiated Fisher rat thyroid cells
FSH: Follitrophin
GH: Growth hormone
GHRH: Growth hormone-releasing hormone
GM-CSF : Macrophage colony stimulating factor
GM P-140 : Granule membrane adhesion protein 140
HBSS : Hanks’ Balanced Salt Solution
H C G : Human chorionic gonadotrophin
HEPES: N-[2-Hydroxy ethyl] piperazine-N’-[2 -ethanesulfonic acid]
HLA : Human leukocyte antigen (equivalent term for animal MHC)
HSF: Hepatocyte stimulating factor, an older term used for IL - 6
la : Immune response associated proteins
IBMX: 3-isobutyl-methyl xanthine
IgD : One of the classes of immunoglobulin
IgE : One of the classes of immunoglobulin
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IgG: One of the classes of immunoglobulin
IgM : One of the classes of immunoglobulin
IGF - 1 : Insulin-like growth factor 1
IGF-II : Insulin-like growth factor 2
l i  : Invariant chain (associated with MHC II, in the endoplasmic
reticulum)
IL -la : Interleukin la
IL Ip : Interleukin ip
IL  I r a  : IL-1 receptor antagonist
IL-2: Interleukin 2
IL-2R: IL-2 receptor
IL 2Ra: One of the subunits of IL-2 receptor or CD25
IL-2RP: One of the subunits of IL-2 receptor
IL - 2Ry: One of the subunits of IL-2 receptor
IL-3: Interleukins
IL-4; Interleukin 4
IL-5: Interleukin 5
IL - 6 : Interl eukin 6
IL-7 : Interleukin 7
IL-10: Interleukin 10
IL -12  : Interleukin 12
IL-13: Interleukin 13
INF-p: Interferon-p
INF-p2 : Interferon P2, an older term used for IL - 6
INF-y: Interferon-y
IP3: Inositol 1,4,5-trisphosphate
L AK : Lymphocyte-activated killer cells
LH: Luteotrophin
LP S : Lipopoly saccharide
Mg: Magnesium
MHC: Major histocompatibility complex
MIT; Monoiodotyrosine
MTT : [3-(4,5-Dimethylthiazol)-2-yl]-2,SDiphenyltetrazolium Bromide;
ThiazolylBiue 
N A : Noradrenaline
NIM 1: Human thyroid carcinoma cell line
NK: Neurokinin
NK 4-10 : a -Neurokinin Fragment 4-10, a specific agonist for the NK2 receptor
NK l : Neurokinin receptor
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NK2: Neurokinin receptor
N K 3 : N eiiroki ni n receptor
N mU : Neuromedin U-25
NPY : Neuropeptide-Y
N S B : Non-specific binding
PA CAP: Pituitary adenylate cyclase activating polypeptide
P B S : Phosphate buffered saline
PHA : Lectin, or Phytohemagglutinin
PM A: Phorbol 12-myristate, 13-acetate
rT3: Reverse triiodothyronine
S-SP: Succinyl-[Asp^, N-Me-Phe^j-Substance P, a specific agonist for the
NK3 receptor 
S CF : Stem-cell factor
sIL- 2R : Soluble interleukin-2 receptor
SMO-SP: [Sar^, Met(0 2 )^  -Substance P, a specific agonist for the N Kl
receptor
SNAP : S-Nitroso-N-acetyl Penicillamine, a stable donor of nitric oxide
SP: Substance P
T3 : L-triiodothyronine
T 4  : L-thyroxine
TAP-1 : Transporters associated with antigen processing-1
TAP-2: Transporters associated with antigen processing-2
TBG: Thyroid binding globulin
TBPA: Thyroid binding pre-albumin
TCR: T cell receptor
TEMED: N,N,N',N'-tetramethylethylenediamine
TG: Thyroglobulin
T G F -P : Transforming growth factor-p
TI Ab: TSH receptor inhibitory antibody
TMB: 3,3',5,5'-tetramethylbenzidine
TNF: Tumour necrosis factor
T N F-R l: TNF receptor
TNF-R2: TNF receptor
TPO: Thyroid peroxidase
TRH: Thyrotrophin releasing hormone
T S Ab : TSH receptor stimulating antibody
T S F s : Antigen specific suppressor factors
TSH : Thyrotrophin or thyroid stimulating hormone
V IP  : Vasoacti ve intestinal peptide
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V IP i : Specific receptor for VIP
V IP 2  : Specific receptor for VIP
202
APPENDIX 2 
LIST OF MATERIALS
The sources and catalogue numbers of consumables and chemicals used for 
this study are given below.
Amersham Life Sciences, Little Chalfont, Bucks, UK
Iodine-125, Carrier-Free, Cat No. IMS 30. 
cAMP Elisa Kit, Cat No. RPN 225 
Amicon Ltd, Stonehouse, Glos, UK
Centriflo Membrane Filter Cones, CF-25 
BBH, Merck Ltd, Poole, Dorset, UK 
Acetic Acid (Glacial) Cat No. 27014 
Acrylamide: Cat No. 15212 
Ammonium Persulphate: Cat No. 10032 
Disodium Hydrogen Phosphate, Anhydrous: Cat No. 10249 
Ethanol (Absolute 99.7-100 %): Cat No. 14007 
Glycerol: Cat No. 10118 
Hydrochloric Acid (Analar): Cat No. 10307 
Methanol (Dried Analar): Cat No. 10473 
N'N'-Methylene-Bis-Acrylamide (Bis): Cat No. 15213 
Sodium Chloride: Cat No. 10241 
Sodium Dihydrogen Phosphate: Cat No. 10245 
Sulphuric Acid (Analar): Cat No. 10276 
Tris [Hydroxymethyl] Amino Methane: Cat No. 10315 
Becton Dickinson Europe, UK:
18 Gauge Needles
Plastipack Syringes 1 ml, 5 ml, 10 ml, 20 ml, and 30 ml
Sterile 6  ml Polypropylene Tubes with Cap, 12 X 75 mm (Falcon Cat
No.2054, 2063)
Vacutainer Tubes 
Bibby Sterilin Ltd. UK.
1 ml Sterile Plastic Pipettes 
5 ml Sterile Plastic Pipettes 
10 ml Sterile Plastic Pipettes 
25 ml Sterile Plastic Pipettes 
Bio-Rad Laboratories Ltd, Hemel Hempstead, Herts, UK
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Bio-Rad Protein Assay Kit 11, Cat No. 500-0002 
British Bio-Technology Products Ltd, Abingdon, UK (Now R&D 
System s)
Basic Fibroblast Growth Factor (Basic FGF) Human Sequence,
Recombinant: Cat No. BD P37
Transforming Growth Factor p-1 (TGFp-1) Human Sequence,
Recombinant: Cat No. 240-B-002 
Calbiochem-Novabiochem UK Ltd, Nottingham, UK 
Ca lonophore A23187: Cat No. 100105 
Phorbol 12-myristate, 13 acetate: Cat No. 524400 
Cambridge Bioscience, Cambridge, UK
S-Nitroso-N-Acetyl Penicillamine: Cat No. N-7892 
European Collection Of Animal Cell Cultures, Porton Down, UK 
FRTL-5 Rat Thyroid Cells 
Gelman Sciences, Northampton, UK
Sterile Acrodisc Syringe Filters: Cat No. 6224192.
Gibco BRL, Life Technologies, Inc. Paisley, Scotland 
1.8 ml Cryotubes: Nunc Cat No. 3 -68638k 
12 ml Sterile Conical Centrifuge Tubes: Nunc Cat No. 3-43141a 
15 ml Sterile Conical Centrifuge Tubes: Nunc Cat No. 3-74632a 
50 ml Sterile Centrifuge Tubes: Nunc Cat No. 3 -73660a 
6  Well Plates: Nunc Cat No. 152795 A
24 Well Plates: Nunc Cat No. 143982 A 
96 Well Plates: Nunc Cat No. 167008 A
25 Cm2 Tissue Culture Rask: Nunc Cat No. 1-63371 A
25 Cm2 Tissue Culture Rask, Filter Cap: Nunc Cat No. 1-36196 A
80 Cm2 Tissue Culture Flask: Nunc Cat No. 1-53732 A
80 Cm2 Tissue Culture Rask, Filter Cap: Nunc Cat No. 1-78905 A
Chicken Serum; Cat No. 16110-033
Foetal Calf Serum: Cat No. 10091-064
L-Glutamine: Cat No. 25030-032
Hanks' Balanced Salt Solution W ithout Sodium Bicarbonate (lOx): Cat 
No. 14060-040
Interleukin-Ip (Murine, Recombinant): Cat No. 332Iss 
Interleukin-4 (Murine, Recombinant): Cat No. 3323ss 
Interleukin- 6  (Human, Recombinant): Cat No. 3240ss 
Penicillin/Streptomycin Solution: Cat No. 15140-031 
Phosphate Buffered Saline: Cat No. 21300-017 
RPMI-1640 Without L-Glutamine: Cat No. 31870-017
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RPMI-1640: Cat No. 041-01875 
Trypsin 1:250: Cat No. 27250-042 
Leo Laboratories, UK
Heparin
Precision Research Biochemicals, London, UK
Recombinant Human Insulin Like Growth Factor-1 (IGF-1): Cat No, 100-11 
Recombinant Human Interferon Gamma (INF-Y): Cat No. 300-02 
Quadratech, Epsom, Surrey, UK
Endotoxin-free heparinised vacuum blood collection tubes (Endotube Et) 
Sigma Chemical Company Ltd, Dorset, UK 
6  Well Plate: Coming Cat No. 25810-6 
12 Well Plate: Coming Cat No. 25815-12 
24 Well Plate: Coming Cat No. 25820-24 
96 Well Plate: Coming Cat No. 25860-96 
Sterile 50 ml Centrifuge Tubes: Coming Cat No. 25330-50 
Vacuum Filtration System (500 Ml): Corning Cat No, F 9893 
Vacuum Filtration System (1000 Ml): Coming Cat No. F I 145 
± Arterenol (± Nor Epinephrine) Bitartrate Salt: Cat No. A 0937 
3-Isobutyl Methyl Xanthine (IBMX): Cat No. 15879 
Adenylate Cyclase Activating Polypeptide-27: Cat No. A 9808 
Albumin Fraction V: Cat No. A 2153 
Amphotericin B: Cat No. A 9528 
Bestatin Flydrochloride; Synthetic: Cat No. B8385 
Bromophenol Blue (Free Acid): Cat No. B 6896 
Coomassie Brilliant Blue (R): Cat No. B 0630 
Dimethyl Sulfoxide (DMSO): Cat No. D 8779 
DL Thiorphan: Cat No. T 6031 
EDTA tetra sodium salt: Cat. No. E 5391 
Endothelin-1 Synthetic: Cat No. E 7764
F-12 Coon’s Modification with L-Glutamine and 0.863 mg Zinc Sulphate per 
litre, without Sodium Bicarbonate: Cat No. F 6636
Gentamicin Solution (50 Mg/Ml): Cat No. G 1397
Glycyl-Histidyl-Lysine Acetate: Cat No. G 7383
Hanks’ Balanced Salt Solution with Sodium Bicarbonate: Cat No. H2513
Hanks’ Balanced Salt Solution with Sodium Bicarbonate, without Calcium
Chloride and Magnesium Sulphate: Cat No. H 8389
Hepes (N-[2-HydroxyethylIPiperazine-N’-[2-Ethanesulfonic Acid]): Cat N o.
H 7523
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Hydrocortisone: Cat No. H 0888 
Insulin: Cat No. I 5500
Lectin (Phytohemagglutinin From Phaseolus Vulgaris): Cat No. L 9132 
Lipopolysaccharide From Salmonella Enteritidis (EPS): Cat No. L 7770 
MEM Amino Acids Solution Without L-Glutamine (50x): Cat No. M 7020 
MEM Nonessential Amino Acid Solution (lOOx): Cat No. M 7145 
MTT {[3-(4,5-Dimethyl thiazol)-2-Yl] -2,5- Diphenyl tétrazolium Bromide; 
Thiazolyl Blue}: Cat No. M 2128
Neurokinin Fragment 4-10: Cat No. N 5141
Neuromedin U-25: Cat No. N 8138
Neuropeptide Y : Cat No. N 3266
Potassium Iodide: Cat No. P 8256
Protein Standard (Bovine Serum Albumin) P 7656
[Sar^, Met (Oa)^ -Substance P: Cat No. S 2150
Sodium Bicarbonate: Cat No. S 8875
Sodium Bicarbonate Solution (7.5 %): Cat No. S 5761
Sodium Hydroxide: Cat No. S 5881
Somatostatin: Cat No. S 1763
Substance P Acetate Salt: Cat No. S 6883
Succinyl-[Asp^,N-Me-Phe^]-Substance P Fragment 6-11: Cat No. S 6772 
T3  (3,3’,5-TriiodO“L-Thyronine)Sodium Salt; Cat No. T 5516 
T4  (L-Thyroxine) {3-[4-(4-Hydroxy-3,5-Diiodophenoxy)-3,5 
Diiodophenyl]-L-Alanine} Sodium Salt, Pentahydrate. Crystalline: Cat No. T
0397
TEMED (N,N,N',N'-Tetramethyl-Ethylenediamine): Cat No. T 8133 
Thyrotropin (TSH) lOU/Vial: Cat No. T 3538 
Transferrin: Cat No. T 7786 
Trypan Blue: Cat No. T 6146 
Vasoactive Intestinal Peptide : Cat No. V 3628 
T Cell Diagnostics Inc, supplied by Laboratory Impex, Teddington, 
UK
CELLFREE Interleukin-2 Receptor test kit: Cat No CK1020
2 0 6
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APPENDIX 3 
REAGENT PREPARATION
REAGENTS FOR STUDY OF sIL-2R RELEASE FROM WHOLE 
BLOOD 
Phosphate Buffered Saline With Bovine Albumin
To 100 ml of sterile phosphate buffered saline (PBS) solution pH 7.4, 200 
mg of bovine albumin was added. The albumin was dissolved by standing at room 
temperature for approximately 30 min. The solution was sterilised again by filtering 
through an Acrodisc syringe filter into a sterile bottle. The bottle was stored at 4° C. 
This solution is named PBS-A.
Lipopolysaccharide
The contents of one vial, 1 mg of Lipopolysaccharide from Salmonella 
enteritidis (LPS), were dissolved in one ml of sterile phosphate buffered saline with 
albumin (PBS-A), to give a final concentration of 1 mg/ml. Portions of 25 jû were 
prepared in sterile Eppendorf tubes, and stored at -20° C. W hen required, portions 
were allowed to thaw at room temperature. Then the tubes were centrifuged at 1000 g 
for 2-3 min, to sediment liquid sticking to the internal wall of the tube.
Phytohaemagglutinin
The contents of one vial, 5 mg of Phytohaem agglutinin from Phaseolus 
V ulgaris (PHA), were dissolved in 5 ml o f sterile PBS-A, to give a final 
concentration of 1 mg/ml. Portions of 25 /d  were prepared in sterile Eppendorf tubes, 
and stored at -2 0 ° C.
PeniciUin/Streptomycin Solution
Portions of 5 ml were made from a concentrated solution of penicillin/ 
streptomycin containing 1 0 0 0 0  U/ml and 10 mg/ml respectively, and kept at -20° C.
I
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Medium
RPM l-1640 medium with 3 g/l L-Glutamine and 2 g/l of NaHCOg was used 
for this section of study. To 500 ml of medium, 5 ml of lOOx concentrated solution of 
penicillin/streptomycin was added to give a final concentration of 100 U/ml of 
Penicillin and 100 ;(g/ml of Streptom ycin. This m edium  was kept at 4° C. 
Immediately before use, the required volume was transferred to a sterile container and 
warmed up to 37° C.
REAGENTS FOR STUDY OF CYTOKINE RELEASE FROM WHOLE 
BLOOD 
Mixture of LPS and PHA
A combined solution of 2 mg/ml LPS from  Salmonella enteritidis and 0.4 
m g/ml PHA was provided by M edgenix D iagnostics. Portions of 80 pi\ w ere 
dispensed into sterile Eppendorf tubes, which were kept at -20° C.
Phorbol 12-Myristate, 13-Acetate Solution
The contents of a vial (5 mg) of Phorbol 12-myristate, 13-acetate (PMA) were 
dissolved in 200 /d  of 100% ethanol, to prepare a stock solution of 25 mg/ml. 
Portions of 5 /d  were made from this solution, and kept at -20° C.
Before an experiment, 2.4 pil from  an aliquot was diluted to 500 //I with 
m edium , to produce an interm ediate concentration of 120 pig/ml. From  this 
intermediate solution, 4  pil was added to 2 ml of fresh medium, to produce the 
working solution. The concentration of this solution was 240 ng/ml.
Ca lonophore A23187 Solution
The contents of a vial ( 1 0  mg) were dissolved in 500 pi\ of DMSO to prepare a 
stock solution of 20 mg/ml. Portions of 1 0  pil were made from this solution, and kept 
at-20° C.
Before an experiment, 2 pil from an aliquot were diluted to 400 pil with 
medium, to produce an intermediate concentration of 100 pig/ml. To 920 pil of fresh 
medium, 80 pil of intermediate solution was added to produce the working solution of 
Ca lonophore. The concentration of this solution was 8  pig/ml.
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M ethimazole Solution
One gram of Methimazole, relative molecular mass of 114.2, was dissolved in 
87.57 ml of distilled water, to produce a stock solution of 100 mmol/1. The solution 
was filtered through a 0 . 2 2  pim sterile syringe filter, into a sterile container. Portions 
of 250 pi\ were made from this solution and stored at -20° C.
Thyrotropin Solution
The contents of one vial (10 U) were dissolved in 1 0  ml of HBSS containing 
0.2 g Bovine Serum Albumin. This gives a solution of TSH containing 1 U/ml. 
Portions of 100 pi\ were made in sterile Eppendorf tubes, and kept at -20° C, for 
preparation of working TSH solution.
The contents of one aliquot were further diluted to 20 ml with medium, to 
have a solution of 5 mU/ml. Portions of 250 /d  were made in sterile Eppendorf tubes, 
and kept at -20° C.
T4  Solution
The contents of one vial (1 mg), of crystalline L-thyroxine sodium salt, 
pentahydrate (T4 ), relative molecular mass of 888.9, were dissolved in 11.25 ml of 
HBSS, containing 0.25 ml of 1 mol/1 NaOH. This gives a solution of 100 /^mol/1. 
Portions of 250 pi\ were made from this solution, and stored at -2 0 ° C.
T3  Solution
The contents of one vial (1 mg), of crystalline 3,3' 5-Triiodo-L-Thyronine 
sodium salt (T3 ), relative molecular mass 673, were dissolved in 13.86 ml of HBSS, 
and one ml of 1 mol/1 NaOH. This gives an intermediate solution of 100 pimo\/\. 
From this intermediate solution, 50 pil were further diluted with HBSS to 5 ml. The 
concentration of this solution is 1 pimol/L Portions of 250 pi\ were made from this 
solution, and stored at -20° C.
Medium
RPM I-1640 medium without L-Glutamine, with 2  g/1 of NaHCOs, was used 
for this study. To 500 ml of medium, 5 ml of a concentrated solution of 200 mmol/1 
L-glutam ine was added, follow ed by 5 ml of 100 x concentrated solution of 
penicillin/streptomycin. The final concentrations of added ingredients were 2 mmol/1
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of L-glutamine, 100 U/ml of penicillin, and 100 pigtmX of streptomycin.
The medium was kept in a refrigerator (4-8° C). Immediately before use, the 
required volume was transferred to a sterile container and warmed to 37° C.
REAGENTS FOR GROWTH OF FRTL-5 CELLS 
Heat Inactivated Foetal Calf Serum
A bottle of 1 0 0  ml of frozen serum was thawed at room temperature. When 
thawed, serum was mixed by gently inverting the bottle several times, avoiding foam 
formation. The bottle was transferred to a pre-heated 56° C water bath and heated for 
one hour. The bottle was cooled at room temperature, washed externally with 75% 
methylated spirit, and transferred to a laminar flow cabinet. Aseptically, the serum 
was divided into 25 or 50 ml aliquots in 50 ml sterile conical tubes and stored at -20°
C.
Insulin Solution, 10 g/1
The contents of a vial (500 mg) were dissolved in 50 ml of Hanks' Balanced 
Salt Solution (HBSS) containing 1 g/1 Bovine Serum Albumin (BSA) and 750 /d  of 1 
mol/1 sodium hydroxide, and stored at -20° C.
Transferrin Solution, 10 g/1
The contents of a vial (100 mg) were dissolved in 10 ml HBSS containing 1 
g/1 BSA. This solution was made as required.
Somatostatin Solution, 500 mg/1
The contents of a vial ( 1  mg) were dissolved in 2 ml of the HBSS containing 
1 g/1 BSA. Aliquots of 0.4 ml were made in sterile Eppendorf tubes, and stored at 
-2 0 ° C.
Glycyl-Histidyl-Lysine Acetate Solution, 50 //g/ml
The contents of a vial (0.5 mg) were dissolved in 10 ml of the HBSS 
containing 1 g/1 Bovine Serum Albumin. Aliquots of 4  ml were made in sterile tubes, 
and stored at -20° C.
210
Hydrocortisone Solution, 0.5 mmol/1
The contents of a vial (1 mg) were dissolved in 165.3 ml of Ethanol, This 
solution was kept at -20° C. 1.5 ml was further diluted to 50 ml with the HBSS to 
give a solution of 0.5 mmol/1. Aliquots of 0.4 ml were made in sterile Eppendorf 
tubes, and stored at -2 0 ° C.
Thyrotropin (TSH) Solution, 2 U/ml
The contents of vial ( 1 0  U) were dissolved in 5 ml of the HBSS containing 1 
g/1 BSA. Aliquots of one ml were made in sterile tubes, and stored at -20° C.
Five Hormones' Mixture
To prepare 200 ml of a concentrated mixture of five hormones, 20 ml of 
insulin solution (10 g/1), 10 ml of transferrin solution (10 g/1), 0.4 ml of somatostatin 
solution (500 mg/1), 4  ml of Gly-His-Lysine solution (50 mg/1), and 0.4 ml of 
hydrocortisone solution (0.5 mmol/1) were added to 165.2 ml of HBSS. The final 
concentrations w ere 1.0 m g/m l insu lin , 0 .5  m g/m l transferrin , 1.0 pg/ml 
somatostatin, 1 . 0  pg/ml Gly-His-Lys, and 1 . 0  pmol/1 hydrocortisone. Aliquots of 10 
ml were prepared and stored at - 2 0  °C till the time of use.
Four Hormones' Mixture
This mixture was prepared by omitting insulin from the above five hormones' 
mixture and replacing its volume with the HBSS. Since the amount of concentrated 
four hormone solution needed during the study was limited, all the volumes were 
divided by 1 0  for preparation of 2 0  ml of this solution.
Five Hormones' Medium
For preparation of five hormones' medium (5H), one vial of Coon’s modified 
F-12 medium containing ascorbic acid and glutamine was dissolved in approximately 
900 ml of sterile distilled water. The container was washed with 40 ml of sterile 
distilled water, and the washings were added to the original medium. W hen the 
powder had dissolved completely, 35.7 ml of 75 g/1  NaHCOa was added, followed 
by 10 ml penicillin streptomycin (ICP U, ICP /fg/ml), 1 ml of Gentamicin (50 mg/ml), 
10 ml of concentrated five hormones’ mixture, and 50 ml of heat inactivated Foetal
211
Calf Serum (FCS). The volume was made up to 1050 ml by addition of sterile 
distilled water. The final concentrations were 10 pg/mi insulin, 5 pg/ml transferrin, 
1 0  ng/ml somatostatin, 10 ng/ml Gly-His-Lys, 10 pmol/1 hydrocortisone, 100 U/ml 
penicillin, 1 0 0  pg/ml streptomycin, 30 pg/ml gentamycin, and 5% serum. After all 
constituents had been added to the medium, it was filtered into a sterile bottle supplied 
with a 0.22 pm filter attached (Sigma).
Six Hormones’ Medium
To prepare six hormones' medium (6 H) with TSH concentration of 2 U/l, 1 
ml of a stock solution of TSH ( 2  U/ml) was added to one litre of 5 hormones' 
medium before filtration. After mixing, the medium was filtered through a 0 . 2  micron 
filter.
Stimulation Medium
For stimulation of cells with added mediators, the 5 or 6  hormone medium 
used for propagation and preparation of the cells was replaced by medium containing 
0.5% serum and additional amino acids. For preparation of this medium the standard 
protocol was followed, except for the fact that 10 ml of 50 x concentrated essential 
amino acid solution in minimum essential medium (MEM) without L-glutamine, and 
10 ml of 100 X concentrated nonessential amino acid solution in MEM were added to 
the medium. The volume of FCS was reduced to 5 ml/1.
Chicken Serum-Trypsin-Collagenase Solution
To separate the FRTL-5 cells from the plate or flask, chicken serum-trypsin- 
collagenase solution (CTC) was used.
To 450 ml of the HBSS without calcium and magnesium, 10 ml of heat 
inactivated chicken serum was added, followed by addition of 745 mg of EDTA 
(sodium salt), 375 mg of trypsin, and 2.5 ml of collagenase (5000 units /ml). After 
all components had dissolved, the volume was adjusted to 500 ml with the HBSS 
without calcium and magnesium. The pH was adjusted to 9.0. The solution was kept 
in a refrigerator for 4  h, then filtered though a 0.2 micron filter, and stored at -20° C. 
The final concentrations were 750 mg/1 trypsin, 250 U/l collagenase, 2 mmol/1 
EDTA, and 2% chicken serum.
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Stopping Solution
To stop the action of trypsin, C oon’s m odified H am ’s F-12 medium 
containing 5% serum and 2 mmol/1 EDTA (1.49 g/1) was used.
Freezing Medium
To store cells in liquid nitrogen, a freezing medium consisting of 90 % foetal 
calf serum and 10 % DMSO was used.
REAGENTS FOR IODINE UPTAKE STUDY
Potassium Iodide
For preparation of a stock solution of potassium iodide (10 mmol/1), 166 mg 
of KI were dissolved in 100 ml distilled water.
Radioactive Iodine
One mCi was supplied in 10 pi\ of NaOH. To prepare a stock solution of 10 
mCi/ml, 90 pi\ of 0.5 mol/1 PBS was added to the vial.
Hanks' Balanced Sait Solution with 10 mmol/1 HEPES
To a one litre bottle of HBSS, 2.383 grams of HEPES (N-[2-Hydroxyethyl] 
piperazine-N ’-[2-ethanesulfonic acid]) was added, and dissolved by shaking the 
bottle for 2-3 min.
Iodine Uptake Medium
On the day of the experiment, the required amount of albumin was added to 
the HBSS containing 1 0  mmol/1 HEPES, to give a final concentration of 5 g/1. The 
required amount of stock solution of potassium iodide ( 1 0  mmol/1) was then added to 
give a final concentration of 10 pmol/1 and the pH of the buffer was adjusted to 7.35 
with 2.5 mol/1 NaOH solution. A t this stage, the buffer was heated to 37° C. 
Immediately before use, the required volume of radioactive iodine was added to the 
buffer to give a concentration of 0.5 pCi/ml, at a specific activity of 50 mCi/mmol.
2 1 3
Substance
A m ount 
p e r  vial
Volume
(ml)
C oncentration 
o f stock
a-N K 1 mg 5.470 2 0 0  /f mol/1
Bestatin 5 mg 13.77 1 mmol/1
basic FGF 25 pig 0.500 50 pig/M
Endothelin-1 lO pg 0.800 4 pimo\/\
IBMX 56 mg 1 0 25.2 mmol/1
IGF-1 1 0 0 /fg 1 . 0 0 0 1 0 0  pig/ml
IL-1 0.5 pg 0 . 1 0 0 5 pig/mi
IL-4 03  pig 0 . 1 0 0 5 pig/mi
ÎL - 6 l.Opig 0 . 2 0 0 5 pig/mi
INF-Y 1 0 0  pg 1 . 0 0 0 1 0 0  pi gl ml
LPS LO mg 1 . 0 0 0 1 . 0  mg/ml
Neuromedin U 1 0 0  pig 0.626 50 ^/mol/1
Noradrenaline 6.39 mg 1 0 . 0 0 2 0  mmol/1
NPY 1 0 0  }ig 0.372 50 //mol/1
PACAP 1 0 0  pig 0 . 2 2 2 1 0 0  //mol/1
SMO-SP 1 . 0  mg 0.508 1 . 0  mmol/1
SNAP 25 mg 1.135 1 0 0  mmol/1
Substance P 500 pig 3.550 83 //mol/1
S-SP 1 . 0  mg 1.188 1 . 0  mmol/1
T3 1 . 0  mg 59.50 25 //mol/1
T 4 1 . 0  mg 50.00 22.5 //mol/1
TGF p-1 2 pig 0.500 4//g/m l
Thiorphan 5 mg 19.74 1 mmol/1
TSH lOU 1 0 . 0 0 lU /m l
VIP 250 mg 1.31 50 //mol/1
Table A 3 : Composition of stock solutions of stimulators. Most were dissolved in 
PBS containing 2 g/1 BSA, except a -N K  (0.5 mol/1 acetic acid with 2 g/1 BSA), 
succinyi-(Asp^, N-Me-Phe^)-substance P (0.05 mol/1 acetic acid with BSA), T 3  
(HBSS with 1 ml of IM  NaOH), T 4  (HBSS), thiorphan (100% ethanol), TSH 
(HBSS with BSA), TGF p - 1  (4 mmol/1 HCl with 5 g/1 BSA), IBMX (methanol) and 
SNAP (DMSO). All were aliquoted and stored at -20° C.
PREPARATION OF STOCK SOLUTIONS OF STIMULATORS
The procedure for preparation of stock solutions of stimulators is described in 
the table 3A .I. All solutions were stored at -20° C.
REAGENTS FOR POLYACRYLAMIDE GEL ELECTROPHORESIS 
Acrylamide/Bis (30% T, 2.67% C)*
On the day of gel preparation, 14.6 g of Acrylamide were dissolved in 40 ml 
of distilled water, followed by 400 mg of N ,N '-methylene-bis-acrylamide (Bis). 
When the powders had dissolved completely, the volume was adjusted to 50 ml. As 
the maximum shelf life of this solution in a dark container at refrigerator temperature 
is 30 days, a small quantity of this reagent was made freshly on the day of gel 
preparation.
* T =: Total monomer concentration. The pore size of the polyacrylamide gel 
is defined by percentage of T, and calculated by the formula below.
^  ^ gimna o f aciylamide + giama o f Bis ^%  I — ----------------------------------------------       X  1 0 0Total yoltmue
* C = Cross linking monomer concentration. In diluting a stock solution, the 
cross linking monomer concentration (%C) is independent of the final total monomer 
concentration. The percentage of C is calculated by the following formula.
%  grams o f Bia_________
grams o f aciylamule + grams o f Bis
T ris-H C l b u ffe r, 1.5 mol/1, pH  8 . 8
For preparation of this buffer, 54.45 g of Tris base {Tris [hydroxymethyl] 
amino methane} was dissolved in 200 ml of distilled water, and the pH of the 
solution was adjusted by addition of 2 mol/1 HCl (approximately 80 ml). The final 
volume was adjusted to 300 ml. The buffer was stored at 4° C.
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Tris-HCI Buffer, 0.5 mol/!, pH 6.8
6  g of Tris base were dissolved in 60 ml of distilled water, and the pH of the 
solution was adjusted by addition of 2 mol/1 HCl (approximately 25 ml). The final 
volume was adjusted to 100 ml. The buffer was stored at 4° C.
Ammonium Persulphate Solution, 10%
One gram of ammonium persulphate was dissolved in 10 ml of distilled 
water. As the solution is unstable, it was made on the day when gel was prepared.
Bromophenol Blue Solution, 1%
100 mg of bromophenol blue were dissolved in 1 0  ml of Tris-HCl buffer, pH
6 .8 .
Sample Buffer
1 ml of Glycerol (99%) was added to 8.5 ml of Tris-HCl buffer (pH 6 .8 ), 
fo llow ed by addition of 0.5 ml o f brom ophenol blue (BPB) solution. The 
concentration of glycerol was 10 %, and that of BPB was 0.05%. This solution was 
stable at 4° C for several months.
Concentrated Electrode Buffer
For preparation of this buffer, 45 g of Tris base were dissolved in 2 1 of 
distilled water, followed by addition of 216 g o f glycine. W hen the powders had 
dissolved completely, the final volume was adjusted to 3 1 with distilled water. For 
preparation of working electrode or running buffer solution, 300 ml of this buffer 
were diluted to 1400 ml with distilled water, and the pH was adjusted to 8.3 with 1 
mol/1 HCl or NaOH. The final volume was adjusted to 1.5 1.
Staining Solution
Staining and fixation were carried out simultaneously with this solution. For 
preparation of one litre, 100 ml of concentrated acetic acid solution were added to 500 
ml of distilled water, followed by addition of 400 ml of 98 % methanol and 1 g of 
Coomassie blue dye (R-250). The solution was mixed until the dye had dissolved 
completely and filtered immediately before use. The concentration of Coomassie blue
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was 0,1% in 10% acetic acid and 40% methanol.
Destaining Solution
This solution contained the same concentrations of acetic acid and methanol as 
the staining solution, but did not contain any dye.
DYE PREPARATION FOR MTT PROTOCOL
A stock solution of MTT (2 g/1) was prepared by dissolving 20 mg of MTT in 
10 ml of the PBS, pH 7.3. The solution was sterilised by filtration (0.22 //m), and 
stored at 4° C, in the dark. This solution was stable for several weeks.
Note: It should be mentioned that the reagents that were common to more than one 
study are not repeated under different headings.
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